<SEC-DOCUMENT>0000939767-18-000136.txt : 20180801
<SEC-HEADER>0000939767-18-000136.hdr.sgml : 20180801
<ACCEPTANCE-DATETIME>20180801161435
ACCESSION NUMBER:		0000939767-18-000136
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20180629
FILED AS OF DATE:		20180801
DATE AS OF CHANGE:		20180801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		18984918

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel2018063010-q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB8A5190479935367BDC0C39DF6AC3E87"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM 10-Q</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For the quarterly period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;29, 2018</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">or</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo2017aa02.jpg" alt="exellogo2017aa02.jpg" style="height:64px;width:192px;"></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">04-3257395</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1851 Harbor Bay Parkway</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Alameda, CA 94502</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(650) 837-7000</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:40%;"></td><td style="width:4%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.    </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;24, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, there were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">298,035,458</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;shares of the registrant&#8217;s common stock outstanding. </font></div><div><br></div><hr style="page-break-after:always"><div><a name="s632E86CCC7D958D1B21AB0D1BC79F458"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:80%;"></td><td style="width:12%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9602258B05695B7B84442DED3B3232A9"><font style="font-family:Calibri,sans-serif;font-size:10pt;">PART I - FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2E492377D8065CFF96BD86BE2241A61C"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2E492377D8065CFF96BD86BE2241A61C">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s8DFA1F1EE3D25504B82224F52515A963"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s8DFA1F1EE3D25504B82224F52515A963">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s000E644B3B035C8FA36638AAF2F179B2"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s000E644B3B035C8FA36638AAF2F179B2">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA1C67766638A50C2A9E1042FD8A81F2A"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA1C67766638A50C2A9E1042FD8A81F2A">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB174DDDBC6FE56F893EE90A7B7315314"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sB174DDDBC6FE56F893EE90A7B7315314">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sBEA336CFC78B5138A5A300C249BF8997"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sBEA336CFC78B5138A5A300C249BF8997">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5C46B7F79F73584599FD327E5640540D"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5C46B7F79F73584599FD327E5640540D">28</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s85597CD03E165DA28A2D68CE5E318259"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s85597CD03E165DA28A2D68CE5E318259">38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE48516439D265B1287EE5EB4C93864A9"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE48516439D265B1287EE5EB4C93864A9">38</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1294CD52B8F65D9C872059043D7DF331"><font style="font-family:Calibri,sans-serif;font-size:10pt;">PART II - OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF67D50CC56BC5F5F81A3C1A594A87422"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF67D50CC56BC5F5F81A3C1A594A87422">39</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s98FC474592BD5201926BF422F5E88EDC"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s98FC474592BD5201926BF422F5E88EDC">39</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s08086493D366578F806544257746B56B"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s08086493D366578F806544257746B56B">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF50EB0BE00E0576BB81598E4E7576C2A"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF50EB0BE00E0576BB81598E4E7576C2A">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE04F156653115687ADE1A06D2F88E4B5"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE04F156653115687ADE1A06D2F88E4B5">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDD10C818272F55A78CB0A8173AE99E51"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDD10C818272F55A78CB0A8173AE99E51">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s63FCFF3A2C52584B9988DF0CA3FBC623"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s63FCFF3A2C52584B9988DF0CA3FBC623">60</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s885F2531770953CF99716ABF0114C1F1"><font style="font-family:Calibri,sans-serif;font-size:10pt;">SIGNATURES</font></a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</font></div></div><hr style="page-break-after:always"><div><a name="s9602258B05695B7B84442DED3B3232A9"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I - FINANCIAL INFORMATION</font></div><div><a name="s2E492377D8065CFF96BD86BE2241A61C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;Item 1. Financial Statements</font></div><div><a name="s8DFA1F1EE3D25504B82224F52515A963"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017*</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">248,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251,516</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">204,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Trade and other receivables, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">167,161</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">686,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">484,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,396</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">911,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,575</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,801</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,849</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,713</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,974</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">115,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financing obligation for build-to-suit lease</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,630</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">136,190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">370,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 297,892,180 and 296,209,426 at June 30, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,142,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,114,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,367,316</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">774,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">911,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div><a name="s000E644B3B035C8FA36638AAF2F179B2"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">105,869</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">197,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">132,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">85,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">202,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,697</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,364</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,913</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,625</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(12,228</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,237</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,766</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,071</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, basic </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,241</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">313,024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div><div><a name="sA1C67766638A50C2A9E1042FD8A81F2A"></a></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">202,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities were nominal and there was </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;income tax expense related to other comprehensive income during those periods. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><a name="sB174DDDBC6FE56F893EE90A7B7315314"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">401(k) matching contributions made in common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,723</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of debt discounts and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,825</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gain on other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(490</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Trade and other receivables, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(85,969</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,087</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,577</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,049</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,048</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,910</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,159</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current and long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">146,577</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of Property and equipment and other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(15,182</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,298</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(227,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(154,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,948</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">200,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from sale of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(91,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,719</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Principal repayments of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(185,788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Taxes paid related to net share settlement of equity awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,976</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,331</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Principal payments on financing lease obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,920</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(172,086</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(15,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supplemental cash flow disclosure - non-cash investing and financing activity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment deemed to have been acquired under build-to-suit lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred to acquire Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><a name="sBEA336CFC78B5138A5A300C249BF8997"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div><a name="s6EF878E0ED705682B1C5E20A5CA72433"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors, and RET: CABOMETYX&#174;&#160;(cabozantinib) tablets approved for advanced renal cell carcinoma (&#8220;RCC&#8221;); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&#174; (cobimetinib) tablets, is an inhibitor of MEK, marketed under a collaboration agreement with Genentech, Inc. (a member of the Roche Group) (&#8220;Genentech&#8221;), and is approved as part of a combination regimen to treat advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2018 will end on December 28, 2018 and fiscal year 2017 ended on December 29, 2017. For convenience, references in this report as of and for the fiscal periods ended June 29, 2018, March 30, 2018 and June 30, 2017, and as of and for the fiscal years ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2018, March 31, 2018 and June 30, 2017, and the years ended December&#160;31, 2018 and December&#160;31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended December 28, 2018 and the first day of the fiscal quarter ended June 29, 2018 are indicated as being as of January 1, 2018 and April 1, 2018, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;business segment that focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts on the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to current period presentation. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, as a result of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">new information received during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the six months ended June 30, 2018, as described further in &#8220;Note 3. Collaboration Revenues - Genentech Collaboration&#8221;, we have reclassified the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in profit on the U.S. commercialization of COTELLIC for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenue in preparing our Condensed Consolidated Statements of Operations for the six months ended June 30, 2018. As a result of this reclassification, for the three months ended March 31, 2018, Collaboration revenues increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$78.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$79.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net revenues increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$212.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$213.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Selling, general and administrative expenses increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$52.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$54.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and Operating expenses increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$96.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$97.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There was no impact on Net income or Net income per share as a result of this reclassification.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-18&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">etrospective transition method in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Condensed Consolidated Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-18, we no longer include purchases </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of restricted cash and proceeds from maturities of restricted cash </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in Net cash provided by investing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 4. Cash and Investments - Cash, Cash Equivalents and Restricted Cash&#8221; for a reconciliation of cash and cash equivalents presented in our previously published Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and Cash, cash equivalents and restricted cash reported in the accompanying Condensed Consolidated Statement of Cash Flows for the same period.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2018, we adopted ASU </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">No. 2014-09, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(&#8220;Topic 606&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605: Revenue Recognition (&#8220;Topic 605&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$258.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to opening accumulated deficit as of January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (&#8220;Ipsen&#8221;) and Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Balance Sheet </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of January 1, 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone from Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">European Medicines Agency (&#8220;EMA&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for cabozantinib, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced hepatocellular carcinoma (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC&#8221;),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;that was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">deemed probable under Topic 606 prior to January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eferred revenue as of January 1, 2018 is related to the up-front, nonrefundable, fees and milestones achieved </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that were allocated to our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development services performance obligation that had not been satisfied as of that date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Contract assets and liabilities are netted by collaboration agreement in our Condensed Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Statements of Operations as of and for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Balances Without the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Effect of Adoption</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Higher / (Lower)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">240,256</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">142,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,005</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Balances Without the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Effect of Adoption</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Higher / (Lower)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">142,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">422,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,750</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">229,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">225,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;recognized in accordance with Topic 606 included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenue, respectively, for a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC. We recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenue for this milestone in the first quarter of 2018 when we deemed achievement of the milestone was probable in accordance with Topic 606. If we had not adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606, we would have recognized the e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ntire </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone as revenue in the second quarter of 2018 upon achievement of the milestone. If we had not adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606, we would also have recognized a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone in the first quarter of 2018 upon the validation of Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">estimates of the amount of consideration to which we are entitled based on the terms of the contract.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to patients, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for product supply; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply, each of these payment types are within the scope of Topic 606. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accounting Standards Codification Topic 808, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;Topic 808&#8221;). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We expect to recognize an annual profit under the agreement for the year ended December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues on the accompanying Condensed Consolidated Statements of Operations. Historically, we had not recognized a profit for any annual period from the commercialization of cobimetinib in the U.S. and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses on the accompanying Condensed Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No.&#160;2016-02,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Leases (Topic 842),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-02&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require a right-of-use asset to be recognized on the balance sheet for both types of leases. ASU 2016-02 also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">amounts recorded in the financial statements. ASU 2016-02 must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU No. 2018-11&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In issuing ASU No. 2018-11, the FASB is permitting another transition method for ASU 2016-02, which allows the transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are currently considering the potential of an early adoption of this standard in the second half of 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the transition method permitted by ASU 2018-11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Based on our initial evaluation of the impact of ASU 2016-02 on our build-to-suit lease of office and research facilities located in Alameda, California, we expect that the amount we have capitalized as Property and equipment related to the building shells and related financing liabilities, will be derecognized upon the adoption of ASU 2016-02. Upon adoption of ASU 2016-02 we will also be required to recognize a right-of-use asset and lease liability related to this lease. The adoption of ASU 2016-02 could also change the nature of future expenses related to the build-to-suit lease, reducing future depreciation and interest expense, which would be offset by an increase in lease expense. We are continuing to assess the impact of ASU No. 2016-02 on our consolidated financial statements.</font></div><div><a name="s86C9FBC17BE054CF8A788AF5C8AD4EA6"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. REVENUES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">172,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">332,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">178,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(26,810</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(12,254</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(51,974</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(21,336</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,370</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included revenues related to the portion of three milestones that were allocated to the transfer of intellectual property licenses and were recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;also included a milestone payment from Bristol-Myers Squibb Company (&#8220;BMS&#8221;). Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and License revenues no longer includes revenues related to the amortization of deferred revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development services performance obligation which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included net product supply revenues from Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Losses on the U.S. commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and therefore Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only net product supply revenues.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Duri</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ng the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net product revenues and License revenues related to goods transferred at a point in time and Research and development services revenues related to services performed over time.  License revenues and Research and development services revenues were recorded in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included the p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net product supply revenues, were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 for all periods presented</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">141,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,421</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,599</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52,809</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">44,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,622</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">137,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,985</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">150,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">287,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">163,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to regions based on the ship-to location. Collaboration revenues are attributed to regions based on the location of our collaboration partners&#8217; headquarters.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and Discounts for Prompt Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other Customer Credits/Fees and Co-pay Assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(30,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(47,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Topic 606</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,835</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,575</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(17,306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$32.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$103.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo Company, Limited (&#8220;Daiichi Sankyo&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><a name="s330EA7E2C2195C6499CB0A9AFBC12C30"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">From time to time, we enter into collaborative arrangements for the development, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for non-refundable up-front license fees, development and commercial performance milestone payments, payments for product supply, development cost reimbursements, royalty payments and/or profit sharing. See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we had achieved various milestones totaling </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$125.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we achieved an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone upon the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">approval of cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">first-line treatment of advanced RCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone upon Ipsen&#8217;s filing with the EMA for cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced HCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;commercial milestone upon </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ipsen&#8217;s achievement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales cumulatively over four consecutive quarters</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The timing and amount of revenue recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for those milestones is described below.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$199.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$40.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone upon the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">approval of cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC, and additional milestone payments for other future indications and/or jurisdictions. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">T</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">he collaboration agreement also provides that we will be eligible to receive contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$519.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with sales volume milestones. We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, which was reached in the second quarter of 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of annual net sales, with separate tiers for Canada and the remainder of Ipsen&#8217;s sales territory. These tiers will reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with BMS; CheckMate 040, the phase 1/2 study evaluating the combination of cabozantinib with nivolumab in patients with both previously treated and previously untreated advanced HCC being conducted in collaboration with BMS (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with the Roche Group. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product will be supplied</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">at our cost, as defined in the agreement, which excludes the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty we are required to pay GSK on Ipsen&#8217;s net sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;after the first commercial sale of cabozantinib, other than </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">U.S. Food and Drug Administration </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified the following performance obligations under the collaboration agreement with Ipsen: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib, as described above; and (2) r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development services, which includes certain committed studies for the development of cabozantinib, p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">harmacovigilance services and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">participation on the joint steering and development committees (as defined in the collaboration agreement).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We evaluated the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration agreement with Ipsen</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;under Topic 606 as of January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on the evaluation as of that date, the up-front, nonrefundable fees, the milestones earned and royalties earned as of December 31, 2017, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone we expected to achieve in the first quarter of 2018 upon Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC, and the estimated reimbursements for our research and development services performance obligation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. The transaction price was allocated to the performance obligations identified based on our best estimate of the relative standalone selling price: for our license, the estimate was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate and for r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;services the estimate was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. Other than the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;HCC filing milestone discussed above, variable consideration related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate to the license transferred to Ipsen and therefore is recognized at the later of when the performance obligation is satisfied or the related sales occur. We re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Revenues related to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time, upon execution of the collaboration agreement in February 2016. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">research and development services performance obligation are being recognized using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union, which is early 2030. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$51.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the transaction price allocated to our research and development services performance obligation had not been satisfied.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenue for a commercial milestone from Ipsen that we earned in the second quarter of 2018 upon Ipsen&#8217;s achievement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in net sales cumulatively over four consecutive quarters. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that sales-based milestones relate entirely to the previously satisfied performance obligations for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the transfer of an</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;intellectual property license and therefore recognized the entire milestone in the quarter the milestone was achieved.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenue of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC by the European Commission (&#8220;EC&#8221;), of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was recognized in the first quarter of 2018. We determined recognition of the milestone during the first quarter of 2018 was appropriate following the Committee for Medicinal Products for Human Use&#8217;s (&#8220;CHMP&#8221;) positive opinion of cabozantinib for the first-line treatment of advanced RCC. The positive CHMP opinion was reviewed by the EC as part of their approval process. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our determination that we expected to achieve the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone resulted in a change in the overall </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">transaction price of the collaboration agreement, as it was probable that a significant reversal of cumulative revenue would not occur. We recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in revenue in the first quarter of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018 which represents </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the portion of the milestone that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license and research and development services. The remainder </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the milestone </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was allocated to research and development services to be recognized in future periods as those services are delivered through early 2030, which included an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;recognized in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the second quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was included in Current portion of deferred revenue and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was included in Long-term deferred revenue on the accompanying Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upfront nonrefundable payment from Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we amended the collaboration agreement to modify the milestones we are eligible to receive under the agreement. As of June 30, 2018, we were eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to second-line RCC, first-line RCC and second-line HCC, as well as additional development,  regulatory and first-sale milestone payments for potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with sales volume milestones. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, and after the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales. These tiers will reset each calendar year. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In accordance with the collaboration agreement, Takeda has opted into and is co-funding</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with BMS. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda, as well as a quality agreement setting forth, in detail, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">respective responsibilities pertaining to the quality requirements of the aforementioned supply to Takeda. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;years of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified the following performance obligations under the collaboration agreement with Takeda: (1) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the transfer of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an exclusive license for the commercialization and further development of cabozantinib, as described above; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">harmacovigilance services and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">participation on the joint executive and development committees (as defined in the collaboration agreement).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We evaluated the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration agreement with Takeda</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;under Topic 606 as of January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on the evaluation as of that date, the up-front, nonrefundable fee </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and the estimated reimbursements for our research and development services performance obligation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. The transaction price was allocated to the performance obligations identified based on our best estimate of the relative standalone selling price: for our license, the estimate was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate and for r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">services the estimate was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. Variable consideration related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license transferred to Takeda and therefore is recognized at the later of when the performance obligation is satisfied or the related sales occur. We re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues related to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time, upon execution of the collaboration agreement in January 2017. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">research and development services performance obligation are being recognized using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in Japan, which is early 2030. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$28.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the transaction price allocated to our research and development services performance obligation had not been satisfied. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Takeda was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was included in Long-term deferred revenue on the accompanying Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty revenues on ex-U.S. sales and our share of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the profits and losses recognized in connection with COTELLIC&#8217;s commercialization in the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,696</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The royalty revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on ex-U.S. sales were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">included in Collaboration revenues. Prior to the adoption of topic 606, royalty revenues from the collaboration agreement with Genentech were based on amounts reported to us by our collaboration partner and were recorded when such information becomes available to us; beginning in the first quarter of 2017 such information became available in the current quarter and for 2016 such information was not available until the following quarter, meaning that through December 31, 2016 we recorded royalty revenues on a one quarter lag. As a result </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of this change, royalty revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in royalty revenues for sales in the fourth quarter of 2016 in addition to the royalty revenues for sales in the first half of 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Losses on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations; Selling, general and administrative expenses also included the profit for the first quarter of 2018 in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 2, 2018 as we were not expecting an overall profit for the year ended December 31, 2018. During the second quarter of 2018, we determined that we now expect an overall profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the year ended December 31, 2018 and therefore we have included the profit for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in Collaboration revenues for those periods; accordingly, we have also reclassified the profit for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">first quarter of 2018 from Selling, general and administrative expenses to Collaboration revenue for that period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GSK Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,628</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">StemSynergy Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy Therapeutics, Inc. (&#8220;StemSynergy&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (&#8220;CK1&#945;&#8221;) a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. We paid</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;StemSynergy an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for initial research and development funding and StemSynergy is eligible to receive up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of such funding. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;payment we made during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;is included in Research and development expenses in the accompanying Condensed Consolidated Statements of Operations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy will also be eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Invenra Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we entered into a collaboration and license agreement with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra, Inc. (&#8220;Invenra&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(the &#8220;lead preclinical asset&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and that we and Invenra intend to pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and second project initiation fee of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of total payments we made during the six months ended June&#160;30, 2018 are included in Research and development expenses in the accompanying Condensed Consolidated Statements of Operations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra is eligible to receive payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$131.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;based on the achievement of specific development and regulatory milestones for a product containing the lead preclinical asset in the first indication. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$325.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product. We also have the right to initiate five additional discovery projects for development subject to an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project basis at any time prior to commercialization, for any or no reason, upon thirty days&#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of our other existing collaboration agreements, see &#8220;Note 2. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that each of our other </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">existing collaboration agreements </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">have one performance obligation, the delivery of an intellectual property license to each collaboration partner, which was satisfied for all such agreements prior to the adoption of Topic 606. As a result, any consideration earned and received from these collaborations will be recognized immediately as the licenses we provided represent functional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">intellectual property </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that was transferred at a point in time prior to the adoption of Topic 606, when the agreements were executed. Potential v</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ariable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon Daiichi Sankyo&#8217;s submission of a regulatory application to the Japanese Pharmaceutical and Medical Devices Agency for esaxerenone as a treatment for patients with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">essential </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">hypertension, we earned a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone, which is included in Collaboration revenues during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div><a name="sB0F214F1336F518D948E378CB2456E12"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. CASH AND INVESTMENTS </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">248,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investments Available-for-sale</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Investments by security type were as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,780</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were nominal during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">200,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross unrealized losses on commercial paper in an unrealized loss position 12 months or greater were less than $1 thousand.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">149</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;investments in an unrealized loss position as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">500,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s89499729A56B5F9E9CDBC8ABB643C317"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">765</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for both the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory expected to be used in production or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Condensed Consolidated Balance Sheets. As of both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the non-current portion of inventory consisted of a portion of our finished goods.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><a name="s815098BDBBDB50FAB9917894FB051F6E"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. PROPERTY AND EQUIPMENT </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">78,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leased Premises Placed in Service</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with Ascentris 105, LLC (&#8220;Ascentris&#8221;) for office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the &#8220;Premises&#8221;). The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet. For a description of the Lease, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">see &#8220;Note 12. Commitments&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In June 2018, we relocated our offices and research facilities to the Premises. Accordingly, we placed into service </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$59.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in related Leasehold improvements, Buildings, Furniture and fixtures and Computer equipment and software, portions of which were included in Construction in progress at prior period ends. We are continuing to review the allocation of these additions between Leasehold improvements and Furniture and fixtures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises, including the building shells, did not qualify as &#8220;normal tenant improvements&#8221; under Accounting Standards Codification Topic 840, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;Topic 840&#8221;). Accordingly, for accounting purposes, we were deemed to be the owner of such portions of the Premises during the construction period. As such, we capitalized the construction costs as a build-to-suit property within Property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. Accordingly, we capitalized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of costs related to the Lease in construction in progress as of May 2, 2017, with a corresponding build-to-suit financing obligation in Other long-term liabilities. In June 2018, upon placing of the assets in service and in accordance with Topic 840, due to our continuing involvement in the Premises the Lease did not qualify for sale-leaseback accounting. Accordingly, the assets placed into service include the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;estimated fair value of the building shells that we are deemed to own. We have also recorded a related financing obligation of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in Other current liabilities and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in Financing obligation for build-to-suit lease in the accompanying Condensed Consolidated Balance Sheets for the buildings and related landlord allowance earned in the second quarter of 2018. Buildings are depreciated over their estimated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year useful life.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div><a name="sA41DFE444DBC594E948219FB1EA0A321"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,427</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,655</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and restricted stock units (&#8220;RSUs&#8221;) to employees, directors and consultants. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19,509,911</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares were available for grant under our equity incentive plans.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value per share of our stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock option activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">818,842</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,141,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(102,177</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,783,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.8 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,249,965</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">271,709</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$39.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of unrecognized compensation expense related to unvested stock options will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.3 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RSU activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">300,670</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(341,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(120,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,601,202</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of unrecognized compensation expense related to unvested RSUs will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2.8 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><a name="s38BC3BB4EB8B53D9A1C358705C897EAD"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;primarily relates to state taxes for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset our federal taxable income.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law. The Tax Cuts and Jobs Act contained significant changes to corporate taxation, included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. Further guidance may be forthcoming from the FASB and the&#160;SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts. The Provision for income taxes for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;did not reflect any adjustment to the impact of the Tax Cuts and Jobs Act enactment that we recorded during the year ended December 31, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div><a name="s24D0C08BA48E55A4B9B066794E1CC78E"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. NET INCOME PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for diluted net income per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,336</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296,874</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">313,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year warrants to purchase an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of our common stock issued in January 2014 (&#8220;2014 Warrants&#8221;) were participating securities. The warrant holders did not have a contractual obligation to share in our losses. The 2014 Warrants were fully exercised in September 2017. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the 2014 Warrants, see &#8220;Note 7. Common Stock and Warrants&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potentially dilutive shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div><a name="sEEFB91C6A484559DAC14C19B5333CB27"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">540,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and there were no transfers of financial assets or liabilities classified as Level 3 during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our remaining financial assets and liabilities include Cash, Trade and other receivables, Unbilled collaboration revenue, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers, and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div><a name="s5C46B7F79F73584599FD327E5640540D"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; &#8220;would,&#8221; &#8220;intend,&#8221; &#8220;continues,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;initiate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;trend,&#8221; or the negative of such terms or other similar expressions identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in Part II, Item&#160;1A of this Form 10-Q, as well as those discussed elsewhere in this report. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this report and the financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;filed with the Securities and Exchange Commission, or SEC, on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors, and RET: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma, or RCC; and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC&#174; (cobimetinib) tablets, is an inhibitor of MEK, marketed under a collaboration agreement with Genentech, Inc. (a member of the Roche Group), or Genentech, and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subject of broad clinical development programs for multiple potential oncology indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX was approved by the U.S. Food and Drug Administration, or FDA, for previously treated patients with advanced RCC in April 2016, and then on December 19, 2017, approximately two months ahead of the assigned Prescription Drug User Fee Act, or PDUFA, action date, the FDA expanded CABOMETYX&#8217;s approval in this indication to include previously untreated patients with advanced RCC. We continue to be highly focused on optimizing the execution of this commercial launch</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the U.S. through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our commercial and medical affairs organizations and established distribution network.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we have entered into license agreements with Ipsen </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pharma SAS, or Ipsen, and Takeda Pharmaceutical Company Ltd., or</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Takeda. Ipsen has been granted rights to cabozantinib outside of the U.S. and Japan, and Takeda has been granted rights to cabozantinib in Japan. Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we are working closely with them on these activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Beyond our currently approved indications for advanced RCC and for MTC, we are pursuing other indications that have the potential to expand the number of cancer patients who could benefit from cabozantinib. Furthest advanced is our evaluation of CABOMETYX as a treatment for patients with previously treated advanced hepatocellular carcinoma, or HCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;On March 15, 2018, we submitted a supplemental New Drug Application, or sNDA, for cabozantinib in this indication to the FDA, and on May 29, 2018, the FDA accepted this filing, assigning a PDUFA action date of January 14, 2019. The data in support of this filing are derived from CELESTIAL,&#160;our company-sponsored, global phase 3 trial comparing cabozantinib to placebo in patients with advanced HCC who had previously progressed on or were intolerant to sorafenib and up to one additional therapy. On October 16, 2017, we announced that at the time of the second planned interim analysis, the study&#8217;s independent data monitoring committee had recommended that CELESTIAL be stopped because it had met its primary endpoint, with cabozantinib providing a statistically significant and clinically meaningful improvement in overall survival, or OS, compared to placebo. Safety data from the study were consistent with the established profile of cabozantinib. The results of the CELESTIAL trial were published in the New England Journal of Medicine, or NEJM, in early July 2018. We believe that the available clinical data demonstrate that cabozantinib has the potential to be broadly active in cancer indications beyond those for which it is already approved.&#160;Accordingly, we are currently evaluating cabozantinib, both as a single agent and in combination with immune checkpoint inhibitors or other compounds, in a broad development program comprising over&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial collaboration partners, sponsor some of the trials, and independent clinicians conduct the remaining trials through our Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program, or NCI-CTEP, or our investigator sponsored trial program. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are particularly interested in examining cabozantinib&#8217;s potential in combination with immune checkpoint inhibitors to determine if such combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of immune checkpoint inhibitors in multiple clinical trials. The most advanced of these combination studies include a phase 3 pivotal trial evaluating cabozantinib in combination with nivolumab in previously untreated, advanced or metastatic RCC, and a phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with both previously treated and previously untreated advanced HCC. Both trials are in collaboration with Bristol-Myers Squibb Company, or BMS. As a further part of our clinical collaboration with BMS, we also plan to evaluate cabozantinib and nivolumab with or without ipilimumab in various other tumor types, including in bladder cancer. Diversifying our exploration of combinations with immune checkpoint inhibitors, we have also initiated COSMIC-021, a phase 1b dose escalation study evaluating the safety and tolerability of cabozantinib in combination with the Roche Group&#8217;s, or Roche&#8217;s, atezolizumab in patients with locally advanced or metastatic solid tumors. Following the completion of the dose escalation portion of the study in the first quarter of 2018, the study is currently enrolling patients into eight tumor expansion cohorts. The protocol for the study is also being amended to include an aggregate of eighteen tumor expansion cohorts, including multiple therapeutic settings of RCC, urothelial cancer, or UC, and non-small cell lung cancer, or NSCLC, and single therapeutic settings of HCC, castration-resistant prostate cancer, or CRPC, triple-negative breast cancer, or TNBC, epithelial ovarian cancer, or EOC, endometrial cancer, gastric or gastroesophageal junction cancer, or GEJ cancer, colorectal adenocarcinoma, differentiated thyroid carcinoma, or DTC, and head and neck cancer of squamous cell histology.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Genentech also continues to make progress with respect to the phase 3 clinical development program for our second approved cancer agent, cobimetinib. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we licensed cobimetinib to Genentech and Genentech has been, and is, solely responsible for the product&#8217;s clinical development. G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enentech is currently conducting two phase 3 pivotal trials exploring the combination of cobimetinib with atezolizumab in BRAF wild type melanoma population </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(IMspire170)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and the combination of cobimetinib with atezolizumab and vemurafenib in BRAF V600 mutant melanoma (IMspire150). The first patient for IMspire170 was enrolled in December 2017, and e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nrollment for IMspire150 was completed in April 2018.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Additionally, although </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">IMblaze 370, a third phase 3 pivotal trial conducted by Genentech evaluating the combination of cobimetinib w</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ith atezolizumab in colorectal carcinoma, or CRC, did not meet its primary endpoint as announced in May 2018, Genentech continues to pursue the cobimetinib development program </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and is conducting a series of early-stage clinical trials investigating the combination of cobimetinib and atezolizumab in multiple tumor settings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Should these trials prove positive and Genentech obtain regulatory approvals based on such positive results, we believe that cobimetinib could provide us with a potentially meaningful source of revenue in the future.&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As we continue to work to maximize the clinical, therapeutic and commercial potential of cabozantinib and cobimetinib, we remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we have resumed internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Notably, these efforts are led by some of the same experienced scientists responsible for the discovery of cabozantinib and cobimetinib, which have been approved for commercialization by regulatory authorities, as well as other promising compounds we have discovered, many of which are in earlier stages of clinical and regulatory development pursuant to our collaborations with Daiichi Sankyo Company, Limited, or Daiichi Sankyo, Merck (known as MSD outside of the U.S. and Canada), BMS and Sanofi.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also focused on augmenting our product pipeline by in-licensing attractive, early-stage oncology assets and then further developing them utilizing our established clinical development infrastructure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. In furtherance of this strategy, in January 2018, we entered into an exclusive global collaboration and license agreement with&#160;StemSynergy Therapeutics, Inc., or StemSynergy, for the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha, or CK1&#945;, a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of this agreement,&#160;we&#160;have partnered with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. Additionally, in May 2018, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we entered into a collaboration and license agreement with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra, Inc., or Invenra</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset, and that we and Invenra intend to pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Second Quarter 2018 Business Updates and Financial Highlights</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the second quarter of 2018, we continued to execute on our commercial, development and financial objectives, generating significant revenue from operations and positioning the business to be able to maximize the clinical and commercial potential of CABOMETYX, COMETRIQ and COTELLIC and to expand the product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter end include:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Updates</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2018, we appointed Maria C. Freire, Ph.D. to our Board of Directors. Dr. Freire currently serves as President and Executive Director and as a member of the board of directors of the Foundation for the National Institutes of Health, an independent 501(c)(3) charitable organization established by Congress to support the National Institutes of Health by raising private funds for biomedical research and fostering partnerships and alliances around the world.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2018, Roche confirmed that IMspire150, its phase 3 pivotal trial evaluating the combination of cobimetinib, atezolizumab and vemurafenib in patients with first-line BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma, completed enrollment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we entered into a collaboration and license agreement with Invenra to discover and develop multispecific antibodies for the treatment of cancer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, Ipsen received regulatory approval from the European Commission, or EC, for CABOMETYX as a treatment for adult patients with previously untreated, intermediate- or poor-risk advanced RCC in the European Union, or EU.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we announced that IMblaze370, Genentech&#8217;s phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab in patients with CRC, did not meet its primary endpoint. However, Genentech continues to pursue the cobimetinib development program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, the FDA determined that our sNDA for cabozantinib for patients with previously treated advanced HCC was sufficiently complete to permit a substantive review. The FDA assigned a PDUFA action date of January 14, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2018, we announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, to add ten new expansion cohorts to the trial (for an aggregate of eighteen cohorts), which now includes patients with RCC, UC, NSCLC, CRPC, HCC, TNBC, EOC, endometrial cancer, GEJ cancer, colorectal adenocarcinoma, DTC and head and neck cancer of squamous cell histology. The primary goal of the study remains to determine the objective response rate in each cohort.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2018, clinical data from cabozantinib were the subject of fifteen presentations at the American Society of Clinical Oncology 2018 Annual Meeting, including a poster presentation covering a sub-group analysis of CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated advanced HCC, comparing outcomes by duration of sorafenib treatment in patients whose only prior treatment was sorafenib and outcomes based on age. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The findings showed that cabozantinib improved OS and progression-free survival compared with placebo irrespective of duration of prior sorafenib treatment or age category.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the second quarter of 2018, Ipsen reached $150.0 million in cumulative net sales of cabozantinib, which resulted in an increase in royalty rate earned by Exelixis to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales by Ipsen. Previously we had been entitled to receive a tiered royalty of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are now entitled to receive a tiered royalty of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of annual net sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2018, we were added to Standard &amp; Poor&#8217;s, or S&amp;P&#8217;s, MidCap 400 index and are classified under S&amp;P&#8217;s Global Industry Classification Standard Biotechnology Sub-Industry index.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2018, the NEJM published results from CELESTIAL, our company-sponsored, global phase 3 pivotal trial comparing cabozantinib to placebo in patients with advanced HCC who had previously progressed on or were intolerant to sorafenib and up to one additional therapy. The data demonstrate that cabozantinib provided a statistically significant and clinically meaningful improvement in OS versus placebo.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Financial Highlights</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income for the second quarter of 2018 was </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$87.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$0.29</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$0.28</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, diluted, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$17.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$0.06</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, basic and diluted, for the second quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for the second quarter of 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$186.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$99.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the second quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues for the second quarter of 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$145.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$88.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the second quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses for the second quarter of 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$42.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$28.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the second quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses for the second quarter of 2018 increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$51.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$40.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the second quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments increased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$595.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;below for a discussion of the detailed components and analysis of the amounts above.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$203.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and $154.2 million for the&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the year ended December 31, 2017, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis and we are unable to predict the extent of long-range future profits or losses. We expect to continue to spend significant additional amounts to fund further development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we will continue to expand our product pipeline through our drug discovery efforts and the evaluation and execution of potential additional in-licensing and acquisition opportunities that align with our oncology drug development expertise, efforts that could involve substantial costs. To offset these costs, we will need to generate substantial revenues. As a result, we are unable to predict the extent of any future profits or losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will continue to face a number of challenges and risks to our business that may impact our ability to execute on our 2018 business objectives. In particular, we anticipate that for the foreseeable future our ability to maintain or meaningfully increase unrestricted cash to fund our commercial operations and our development and discovery programs is dependent upon the successful commercialization of CABOMETYX for the treatment of advanced RCC in territories where it has been or may soon be approved and in potential other indications for which we are in late-stage development or intend to seek regulatory review, such as previously treated advanced HCC. The commercial opportunity for CABOMETYX as a treatment for advanced RCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of advanced RCC. Our ability to maintain or meaningfully increase product revenues from CABOMETYX is also affected by a number of other factors, including the highly competitive markets for which we intend to pursue regulatory approval of cabozantinib and the prospect for new competitive therapies and generic competition, and the extent to which coverage and reimbursement for CABOMETYX is available from government and other third-party payers. Obtaining and maintaining appropriate coverage and reimbursement for CABOMETYX is increasingly challenging due to, among other things, the attention being paid to healthcare cost containment and other potential austerity measures being discussed in the U.S. and worldwide, as well as increasing policy interest in the U.S. with respect to pharmaceutical drug pricing practices. To fulfill the commercial potential of cabozantinib also depends on whether data generated by our clinical development activities will support regulatory approval of cabozantinib in additional indications. Achievement of our 2018 business objectives will also depend on our ability to adapt our development and commercialization strategy to navigate increased competition, including that from, but not limited to, immune checkpoint inhibitors, as well as the use of combination therapy to treat cancer. Furthermore, our research and development objectives may be impeded as we work to scale our organization to meet the demands of expanded drug development and discovery activities. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or we may not be able to successfully identify appropriate candidates for in-licensing or acquisition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the pharmaceutical industry with development and commercial operations. For an extensive discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal Year Convention</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2018 will end on December 28, 2018 and fiscal year 2017 ended on December 29, 2017. For convenience, references in this report as of and for the fiscal periods ended June 29, 2018, March 30, 2018 and June 30, 2017, and as of and for the fiscal years ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2018, March 31, 2018 and June 30, 2017, and the years ended December&#160;31, 2018 and December&#160;31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended December 28, 2018 and the first day of the fiscal quarter ended June 29, 2018 are indicated as being as of January 1, 2018 and April 1, 2018, respectively.</font></div><div><a name="s0C38CA95E2EA5FD98FE203A8C3FE4F26"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year to Date 2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">266</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">420</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">122</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;were impacted by our adoption of Accounting Standards Update, or ASU, No. 2014-09, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Accounting Standards Codification Topic 606)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or Topic 606. For additional information on our adoption of Topic 606, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements - Revenue&#8221;, &#8220;Note 2. Revenues&#8221; and &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part I, Item 1 of this Quarterly Report on Form 10-Q</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>Year to Date 2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">141,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">75</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(26</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in net product revenues for CABOMETYX for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to a 64% and 78% increase, respectively, in the number of units of CABOMETYX sold, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and to a lesser extent,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;an increase in the average selling price of the product. The increase in CABOMETYX sales volume </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the continued growth of CABOMETYX in advanced RCC. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in net product revenues for COMETRIQ for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were due to a 35% and 28% decline, respectively, in the number of units of COMETRIQ sold. COMETRIQ sales volume has been decreasing since the launch of CABOMETYX in April 2016. The adoption of Topic 606 did not impact our net product revenues.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Condensed Consolidated Financial Statements&#8221;&#160;contained in Part I, Item 1 of this Quarterly Report on Form 10-Q. We expect our discounts and allowances as a percentage of gross product revenues to increase during the remainder of 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as our business evolves, the number of patients participating in government programs increases, the discounts and rebates paid to government payers increase, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and as a result of the engagement in commercial contracting that may result in additional discounts or rebates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>Year to Date 2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,370</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included revenues related to the portion of three milestones that were allocated to the transfer of intellectual property licenses and were recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;also included a milestone payment from BMS. Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and License revenues no longer includes revenues related to the amortization of deferred revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development services that are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described in (1) above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included net product supply revenues from Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Losses on the U.S. commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and therefore Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;included only net product supply revenues.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues increased to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$40.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$119.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$23.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases in collaboration revenues were primarily the result of increases in collaboration revenues from milestones, as well as increases in royalties under our collaboration agreement with Ipsen, increases in royalties and profit sharing under our collaboration agreement with Genentech, and increases in development cost reimbursement revenues; those increases were partially offset by decreases in the recognition of deferred revenue due to the adoption of Topic 606 and increases in losses under our product supply agreement with Ipsen. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenue for a commercial milestone from Ipsen that we earned in the second quarter of 2018 upon Ipsen&#8217;s achievement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in net sales cumulatively over four consecutive quarters.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenue of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC by the EC, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was recognized in the first quarter of 2018. We determined recognition of the milestone during the first quarter of 2018 was appropriate following the Committee for Medicinal Products for Human Use&#8217;s, or CHMP&#8217;s, positive opinion of cabozantinib for the first-line treatment of advanced RCC. The positive CHMP opinion was reviewed by the EC as part of their approval process. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our determination that we expected to achieve the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone resulted in a change in the overall </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">transaction price of the collaboration agreement, as it was probable that a significant reversal of cumulative revenue would not occur. We recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in revenue in the first quarter of 2018 which represents </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the portion of the milestone that was allocated to the previously satisfied performance obligations for the transfer of an intellectual </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">property license and research and development services. The remainder </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the milestone </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was allocated to research and development services to be recognized in future periods as those services are delivered through early 2030, which included an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;recognized in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the second quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;also included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in revenue </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone earned in February 2018 upon Daiichi Sankyo&#8217;s submission of a regulatory application to the Japanese Pharmaceutical and Medical Devices Agency for esaxerenone as a treatment for patients with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">essential </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">hypertension. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;reflect recognition of a $2.5 million milestone </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">earned from the ROR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;collaboration agreement with BMS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">R</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan increased to $5.4 million and $9.7 million </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively as compared to $0.2 million and $0.4 million for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Ipsen reached $150.0 million in cumulative net sales of cabozantinib, which resulted in an increase in royalty rate earned by us to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales by Ipsen. Previously we had been entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Moving forward, we are now entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">connection with our collaboration arrangements with Ipsen and Takeda </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increased to $5.1 million and $10.8 million </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $2.2 million and $3.3 million for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;primarily as a result of their participation in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 9ER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;study.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized $1.7 million and $3.6 million, respectively, in revenues from the amortization of deferred revenue, including revenue deferred for the upfront payments received in 2016 and 2017 in connection with our collaboration arrangements with Ipsen and Takeda. Revenues from the amortization of deferred revenue were $7.6 million and $13.8 million during the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The decrease in such revenues was a result of the adoption of Topic 606. Upon adopting Topic 606 on January 1, 2018, we recorded a $236.7 million reduction of the unrecognized upfront and non-substantive milestone payments previously received and recorded from our collaboration partners that had been included in deferred revenue at December 31, 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on ex-U.S. net sales of COTELLIC under our collaboration agreement with Genentech were $4.2 million and $7.0 million </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $1.4 million and $3.7 million for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the three months ended June 30, 2018, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">w</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">e determined that we expect an overall profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the year ended December 31, 2018 and have therefore included the profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in Collaboration revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; losses on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;were included in Selling, general and administrative expenses. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty revenues on ex-U.S. net sales of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in royalty revenues for sales in the fourth quarter of 2016 in addition to the royalty revenues for sales in the first half of 2017 as a result of a change in the timing of when we receive sales information from Genentech in the first quarter of 2017. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Following a commercial review, commencing in January 2018 we and Genentech scaled back the personal promotion of COTELLIC as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma in the U.S. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The losses for product supply revenues, net increased to $1.1 million and $2.2 million </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $0.3 million and $0.7 million for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As part of the collaboration agreement with Ipsen, we entered into a supply agreement pursuant to which we supply finished, labeled product to Ipsen at our cost, as defined in the agreement, which excludes the 3% royalty we are required to pay GlaxoSmithKline, or GSK, on Ipsen&#8217;s net sales of any product incorporating cabozantinib. As a result, as royalty generating sales of cabozantinib by Ipsen have increased as described above, our losses on the related product supply agreement have also increased. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The cost of goods sold and our gross margins were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - <br>Year to Date 2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty payable to GSK on net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing the product, write-downs related to expiring and excess inventory, and other third party logistics costs. Portions of the manufacturing costs for inventory were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. Cost of goods sold included a 6% and 3% reduction related to materials that had been previously expensed during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to an 11% and 8% reduction during the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;amounts related to previously expensed materials remaining in our inventory balance as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Write-downs related to excess and expiring inventory were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Cost of goods sold for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to the growth in sales of CABOMETYX, partially offset by the reductions described in the prior paragraph. We do not expect our gross margin to change significantly during the remainder of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total research and development expenses were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of personnel expenses, clinical trial costs, license costs, consulting and outside services, stock-based compensation and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in research and development expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in personnel expenses, license costs, clinical trial costs, stock-based compensation and consulting and outside services. Personnel expenses increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">support our development and discovery efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">License costs increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, f</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily as a result of the collaboration agreements we entered into with&#160;Invenra and StemSynergy. The increase in clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials, was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increase in clinical trial costs was primarily due to start-up </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with CheckMate 9ER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, a phase 3 pivotal trial of cabozantinib plus immunotherapy in patients with previously untreated RCC that is being conducted with BMS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">start-up </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">COSMIC-021, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our phase 1b trial of cabozantinib and atezolizumab in locally advanced or metastatic solid tumors; those increases were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partially offset by decreases in costs related to METEOR, our completed phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC. Stock-based compensation increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount and an increase in the value of grants made in the previous 12 months as a result of the increase in the market price of our stock. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened research and development expenses on a project-by-project basis.&#160;We group our research and development expenses into three categories: development, drug discovery and other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Research and development expenses by category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,048</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">57,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,280</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,243</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Primarily includes personnel expenses, consulting and outside services, laboratory supplies and license costs for our exclusive collaboration and license agreements with&#160;Invenra and StemSynergy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation and the allocation of general corporate costs to research and development. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, the results of and data from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy, which includes the pursuit of commercial collaborations with major pharmaceutical and biotechnology companies for the development of our drug candidates. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development and commercialization efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound, and as a result, we expect our near-term research and development expenses to primarily relate to the clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising over </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ongoing or planned clinical trials across multiple indications. Notable studies of this program include CheckMate 9ER and CheckMate 040, each in collaboration with BMS, as well as COSMIC-021, the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result, we expect our research and development expenses to increase in 2018 as we continue to expand the cabozantinib development program and our product pipeline. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications, and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any of our other research and development projects. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total Selling, general and administrative expenses were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">105,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation, corporate giving, marketing costs, travel and entertainment, facility costs, and legal and accounting costs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Selling, general and administrative expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in corporate giving, personnel expenses, consulting and outside services, stock-based compensation and marketing costs; those increases were partially offset by a decrease in legal and accounting costs. Corporate giving, consisting predominantly of donations to independent patient support foundations, increased $2.3 million and $9.1 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Personnel expenses increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in general and administrative headcount to support our commercial and research and development organizations. Consulting and outside services increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and marketing costs increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in marketing activities, offset by a decrease in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">losses on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC; for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;such losses were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations; during the second quarter of 2018, we determined that we now expect an overall profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the year ended December 31, 2018 and therefore we have included the profit for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in Collaboration revenues for those periods</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Stock-based compensation increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount and an increase in the value of grants made in the previous 12 months as a result of the increase in the market price of our stock. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Legal and accounting costs decreased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to legal costs incurred in 2017 related the resolution of our dispute with Genentech.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Income (Expenses), Net</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other income (expenses), net, were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,913</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expenses), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(12,228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Interest income increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">94%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as a result of both an increase in our investment balances and an increase in the yield earned on those investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in Interest expense during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were due to the June 2017 repayment of our Secured Convertible Notes due 2018, or the Deerfield Notes, and the March 2017 repayment of our term loan with Silicon Valley Bank. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in Other, net during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a $6.2 million loss on extinguishment of debt incurred </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as a result of the prepayment penalty associated with the early repayment of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deerfield Notes in June 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For more information on the repayment of these debt instruments, see &#8220;Note 6. Debt&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Provision for Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes was as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>Q2 2018 v. Q2 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br>2018 v. 2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">378</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2017 primarily relates to state taxes for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset our federal taxable income.</font></div><div><a name="s418B5BE350CC5C7A9E2F8E4FF76AAF34"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$203.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and $154.2 million for the&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the year ended December 31, 2017, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; our share of the net profits and losses for the commercialization of COTELLIC in the U.S. under our collaboration with Genentech; the amount of royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech; other license and contract revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We have limited commercialization experience and expect to continue to spend significant additional amounts to fund the continued development and commercialization of cabozantinib. In addition, we will continue to expand our product pipeline through our drug discovery efforts and the evaluation of in-licensing and acquisition opportunities that align with our oncology drug expertise, which efforts could involve substantial costs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$595.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$594.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;available for operations, as compared to $457.2 million&#160;in cash and investments, which included&#160;$452.0 million&#160;available for operations, as of&#160;December&#160;31, 2017. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report. The sufficiency of our cash resources depends on numerous assumptions, including assumptions related to product sales and operating expenses, as well as the other factors set forth in &#8220;Risk Factors&#8221; under the headings &#8220;Risks Related to our Capital Requirements and Financial Results,&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.&#160;Our assumptions may prove to be wrong or other factors may adversely affect our sources of cash, and as a result we may not have the cash resources to fund our operations as currently planned, which would have a material adverse effect on our business. In addition, we may choose to raise additional funds through the issuance of equity or debt due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current and future operating plans. For example, we may choose to raise additional capital to fund in-licensing or product acquisition opportunities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes our cash flow activities (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,788</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in operating assets and liabilities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(78,562</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">146,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(91,800</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,920</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(172,086</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,697</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(15,974</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our operating activities provided cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$146.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$74.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as depreciation and amortization and share-based compensation charges; and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Results of Operations. The most significant of those timing differences are related to our Collaboration revenues; during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$71.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">related to two </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestones from Ipsen that are included in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade and other receivables, net</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that will be </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">receive</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">d in a future period. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factor that contributed to the increase in cash provided by operating activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$123.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in net product revenues and $30.0 million in milestone payments received from Ipsen and Daiichi Sankyo. This was partially offset by the impact of the upfront nonrefundable payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;received from Takeda in 2017 in consideration for the exclusive license and other rights contained in our collaboration agreement with Takeda along with a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$65.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in operating expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our investing activities used cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$91.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$81.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided during the same period in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily due to investment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$227.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$139.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by investing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was primarily due to cash provided by the maturity of investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the sale of investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$37.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash used for investment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$154.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$172.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;cash used during the same period in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided financing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily a result of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of taxes paid related to net share settlements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in financing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily a result of $185.8 million paid for all amounts outstanding under the Deerfield Notes and our term loan with Silicon Valley Bank.</font></div><div><a name="sC7808F43E3AD52F7BE94D729E86959DD"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Except as follows, there were no material changes outside of the ordinary course of business in our contractual obligations from those as of December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy. We may be required to pay </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in research and development funding. StemSynergy will be eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">May 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we entered into a collaboration and license agreement with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra is eligible to receive payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$131.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;based on the achievement of specific development and regulatory milestones for a product containing the lead preclinical asset in the first indication. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$325.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product. We also have the right to initiate five additional discovery projects for development subject to an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For more information on the collaboration and license agreements with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy and Invenra,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">see &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part I, Item 1 of this Quarterly Report on Form 10-Q</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</font></div><div><a name="s1FA1F7BB7CAC5FF5A706479DF6B00DA1"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and stock-based compensation reflect the more significant estimates and judgments used in the preparation of our Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Except with respect to revenue recognition, there have been no significant changes in our critical accounting policies and estimates during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We adopted Topic 606 on January 1, 2018, resulting in a change to our accounting policy for revenue recognition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revenue Recognition - Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for product supply; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We use key assumptions to determine the standalone selling price, which may include forecast revenues and costs, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. At the end of each subsequent reporting period, we re-evaluate the probability of earning of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. In addition, in recording revenues for our research and development services performance obligation, we use internal development projected cost estimates to determine the amount of revenue to record as we satisfy this performance obligation, known as the inputs method.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues and U.S. profits and losses under the collaboration agreement with Genentech based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical activity, adjusted for any changes in facts and circumstances, as appropriate. We base our estimates on the best information available at the time provided to us by our collaboration partners. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases are generally considered to be changes in estimates and will be reflected in our Condensed Consolidated Statements of Operations in the period they become known.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div><a name="s85597CD03E165DA28A2D68CE5E318259"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our market risks at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;have not changed significantly from those discussed in Item&#160;7A of our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our exposure to market risk for changes in interest rates relates to our investment portfolio. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, an increase in the interest rates of one percentage point would have had a net adverse change in the fair value of interest rate sensitive assets of $2.1 million as compared to $1.6 million as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><a name="sE48516439D265B1287EE5EB4C93864A9"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Controls and Procedures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the effectiveness of controls.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in internal control over financial reporting. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div><a name="s1294CD52B8F65D9C872059043D7DF331"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II. OTHER INFORMATION</font></div><div><a name="sF67D50CC56BC5F5F81A3C1A594A87422"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are not a party to any material legal proceedings. We may from time to time become a party or subject to various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</font></div><div><a name="s98FC474592BD5201926BF422F5E88EDC"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the factors discussed elsewhere in this report and our other reports filed with the SEC, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have marked with an asterisk (*) those risk factors below that reflect substantive changes in risks facing us from the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 29, 2017 filed with the SEC on February 26, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our future prospects are critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our mission is to maximize the clinical and commercial potential of cabozantinib and cobimetinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline. We anticipate that for the foreseeable future our ability to maintain or meaningfully increase unrestricted cash flow to fund our commercial operations and our development and discovery programs is dependent upon the successful commercialization of CABOMETYX for the treatment of advanced RCC in territories where it has been or may soon be approved and in potential other indications for which we are in late-stage development or for which we have sought regulatory review. The commercial opportunity for CABOMETYX as a treatment for advanced RCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of advanced RCC.&#160;If revenue from CABOMETYX decreases or remains flat, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plan, which may have a material adverse effect on our business and financial condition, results of operations and growth prospects. Furthermore, as a consequence of our collaboration agreements with Ipsen and Takeda, we rely heavily upon their regulatory, commercial, medical affairs, market access and other expertise and resources for commercialization of CABOMETYX in territories outside of the U.S. If our collaborators are unable to, or do not invest the resources necessary to successfully commercialize CABOMETYX in the EU and other international territories where it may be approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even following the approval of CABOMETYX for the treatment of advanced RCC in the U.S. and EU, our success remains contingent upon, among other things, successful clinical development, regulatory approval and market acceptance of cabozantinib, the active ingredient in CABOMETYX, in potential additional indications, such as advanced HCC. We cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in clinical testing to receive regulatory approval. Should we prove unsuccessful in advancing the further clinical development and commercialization of cabozantinib beyond its approved indications, we may be unable to execute our business plan and our financial results and condition could be materially adversely affected. Even if we and our partners receive the required regulatory approvals to market cabozantinib for any additional indications or in additional jurisdictions, we and our partners may not be able to effectively commercialize CABOMETYX. Our ability to grow CABOMETYX product sales in future periods is also dependent on price increases, and we periodically increase the price of CABOMETYX. Proposed government regulations, negative publicity regarding drug pricing and price increases generally, whether for CABOMETYX or products distributed by other pharmaceutical companies, could </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negatively affect market acceptance of, and sales of, CABOMETYX. In any event, we cannot assure that price increases we have taken or may take in the future will not negatively affect CABOMETYX sales.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The commercial success of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent to which CABOMETYX gains market acceptance among physicians, patients, government health care payers such as Medicare and Medicaid, commercial health care plans and the medical community. If CABOMETYX does not achieve an adequate level of acceptance, we may not generate significant future product revenues. The degree of market acceptance of CABOMETYX will depend upon a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the effectiveness, or perceived effectiveness, of CABOMETYX in comparison to competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the safety of CABOMETYX, including the existence of serious side effects of CABOMETYX and their severity in comparison to those of competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#8217;s relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">potential unexpected results connected with analysis of data from future or ongoing clinical trials of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of CABOMETYX label expansions for additional indications, if any, relative to competitive treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the price of CABOMETYX relative to competitive therapies and any new government initiatives affecting pharmaceutical pricing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the strength of CABOMETYX sales efforts, marketing, medical affairs and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the sufficiency of commercial and government insurance coverage and adequacy of reimbursement for CABOMETYX; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights with respect to CABOMETYX.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The pharmaceutical, biopharmaceutical and biotechnology industries are competitive, highly diversified and are characterized by rapid technological change, particularly in the area of novel oncology therapies. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage. Further, our competitors may be more effective at using their technologies to develop commercial products. As a result, our competitors may be able to more easily develop technologies and products that would render our technologies and products, and those of our collaborators, obsolete and noncompetitive. There may also be drug candidates that we are not aware of at an earlier stage of development that may compete with our marketed products and product candidates. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Delays in the development of cabozantinib or cobimetinib for the treatment of additional tumor types, for example, could allow our competitors to bring products to market before us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, the advanced RCC indications for which CABOMETYX is approved are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. CABOMETYX in particular may become less marketable if we are unable to successfully adapt our development strategy to address the fact that this recent approach to treating cancer with immune checkpoint inhibitors has and will continue to become more prevalent in indications for which our products are approved, most notably advanced RCC, and in additional indications for which our products are under regulatory review, such as previously treated advanced HCC. Furthermore, the complexities of such a strategy has and may continue to require collaboration with some of our competitors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also may in the future face competition from manufacturers of generic versions of our marketed products. In this regard, in February 2018, the FDA published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active ingredient in CABOMETYX and COMETRIQ. The FDA regularly issues product specific bioequivalence guidance for products following their approval. The February 2018 draft guidance for drug products containing cabozantinib could have been issued by the FDA as a matter of its own standard practice; it could also indicate that a generic drug manufacturer is investigating whether to submit an Abbreviated New Drug Application, or ANDA, for cabozantinib. The ANDA process is discussed in more detail under "Item I. Business</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8212;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Government Regulation</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8212;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Hatch-Waxman Act&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our Annual Report on Form 10-K for the year ended&#160;December&#160;31, 2017&#160;filed with the SEC on&#160;February&#160;26, 2018. Generic competition often results in decreases in the prices at which branded products can be sold.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or scale adequate sales, marketing, market access and distribution capabilities for CABOMETYX or enter into or maintain agreements with third parties to do so, we may be unable to maximize product revenues and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with managing such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial-stage oncology-focused biotech companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded, and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access and product distribution capabilities, we may be unable to maximize the commercial potential of CABOMETYX and COMETRIQ in their approved indications. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly judge the requisite size and experience of the commercialization teams or the scale of distribution necessary to market and sell CABOMETYX successfully. If we are unable to maintain or scale our organization appropriately, we may not be able to maximize product revenues, and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize CABOMETYX and COMETRIQ will depend, in part, on the extent to which we are able to adequately distribute the products to eligible patients. We currently rely on third-party providers to handle storage and distribution for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. Furthermore, we rely on our collaboration partners for the commercialization and distribution of CABOMETYX and COMETRIQ in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs) with the effect of introducing earlier patient access to CABOMETYX and COMETRIQ.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply cabozantinib to the marketplace on a timely and competitive basis. These third parties may not provide services in the time required to meet our commercial timelines and objectives or to meet regulatory requirements. We may not be able to maintain or renew our arrangements with third parties, or enter into new arrangements, on acceptable terms, or at all. Third parties could terminate or decline to renew our arrangements based on their own business priorities. If we are unable to contract for these third-party services related to the distribution of CABOMETYX and COMETRIQ on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper conduct, the laws that may affect our ability to operate include, without limitation:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, or AKS, which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The AKS has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others. Among other things, this statute prohibits persons and entities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. Remuneration is not defined in the AKS and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Federal Food, Drug, and Cosmetic Act, or FDCA, and its regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals) and its foreign equivalents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs, as well as certain state and municipal government price reporting laws that require us to provide justifications where drug prices exceed a certain price increase threshold (and participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and could potentially affect our ability to offer certain marketplace discounts); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state financial and drug pricing transparency laws, which generally require certain types of expenditures in the U.S. to be tracked and reported (and compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships with healthcare providers and healthcare entities, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These federal and state healthcare fraud and abuse laws, FDA rules and regulations, as well as false claims laws, including the civil False Claims Act, govern certain marketing practices, including off-label promotion. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. Such individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially then share in amounts paid by the entity to the government in fines or settlement. The filing of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend civil False Claims Act actions. When an entity is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, that govern the collection, use and disclosure of personal information. In addition, most healthcare providers who are expected to prescribe our products, and from whom we obtain patient health information, are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU Data Privacy Directive (95/46/EC) and implementing legislation in the various national Member States of the EU was replaced on May 25, 2018 by the more restrictive General Data Protection Regulation (Regulation (EU) 2016/679), or GDPR, and the Swiss Federal Act on Data Protection, which now regulate the processing of personal data within the EU and between countries in the EU and countries outside of the EU, including the U.S. In connection with these new laws, we have modified certain of our policies and procedures with respect to the processing of personal data to the extent necessary given our operations and commensurate with similar companies in our industry, and we will continue to review all future privacy and other regulations implemented pursuant to these new laws to assess whether additional procedural safeguards are warranted. Failure to provide adequate privacy protections and maintain compliance with these laws and regulations could jeopardize business transactions across borders, create liability for us, including the imposition of sanctions or other penalties, and/or could increase our cost of doing business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain both sufficient coverage and adequate reimbursement from third-party payers for CABOMETYX or COMETRIQ, our revenues and prospects for profitability will suffer.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize CABOMETYX or COMETRIQ successfully is highly dependent on the extent to which coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Patients may not be capable of paying for CABOMETYX or COMETRIQ themselves and may rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and prospects for profitability will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ. Third-party payers continue to scrutinize and manage the prices charged for pharmaceutical products and services, and many also limit reimbursement for newly-approved products and indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may affect our ability to sell CABOMETYX and COMETRIQ profitably.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell CABOMETYX and COMETRIQ profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since its enactment, there have been judicial and Congressional challenges to numerous provisions of the&#160;Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as well as recent efforts by the Trump administration and Congress to repeal or replace certain aspects of the PPACA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since January 2017, President Trump has signed two Executive Orders as well as other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the PPACA have been enacted. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on January 23, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain PPACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018 among other things, amends the PPACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; It is expected that Congress will continue to consider legislation to repeal and replace other elements of the PPACA. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, certain politicians, including the President, have announced plans to regulate the prices of pharmaceutical products. On May 11, 2018, President Trump&#8217;s administration released a &#8220;Blueprint&#8221; describing strategies for reducing drug prices and patient out-of-pocket costs. The Blueprint describes four "challenges" in the U</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">S</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;drug market: (i) "high list prices for drugs"; (ii) "seniors and government programs overpaying for drugs due to lack of the latest negotiation tools"; (iii) "high and rising out-of-pocket costs for consumers"; and (iv) "foreign governments free-riding off of American investments in innovation." The Blueprint describes two "phases" for addressing these challenges: (i) "actions the President may direct [the U.S. Department of Health and Human Services, or HHS,] to take immediately" and "actions HHS is actively considering, on which feedback is being solicited</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">." While the Blueprint provides broad proposals for reform, we cannot know what form these proposals may take,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;when and if they are finalized. Congress has also signaled an intent to address pharmaceutical pricing, with Senate hearings to examine the cost of prescription drugs, which were held on June 13, October 17 and December 12, 2017. Federal legislators previously proposed legislation that would require pharmaceutical manufacturers to report price increases and provide a public justification for increases that exceed given benchmarks and authorize HHS to negotiate the price of Part D prescription drugs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing, including the National Medicaid Pooling Initiative. We cannot know what form any such measures may take or the market&#8217;s perception of how such proposals and provisions would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may limit our ability to generate revenue or commercialize our current products and/or those for which we may receive regulatory approval in the future.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which will reauthorize the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which manufacturers of such products partially pay for the FDA&#8217;s pre-market review of their product candidates. The legislation includes, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; health care costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In January 2018, the FDA took steps to implement the Drug Competition Action Plan, among other steps, and released guidance to streamline aspects of the submission and review of ANDAs for generic drugs, as well as generics&#8217; participation in shared Risk Evaluation and Mitigation strategies. We cannot currently predict the specific outcome or impact on our business of such regulatory actions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the U.S., third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. These entities could refuse or limit coverage for CABOMETYX and COMETRIQ, such as by using tiered reimbursement, which would adversely affect demand for CABOMETYX and COMETRIQ. They may also refuse to provide coverage for uses of CABOMETYX and COMETRIQ for medical indications other than those for which the FDA has granted market approval. As a result, significant uncertainty exists as to whether and how much third-party payers will cover newly approved drugs, which in turn will put pressure on the pricing of drugs. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, third-party payer or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on our revenues and profitability.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many companies in our industry have received a governmental request for documents and information relating to drug pricing and patient support programs. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, such findings could further harm our business, reputation and/or prospects. It is possible that such inquiries could result in: negative publicity or other negative actions that could harm our reputation; changes in our product pricing and distribution strategies; reduced demand for our approved products; and/or reduced reimbursement of approved products, including by federal health care programs such as Medicare and Medicaid and state health care programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, reform government program reimbursement methodologies for drugs, and facilitate value-based arrangements between manufacturers and payers. For example, the Trump Administration&#8217;s budget proposal for fiscal year 2019 contains drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, both Congress and the Trump Administration have indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">State and local governments continue to consider prescription drug pricing transparency proposals. For example, in October 2017, California Governor Jerry Brown signed legislation requiring pharmaceutical manufacturers to disclose and provide justification for certain price increases; however, the regulations under which we will be required to operate have not yet been promulgated, and the legislation is currently being challenged in court. While we have taken and will continue to take appropriate actions to ensure compliance with this new law, without knowing the final regulations applicable to us or the outcome of the court case, we cannot comprehensively assess the potential impact on our business. Additionally, in March 2018, Oregon Governor Kate Brown signed legislation requiring manufacturers to report an increase in the wholesale acquisition cost of a drug if the wholesale acquisition cost is $100 or more for a one-month supply, or for a course of treatment lasting less than one month and there is a net increase of 10 percent or more in the wholesale acquisition cost of the drug over the course of the previous calendar year. We cannot predict the outcome of any future proposals, the market&#8217;s perception of them or their potential impact on us. If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in some foreign countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control under the respective national health system. In these countries, price negotiations with governmental authorities or payers can take six to twelve months or longer after marketing authorization is granted for a product, which has the potential to substantially delay broad availability of the product in some of those countries. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner, Ipsen, may be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies to support health technology appraisal. The conduct of such a study could result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives could decrease the price we and our collaboration partner, Ipsen, might establish for CABOMETYX, which would result in lower license revenues to us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are heavily dependent on our partner, Genentech, for the successful development, regulatory approval and commercialization of cobimetinib, marketed as COTELLIC.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The terms of our collaboration agreement with Genentech provide Genentech with exclusive authority over the global development and commercialization plans for cobimetinib and the execution of those plans. We have limited effective influence over those plans and are heavily dependent on Genentech&#8217;s decision making. Any significant changes to Genentech&#8217;s business strategy and priorities, over which we have no control, could adversely affect Genentech&#8217;s willingness or ability to complete their obligations under our collaboration agreement and result in harm to our business and operations.&#160;Subject to contractual diligence obligations, Genentech has complete control over and financial responsibility for cobimetinib&#8217;s development program, as well as over regulatory and commercial strategy and execution, and we are not able to control the amount or timing of resources that Genentech will devote to the product.&#160;Of particular significance are </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Genentech&#8217;s development efforts with respect to the combination of cobimetinib with immune checkpoint inhibitors, a competitive area of clinical research. Regardless of Genentech&#8217;s efforts and expenditures for the further development of cobimetinib, the results of such additional clinical investigation may not prove positive and may not produce label expansions or approval in additional indications, which could have a material adverse impact on our long-term revenue prospects. For instance, we announced in May 2018 that IMblaze370, Genentech&#8217;s phase 3 pivotal trial evaluating the combination of cobimetinib and atezolizumab versus regorafenib, in unresectable locally advanced or metastatic CRC patients who have received at least two lines of prior cytotoxic chemotherapy, did not meet its primary endpoint; should Genentech obtain negative or inconclusive results in either of the other two phase 3 pivotal trials evaluating cobimetinib in combination with other therapies, cobimetinib&#8217;s prospects, and its ability to contribute meaningfully to our business, will be substantially impaired.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. In this regard, in February 2018, the FDA published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active ingredient in CABOMETYX and COMETRIQ. The FDA regularly issues product specific bioequivalence guidance for products following their approval. The February 2018 draft guidance for drug products containing cabozantinib could have been issued by the FDA as a matter of its own standard practice; it could also indicate that a generic drug manufacturer is investigating whether to submit an ANDA for cabozantinib. The FDA can also approve a 505(b)(2) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">New Drug Application, or NDA, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that relies on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. In either case, we will have to engage in litigation with a potential generic competitor to protect our patent rights, which would require us to incur significant expense and result in distraction for our management team, and could also have an adverse impact on our stock price. Moreover, if any such ANDAs or 505(b)(2) NDAs were to be approved, and if our patents covering cabozantinib were held to be invalid (or if any such competing generic versions of cabozantinib were found not to infringe our patents), the resulting generic competition would negatively affect our business, financial condition and results of operations. In this regard, generic equivalents, which must meet the same quality standards as the branded drugs, would be significantly less costly than ours to bring to market. Companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, regardless of the regulatory approval pathway, the introduction of a generic version of any of our marketed products could result in a significant decrease in the sales of these marketed products and materially harm our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of cabozantinib for new indications, or of new potential product candidates is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that  cabozantinib, despite its approval for certain indications, or a new potential product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval in a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and later stage clinical trials may fail to confirm the results observed in earlier stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of cabozantinib in new indications</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or of our other product candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of efficacy or an effective safety profile;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results may require us to conduct further testing or to abandon projects that we had expected to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patient registration or enrollment in our clinical testing may be lower than we anticipate, resulting in the delay or cancellation of clinical testing; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaborators to provide us on a timely basis with an adequate supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organization or investigators to satisfy their contractual obligations, including deviating from trial protocol; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulators or institutional review boards may withhold authorization to commence or conduct clinical trials of cabozantinib or another product candidate, or delay, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their determination that participating patients are being exposed to unacceptable health risks.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we were to have significant delays in or termination of the clinical testing of cabozantinib or our other product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our clinical and commercial collaboration partners to fund a significant portion of the clinical development of cabozantinib and our product candidates. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for the financial obligations associated with the further development of cabozantinib or our other product candidates, and as a result, we may be unable to execute our business plan, and our financial results could be materially adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to rapidly or effectively continue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions, including those identified based on our discussions with the FDA or such other regulatory authorities. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">characteristics of the product candidate under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of patients who ultimately participate in the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of clinical sites included in the trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the length of time required to enroll suitable patient subjects.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain, and may not result in regulatory approvals for cabozantinib or our other product candidates, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. We have only limited experience in preparing and submitting the applications necessary to gain regulatory approvals. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the European Medicines Agency or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual, additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more indications beyond advanced RCC and MTC, or one of our other product candidates, the approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, advertising, promotion, marketing and/or production of the product and could impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. For example, in connection with the FDA&#8217;s approval of COMETRIQ for the treatment of progressive, metastatic MTC, we are subject to a post-marketing requirement to conduct a clinical study comparing a lower dose of cabozantinib to the approved dose of 140 mg daily cabozantinib in progressive, metastatic MTC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or eliminate the commercialization of cabozantinib. Further, these agencies may also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we are pursuing internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including where the research methodology used may not be successful in identifying potential product candidates, or where potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profile or other characteristics suggesting that they are unlikely to be effective products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive.&#160;Established companies, in particular, may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160; We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to develop suitable product candidates through internal discovery effort or if we are unable to successfully obtain rights to suitable product candidates, our business, financial condition and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we do not intend to disclose material, nonpublic information through these means.  Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or inadvertent disclosure of material, nonpublic information through these means, may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements and Financial Results</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to maintain or increase profitability.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$203.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and $154.2 million for the&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the year ended December 31, 2017, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; our share of the net profits and losses for the commercialization of COTELLIC in the U.S. under our collaboration with Genentech; the amount of royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech; other collaboration revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We expect to continue to spend significant additional amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we will continue to expand our product pipeline through our drug discovery efforts and the evaluation and execution of potential additional in-licensing and acquisition opportunities that align with our oncology drug development expertise, which efforts could involve substantial costs. To offset these costs, we will need to generate substantial revenues. If these costs exceed our expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be forced to limit the expansion of our product development programs or commercialization efforts.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$595.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$594.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;available for operations, as compared to $457.2 million&#160;in cash and investments, which included&#160;$452.0 million&#160;available for operations, as of&#160;December&#160;31, 2017. Our business operations grew substantially during 2017 and experienced further expansion during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. In order to maintain business growth and maximize the clinical and commercial opportunities for cabozantinib, we plan to continue to execute on the U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib, both alone and in combination with other therapies, research and development activities, as well as through in-licensing and acquisition efforts. Our ability to execute on these business objectives will depend on many factors including but not limited to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, medical affairs and distribution capabilities for CABOMETYX and COMETRIQ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones under our collaboration agreements with Ipsen and Takeda; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of COTELLIC and the revenues generated through our share of related profits and losses for the commercialization of COTELLIC in the U.S. and royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the potential regulatory approval of cabozantinib as a treatment for patients with previously treated advanced HCC, and in other indications, both in the U.S. and abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and corporate development activities;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to control costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the cost of clinical drug supply for our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib, increasing drug discovery activities as well as through in-licensing and acquisition efforts, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations, licensing arrangements, and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets.&#160;Economic conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160; Accordingly, we do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to limit the expansion of our product development programs or commercialization efforts, which could have a material adverse effect on our business and growth prospects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. The preparation of our financial statements requires us to make significant estimates, assumptions and judgments that affect the amounts of assets, liabilities, revenues and expenses and related disclosures. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and stock-based compensation reflect the more significant estimates and judgments used in the preparation of our Condensed Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations, particularly those relating to the way we account for revenues and costs. New pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses our ability to maintain profitability or our current financial position. For example, on January 1, 2018, we adopted Topic 606 which has replaced prior revenue recognition guidance in U.S. generally accepted accounting principles when it became effective for us in the first quarter of fiscal year 2018. For a detailed description of the impact that Topic 606 has had and other new accounting standards could have on our reported results, see &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item I of this Quarterly Report on Form 10-Q. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subjects us to a number of risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading pharmaceutical and biotechnology companies, including, Ipsen, Takeda, Genentech, Daiichi Sankyo, Merck, BMS and Sanofi for the development and ultimate commercialization of certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">compounds generated from our research and development efforts. Our dependence on our relationships with collaborators for the development and commercialization of compounds subjects us to, a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we are not able to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we are not able to control the U.S. commercial resourcing decisions made and resulting costs incurred by Genentech for cobimetinib, which costs we are obligated to share, in part, under our collaboration agreement with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial, deliver product that results in a market recall or withdrawal, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may experience financial difficulties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may not be successful in their efforts to obtain regulatory approvals in a timely manner, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may not comply with applicable healthcare regulatory laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we may be precluded from entering into additional collaboration arrangements with other parties in an area or field of exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of development of our drug candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, our product development efforts could be delayed and our business, operating results and financial condition could be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib for the treatment of additional indications beyond advanced RCC and MTC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib independently, including our post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond its approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our drug discovery efforts, which would impede our ability to identify, develop and commercialize our product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce cabozantinib for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing or distribution facilities for clinical or commercial production and distribution of CABOMETYX and COMETRIQ. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. We expect that this will continue for the foreseeable future for both our current and future commercial products. To establish and manage this supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to ensure compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations. Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude our ability to meet our commercial supply requirements, or our supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and our business, operating results and financial condition could be adversely affected. As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the manufacturing and supply of cabozantinib products for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our collaborators&#8217; ability to successfully develop and commercialize cabozantinib and generate revenues to which we are entitled under the collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our collaborations with outside scientific advisors and collaborators may be subject to restriction and change.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts. These advisors and collaborators are not our employees and may have other commitments that limit their availability to us. Although these advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. In such a circumstance, we may lose work performed by them, and our development efforts with respect to the matters on which they were working may be significantly delayed or otherwise adversely affected. In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches, cyber-attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners. We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cyber-security efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we have </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks continue to become more prevalent and much harder to detect and defend against. Our network and storage applications and those of our contract manufacturing organizations, contract research organizations or vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees and others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cyber-security systems at the level necessary to prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, should any third parties receive FDA approval of an ANDA for a generic version of cabozantinib or an 505(b)(2) NDA with respect to cabozantinib, and if our patents covering cabozantinib were held to be invalid (or if such competing generic versions of cabozantinib were found to not infringe our patents), then they could introduce generic versions of cabozantinib or other such 505(b)(2) products before our patents expire, and the resulting generic competition would negatively affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical personnel, in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain product candidates, which could severely harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have moved our headquarters and may face disruption and turnover of employees.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the second quarter of 2018, we moved our corporate headquarters from South San Francisco, California to Alameda, California. As a result, we have incurred and expect to continue to incur additional expenses, including those related to tenant improvements, furniture and equipment for the new corporate headquarters, as well as moving and exit costs, and may encounter disruption of operations related to the move, all of which could have an adverse effect on our financial condition and results of operations. In addition, relocation of our corporate headquarters may make it more difficult to retain certain employees, and any resulting loss of talent and need to recruit and train new employees could be disruptive to our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. In addition, the physical expansion of our operations and change of location of our corporate headquarters may lead to significant costs and may divert our management and capital resources. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plan. Retaining and, where necessary, recruiting qualified clinical, commercial and scientific personnel will be critical to support activities related to advancing the development program for cabozantinib and our other compounds, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial and scientific personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our headquarters are located near known earthquake fault zones, and the occurrence of an earthquake or other disaster could damage our facilities and equipment, which could harm our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current headquarters in Alameda is located in the San Francisco Bay Area, California and, therefore our facilities are vulnerable to damage from earthquakes. We have limited earthquake insurance, which may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events since any insurance we may maintain may not be adequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired. In addition, the unique nature of our research activities could cause significant delays in our programs and make it difficult for us to recover from a disaster. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability and have a material adverse impact on our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">insurance coverage and our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, any hazardous materials used by these parties. Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaborators develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical, biopharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline, causing investor losses.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">customer ordering patterns for CABOMETYX and COMETRIQ, which may vary significantly from period to period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the overall level of demand for CABOMETYX and COMETRIQ, including the impact of any competitive products and the duration of therapy for patients receiving CABOMETYX or COMETRIQ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of COTELLIC and the revenues generated through our share of related profits and losses for the commercialization of COTELLIC in the U.S. and royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in the amount of deductions from gross sales, including changes to the discount percentage of rebates and chargebacks mandated by the government programs in which we participate, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government rebates and chargebacks and changes in patient demographics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our sales, marketing, medical affairs and distribution capabilities for CABOMETYX, COMETRIQ and COTELLIC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to obtain regulatory approval for cabozantinib as a treatment for patients with previously treated advanced HCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones, under our collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the progress and scope of other development and commercialization activities for cabozantinib and our other compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and business development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognition of upfront licensing or other fees or revenues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the introduction of new technologies or products by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and willingness of collaborators to further develop or, if approved, commercialize our product candidates out-licensed to them;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the termination or non-renewal of existing collaborations or third-party vendor relationships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adjustments to expenses accrued in prior periods based on management&#8217;s estimates after the actual level of activity relating to such expenses becomes more certain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general and industry-specific economic conditions that may affect our or our collaborators&#8217; research and development expenditures; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">other factors described in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance. As a result, in some future quarters, our operating results may not meet the expectations of securities analysts and investors, which could result in a decline in the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse or inconclusive results or announcements in our or our collaborators&#8217; clinical trials or delays in those clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaborators&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for cabozantinib or any of our other programs or compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates at earlier stages of clinical development or with lesser developed data sets and the speed with which the FDA is conducting regulatory reviews;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products by our competitors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications seeking a path to U.S. approval of generic versions of our marketed products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in our relationships with our collaborators, including the termination or modification of our agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">conflicts or litigation with our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure to achieve operating results projected by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">departures of key personnel or board members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">extent to which coverage and reimbursement is available for both CABOMETYX and COMETRIQ from government and health administration authorities, private health insurers, managed care programs and other third-party payers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disposition of any of our technologies or compounds; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of the United Kingdom&#8217;s pending withdrawal from the EU and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and health care spending and delivery, including the repeal of the individual mandate and the potential repeal and/or replacement of other portions or all of the PPACA, or greater restrictions on free trade stemming from Trump Administration policies, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Future sales of our common stock or the perception that such sales or conversions may occur, may depress our stock price.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A substantial number of shares of our common stock are reserved for issuance upon the exercise of stock options, upon vesting of restricted stock unit awards and upon a purchase under our employee stock purchase plan. The issuance and sale of substantial amounts of our common stock or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or equity-related securities in the future at a time and price that we deem appropriate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a classified Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability of our stockholders to call special meetings of stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">limitations on the removal of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017 that significantly reforms the Internal Revenue Code of 1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction of future net operating losses to 80% of current year taxable income and elimination of net operating loss carry-backs, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new capital investments instead of deductions for depreciation expense over time, and modifying, reducing or repealing many business deductions and credits (including reducing the business tax credit for certain clinical trial expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Cuts and Jobs Act is uncertain and our business and financial condition could be adversely affected. The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2017 and June 30, 2018, or are expected to be recorded in future periods. Additionally, further guidance may be forthcoming from the FASB and SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including the passage of the Tax Cuts and Jobs Act, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, our utilization of federal and state net operating losses, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2017, we had federal and state net operating loss carry-forwards of approximately $1.5 billion. The federal and state net operating loss carry-forwards will begin to expire, if not utilized, beginning in 2024 for federal income tax purposes and 2028 for California state income tax purposes. These net operating loss carry-forwards could expire unused and be unavailable to offset future income tax liabilities. While the Tax Cuts and Jobs Act allows for federal </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">net operating losses incurred in 2018 and in future years to be carried forward indefinitely, the deductibility of such federal net operating losses incurred in 2018 and in future years will be limited.&#160; In addition, under the Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carry-forwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carry-forwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2017, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses other than the net operating losses expected to be utilized to offset income in 2017, is conditioned upon our maintaining profitability and generating U.S. federal taxable income. We do not know whether or when we will generate the U.S. federal taxable income necessary to utilize our remaining net operating losses. A full valuation allowance has been provided for the entire amount of our remaining net operating losses.</font></div><div><a name="s08086493D366578F806544257746B56B"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sF50EB0BE00E0576BB81598E4E7576C2A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sE04F156653115687ADE1A06D2F88E4B5"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sDD10C818272F55A78CB0A8173AE99E51"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Other Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s63FCFF3A2C52584B9988DF0CA3FBC623"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Exhibits</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5/25/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511330584/d265434dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12/5/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specimen Common Stock Certificate</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">S-1,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">333-96335</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4/7/2000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20180630exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20180630exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment to Lease Agreement dated June 13, 2018 to Lease Agreement dated May 2, 2017 between Ascentris 105, LLC and Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20180630exhibit121.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Statement Re Computation of Earnings to Fixed Charges</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20180630exhibit311.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20180630exhibit312.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32.1&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20180630exhibit321.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Labels Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Confidential treatment requested for certain portions of this exhibit.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8225;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><a name="s885F2531770953CF99716ABF0114C1F1"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:678px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s632E86CCC7D958D1B21AB0D1BC79F458"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</font></a><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">E</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">I</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">NC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">August&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief&#160;Financial&#160;Officer </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">(Duly Authorized Officer and Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">62</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel20180630exhibit101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8C381C3BE91526C323A0F1D4D57A0EE6"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:13pt;"><font style="font-family:Calibri,sans-serif;font-size:13pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIRST</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is entered into as of March 22, 2018 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Collaborator</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Exelixis and Collaborator may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#2e2e2e;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Collaborator are parties to the Collaboration and License Agreement dated January 30, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib in Japan; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parties desire to enter into this Amendment to modify certain milestone payments payable under the License Agreement on the terms and conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following section shall be added as Section 1.83 of the License Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;1.83&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Investigator-Initiated Clinical Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Clinical Trial for the Product (a) which is sponsored and conducted by a Third Party independent investigator or institution in accordance with Applicable Laws and is not sponsored by Collaborator or its Affiliate; and (b) for which Collaborator or its Affiliate provides funding and/or Product supply, but does not receive any payments or other compensation from such investigator or institution in association with such Clinical Trial (except that Collaborator or its Affiliate shall be permitted to receive information and data generated from the performance of such Clinical Trial). &#8221; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 1.79 of the License Agreement is hereby deleted in its entirety and replaced with the following: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;1.79&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tier 2 Indication</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means [*].&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;The following section shall be added as Section 1.84 of the License Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:46px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;1.84&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tier 3 Indication</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means [*]. &#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise defined in this Amendment, all capitalized terms have the meaning as defined in the License Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;FINANCIAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 8.3(a) of the License Agreement is hereby deleted in its entirety and replaced with the following: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.3(a)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Development Milestones</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the remainder of this Section </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.3(a)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Collaborator shall pay to Exelixis the non-refundable, non-creditable payment set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Collaborator, Exelixis, or their Affiliates, licensee(s) of Exelixis, or Sublicensees):</font></div><div style="line-height:120%;font-size:13pt;"><font style="font-family:Calibri,sans-serif;font-size:13pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.64285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:18%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:10%;"></td><td style="width:10%;"></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Milestone Event</font></div></td><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">&#160;<br>Milestone Payments</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">For HCC  <br>(2</font><font style="font-family:Calibri,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;line)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">For RCC  <br>(2</font><font style="font-family:Calibri,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;line)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">For RCC  <br>(1</font><font style="font-family:Calibri,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;line) as a combination therapy (including, for clarity, the Takeda 9ER Trial Opt-In)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">For RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;line) as a single agent </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Tier 1 Indications</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Tier 2 Indications</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Tier 3 Indications: Clinical Trial sponsored by Collaborator or its Affiliate</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Tier 3 Indications: Investigator-Initiated Clinical Trial</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Milestone #1: Upon [*] the first Phase 3 Clinical Trial for the Product in Collaborator Territory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Milestone #2: Upon [*] the first MAA for the Product in Collaborator Territory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Milestone #3: Upon First Commercial Sale for the Product in the relevant indication in Collaborator Territory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">[*]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For HCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line), RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line), RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) as a combination therapy, and RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) as a single agent, each milestone payment shall be paid only once for the first achievement of the applicable event described above for each different applicable Product.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestone #1 shall be deemed achieved and payable, if not already achieved, upon achievement of any of Milestone #2 and/or Milestone #3 for the same indication.  Milestone #2 shall be deemed achieved and payable, if not already achieved, upon achievement of Milestone #3 for the same indication.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Without limiting the foregoing, with respect to RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) and RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line), if Milestone #3 is achieved for RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) prior to being achieved for RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line), then Milestone #3 for RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) shall be deemed achieved and payable upon achievement of Milestone #3 for RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line), except if Collaborator is, at the time of such achievement, diligently engaged in the performance of Development or regulatory activities with respect to Products for the express purpose of achieving Milestone #3 for both RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) and RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line), in which case Milestone #3 for RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line) shall not be deemed achieved and payable unless and until achieved by a Product for RCC (2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;line).&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The License Agreement as modified by this Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;Severability.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;Counterparts; Electronic or Facsimile Signatures.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;{SIGNATURE PAGE FOLLOWS}</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties hereto have caused this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="padding-bottom:16px;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br></font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  /s/ Michael M. Morrissey</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Michael M. Morrissey, Ph.D.</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  President and Chief Executive Officer</font></div></td><td style="vertical-align:top;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="padding-bottom:16px;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TAKEDA PHARMACEUTICAL COMPANY LIMITED</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  /s/ Tsudoi Miyoshi</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Tsudoi Miyoshi</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  Head of Japan Oncology Business Unit</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exel20180630exhibit102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s525C0EAA79B9B41F6DDBCD3E3E2C744D"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECOND AMENDMENT TO LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">THIS SECOND AMENDMENT TO LEASE AGREEMENT (this &#8220;Second Amendment&#8221;) effective as of June&#160;13, 2018 (the &#8220;Second Amendment Effective Date&#8221;), is made and entered into by and between ASCENTRIS 105, LLC, a Colorado limited liability company (&#8220;Landlord&#8221;), and EXELIXIS, INC., a Delaware corporation (&#8220;Tenant&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A.&#160;&#160;&#160;&#160;Landlord and Tenant are parties to (i)&#160;that certain Lease Agreement dated May&#160;2, 2017 (the &#8220;Original Lease&#8221;) for premises consisting of approximately 110,783 square feet of Rentable Area (the &#8220;Original Premises&#8221;) in the multiple building project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California (as further defined in the Original Lease, the &#8220;Project&#8221;), and (ii)&#160;that certain Agreement for Conditional Option to Amend Lease dated as of May&#160;2, 2017 (the &#8220;Additional 1801 Space Option Agreement&#8221;), pursuant to which Tenant has the right to add Suite&#160;125 consisting of approximately 17,075 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached to the First Amendment (as defined below) (the &#8220;Additional 1801 Space&#8221;) on the first floor of the 1801 Building (as defined in the Original Lease) to the Premises, by amending the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B.&#160;&#160;&#160;&#160;Landlord and Tenant are parties to that certain First Amendment to Lease Agreement dated October&#160;16, 2017 (the &#8220;First Amendment&#8221;), pursuant to which the Original Premises was expanded to include the Additional 1801 Space and the premises known as Suite&#160;115 consisting of 2,703 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A&#8209;2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached to the First Amendment (the &#8220;Additional 1751 Space&#8221;) on the first floor of the 1751 Building (as defined in the Original Lease).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">C.&#160;&#160;&#160;&#160;The Original Premises, as expanded by the Additional 1801 Space and the Additional 1751 Space, is hereby referred to as the &#8220;Existing Premises.&#8221;  The Original Lease, as amended by the First Amendment, is hereby referred to as the &#8220;Lease.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">D.&#160;&#160;&#160;&#160;Tenant desires to expand the Existing Premises to include the premises known as Suite&#160;150 consisting of 4,204 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A&#8209;3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto (the &#8220;Second Amendment Expansion 1751 Space&#8221;) on the first floor of the 1751 Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">E.&#160;&#160;&#160;&#160;Landlord and Tenant hereby amend the Lease to: (i)&#160;further expand the Premises under the Lease to include the Second Amendment Expansion 1751 Space; (ii)&#160;modify the definition and Rentable Area of the 1751 Space and the Premises; (iii)&#160;modify the Base Rent; (iv)&#160;modify the 1751 Building Share and the 1751 Project Share; (v)&#160;provide for 61&#160;additional parking spaces; (vi)&#160;provide for Tenant&#8217;s performance of the HVAC work in the 1801 Building; (vii)&#160;provide for the roof replacements of the 1801 Building and the 1851 Building; (viii)&#160;provide for sustainability provisions; (ix)&#160;modify the Work Letter provisions; and (x)&#160;make certain other modifications to the Lease as more particularly set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">NOW THEREFORE, in consideration of the mutual agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties do hereby agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Defined Terms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All capitalized terms used but not defined in this Second Amendment will have the meanings set forth for such terms in the Lease.  All terms that are defined in this Second Amendment and used in any provisions that are added to the Lease pursuant to this Second Amendment will have the meanings in the Lease set forth for such terms in this Second Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Delivery and Demise of the Second Amendment Expansion 1751 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms, covenants, conditions and provisions of the Lease, as amended by this Second Amendment, Landlord leases to Tenant and Tenant leases from Landlord the Second Amendment Expansion 1751 Space for the remainder of the Term commencing on the date that Landlord Delivers the Second Amendment Expansion 1751 Space to Tenant (the &#8220;Second Amendment Expansion 1751 Space Start Date&#8221;).  Landlord represents that (i)&#160;the Second Amendment Expansion 1751 Space is currently occupied by a tenant pursuant to a lease (the &#8220;Current 1751 Space Lease&#8221;) that is set to expire on June&#160;30, 2018, (ii)&#160;the Current 1751 Space Lease has no right to renew or extend the term of the Current 1751 Space Lease, and (iii)&#160;the tenant under the Current 1751 Space Lease has not communicated with Landlord its intent to hold over its tenancy of the Second Amendment Expansion 1751 Space.  Landlord will use commercially reasonable efforts to Deliver the Second Amendment Expansion 1751 Space within 15 days following the date that the tenant under the Current 1751 Space Lease vacates the Second Amendment Expansion 1751 Space.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Effective Date, Section&#160;1.1(d)(i) of the Lease is hereby amended by the addition of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;As of the Second Amendment Expansion 1751 Space Start Date (as defined in the Second Amendment to Lease Agreement by and between Landlord and Tenant (the &#8220;Second Amendment&#8221;)), the Premises will also include the Second Amendment Expansion 1751 Space (Suite 150 located on the first floor of the 1751 Building and identified on Exhibit&#160;A-3 to the Second Amendment).  Upon the Second Amendment Expansion 1751 Space Start Date, the &#8220;1751 Space&#8221; will include the Second Amendment Expansion 1751 Space and consist of approximately 18,872 square feet of Rentable Area, which shall not be subject to re&#8209;measurement except as set forth in Section 2.6 below;&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rentable Area of the Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The first sentence of the last paragraph of Section&#160;1.1(d) of the Lease is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The Premises contains a total of: (i)&#160;effective as of the First Amendment Effective Date, 101,521 square feet of Rentable Area (plus 11,965 square feet of Rentable Area making up the Temporary Premises), (ii)&#160;effective as of the Commencement Date, 113,486 square feet of Rentable Area, (iii)&#160;effective as of the Additional 1801 Start Date, 130,561 square feet of Rentable Area, and (iv)&#160;effective as of the Second Amendment Expansion 1751 Space Start Date, 134,765 square feet of Rentable Area.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Effective as of the Second Amendment Effective Date, the Rentable Area table set forth in Exhibit&#160;A of the Lease is hereby replaced with the Rentable Area table attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of this Second Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Exhibits</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Effective Date, Exhibit&#160;A-3 attached to the First Amendment is hereby replaced by the updated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Base Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Effective Date, Section&#160;1.1(i) of the Lease is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(i)&#160;&#160;&#160;&#160;&#8220;Base Rent&#8221; means the Rent payable according to Section&#160;3.1, which will be in an amount per month or portion thereof commencing on the Commencement Date and throughout the Term as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:54px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.56349206349206%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Period</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Monthly Rental Rate / SF of Rentable Area</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Base Rent Payable Per Month</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2018 &#8211; February&#160;18, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$187,251.90*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;19, 2018 &#8211; Day before Second Amendment Expansion 1751 Space Start Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$215,425.65*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment Expansion 1751 Space Start Date &#8211; January&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$222,362.25*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2019 &#8211; January&#160;31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$229,100.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2020 &#8211; January&#160;31, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$235,838.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2021 &#8211; January&#160;31, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$242,577.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2022 &#8211; January&#160;31, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$250,662.90</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2023 &#8211; January&#160;31, 2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$257,401.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2024 &#8211; January&#160;31, 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$265,487.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2025 &#8211; January&#160;31, 2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$273,572.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2026 &#8211; January&#160;31, 2027</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$281,658.85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2027 &#8211; January&#160;31, 2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$289,744.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">* </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Rent Abatement.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Base Rent will be partially abated in the amount of $88,251.90 per month (the &#8220;Initial Rent Abatement&#8221;) for the period beginning on the Commencement Date and ending on January 31, 2019 (the &#8220;Initial Rent Abatement Period&#8221;).  In addition, Base Rent will be further abated in the amount of $28,173.75 per month (the &#8220;Additional 1801 Space Rent Abatement&#8221;) beginning on the Additional 1801 Space Start Date and ending on the earlier of (A) four months after the Additional 1801 Space Start Date, and (B) Tenant&#8217;s occupancy of the Additional 1801 Space for the conduct of business (such date, the &#8220;Additional 1801 Space Completion Date&#8221; and such period the &#8220;Additional 1801 Rent Abatement Period&#8221;).  However, if Landlord terminates this Lease as a result of a &#8220;Default&#8221; (as defined in Section 20.1) at any time during the Term, in addition to all other remedies available to Landlord, the unamortized portion of the Initial Rent Abatement and the Additional 1801 Space Rent Abatement will automatically become immediately due and payable.  At any time during or before the Initial Rent Abatement Period or the Additional 1801 Rent Abatement Period, upon notice to Tenant, Landlord shall have the right to purchase any Initial Rent Abatement and/or Additional 1801 Rent Abatement relating to the remaining Initial Rent Abatement Period and/or Additional 1801 Rent Abatement Period, as applicable, by paying to Tenant an amount equal to the &#8220;Rent Abatement Purchase Price&#8221; (as defined below).  As used herein, &#8220;Rent Abatement Purchase Price&#8221; shall mean the aggregate amount of the Initial Rent Abatement and the Additional 1801 Space Rent Abatement remaining during the Initial Rent Abatement Period and/or Additional 1801 Rent Abatement Period, as applicable, as of the date of payment of the Rent Abatement Purchase Price by Landlord.  Upon Landlord&#8217;s payment of the Rent Abatement Purchase Price to Tenant, Tenant shall be required to pay Rent in accordance with the provisions of Sections 1.1(i) and 3.1 and there shall be no further Initial Rent Abatement or Additional 1801 Space Rent Abatement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Proration for Partial Months</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If the Additional 1801 Space Abatement Period ends on a date that is not the last day of the month, then on the first day of the first full calendar month after the expiration of the Additional 1801 Space Rent Abatement Period (the &#8220;First Full Month&#8221;), Tenant shall pay Rent for the First Full Month together with prorated Rent based on the days in the prior calendar month following the expiration of the Additional 1801 Space Rent Abatement Period.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;1751 Building Share; 1751 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Expansion 1751 Space Start Date, the Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Building Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 1.1(j)(i) of the Lease is hereby further amended so that the 1751 Building Share is 25.37%, subject to adjustment pursuant to Section&#160;2.6 of the Original Lease.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section&#160;1.1(k)(i) of the Lease is hereby further amended so that the 1751 Project Share is 4.90%, subject to adjustment pursuant to Section&#160;2.6 of the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Parking</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Expansion 1751 Space Start Date, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 471 unassigned parking spaces within the Project at no charge.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;1801 Building HVAC Work and Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Sections&#160;32 of the Lease is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">32.&#160;&#160;&#160;&#160;1801 BUILDING HVAC WORK</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">32.1&#160;&#160;&#160;&#160;1801 Building HVAC Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  As part of Tenant&#8217;s Work in the 1801 Space, Tenant shall update the base building HVAC and boiler systems in the 1801 Building (the &#8220;1801 HVAC Systems&#8221;) by replacing the existing equipment listed on the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto (the &#8220;HVAC Equipment List&#8221;) in the 1801 Building with new, substantially similar equipment, which work shall be referred to herein as &#8220;1801 Building HVAC Work.&#8221;  Tenant will work with Landlord collaboratively to produce the plans and specifications for 1801 Building HVAC Work so that it is designed and constructed to maximize efficiency and meet the needs of Tenant.  Tenant and &#8220;Contractor&#8221; (as defined in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) shall perform or cause to be performed 1801 Building HVAC Work in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, as amended, including, without limitation, Paragraphs 10 through 14 of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord hereby agrees that XL Construction Corporation is an approved Contractor.  Tenant may begin performing 1801 Building HVAC Work after the last Start Date for the 1801 Space (as set forth in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, as amended) and use commercially reasonable efforts to complete 1801 Building HVAC Work on or before Tenant&#8217;s occupancy of the 1801 Space.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">32.2&#160;&#160;&#160;&#160;1801 HVAC Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Throughout the Term, Tenant will be solely responsible for all costs and expenses incurred in updating, operating, maintaining, repairing and replacing the 1801 HVAC Systems in accordance with Section&#160;5; provided, however, that Landlord will pay for the cost of 1801 Building HVAC Work up to a maximum of $600,000.00 (&#8220;1801 HVAC Allowance&#8221;), and Tenant shall pay for 1801 Building HVAC Work to the extent that the cost of 1801 Building HVAC Work exceeds the 1801 HVAC Allowance.  A condition precedent to Landlord&#8217;s payment of the 1801 HVAC Allowance will be that Landlord has received from Tenant the following: (a)&#160;written notice from Contractor (or other evidence reasonably satisfactory to Landlord) that 1801 Building HVAC Work has been completed; (b)&#160;final and unconditional lien waivers from Contractor and all subcontractors, suppliers, materialmen and other parties who performed labor at, or supplied materials to, the 1801 Building in connection with 1801 Building HVAC Work.  Tenant will not be entitled to any credit if the 1801 HVAC Allowance exceeds the cost of the 1801 Building HVAC Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">32.3&#160;&#160;&#160;&#160;Title and Liability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Without limiting Tenant&#8217;s obligations under this Section&#160;32, once installed, title in and to the 1801 HVAC Systems and all equipment related thereto will be Tenant&#8217;s property throughout the Term of this Lease and shall automatically become Landlord&#8217;s property upon termination of this Lease, or termination of Tenant&#8217;s right to possession of the 1801 Space, without compensation to Tenant.  Subject to this Section&#160;32 and except to the extent caused by the willful misconduct or grossly negligent act or omission by Landlord, to the fullest extent permitted by applicable laws, codes, rules and regulations, Tenant will indemnify and hold Landlord, its affiliates, its property manager and their respective managers, members, officers, directors, employees and agents harmless from and against any and all claims, costs and liabilities (including reasonable attorneys&#8217; fees) arising out of or in connection with Tenant&#8217;s installation, use, operation, maintenance, repair and replacement of the 1801 HVAC Systems.  In no event shall Tenant be required to restore the 1801 Building HVAC Work at the expiration or earlier termination of the Lease.  This Section&#160;32 will survive the expiration or earlier termination of the Term.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Roof Work and Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The following provision is added as Section&#160;34 of the Original Lease:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">34.&#160;&#160;&#160;&#160;ROOF WORK AND ALLOWANCE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">34.1&#160;&#160;&#160;&#160;Roof Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  As part of Tenant&#8217;s Work in the 1801 Space and the 1851 Space, Tenant shall replace the existing roofs on the 1801 Building and the 1851 Building with TPO Roof Overlays of similar or greater quality with 20-year roof warranties, which work shall be referred to herein as the &#8220;Roof Work.&#8221;  Tenant will work with Landlord collaboratively to produce the plans and specifications for Roof Work so that </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">it is designed and constructed to maximize efficiency and meet the requirements of the respective Single User Buildings.  Tenant and Contractor shall perform or cause to be performed Roof Work in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, as amended, including, without limitation, Paragraphs&#160;10 through 14 of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant may begin performing Roof Work after the last Start Date for the Additional 1801 Space (as provided in the First Amendment) and use commercially reasonable efforts to complete Roof Work on or before Tenant&#8217;s occupancy of the applicable Single User Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">34.2&#160;&#160;&#160;&#160;Roof Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant will be solely responsible for all costs and expenses incurred in connection with the Roof Work; provided, however, Landlord will pay for the cost of Roof Work up to a maximum of $225,000.00 (&#8220;Roof Allowance&#8221;), and Tenant shall pay for Roof Work to the extent that the cost of Roof Work exceeds the Roof Allowance.  A condition precedent to Landlord&#8217;s payment of the Roof Allowance will be that Landlord has received from Tenant the following: (a)&#160;written notice from Contractor (or other evidence reasonably satisfactory to Landlord) that Roof Work has been completed; (b)&#160;final and unconditional lien waivers from Contractor and all subcontractors, suppliers, materialmen and other parties who performed labor at, or supplied materials to, such Single User Buildings in connection with Roof Work; and (c)&#160;the 20-year roof warranties for the Roof Work are transferred to Landlord and can be assigned to any lender or future owner of the respective Single User Buildings.  Tenant will not be entitled to any credit if the Roof Allowance exceeds the cost of Roof Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">34.3&#160;&#160;&#160;&#160;Tenant&#8217;s Services (and Repair, Maintenance and Replacement Responsibilities) for the Roofs of Single User Buildings</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Throughout the Term, other than Major Replacement Expenditures, Tenant will be solely responsible for all costs and expenses incurred in updating, operating, maintaining, repairing and replacing the roofs of the Single User Buildings, subject to Sections&#160;5.7 and 5.8.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">34.4&#160;&#160;&#160;&#160;Title and Liability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Without limiting Tenant&#8217;s obligations under this Section&#160;34, once installed, title in and to the roofs of such Single User Buildings shall automatically become Landlord&#8217;s property upon installation, without compensation to Tenant.  Subject to this Section&#160;34 and except to the extent caused by the willful misconduct or grossly negligent act or omission by Landlord, to the fullest extent permitted by applicable laws, codes, rules and regulations, Tenant will indemnify and hold Landlord, its affiliates, its property manager and their respective managers, members, officers, directors, employees and agents harmless from and against any and all claims, costs and liabilities (including reasonable attorneys&#8217; fees) arising out of or in connection with Tenant&#8217;s installation, use, operation, maintenance, repair and replacement of the roofs of the Single User Buildings.  This Section&#160;34 will survive the expiration or earlier termination of the Term.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Sustainability Provisions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Effective Date, the Lease is amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  A proportion of  costs attributable to the &#8220;Projected Annual Savings&#8221; (as defined in Section&#160;10(e) below) will be included in Costs.  Section&#160;1.3(f) of the Original Lease is hereby amended accordingly.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Occupancy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall use commercially reasonable efforts to ensure energy efficient operation of the Premises, and for the proper protection and functioning of the Building systems by reasonably minimizing unnecessary use of electricity, water, heating and air conditioning. Tenant shall reasonably cooperate with Landlord in any utility conservation effort to meet its Project-wide sustainability targets.  Section&#160;4.3 of the Original Lease is hereby amended accordingly.  For the avoidance of doubt, this Section&#160;10(b) shall not require Tenant to expend any funds to meet any such sustainability targets or to minimize unnecessary use.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Alterations by Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any Tenant Alteration will meet all applicable energy efficiency building code requirements, and shall be performed in accordance with Landlord&#8217;s reasonable sustainability practices, unless Landlord expressly consents in writing otherwise.  Tenant is encouraged to purchase products with recycled content and low VOC emissions, to install energy and water-efficient systems, and to recycle construction waste; provided, however, that failure to do so shall not be deemed a breach of this Lease.  All appliances and electronics installed after the completion of the Leasehold Improvements shall be ENERGY STAR rated, to the extent reasonably possible.  Section&#160;7.1 of the Original Lease is hereby amended accordingly.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Environmental Performance Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  To facilitate sustainability analysis and reporting compliance, both Landlord and Tenant, upon request of the other party, will share any utility consumption data it has from ENERGY STAR or any other source (the &#8220;Environmental Performance Data&#8221;) that relates to the Premises.  The Environmental Performance Data shall be shared no more frequently than monthly, and may include information relating to energy consumption, water consumption, waste production, greenhouse gas emissions, and other sustainability or environmental metrics.  The Environmental Performance Data shall only be used for the purposes of: (i) monitoring and improving the environmental performance of the Premises or the Project; (ii) measuring the environmental performance of the Premises or the Project to create or benchmark against any sustainability targets; and (iii) reporting, on a consolidated basis, to third parties who require the submission of Environmental Performance Data in conjunction with a related certification, score or other sustainability-related assessment.  The Environmental Performance Data shall be kept confidential and shall only be shared with third parties as necessary to facilitate the activities in the preceding sentence, and otherwise may only be shared in compliance with a court order or statutory disclosure requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Utility System Enhancements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything in the Lease to the contrary, Landlord shall have the right, from time to time during the Term and subject to applicable Laws, to install energy- or water-related systems and equipment at the Project, including, without limitation, in the Common Areas of the Project (collectively, the &#8220;Utility System Enhancements&#8221;).  Landlord shall be entitled to install, or cause to be installed, the Utility System Enhancements in and around the Buildings and the Premises as necessary for such enhancements to benefit the Project or any part thereof.  Tenant hereby agrees to reasonably cooperate with Landlord in connection with the foregoing, and Landlord agrees that it will use commercially reasonable efforts to minimize any interference with Tenant&#8217;s operations as a result of any Utility System Enhancements and will provide Tenant advance notice if any utility systems will be unavailable during any such enhancements.  In the case of Utility System Enhancements that an &#8220;Engineer&#8221; (as defined below) determines and certifies in writing, based on its calculated projections, and using reasonable assumptions and qualifications will, on an annual basis, reduce a Building or Project&#8217;s consumption of utilities (&#8220;Projected Annual Savings&#8221;), Landlord may include the costs of such Utility System Enhancements in Costs, in an amount not to exceed 90% of the Projected Annual Savings.  By way of example: If the Projected Annual Savings are $10,000, then Landlord may include $9,000 annually ($750 monthly) as Cost for the duration of the Term.  In addition, to the extent Landlord receives any rebates, incentive payments or any other monetary benefit from any government entity, utility or other agency as a result of the Utility System Enhancements, then Landlord shall pass such benefits through to Tenant in accordance with the agreed upon allocation for Projected Annual Savings set forth in this Section&#160;10(e).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For the purposes of this Section&#160;10(e), &#8220;Engineer&#8221; shall mean an independent engineer chosen by Landlord and reasonably approved in writing by Tenant, and who has performed a commercially reasonable investigation into all material impacts any Utility System Enhancements may have on Costs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(f)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained herein, (i)&#160;Landlord must obtain the written consent of Tenant prior to installing, or causing to be installed, any Utility System Enhancement, which consent may not be unreasonably withheld, provided that it shall be deemed reasonable for Tenant to withhold its consent if any such Utility System Enhancement will not be reasonably beneficial for Tenant, (ii)&#160;in no event will Tenant&#8217;s cumulative Costs increase because of any Utility System Enhancements, and (iii) if either Landlord or Tenant reasonably determines that a revision to the cost allocation approach set forth herein with respect to the Utility System Enhancements is in the best interest of both parties, then the parties shall negotiate in good faith to amend the Lease accordingly.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;Work Letter Provisions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant acknowledge and agree that Tenant will construct Leasehold Improvements in the Second Amendment Expansion 1751 Space in accordance with the Work Letter attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Lease.  Effective as of the Second Amendment Effective Date, the Work Letter is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Start Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The estimated Start Date for the Second Amendment Expansion 1751 Space is July&#160;1, 2018.  The Start Date for the Additional 1801 Space  occurred on February&#160;19, 2018.  Paragraph&#160;1(b) of the Work Letter of the Original Lease, as previously amended, is hereby further amended accordingly.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Maximum Allowance Amount</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The first phrase of Paragraph 1(j) of the Work Letter is hereby deleted in its entirety and replaced with the following:</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Maximum Allowance Amount&#8221; means $6,729,842.00 (which is approximately $48.00 per rentable square foot for the Second Amendment Expansion 1751 Space and $50.00 per rentable square foot for the Existing Premises);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;Occupancy Estoppel Certificate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Second Amendment Effective Date, the form of Occupancy Estoppel Certificate attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Original Lease, as previously amended, is hereby further amended to include the Start Date and the move-in date for the Second Amendment Expansion 1751 Space.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;Premises Occupancy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord hereby acknowledges and consents to the occupancy of the Premises by employees of any wholly owned subsidiary of Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;Brokers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant represent and warrant that no broker or agent negotiated or was instrumental in negotiating or consummating this Second Amendment except Cushman Wakefield and Kidder Matthews (the &#8220;Brokers&#8221;).  Neither party knows of any other real estate broker or agent who is or might be entitled to a commission or compensation in connection with this Second Amendment.  Landlord will pay all fees, commissions or other compensation payable to the Brokers pursuant to a separate agreement.  Tenant and Landlord will indemnify and hold each other harmless from all damages paid or incurred by the other resulting from any claims asserted against either party by brokers or agents claiming through the other party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;Whole Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Second Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements.  Except as amended herein, or in a future writing signed by both parties, there shall be no other changes or modifications to the Lease between the parties and the Lease and the terms and provision contained therein shall remain in full force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;Successors and Assigns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Second Amendment shall be binding upon the parties hereto, their heirs, successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;Ratification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as amended hereby and by this Second Amendment, the Lease has not been amended, and the parties ratify and confirm the Lease, as amended hereby and by the Second Amendment, as being in full force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;Counterparts; Execution by Telecopy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Second Amendment may be executed in counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one agreement.  Executed copies hereof may be delivered by telecopier or other electronic means, and upon receipt will be deemed originals and binding upon the parties hereto, regardless of whether originals are delivered thereafter.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signatures appear on next page]</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment to be effective as of the Second Amendment Effective Date.</font></div><div style="line-height:120%;padding-left:126px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:32%;"></td><td style="width:68%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LANDLORD:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:32px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ASCENTRIS 105, LLC, <br>a Colorado limited liability company</font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Jake Rome</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br>Name: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Jake Rome</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br>Title: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Authorized Representative</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">TENANT:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:32px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC., <br>a Delaware corporation</font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey, Ph.D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:   </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Michael M. Morrissey, Ph.D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President and CEO</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s5B6D3BF2557606550C6FCD3E3E5E9CCC"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT A-3 <br>PLAN DELINEATING THE PREMISES AND TENANT MAINTAINED OUTDOOR AREAS AS OF THE SECOND AMENDMENT EFFECTIVE DATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1.jpg" alt="exhibit102image1.jpg" style="height:525px;width:622px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A-3-1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image2.jpg" alt="exhibit102image2.jpg" style="height:449px;width:622px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A-3-2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image3.jpg" alt="exhibit102image3.jpg" style="height:426px;width:549px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image4.jpg" alt="exhibit102image4.jpg" style="height:413px;width:549px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A-3-3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image5.jpg" alt="exhibit102image5.jpg" style="height:434px;width:574px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image6.jpg" alt="exhibit102image6.jpg" style="height:402px;width:534px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A-3-4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image7.jpg" alt="exhibit102image7.jpg" style="height:353px;width:672px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A-3-5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TENANT MAINTAINED OUTDOOR AREAS</font></div><div style="line-height:120%;text-align:center;"><img src="exhibit102image8.jpg" alt="exhibit102image8.jpg" style="font-family:Calibri,sans-serif;font-weight:bold;height:399px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A-3-6</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>exel20180630exhibit121.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF84ED0A483905675A316D56C857C8D40"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 12.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">STATEMENT RE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Our earnings were insufficient to cover fixed charges for the periods presented except for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and the year ended December&#160;31, 2017. The following table sets forth our ratio of earnings to fixed charges for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and the year ended December&#160;31, 2017, and our deficiency of earnings to cover fixed charges for the other periods presented.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Fixed charges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest portion of rental expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">755</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,271</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings available for fixed charges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,297</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Fixed charges per above</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,781</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total earnings available for fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">167,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36,441</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(120,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(219,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ratio of earnings to fixed charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,544</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deficiency of earnings available to cover fixed charges</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exel20180630exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE9B070E4AB08508EACC3A9BFA9A2D785"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">August&#160;1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exel20180630exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s07658E1AE58F5A47BA77D1243B0C36B3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">August&#160;1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exel20180630exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8D151861A9635F5E8A5A858E3A5636B0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;29, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">1st</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">August 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>exel-20180629.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:810f3f6ff4a44dcd8843f0e93b843bb6,x:5d3c1b907ebd4735a9c1592f9698b92d-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:exel="http://www.exelixis.com/20180629" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="exel-20180629.xsd" xlink:type="simple" />
	<xbrli:context id="D2018Q2DEC30-JUN29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3JUL24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Fiscal">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201618Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_EMAApprovalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAApprovalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_exel_MilestoneObjectiveAxis_exel_EMAApproval1LRCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAApproval1LRCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_exel_MilestoneObjectiveAxis_exel_EMAApproval1LRCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAApproval1LRCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAFilingAcceptanceHCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Fiscal_exel_MilestoneObjectiveAxis_exel_EMAApproval1LRCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAApproval1LRCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:ProductsDerivedfromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:OtherGeographicalAreasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2MAY31_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:ProductCommercializationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_exel_PeriodGeneratedAxis_exel_Q416Member_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:PeriodGeneratedAxis">exel:Q416Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_RevenueAchievementsMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:RevenueAchievementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:SecondMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1JAN01-JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2MAY2018_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2MAY31_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2MAY2018_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29_exel_MilestoneObjectiveAxis_exel_EMAApprovalHCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:EMAApprovalHCCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4IpsenToDate_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-01</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1JAN31_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:FirstProductToReachMarketMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb01-29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-01</xbrli:startDate>
			<xbrli:endDate>2016-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1JAN01-JAN01_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:GlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2JUN2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OperatingLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2JUN2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2DEC31-JUN30_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="D2018Q2DEC30-JUN29" id="Fact-21BEE0D546125CBDB5900AFDE0B7A878">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="D2018Q2DEC30-JUN29" id="Fact-B4557F0538A757F59FAF01C4752124F1">--12-28</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="D2018Q2DEC30-JUN29" id="Fact-CE71F9957B255EB0B1A2892250EEFBF6">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="D2018Q2DEC30-JUN29" id="Fact-282102EB8F4F54BDB5FE38D3113EC709">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="D2018Q2DEC30-JUN29" id="Fact-2C377906E24B5ADAB2113F84796FC216">2018-06-29</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="D2018Q2DEC30-JUN29" id="Fact-5ED1DB6B5C0A5A5F966CF3CD8EAF8ACE">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="D2018Q2DEC30-JUN29" id="Fact-43415FD3470E586E98CA4826756AFC66">0000939767</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q3JUL24" decimals="INF" id="Fact-295C1CD701055EB5A571712D717BD095" unitRef="shares">298035458</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="D2018Q2DEC30-JUN29" id="Fact-1385B6A1716F51C394E0EA40D9D165B7">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="D2018Q2DEC30-JUN29" id="Fact-29A28F348AB753CC86759E8AF7471EE3">EXELIXIS, INC.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="D2018Q2DEC30-JUN29" id="Fact-14AA03CD5E5F5872908C7F15E6C700CD">exel</dei:TradingSymbol>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-3B8983E2C88C5EF48A7C2E2F7E28A37B" unitRef="usd">19849000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-C364BBC503325E548970330456EBF094" unitRef="usd">16801000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-4492ED1CFCA2523DA94F38574EA767FA" unitRef="usd">8974000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-1CD24EC1D0B0519B9BD98B0C80C32DB1" unitRef="usd">7713000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:ClassofWarrantorRightPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" id="Fact-9227DFF7FE9550B680399BECE6718B1E">P2Y</exel:ClassofWarrantorRightPeriod>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-CC8D2B4F8A7054549CB5C3D5194FB553">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" id="Fact-C9E1FFCE136B50A7B49C705273373BED">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-C329ACA18E6692A330E6CD1CE61E911C" unitRef="usd">-1407000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-F0F3DE27EB63491C7366CD1D8100B758" unitRef="usd">4069000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-84E7C05FD2CB3F8B9AB9CD1D57F05293" unitRef="usd">2696000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-50BC88BA95AF707DB09BCD1D5C564935" unitRef="usd">-781000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-A553B51F6CD753FA8EACB347CF250CC3" unitRef="usd">100000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-84536917A6445CEFB0ADD9395B582D15" unitRef="usd">471000</exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues>
	<exel:ContractWithCustomerAssetCurrentOtherAdjustments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-BC1581B934BD5441A367AF6EA1E33592" unitRef="usd">-950000</exel:ContractWithCustomerAssetCurrentOtherAdjustments>
	<exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-252017E3BCA05CD2B8269DB29FA888F6" unitRef="usd">2534000</exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues>
	<exel:ContractWithCustomerAssetNoncurrentOtherAdjustments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-9E2F0E143EDC5A4A820CF3E7BDC9482E" unitRef="usd">-14781000</exel:ContractWithCustomerAssetNoncurrentOtherAdjustments>
	<exel:ContractWithCustomerLiabilityCurrentDeductions contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-6246CFCA062C5AF2A9CB776A1A3EEAB7" unitRef="usd">4977000</exel:ContractWithCustomerLiabilityCurrentDeductions>
	<exel:ContractWithCustomerLiabilityCurrentOtherAdjustments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-15909A029A9B59E589FA0A22AE470B5F" unitRef="usd">1575000</exel:ContractWithCustomerLiabilityCurrentOtherAdjustments>
	<exel:ContractWithCustomerLiabilityNoncurrentDeductions contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-E7381851B6B75DCCBF4A5C7D77CD8AB8" unitRef="usd">0</exel:ContractWithCustomerLiabilityNoncurrentDeductions>
	<exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-BA185E2EC95D59BFA785E2263F9032DB" unitRef="usd">-17306000</exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments>
	<exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-96074710C40F5285A531F57FE1589B08" unitRef="usd">948000</exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue>
	<exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-D30E4EB0DB1457A186A5FB372D20D025" unitRef="usd">3835000</exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B3A79287D96E5E37AC0C2A4396BF3024" unitRef="usd">22698000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-91411AADC5C75CADB19527C3DBB86BFD" unitRef="usd">20047000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-C7377F6376165CF9B06265F0BD367864" unitRef="usd">2651000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2018Q2Q2" decimals="-3" id="Fact-9D3B06296EEE577D9076AF25FD030529" unitRef="usd">4155000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-9BA0CE478C0653E59C6683B0B8C41772" unitRef="usd">2495000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-67CECDA742B65AF291EED70F4AA1E77D" unitRef="usd">1660000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2017Q4Dec29" decimals="-3" id="Fact-1A2B6C5CA38F5CD68C1D7322ECBC9B58" unitRef="usd">45000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-7E2FAEAAD460519E9A5A6FE9634B555F" unitRef="usd">36000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-2C6F7EC02DE25272A8F09C6ED0E1BD4C" unitRef="usd">9000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2018Q2Q2" decimals="-3" id="Fact-675727186DC15089A5C6DBA22584869C" unitRef="usd">5000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-401FCD7DBCC35544A47A26DDD7DFE7C0" unitRef="usd">5000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-8C198993C6BE5E5382F21F6F616BDC22" unitRef="usd">0</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2017Q4Dec29" decimals="-3" id="Fact-179108BB8F6B5C459C5C6BB1B159505F" unitRef="usd">154357000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-58B7CB81E21E5EF5B485CEDC3985E3BA" unitRef="usd">140746000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-1458C0D790895B0AADCE2BFA9FE5487D" unitRef="usd">13611000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2018Q2Q2" decimals="-3" id="Fact-0EAC3587B7B05E8E9D63204D3632ADD7" unitRef="usd">195947000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-FB05FF423B7F51A48E4E87602E929E33" unitRef="usd">177129000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-48F8DDF774665D4FA7F85F2B8BDAD7B7" unitRef="usd">18818000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2017Q4Dec29" decimals="-3" id="Fact-76C750D678C15BDCAAB3C4FF51F6E3FC" unitRef="usd">319000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-A2DED582B6BB5089B242AFF19F8D2302" unitRef="usd">296000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-F8A4FA44EED05C5D8AFF839F9B1689AA" unitRef="usd">23000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2018Q2Q2" decimals="-3" id="Fact-5A7B10BE70265E3EA187C95E48AAF0EF" unitRef="usd">780000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-C5546C682C435E47AD245A4000AAA528" unitRef="usd">725000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-616B9DE53C455854B8A71C2E90F7BB22" unitRef="usd">55000</exel:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="D2017Q2DEC31-JUN30" decimals="INF" id="Fact-43774E471EA08787AAEEDC6C2B0B7D33" unitRef="usd">0</exel:DebtSecuritiesAvailableForSaleRealizedGainLoss>
	<exel:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-0CC63C5C5C3D32F4DD7CDC6C2B1CB0A0" unitRef="usd">0</exel:DebtSecuritiesAvailableForSaleRealizedGainLoss>
	<exel:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="D2018Q2Q2QTD" decimals="INF" id="Fact-DAE7B9E052ED1AA38BC9DC6C2B13E7AE" unitRef="usd">0</exel:DebtSecuritiesAvailableForSaleRealizedGainLoss>
	<exel:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="FD2017Q2QTD" decimals="INF" id="Fact-B71BC3C53CB0B1C402DFDC6C2B0533E6" unitRef="usd">0</exel:DebtSecuritiesAvailableForSaleRealizedGainLoss>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2DA9BE9FA35454CE8CD3035A52EC1EFC" unitRef="usd">177055000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-C2E6D761FE175D378ED4012E09617CF6" unitRef="usd">160793000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-DD18FA5AD4E75E91B674E70D6B7E02C6" unitRef="usd">16262000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2018Q2Q2" decimals="-3" id="Fact-4F442FA0C7095E20A1D375AE76E892C6" unitRef="usd">200102000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-9B119CC7ECAD5B5BAB3B1FF0A9AC3C7D" unitRef="usd">179624000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-A44003A0DEB75F4AAFFBC009EA82B816" unitRef="usd">20478000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2017Q4Dec29" decimals="-3" id="Fact-4DD52A5FAE185788BBC4ABF284B26E89" unitRef="usd">364000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-0F0E9E8C364751BA9903F454F89B01E3" unitRef="usd">332000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-522A6FFBB1315445895544FD9BE79D45" unitRef="usd">32000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2018Q2Q2" decimals="-3" id="Fact-E5A92DE9AF60546A834DFB8641F5E058" unitRef="usd">785000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-9220EE2AB4A55826AB6BA432C7D0EFAA" unitRef="usd">730000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-C17DC8BE1AFD56B5AE3B0C116644109B" unitRef="usd">55000</exel:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2016Q1Feb29_exel_MilestoneObjectiveAxis_exel_EMAApprovalHCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-EF3A8D0443BD56768FBC0E0D791BEA2B" unitRef="usd">40000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-3665BF09E751579C968D72692C07AB18" unitRef="usd">199000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q1JAN31_exel_MilestoneObjectiveAxis_exel_FirstProductToReachMarketMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-D6E2C783C90D50B3AA86A45E75AD9FDB" unitRef="usd">56500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q1JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-46E36566244A502C8D2838FAB5DE3173" unitRef="usd">3500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q2MAY31_exel_MilestoneObjectiveAxis_exel_DevelopmentAndRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-F0D43ADDD1DE7B8DE38DCD25EAB40CAF" unitRef="usd">131500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q2MAY31_exel_MilestoneObjectiveAxis_exel_ProductCommercializationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-4CDD7877365A276C13DACD2AA5D35FD7" unitRef="usd">325000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2018Q2Q2_exel_MilestoneObjectiveAxis_exel_EMAApproval1LRCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-93E7792889115E678D9139906CEAF713" unitRef="usd">50000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-238301B6D990545CB95367F976C51562" unitRef="usd">549000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-EE45638C8BC355F28D86C87C2D91A180" unitRef="usd">-3048000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-8C42C64E41325B1BA8B46902CBF2FE95" unitRef="usd">5873000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-19B71D3AA90D528D80ADB55C5EFB2622" unitRef="usd">-1261000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-EE8D0B501CA6557A9711CE207994B041" unitRef="usd">519900000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-F78E2E2EBCAD5B70B844D6B202A86CF8" unitRef="usd">83000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:MilestonePaymentsEarned contextRef="D2017Q4IpsenToDate_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-D76A6F6E97ED58FC93A3D1086507BF47" unitRef="usd">125000000</exel:MilestonePaymentsEarned>
	<exel:MilestonePaymentsEarned contextRef="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_EMAFilingAcceptanceHCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-321C4E490F8859489F1C6979068777E3" unitRef="usd">10000000</exel:MilestonePaymentsEarned>
	<exel:MilestonePaymentsEarned contextRef="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_RevenueAchievementsMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-D8AECF6AF0962F2463F9CD084A60F57F" unitRef="usd">25000000</exel:MilestonePaymentsEarned>
	<exel:MilestonePaymentsMinimumNetSalesAchievementAmount contextRef="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_RevenueAchievementsMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-0EF081CB4549D1F80B03CD0D5B3261D5" unitRef="usd">100000000</exel:MilestonePaymentsMinimumNetSalesAchievementAmount>
	<exel:MilestonePaymentsMinimumNetSalesAchievementAmount contextRef="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_RevenueAchievementsMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-40D280D6B459A106F6CACD09C0B47EB4" unitRef="usd">100000000.0</exel:MilestonePaymentsMinimumNetSalesAchievementAmount>
	<exel:NumberofProductsinCommercialMarket contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-1E404B1650D3560B984FE0C8818A1E47" unitRef="product">3</exel:NumberofProductsinCommercialMarket>
	<exel:NumberofProductsinCommercialMarket contextRef="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember" decimals="INF" id="Fact-223A4C05BDFF538DB48147E77215381B" unitRef="product">2</exel:NumberofProductsinCommercialMarket>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-FB9E2A5FC9AB5226BE923EA21232014A" unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-0BF23DAEA9F55A0CB8C31B7E4E5C3E45" unitRef="number">0.3</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-1A7F2A1761DB5D819000DF71A33EC993" unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-5E7D5C67388D56E684181A1BBE708DE5" unitRef="number">0.2</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-EBA0E2650A1C51359B3848E95C489DC9" unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-D54771FA38C25B75AD9ADFC0BF1B73F5" unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-4F7A5B62577C5AD8871E43BD5AB2C17E" unitRef="number">0.02</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-0BEEFE069AEE55FAA315AAC0F1F1CB8F" unitRef="number">0.12</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="2" id="Fact-112115B2F394561487B154025B3456A1" unitRef="number">0.03</exel:PercentOfRoyaltyOnNetSale>
	<exel:PeriodOfSpecificSalesVolumeThreshold contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-BDF4F036C1EF5C1CAC7DE557E98D7AE7">P6Y</exel:PeriodOfSpecificSalesVolumeThreshold>
	<exel:ProjectInitiationFeePayment contextRef="D2018Q2MAY2018_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-B3BC888F4E7F029F673DCD2D57F1F1FA" unitRef="usd">2000000</exel:ProjectInitiationFeePayment>
	<exel:PropertyPlantAndEquipmentAdditionsAndTransfers contextRef="D2018Q2JUN2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" decimals="-5" id="Fact-8334756CD44034947940CDADF5D3D6CD" unitRef="usd">59500000</exel:PropertyPlantAndEquipmentAdditionsAndTransfers>
	<exel:ResearchAndDevelopmentServiceRevenue contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-066D6E3DFCBC5862AA30B25CBCDE96A8" unitRef="usd">3307000</exel:ResearchAndDevelopmentServiceRevenue>
	<exel:ResearchAndDevelopmentServiceRevenue contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-1BAE082D015F5CCD9337CD7BFAA6D481" unitRef="usd">16904000</exel:ResearchAndDevelopmentServiceRevenue>
	<exel:ResearchAndDevelopmentServiceRevenue contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-5AD11DE5CFF3072B8F73CCA475AE5C16" unitRef="usd">6805000</exel:ResearchAndDevelopmentServiceRevenue>
	<exel:ResearchAndDevelopmentServiceRevenue contextRef="FD2017Q2QTD" decimals="-3" id="Fact-918C7A3FB5D3B5F3BECDCCA477D07AF9" unitRef="usd">2175000</exel:ResearchAndDevelopmentServiceRevenue>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-74380E90430A501B96F388184075D5BE" unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="2" id="Fact-BC78C8A59B82530EABCB6EAFE9AF8FB9" unitRef="number">0.20</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="2" id="Fact-D11AFB2181175D4991202D18FFBDEC49" unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:RoyaltyTier contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-D3ABBAC456905FA1B3DFD853E6247D81" unitRef="usd">150000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2018Q2DEC30-JUN29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-C242B1474B635FAAAEA8B16931F3B9C4" unitRef="usd">300000000.0</exel:RoyaltyTier>
	<exel:SalesRevenueDiscountExpectedtobeEarnedPercent contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-ADD8075E0BFF5709B479CBDFDD671408" unitRef="number">1</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
	<exel:SalesRevenuePercentDiscountForPromptPayment contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-4F5D7FFD77B75451915C0EA669488732" unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue contextRef="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-C3FB0AE2DFEC54E2BC1EE683E572F925" unitRef="usd">77498000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-C42EA91A2F235660823149558C9D4369" unitRef="shares">341572</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-6BD82F5413145F179E39E3D36EB579FC" unitRef="usdPerShare">7.75</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue>
	<exel:UpfrontAndMilestonePayments contextRef="D2018Q1JAN01-JAN31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithStemSynergyMember" decimals="-5" id="Fact-5153F413ECB155FE9B25C5EE4268F32A" unitRef="usd">3000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontAndMilestonePayments contextRef="D2018Q2MAY2018_exel_MilestoneObjectiveAxis_exel_DiscoveryProjectMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-0B57A03B85CA64562CE2CD2B94026F8E" unitRef="usd">2000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontAndMilestonePayments contextRef="D2018Q2MAY2018_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-8657CF79887DF6FBBA4CCD1FFD7184E8" unitRef="usd">2000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontPayments contextRef="D2016Q1Feb01-29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-D3E5F949F83A56FABDC5E266B7BD47DA" unitRef="usd">210000000</exel:UpfrontPayments>
	<exel:UpfrontPayments contextRef="D2017Q1JAN01-JAN01_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-A4A9B5A446B557AF94D5A59DA19C37B5" unitRef="usd">50000000</exel:UpfrontPayments>
	<exel:UpfrontPaymentsAndProjectInitiationFeesPayments contextRef="D2018Q2MAY2018_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementWithInvenraMember" decimals="-5" id="Fact-FD46CD3AB3AD73C190D1D4B41BB7C42B" unitRef="usd">4000000</exel:UpfrontPaymentsAndProjectInitiationFeesPayments>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-A869C058B11B5ED1A63E8A8ECF9F8217" unitRef="usd">52742000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-A54BC23396F45BE7B5C1E27969E26E7D" unitRef="usd">6336000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-5219E83BC55850D288CBDF9569A9D1F7" unitRef="usd">14318000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-A724F526DE4B59269593C7A0BE0FDE25" unitRef="usd">32088000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-C22F0716AAE05702B9034C1172C943BC" unitRef="usd">-769000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-3B953D04282E5002B7B4754AE5ACFE4A" unitRef="usd">0</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-1601DD3BF13C522D8E9B58894C023FED" unitRef="usd">-32000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-A63B85D643E75B68BA0D8A605BDB986D" unitRef="usd">-737000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
	<us-gaap:AccountsPayableCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8C4772BEA2605E5A82B78E7D696FCF52" unitRef="usd">9575000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-EF5F02FB44555C6BA5B228DD45F9C99E" unitRef="usd">13023000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-204B1901855A5FB7A1AC94E521439556" unitRef="usd">21073000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-BD9D20219CE357F682836C6C0CA2EE88" unitRef="usd">21538000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F2B024FA3A285A62BF5FCF4B2263E0D5" unitRef="usd">22800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I2018Q2Q2" decimals="-3" id="Fact-3413A0309A7F5231A19E712275145C8A" unitRef="usd">14154000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2930D2E22DC3578DB678C600F3796D06" unitRef="usd">-347000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q2Q2" decimals="-3" id="Fact-E13B2CB413635D6184AFD40CD89B3B73" unitRef="usd">-731000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="I2017Q4Dec29" decimals="-3" id="Fact-42F4C651A10853E48C7843EAC7477F0B" unitRef="usd">2114184000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="I2018Q2Q2" decimals="-3" id="Fact-E34CD6FDD37A504EA684E33E197B6D56" unitRef="usd">2142717000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-B092610177EE505D8F45EEF9CBDE62F9" unitRef="usd">9740000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q2DEC31-JUN30_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-11152DC2156259788E9B074E469D99C8" unitRef="usd">3078000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q2DEC31-JUN30_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-B06C29029CDE5366B6D93A61685822EE" unitRef="usd">6662000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-ACC540A85A5C5670BA31907D66079330" unitRef="usd">18588000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-2235228726A35F57A910D8F652BB74E6" unitRef="usd">5933000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-F534DDC97105576FA41EE02CB38EEA5E" unitRef="usd">12655000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-4A8AED8ECC1C5227B9BC245BC00AF554" unitRef="usd">9283000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F6FD0BA0ADCD530DBAE730574590C5F9" unitRef="usd">2900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-DFB7443C61435CCB86806D955023EEF0" unitRef="usd">6383000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-EB0E01E9B13958C6B768AE40E8A0B886" unitRef="usd">5027000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-86C0F10ADA495313A6DAC7A01983212F" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-676DC0F5269B53E19DAB9DE02DCADBD1" unitRef="usd">3427000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-7F66951B60615DEEAC85992B0B65E2D9" unitRef="usd">182000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-64FEE15AF7515A138C13349B2CA98B7C" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-EDAA69637DA856DD9AECED1815A7198D" unitRef="shares">1633000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q2DEC31-JUN30_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-5FAA43F0C41C552A85BD4CB917F72A5B" unitRef="shares">1633000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-E95CB94F090C5EF0BAF5D706C7E449F7" unitRef="shares">2606000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q2DEC30-JUN29_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-006878DF48CA54A29F785B620CBE5863" unitRef="shares">2606000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-98C41F5CAF105DE6A090FB7CE40C7218" unitRef="shares">5163000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2018Q2Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-18B8769CA3C752DABD1372D4701847AB" unitRef="shares">5163000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD" decimals="-3" id="Fact-D177000D6E475FB38C32C309943784E7" unitRef="shares">1747000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-235DEA821E145AB4AD2CC8486E5F97C5" unitRef="shares">1747000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="FI2018Q2_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="INF" id="Fact-BB53485E6034A7E9D8D6CDB11C7E0FAB" unitRef="sqft">134765</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5141754A7D0256C0A63A8E8635EC72C8" unitRef="usd">655294000</us-gaap:Assets>
	<us-gaap:Assets contextRef="I2018Q2Q2" decimals="-3" id="Fact-40EB55C8D8F35C27B06252B485FE772F" unitRef="usd">911158000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F177983F35E7570CBE3831EFD2EBDCED" unitRef="usd">484874000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-47C6135C31305F8EAF337D4D5DDAF573" unitRef="usd">686286000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29" decimals="-3" id="Fact-25E757A055CF5D81AFB80BBC0EA92F40" unitRef="usd">440410000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-2AD304B6997E502AB310262DB8A317AE" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E32C7F4972CD50DB85A905532F719633" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-A38D6A8D7F3C57A5A199E90FDD861A42" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-F959DE73D5DA5BC2895FB9EE4482EAE0" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-2085CC281A2F5851A79EA25F743DDDCD" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-DBBFD4BFD49358818CDCCE8E8852ACF6" unitRef="usd">394932000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-A1F38CAA5B425F85A2D2F0BFBE3A6107" unitRef="usd">199647000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-D6142236B91458A485CBA108D2C61C5C" unitRef="usd">179022000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-5C8F3B8E4200566CBAB58B639792E726" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-DDE96045BF965E528F336BAB9784CC7F" unitRef="usd">16263000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B4147F8611295548AD34DBC725FCFC6C" unitRef="usd">199647000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-3089C32D0F3F51D3968A8EDD597033B7" unitRef="usd">179022000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-293BAD4826065E4D935C8B0EE2A3D81F" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-FE0B4D204A7551B9991902D15F77F561" unitRef="usd">16263000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2" decimals="-3" id="Fact-2DA940BB194D5FBEA4BEB002E661586D" unitRef="usd">594876000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-8888CB43D6945D50BF547967D22B6392" unitRef="usd">54546000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-CBE2622BD327E5A5EF41CDEFA6139DFE" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-30D6FB801F075F458CCAE76B10E0AAE6" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-7AC4B382AA2A5E1D9C73355AAFD9A53B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-DAFC81CA8AB35147BC76DA0D0BB266C4" unitRef="usd">54546000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-7A8EAF2965185378BC7D8FA337B31A58" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-098CDCA455195463823FB1D61F71AC4B" unitRef="usd">540330000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-D6143A7F10092463BDF3CDEFAA955331" unitRef="usd">21095000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-75786401BBFB58BAB47AF5F4ED6D1731" unitRef="usd">280654000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E6322A6D5FFA5C7BA7154C378AA6691F" unitRef="usd">218104000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-75854E39C029597B8C3A28C11CD13540" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-F14CC7CBDC43505DA2F2866F87D5076B" unitRef="usd">20477000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-E1EF9886FA9C7A7D3B64CDEFAF7E929D" unitRef="usd">21095000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-92ACB7596B9B580FA1C41739AC917148" unitRef="usd">280654000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-4B600FC0C35456E78E7230019E7D901C" unitRef="usd">218104000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-25889E9E621E527D89B59119102A9A71" unitRef="usd">54546000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-4E6D9363506E5B5DB3A67C54BA5052F8" unitRef="usd">20477000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-552A02AA7B6F5A7AA4E2CE8098FE4743" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E0294D3BAB575DD49CC2CCD7E7671037" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-B91649A609FA54BC8EEAA862040C5B77" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-0780AB29D9CE5A49B2A02E0AF0354F8E" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-F0F75113950D5047805CD29025185763" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2018Q2Q2" decimals="-3" id="Fact-2D88762A2DC75EBC9547A7FC14B21733" unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-8EEEB7139C82B1146BA0CD710722F6F5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-474694CFCCF254CAAEC577FA8DAF0C7E" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-EBED0FC006DB544F826335E7AD81C9AC" unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-EF2E6890C3D251B5AA1F96D1FA356A31" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-1FF24751F87A54A79E1A27BC31E4C1F4" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E2933F884626521CA1C08CB278D19060" unitRef="usd">364000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-7C46C99F85945D87916AAFA39E813C8E" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-3BA39E85767B5807AFAD15FE50410AC3" unitRef="usd">332000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-D80CE09E6858577CBE4998A9B6BED5AE" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-27A13A873E8C5DEA96061D17309CD9E2" unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2018Q2Q2" decimals="-3" id="Fact-E4ADC79EECBA5CA49A90FD818C1A545D" unitRef="usd">785000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-5F73476B910CC31BE9A9CD7109160943" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-5DC65AD387255DCF9A2AF3A162EC131B" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-DC7CA0E8963C5EC699306693B7C99247" unitRef="usd">730000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-462D24F1385C560BA795EB57FFE746D0" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-581D4EA9BEFA57B68FEE2ACA4888BBE2" unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29" decimals="-3" id="Fact-892AC846B6C25FA2884E02BD3615DA13" unitRef="usd">440756000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-D89A1899D05E53899A13DBB73BF9FC3C" unitRef="usd">199647000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-B129CB478036596F9BA225A4EC4BAEDD" unitRef="usd">179336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-485445362177570B99BD7E3CB2A261F1" unitRef="usd">45478000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-F43D5DEC1FF5571D8036E9C2FE954C84" unitRef="usd">16295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2018Q2Q2" decimals="-3" id="Fact-30672651C74654B7A826A1C7A14D15F0" unitRef="usd">595607000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-9FAEE7D28CB8EADD16F6CD71052A62BB" unitRef="usd">21095000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-9BADF468775651C8B376AF790446B012" unitRef="usd">280654000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-6D3C49EBAEF053A2B0211241EB43AFDF" unitRef="usd">218780000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-A075B2F0F1AF5C98BB6F45B3DDA49C13" unitRef="usd">54546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-DB10226265F15F9CB7343EB2F9FD8668" unitRef="usd">20532000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-340DD1FE83045D0DABF6E1A7A5EF9539" unitRef="usd">63255000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="I2018Q2Q2" decimals="-3" id="Fact-6F88854DD29154E4BAF7248691628851" unitRef="usd">94396000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-DB9A112F0C285738980EF8E687357B8B" unitRef="usd">377155000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="I2018Q2Q2" decimals="-3" id="Fact-D0CA7C0BD9C55AF79251C795A64D5491" unitRef="usd">500480000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2314F19581195D2F8A5C05698ECA2168" unitRef="usd">440410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E7C170580CC3574AAA44D597BCF74472" unitRef="usd">199647000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-589D72B79477547A8F1CF3E28D1308F1" unitRef="usd">179022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-6A0823848F29549E95012ACBF58CA08F" unitRef="usd">45478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-D8E7C2F34EDE5BA682817AFCADE67CCA" unitRef="usd">16263000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2018Q2Q2" decimals="-3" id="Fact-DE19F5B850245BA59E25D0068211D9D4" unitRef="usd">594876000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-01D0AD83D0FBA19D3A98CD710B0A9896" unitRef="usd">21095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-565687051A355E6089AB3958702FC804" unitRef="usd">280654000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-5166C96D4DDE5EA69A92F36A3C8CB188" unitRef="usd">218104000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-983DED539394502F900CEB44428C1A32" unitRef="usd">54546000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2018Q2Q2_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-7D5266BA304557C1B298E3C7783D32B3" unitRef="usd">20477000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 contextRef="I2017Q4Dec29" decimals="INF" id="Fact-DF2C076F02C95A85981DC1AFBBCBAFE9" unitRef="investment">134</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
	<us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 contextRef="I2018Q2Q2" decimals="INF" id="Fact-FCBB30E37AC85C07A6AC5C7ACBDF2D8C" unitRef="investment">149</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-2E4605893F56D079ECABCAA2A9C8175B" unitRef="usd">531000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-5CF8450728ED60652F32CAA2A9D3D3D3" unitRef="usd">13972000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalLeaseObligationsCurrent contextRef="I2018Q2Q2" decimals="-5" id="Fact-B6EDA3951CD5D9A9E669CDB419256CF3" unitRef="usd">700000</us-gaap:CapitalLeaseObligationsCurrent>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-BF9813D18511037576EFD37F1AAA517A" unitRef="usd">14530000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="I2018Q2Q2" decimals="-5" id="Fact-C870AC1E9C0A0DF59B5ACDB4874FEDE0" unitRef="usd">20600000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-BD61AF3474EF4D5D8D30D37F1A9CC708" unitRef="usd">20646000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q2" decimals="-3" id="Fact-6A4C45BE3B5C25CBA60FCD762C127F07" unitRef="usd">135212000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-08912BE7A36055E0B405A51AE51FFAFE" unitRef="usd">151686000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-3CFD1261A32A5D4F9771139B5495ACBF" unitRef="usd">183164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2018Q2Q2" decimals="-3" id="Fact-AC14FF68E1535FE39D8C923F61AC5557" unitRef="usd">248407000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q2" decimals="-3" id="Fact-17E2FCB1A1B056AC8839EA85EF5EBFBD" unitRef="usd">139862000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2016Q4Dec30" decimals="-3" id="Fact-E26BF08124EB59F68352CAD4B6F509DF" unitRef="usd">155836000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2017Q4Dec29" decimals="-3" id="Fact-CEAC1AB035DF53EFB333773CE85EFD3D" unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2018Q2Q2" decimals="-3" id="Fact-F8072A0792435A39B1456500D8FB7FB7" unitRef="usd">250011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-52A0FEB5A54556B5A6CA724AA6C59AE5" unitRef="usd">-15974000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-92DC7416984259EC9B47DC31118BBD32" unitRef="usd">61697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-EAB74E1F81D75F769326B7CB3944CDD6" unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="I2017Q4Dec29" id="Fact-79840E9FBDDE5A23AC57AF5EE5774CFB" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="I2018Q2Q2" id="Fact-04B6C36546BC5A5EB1402E7DF3F0A827" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q4Dec29" decimals="INF" id="Fact-0E2F73243A29562AB215799306DCDEEC" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2018Q2Q2" decimals="INF" id="Fact-209D26B4A621532597045A5A7CAB7877" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2017Q4Dec29" decimals="INF" id="Fact-E77231C565015324B9AD647CE2816AB8" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2018Q2Q2" decimals="INF" id="Fact-D42AC96110845321B2AD8B167A34C776" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="I2017Q4Dec29" decimals="INF" id="Fact-907F8E039D1552278B21DD91FEB3A7C7" unitRef="shares">296209426</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="I2018Q2Q2" decimals="INF" id="Fact-13D6B39D6A605922A2BC56BB0D25D87E" unitRef="shares">297892180</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29" decimals="INF" id="Fact-A290675A84665F72BDFC21AE9EBC94D3" unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2018Q2Q2" decimals="INF" id="Fact-6A371EC4BA3F516999FFED9CAC3E50AC" unitRef="shares">297892180</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-832123DC7112596F87C72C67F4AE6634" unitRef="usd">296000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="I2018Q2Q2" decimals="-3" id="Fact-7C9A90B73BD65BDCB8DD844871274FF9" unitRef="usd">298000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-594B8751BC865F24937E96196700A198" unitRef="usd">34653000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-CB64BEF216B05191A5C02535357A7909" unitRef="usd">202967000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-F66C8CBB346A579CBFFE04AE20D91B76" unitRef="usd">87650000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q2QTD" decimals="-3" id="Fact-936E0487ED8350379C469CAF8965635C" unitRef="usd">17863000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-88FEF1E20A3E046B3DD7D499764D77E6" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-9E0151FC681C6522DD65CCA702FAA55F" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-B1957D4894A740C1FE5BCCA703343DFD" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-AAF568D3935B8EECA5ECCCA702BFAA8C" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-3D2575847B8DCF696F30CCA70304814D" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-F79A7A85809877F20FEACCA702E3BCBC" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q2DEC31-JUN30_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="2" id="Fact-66F28E13B03F481B812FD4996AAE067B" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-7FC07E5F6DF83DDDC344D49971198AB4" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-825EFD5D9540AAA7922BCCA702EF1157" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-FEDB87F087AB979CA713CCA70316BA0B" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-F143DDA186756183CB7BCCA702D383C7" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-12C2252D4C09605A0A3ACCA7031396AE" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-8C809CC6A2FBFF4D54B8CCA7032A4C91" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="2" id="Fact-D33673F544CB3B160746D499619C675C" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-E39CE5940C1247D09590D4979B4B64DB" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-F1124349F8AEF4EB14A9CCA70867B478" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-337A73D10A4610DC4AAC6B17265EED9B" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-81D9CA188DFD772B7D286B171DDE8458" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-C263B0115BB1812BA5B06B172ED44EDD" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-81147804C840A45B4B796B1715759C77" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="2" id="Fact-F3DB8160B5A55DA118FCD49790074D2A" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-74AC63376A145F91AB01D497A1AB2A67" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-C5C127B8308083682CEFCCA7082CBD66" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-A7CDDD5DD0C2189971E56B172AEFE337" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-13AC97E84ADD8EA2495D6B1722706CA3" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-DB7D5BFBFE00FC6BF5906B1733642D50" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-B15B24A6903F54293DC36B1719FA6990" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="2" id="Fact-7756FB56408BC8964A89D49795EED061" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-E59B7830E4EFCEF3939CCAA0AE7A29B4" unitRef="usd">14530000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-B9F00CBFE0343249BEC8CAA0AE7E8CB6" unitRef="usd">6864000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-2A14E7FD05279D498151EDCD60B4E3B4" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-FBB0A02D0C9617357F78B49BD90A64EF" unitRef="usd">9588000</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-64CC832BEDE12B5ADED3B49BD68B801F" unitRef="usd">9588000</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-21D3BEEF88A7570FB85BD4B524EA9CA8" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-A7123D83CE35B19D333BEDCD60A9DE01" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-810291BFB003BE38E55FB49BDEE45C62" unitRef="usd">12247000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-AA10185EDF6CCF796160B49BDBF7E8B9" unitRef="usd">12247000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-C308496D82C250699E24D7478A38E610" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
	<us-gaap:ContractWithCustomerAssetReclassifiedToReceivable contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-A3CBC0E1820D5E53AD003F4641BC9C0E" unitRef="usd">9109000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
	<us-gaap:ContractWithCustomerLiability contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-602618EE7F3B54DF9378DF9CF5EDBA22" unitRef="usd">15200000</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiability contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-25EEC19913DC536B93CF2D2532E9DE44" unitRef="usd">2700000</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2DA2A2CBBD1D5D558663EA68EFA9C02B" unitRef="usd">31984000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-888B173217F412226697EDCD60BEC1B7" unitRef="usd">31984000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-651AD6E42DC5AE2CC52EB49BE75D4D01" unitRef="usd">8393000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-2400F88378A2591E4924B49BE50CACA0" unitRef="usd">-23591000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-45C3608D66B85FF4A4EC3D6954657946" unitRef="usd">5939000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-B2279F099EB90AD2BB90CD0E2D411DE5" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-FDA6B7665BAD5D818EAB3BD2BDB66005" unitRef="usd">238520000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-6B501C56B11DAC4EA5EFEDCD60BB7642" unitRef="usd">238520000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2018Q1Dec30" decimals="-3" id="Fact-D3BBF8DEDC3ABA8923F5B49BEC90F95C" unitRef="usd">25441000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-0581A9D12E4F841B397AB49BEA4AAA1E" unitRef="usd">-213079000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-908FD539D65C576DA83DA45E9E046767" unitRef="usd">11970000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-A4C4D3C9342BF99B7CBBCD0E2C022817" unitRef="usd">9300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="D2018Q2DEC30-JUN29" decimals="-5" id="Fact-91733084250B58FBBC1923F5F066B701" unitRef="usd">103800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
	<us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="D2018Q2Q2QTD" decimals="-5" id="Fact-B77598D5AB0DFA47D237CCB4E89836C5" unitRef="usd">32200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
	<us-gaap:ContractsRevenue contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-7CDAB275AB6A50E8A9A4D0FC773E1987" unitRef="usd">23014000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2017Q2DEC31-JUN30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-E4436DF6E6AB549C8191DEAACFD57EF7" unitRef="usd">10024000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2017Q2DEC31-JUN30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-2AEB520A5934533DABABD471AEABE020" unitRef="usd">6825000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q1Fiscal" decimals="-5" id="Fact-702CE11C0CA41A627D5ACC2C41A967B4" unitRef="usd">79400000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-5" id="Fact-73EF890B45EBB04BEE83CC292580679D" unitRef="usd">1400000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-5" id="Fact-57D6ADFF110896534E44CC2C415CB94B" unitRef="usd">78100000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-F88873E29C465255AF3B4A9DE26F1EB6" unitRef="usd">119719000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-1FB5FA624E48AD9052B5CC4286F7603F" unitRef="usd">-22750000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-1A7CB6B65FE1526DA710CC428587EC4C" unitRef="usd">142469000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-D9AD0671456E557280D7F973BF80673E" unitRef="usd">87852000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-B8C81096E4A55BC68588E95D6CDD5DD2" unitRef="usd">4903000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-236BCFACF81551FF817ACA7B2CDAC971" unitRef="usd">40272000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-41576BDDD8F78A23DE2BCC4134E02FD9" unitRef="usd">-54148000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-BA633DA39884EA83FBE6CC4115D22EE1" unitRef="usd">94420000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-5562F0C7B0CAA067C583CD194162ECC0" unitRef="usd">34043000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-01025E07E4135389B43C4F457F039CFF" unitRef="usd">1986000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD" decimals="-3" id="Fact-D993197CC3C5F36B87A6CA7B2E79D83C" unitRef="usd">11004000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-732AC8037008410E1CADCD19457CC745" unitRef="usd">5494000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-0BAA64DDC481E33D649ECD1D287F2E9C" unitRef="usd">4143000</us-gaap:ContractsRevenue>
	<us-gaap:CostOfGoodsSold contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-A8CE5E45F0465E54B9642C20626B321B" unitRef="usd">6217000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-D763CE2EBCB85FA29A89CC489636B04D" unitRef="usd">11636000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-D96489B0D28AFAB9389DCA7B34043138" unitRef="usd">5997000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q2QTD" decimals="-3" id="Fact-B64C3118C68459EC8D48FB3BB56C1534" unitRef="usd">3014000</us-gaap:CostOfGoodsSold>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9A435F27A2A654D2BE42D4C637872605" unitRef="usd">7565000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-5A407EFCE3745A6CBF0682BE10DD148C" unitRef="usd">11143000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:Depreciation contextRef="D2018Q2DEC30-JUN29" decimals="-5" id="Fact-EF4A99A26F50590D981CBF826518C1F8" unitRef="usd">1200000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q2YTD" decimals="-5" id="Fact-433DC98D270B5344B82E8DAA7A93E733" unitRef="usd">600000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-0A0303A45B13590BA054837417566D82" unitRef="usd">563000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-C39AD753129F5A09B06A3F38D4550778" unitRef="usd">1176000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q2DEC31-JUN30" decimals="2" id="Fact-C4A69E017F305E4BAA517957F130AEA0" unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2DEC30-JUN29" decimals="2" id="Fact-D56E0F4CE65E5BA7990D52592EFDE817" unitRef="usdPerShare">0.68</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="2" id="Fact-EBB6CCAF0AE9A05A50AECC42B105C967" unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="2" id="Fact-FCA24BA82AFA31118F25CC42AF034A60" unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2Q2QTD" decimals="2" id="Fact-73133A1EEDAE9C1E4C6ACA7B4F2A21FB" unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="2" id="Fact-0F2C027ED12F176EB5AACC413C5DB473" unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="2" id="Fact-DE66A7C58CD218381AFDCC411CA87AC7" unitRef="usdPerShare">0.47</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-062E34AAE5DE1B92C977CA7B4FD4AFE1" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q2DEC31-JUN30" decimals="2" id="Fact-22F3B6B78F675F99B9442A45A628A9F7" unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2DEC30-JUN29" decimals="2" id="Fact-560576F738E05226A2D85A6D36699EB7" unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="2" id="Fact-B7FD2ACDDE1E1B9CF78FCC42B8D3627E" unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="2" id="Fact-6DDFF4A3346C7B04447DCC42B6DBD464" unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2Q2QTD" decimals="2" id="Fact-8BE2E06E4374BD4DCB7FCA7B50325CA2" unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="2" id="Fact-6EC550102716B4DFD629CC413D565984" unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="2" id="Fact-C247E0A1AC6E540F9B71CC411DA45623" unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-8BC64BA4C2723C0E1433CA7B50D9E3D6" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-59F4C138615958238D50CCB7E9434E96" unitRef="usd">39100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-11950BD555BF5F50B87BD8513260E016" unitRef="usd">56800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B3B00DEE6F055D2AAE1B7584D597C5B0">P2Y3M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-363D81990B1D59459D4DC9FE1C62E729">P2Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-DFED33467D4B5783A82F1814E793385C" unitRef="usd">639000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-72FFA6F229455029954CD821A0EC72AA" unitRef="usd">209000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-857839B0866D547F9E9D059D822C2632" unitRef="usd">-6239000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-CA6179EC9DD056A68BDDAD421ED40AFC" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C8263A8402A05DC3980B5C06A1BA3E38" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2018Q2Q2" decimals="-3" id="Fact-E8BF2B2837F856D0A93BAF5C96B0D325" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-F1E4A0570CB95832A4DE990B4CB39636" unitRef="usd">35071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-DFEDD9B5C89E550281CDA1927ECE6195" unitRef="usd">206766000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-57DE3CABC5CFF6F324CCCC429DC1EE78" unitRef="usd">-22750000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-81CB22195B26E4984FC6CC429C57D8F0" unitRef="usd">229516000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-1268DFD970FE54F496E46FDA708CC66F" unitRef="usd">88395000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-1FA95FC31DB38E94B1E4CC4138C845D1" unitRef="usd">-54148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-63AE6A5759AD9B2A6478CC4119C04B00" unitRef="usd">142543000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q2QTD" decimals="-3" id="Fact-2D4B78D3C6AC21A329FFCA7B4CFEEB35" unitRef="usd">18237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-62C41D0C4D2B538E91037CF52144E3FE" unitRef="usd">715000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-9AB6FA9D431A5F09AC34AD28F48C6813" unitRef="usd">3415000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-C1501E9D1A611454CFCFCC42A51FFF0C" unitRef="usd">-114000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-549344672B2E57046344CC42A3A5B2A5" unitRef="usd">3529000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-57E8A99FA0245BA9BE753276BD87A58B" unitRef="usd">901000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-5562FDA8E2648C2DCE41CC413A66FCF2" unitRef="usd">-1005000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-82A6F8711D4BA9C8D5F1CC411AB482D0" unitRef="usd">1906000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q2QTD" decimals="-3" id="Fact-132D15E18C875C53A0C9E5E515B2F202" unitRef="usd">581000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-7703816ED9C25F31996D4CA578304E24" unitRef="usd">2581000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-BB3A3C80794459788DDEF128E3C3D468" unitRef="usd">85969000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-96387F69EE3B5C729C458A778855BDC3" unitRef="usd">472000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-0E6058688643566CAEE4A5851ADC7B52" unitRef="usd">-1535000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-E3EB611EBEE0520482D7160106761E18" unitRef="usd">28159000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-07ED1B8A3D4A55578957863849D950BA" unitRef="usd">5910000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-A98B51008CCB5E9698C4176422632187" unitRef="usd">-4779000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-772C06535C7C57A7984A749B63242DCA" unitRef="usd">465000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-12EBB65A94B65899AF4BD235E15CD4BF" unitRef="usd">2087000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-DDF72B25E65B56F5946CBC64BB111E6C" unitRef="usd">1714000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-4CBDA919611555B698C4F66AAF3659B9" unitRef="usd">-519000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-5D79AD30896C531BA24503A240EC7464" unitRef="usd">-3000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-50A21F9E951A570B922DD225C8E7885B" unitRef="usd">7457000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-CD2FEDD88D0056B6AACCA00FC7A0A852" unitRef="usd">10164000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-5ABAB6CA32F959EBBB9CFDB6B5CDBB5E" unitRef="usd">-1049000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-10A6CC6FBE0D5C2F9655137E2C01638B" unitRef="usd">1577000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-B305DD940B6D53D3BF888FEA8C0C0E42" unitRef="usd">8679000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-16146484826F5B96B16E08BDE1373C47" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-BEABE6B9220054DFB7A7B6358CE98791" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-3DA9C4516E1C5C348F8EBF4534B74A3E" unitRef="usd">4259000</us-gaap:InterestExpense>
	<us-gaap:InterestIncomeOther contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-7DBE53B4CDCF5619BFBA1AC84A9F95F4" unitRef="usd">2364000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-711BA372097D57ADAEC876AC3A13D865" unitRef="usd">4592000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-DC562F323A769C831E76CA7B42792073" unitRef="usd">2697000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="FD2017Q2QTD" decimals="-3" id="Fact-EB0BA4868540ACF108FBCA7B441C82BC" unitRef="usd">1251000</us-gaap:InterestIncomeOther>
	<us-gaap:InventoryFinishedGoods contextRef="I2017Q4Dec29" decimals="-3" id="Fact-70C174B1D6045FE48AB41CAD28AE4187" unitRef="usd">2854000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="I2018Q2Q2" decimals="-3" id="Fact-3FE04105F00C5BF893C021C4D1864DDA" unitRef="usd">3265000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-EFB9F7F0F014566BAB474DD3A653358B" unitRef="usd">7349000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" decimals="-3" id="Fact-E960F4D3D0D55CA99730C81F60D605BF" unitRef="usd">692000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-0C2ED9B967BA53C3845A7E425E3D1732" unitRef="usd">6657000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2018Q2Q2" decimals="-3" id="Fact-BE2490B11D185BE287DC7D7A7271AEA7" unitRef="usd">9136000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2018Q2Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" decimals="-3" id="Fact-429D92B0D0655DF2AE674271CD736FA9" unitRef="usd">765000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2018Q2Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-474CD469FAEF5A4EAC4F923FD5B31880" unitRef="usd">8371000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-922BC016423853B89E782868043322CC" unitRef="usd">6657000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="I2018Q2Q2" decimals="-3" id="Fact-CD9ADDFD080C5F7D9D996C7146715E22" unitRef="usd">8371000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterials contextRef="I2017Q4Dec29" decimals="-3" id="Fact-D0BD91FB37CF5E15978BFAF56007851B" unitRef="usd">498000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials contextRef="I2018Q2Q2" decimals="-3" id="Fact-88262909A4FA5B808815333F04E10534" unitRef="usd">2134000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess contextRef="I2017Q4Dec29" decimals="-3" id="Fact-3029AC244CC75F5D85164C401363415E" unitRef="usd">3997000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="I2018Q2Q2" decimals="-3" id="Fact-BFF40ECCA4355AF8BE96A6B65979BFAC" unitRef="usd">3737000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWriteDown contextRef="D2017Q2DEC31-JUN30" decimals="-5" id="Fact-16CF829712575540B2E110611454B3F0" unitRef="usd">500000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="D2018Q2DEC30-JUN29" decimals="-5" id="Fact-B7067538671B54FBA3184E8B4418FFEC" unitRef="usd">500000</us-gaap:InventoryWriteDown>
	<us-gaap:Liabilities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-328533F3A3835D2F97473D03FF3388D6" unitRef="usd">370333000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="I2018Q2Q2" decimals="-3" id="Fact-E763C7FE8526573C9D5AD7ED9CE2F6E9" unitRef="usd">136190000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A4B116F682245F3FA60645658899F938" unitRef="usd">655294000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2018Q2Q2" decimals="-3" id="Fact-53FC0CF887785840B5233C0DE6BF9682" unitRef="usd">911158000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8B53E46E72F95E26BAE0D95E17161693" unitRef="usd">115170000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-F4448DB4D352541EB7C3C69FE1930D21" unitRef="usd">99944000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LicensesRevenue contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-411C8E2ED8F554768E2A3FA8BD77AE02" unitRef="usd">20370000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2018Q1Fiscal_exel_MilestoneObjectiveAxis_exel_EMAApproval1LRCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-BB4EC9CE2C754B3D5CD6D386F538845E" unitRef="usd">45800000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-A508A6D4AB7F5C53A51AB243BB07E8E7" unitRef="usd">100938000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2018Q2DEC30-JUN29_exel_MilestoneObjectiveAxis_exel_EMAApprovalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-03356131A573566E8C50E1A642C08926" unitRef="usd">46000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-7FB0246AEC0E0334F52DCCA47228709D" unitRef="usd">31908000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2018Q2Q2QTD_exel_MilestoneObjectiveAxis_exel_EMAApproval1LRCCMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-65D0B15B7BBF59D71764D38693231259" unitRef="usd">200000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q2QTD" decimals="-3" id="Fact-A3331DFC76520D9E869BCCA4743D7C96" unitRef="usd">9156000</us-gaap:LicensesRevenue>
	<us-gaap:LongTermInvestments contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C46098D6E8BC59E4BACB8C206AB43465" unitRef="usd">64255000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="I2018Q2Q2" decimals="-3" id="Fact-D63A9559A1145D3B975CBEB543D451A6" unitRef="usd">94396000</us-gaap:LongTermInvestments>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-28F9B36E2855527799FBB9A0232994A5" unitRef="usd">-172086000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-F42D15A53DB652AB81575DEF73066242" unitRef="usd">6920000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-C2A268AB0C355DD88CED8D5FEEA3E727" unitRef="usd">81719000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2017Q2DEC31-JUN30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member" decimals="-5" id="Fact-B6716354E792044994C5D38C45731C83" unitRef="usd">500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-1714EEAB1299543988D245DB7D9E1AAB" unitRef="usd">-91800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-CB66F795032952C888D37D0AA10C305C" unitRef="usd">74393000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-D06265F52DEC5026BEF618747F4343BC" unitRef="usd">146577000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-205283F4224B5169BDE0AE684F2FE427" unitRef="usd">34356000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-8206714ED9985910B26091190D76B968" unitRef="usd">203351000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-3F9BABA221A0FECFD25DCC42AAC80A88" unitRef="usd">-22636000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-98B8CFCA98A47831151FCC42A9760360" unitRef="usd">225987000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-D99B805E648BEEDD0838CA7B4E34B72C" unitRef="usd">87494000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-60F96DBADA618249389DCC413B6AC7B3" unitRef="usd">-53143000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-E5F6216142112F5D36E7CC411BAE3590" unitRef="usd">140637000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-B0BF097B723758ACA7233ED2D90DE49E" unitRef="usd">17656000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-4B8CD07789245CCDB1A708648607CAB6" unitRef="usd">34239000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-8056A7DDF6B55F3A8894D19811FBD0B4" unitRef="usd">203351000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-8E27EA01B2D95E59A5E0056041CC248D" unitRef="usd">87494000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-5F97ACDB09F95C97A3EAF05B1DF4E272" unitRef="usd">17596000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-FCF5E20F3EF151A998297F513D2A5723" unitRef="usd">34246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-84B2F8F99B7754089D8111E3C1C946B3" unitRef="usd">203351000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-BADEBBCA54735E4897348C4748866F35" unitRef="usd">87494000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2017Q2QTD" decimals="-3" id="Fact-BA7FDABECA6D54359E65D6420C946E8F" unitRef="usd">17600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-55DEE224D8C6578693574C24EC29844A" unitRef="usd">-12228000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-592C687B74E45E209D4DAFA6EB631771" unitRef="usd">4689000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-18A45D17892E4D4238D3CA7B4AE9EBD7" unitRef="usd">2625000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-8C5743BC194758A8A3D0244FF864F999" unitRef="usd">-8876000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NumberOfOperatingSegments contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-0187EEA3BF2959829D24871B0BA8A159" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-20DEC0A521855CE385DA9425CFB1F635" unitRef="usd">132596000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q1Fiscal" decimals="-5" id="Fact-BA9BE014DECE6661B1D1CC3111CDC7D1" unitRef="usd">97400000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-5" id="Fact-22A9F33F9845C80D1D9DCC31117D3DED" unitRef="usd">96000000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-48CBB44E7A30546199258D4238142A1B" unitRef="usd">197750000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-9B773A36CDF2D615F4FCCA7B3B4D9D6E" unitRef="usd">100338000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2QTD" decimals="-3" id="Fact-6BDB21174119900B4DB1CA7B3CEEA457" unitRef="usd">71895000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-4D365D05821E56C483FC43E7E26D2D98" unitRef="usd">47299000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-FEB5B016941D552A8887E784DC56A1F0" unitRef="usd">202077000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-2B9AC14E125BFEDB677FCA7B3DFD10D2" unitRef="usd">85770000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-A4456BAFCD370D328862CA7B3F8EB354" unitRef="usd">27113000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-54F19A7181DD527E8418DCDC1A908FAE" unitRef="usd">16150000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-A789D9B000C65FFDA7C6ADA4671FC556" unitRef="usd">23787000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-69D1A75663AA5E58B98A7BBB86EEDF5F" unitRef="usd">12092000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-DFBAF496328C5044BB6FADA5E5E65738" unitRef="usd">948000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-C04AA68F6D2A5B4EA0E928F0EC2BE435" unitRef="usd">297000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-6C8E3165ED2E542AAA62864DB3D22DDF" unitRef="usd">-384000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-2B6F65C36FD257B1A2783FB83483ADA0" unitRef="usd">156000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q2QTD" decimals="-3" id="Fact-2F9A92AF2A0F538DAD8E99D3FA5A4D6A" unitRef="usd">207000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2017Q2DEC31-JUN30" decimals="INF" id="Fact-0149F8B1F27D5100A3CBFD288D2B19C0" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-FC540F2C43AB55848EFB5A7AB199DFED" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2018Q2Q2QTD" decimals="INF" id="Fact-AB46572EF6585C09AE148CF1B5EAF3B2" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2017Q2QTD" decimals="INF" id="Fact-26BA0CF63D885D1083F18DCDC1989FD5" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2017Q2DEC31-JUN30" decimals="INF" id="Fact-0AF1A065C5935EABAC6A1172099CCDB2" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-43DD5307FC055325B1DD5E4B4CD9B203" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2018Q2Q2QTD" decimals="INF" id="Fact-23BB62A623B5569CA36D5926F9A083E3" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="FD2017Q2QTD" decimals="INF" id="Fact-8AF6FB3DA2D0501CB9F7DA8996ED1D06" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9F639AE6CBA250F096722B570C741CCD" unitRef="usd">2113000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-9E7AB47C3A955EBF93042182D95DA9F5" unitRef="usd">3630000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-658C1038D77F5CEBB4DC8626112AACC9" unitRef="usd">-148000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-8783168E71A55EDDBAD86B4065BDAC15" unitRef="usd">490000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-0DFA01064A465045AE4C7DC2DA7544FE" unitRef="usd">-5913000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-64D249AE9C76502A92E6A9AF676A0C80" unitRef="usd">97000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-899EAD6BFC2B5D12B726235C2CBE9D17" unitRef="usd">-72000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-8045B96789CD52E4955534A89E88D5F9" unitRef="usd">-5868000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-9569EEFEB1CF5CCEA9DA528D3494CA38" unitRef="usd">-663000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-415CA5930AB258339AC41962A81E99BE" unitRef="usd">1877000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-1A9E5E0199E1B3F20E4DCCA4790CFBB7" unitRef="usd">1559000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-BF84FE0B2534FA6289F9CCA47B11ED73" unitRef="usd">-327000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="D2017Q2DEC31-JUN30" decimals="INF" id="Fact-A8CFECEE16F4512BADE4EF43B0426984" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-DC50081178B6C7056AFEDC62195D5958" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="D2018Q2Q2QTD" decimals="INF" id="Fact-85AA858CF9CDD8D830ADDC61FE79459F" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2017Q2QTD" decimals="INF" id="Fact-5DEC62A5E92E2DCBDACADC620DD185F3" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaidInKindInterest contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-6F88811B51225501B194489F839F68A3" unitRef="usd">-11825000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-2E60E0D916A95BCE9939CC5DCC255D03" unitRef="usd">0</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-41899834174655CF80ACB211A91832AC" unitRef="usd">2331000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-37926FD847EB5858903902E1010340F6" unitRef="usd">2976000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-D9BD89AC483D5FE899860BC7541A554E" unitRef="usd">154809000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-077D948E4B1953C2962C5E07E9DA41D3" unitRef="usd">227012000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-F32789047D6F53CA956497DCF4BD610D" unitRef="usd">2298000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-865D83BF3E085713938D3F826322605D" unitRef="usd">15182000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-3A23F9A03E2A50EB56B5CA8A219AAB6A" unitRef="usd">998000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
	<us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-0233C8A2EB3E4E8CBEA2CA8A219F0FCB" unitRef="usd">2723000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2017Q4Dec29" decimals="INF" id="Fact-2DC56BC4102E58438C6A58949E8DEE57" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2018Q2Q2" decimals="INF" id="Fact-54CEDC741C5555EF83913A94B245E972" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2017Q4Dec29" decimals="INF" id="Fact-CF534C239BC7510F8839A97EBD213A4D" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2018Q2Q2" decimals="INF" id="Fact-4C0D4DFEBC2B55AF8C3874B313970C5E" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="I2017Q4Dec29" decimals="INF" id="Fact-8DC4F7CA191A568D8D6B4528340C4C7B" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="I2018Q2Q2" decimals="INF" id="Fact-C6ED0B5ECD1E54869DFFA25A119B1FAA" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2B5C5E5F17BF577B9592EE42E5707AD8" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="I2018Q2Q2" decimals="-3" id="Fact-5B49A733682D50B783846E9B701E5484" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-701A26EEBC0C5EF78E5246CD25EF014B" unitRef="usd">8750000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-A8A5D39095235903A4D6E92BCEF0B5ED" unitRef="usd">10327000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-FFD802DEDD1F5ECC89EFABFB24F9C3C6" unitRef="usd">200893000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-2B9175F26F3252EF97E5CD14506B2A38" unitRef="usd">139948000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-E6E1344229635BC5B42EE0ED6D17A7B1" unitRef="usd">639000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-C1601CA9D73259F18EAAFAC62873A6BB" unitRef="usd">209000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-FC648874C1CD54C49FADA9DBEE3767FC" unitRef="usd">37294000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-8D830C2C5C4C56C186D71B379A5812A0" unitRef="usd">10237000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-E354326971E95E6B9E69D1AD1E0FB98B" unitRef="usd">12980000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-4C232201BF455C168A762AFF58B0E3BF" unitRef="usd">6550000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockPlans contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-91571F0437AB55598785BFC637075682" unitRef="usd">3053000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-61E7A5F7899557B5BA79DDBFDD62BD0B" unitRef="usd">3650000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5715B1313B135E799F9DF673FC96A85B" unitRef="usd">48543000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-42AB06D43F855B57A43B0BEA95B19AA8" unitRef="usd">14146000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-CEDF62919B2C5A2380794D80C156C1DA" unitRef="usd">5959000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" decimals="-3" id="Fact-327C16075B55D0D6261ACDA658F689ED" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-2B083C4B2F665CE58BA923F15D6D6901" unitRef="usd">22114000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-AC2BF35475C05245856F547C20C5F552" unitRef="usd">1609000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-15556E17EEB359A4AE74927A0007502D" unitRef="usd">4715000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2" decimals="-3" id="Fact-AAFA7893062C54EBA1AFC54DC86DC27F" unitRef="usd">78898000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-873BE33FA4ED5E77AEA2BCF048830FC8" unitRef="usd">15507000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-43AFE1B8218756D2B5BA683D697AC0E5" unitRef="usd">1991000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" decimals="-3" id="Fact-74FB07E1E9401DB10BDCCDA655CAC40A" unitRef="usd">14530000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-E14E22017EA05B85828C9AC3D9DC71F4" unitRef="usd">1839000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-631B6D6FD04E55628BAE6DCACBD47DF7" unitRef="usd">4028000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2018Q2Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-5749F00CCB095DB18E35E540BCB6F2FB" unitRef="usd">41003000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A91A163F98D55C448399F51DFE3FF68F" unitRef="usd">25743000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2018Q2Q2" decimals="-3" id="Fact-2F883470D4815845BA66BC672FEC4DA7" unitRef="usd">64744000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2018Q2JUN2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" id="Fact-2B1DC3EE64DDD5A3045ACDB5B8C7EC32">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReceivablesNetCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A95B889141605E8DA059CC25F4AE920F" unitRef="usd">81192000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-1FA6E096B9B95A38879EF5855A4D483E" unitRef="usd">167161000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-79D211043122E2610008CA9CF036EB67" unitRef="usd">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-A22AF287EBB095CBE4B8CA9CF032FA78" unitRef="usd">304000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-32DC05A400765C47A36C5FEFB2B6B595" unitRef="usd">185788000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-CA6ABF60D1DB5544B7904CA8E896BB12" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-AA8BD69DE5835D1AA9C5D85D32087B17" unitRef="usd">51424000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-489DD190F6BC55EE99009B61C6C49777" unitRef="usd">80245000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-C714162E00AF5C40862DBD10DE6B6D19" unitRef="usd">42488000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-B8BA66FF778BF8E1E215CA7B37BA0FCB" unitRef="usd">28214000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-5F3A0AE0D6EB257A9F6CCD762C00D4A6" unitRef="usd">0</us-gaap:RestrictedCashAndInvestmentsCurrent>
	<us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-66D2AD84443752FBADA6D01DE7F37D2E" unitRef="usd">0</us-gaap:RestrictedCashAndInvestmentsCurrent>
	<us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-BF183A7CEB115A28A1BB628289733006" unitRef="usd">504000</us-gaap:RestrictedCashAndInvestmentsCurrent>
	<us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-81983AAADE2A5E338076680CC3646EF6" unitRef="usd">504000</us-gaap:RestrictedCashAndInvestmentsCurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-7BFC837533BCCE222983CD762C1AD27A" unitRef="usd">4650000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-FC7A04134DAF591BBD3CB0DD98EE07A2" unitRef="usd">4150000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-243084626BAA5FC3856C42BDFB34488C" unitRef="usd">4646000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="I2018Q2Q2" decimals="-3" id="Fact-957B4FD6783F5385B54CD295B54E3165" unitRef="usd">1100000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2017Q4Dec29" decimals="-3" id="Fact-7363991F1FFC58B5B81CF6969CBD0D5D" unitRef="usd">-1829172000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2017Q4Dec29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-109A49511DD2FFEBFABAEDCD60B8F5D1" unitRef="usd">-1829172000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Dec30" decimals="-3" id="Fact-F3B570F39587E0EBC086B49BF0C533F0" unitRef="usd">-1570667000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-E9CF5BA949746323AFE1B49B278D5384" unitRef="usd">258505000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q2Q2" decimals="-3" id="Fact-6A0DC6F6E83F53998923B3959B7A308F" unitRef="usd">-1367316000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2018Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="-5" id="Fact-D969AC439DA9566C85A4644BDDD472F3" unitRef="usd">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRemainingPerformanceObligation contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-B3E52BB1FC265A278EDB2FD7ACAB055A" unitRef="usd">51600000</us-gaap:RevenueRemainingPerformanceObligation>
	<us-gaap:RevenueRemainingPerformanceObligation contextRef="I2018Q2Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-87C8D627EEBE59CBAAFA50F53B97A9C4" unitRef="usd">28900000</us-gaap:RevenueRemainingPerformanceObligation>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-404181E5D61251648ECC18D02D8616E0" unitRef="usd">179895000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-0B28CC1654285C2C820708974E1108B1" unitRef="usd">23059000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-45414877570A5D37816E670154E79FA2" unitRef="usd">24124000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-9A9AC087316C508098A60D137FA210DF" unitRef="usd">32254000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-532014A6B991569EB5B506BC81AFB832" unitRef="usd">42449000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-9797D45E000959F6BD3D6456CC7C7F92" unitRef="usd">10024000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-9A9BE365E0FE4A4979BBD49968441099" unitRef="usd">47985000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-CFD063F02B0450C697D89C6EB51A099A" unitRef="usd">143220000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-D77FDF9DDA6152A98642F9140E125BB0" unitRef="usd">13661000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-67560CC649B95DAC821D0F376D135327" unitRef="usd">156881000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-3AEF0ACA2101526182A9D3766946B7A9" unitRef="usd">163046000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-8FF026F607555DD6AD93834EF5CA5A60" unitRef="usd">6825000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q2DEC31-JUN30_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-9EE1C6C02EB05B91A9BB0931A8A6CA81" unitRef="usd">10024000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q1Fiscal" decimals="-5" id="Fact-F317B11B617F70549946CC2EB4280557" unitRef="usd">213700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-5" id="Fact-593D880BD2DB3013DF61CC2EB40B25B0" unitRef="usd">212300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-09C6DA06A9935A149902C5FBD01AA838" unitRef="usd">399827000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-F41ADFCF7722B106FCF8CC428CB149D2" unitRef="usd">-22750000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-8A87016FF9D544854CEFCC428B3122C4" unitRef="usd">422577000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-44AEE01D90DA5F29B2AFBDE52D6799AB" unitRef="usd">38000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-E19AF432392057A192CFD30C455D24A5" unitRef="usd">44652000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-33390A53EF2C5303B95AE5F9ECF10CB1" unitRef="usd">52809000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-2C23F5FA3D6851F6A1727A3A1093E9AD" unitRef="usd">38622000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-C7FE9F9630FE5317B733EB049D18BB84" unitRef="usd">87852000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-ADD1E4DA74CE9CAF868FD4995F6C9709" unitRef="usd">137892000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-587AE09C4A3C5B279D73CB8DB483BBA0" unitRef="usd">270055000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-AEE9A4AFDD63505EA1F115BCBB50579B" unitRef="usd">10053000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-0DE6BD9426115DCE8217368E9C3F260C" unitRef="usd">280108000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-04A6F59A35C15BFC880B86606D0716F4" unitRef="usd">287072000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-592E78D032D05064B65DF9310261F221" unitRef="usd">24903000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-7AF08D06633A51C7ABE23ADC85FDCF13" unitRef="usd">87852000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-25A33B74918A84C5A3BFCA7B2F736935" unitRef="usd">186108000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-9B7BC7E547E406D4DEC3CC4135DB98D0" unitRef="usd">-54148000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" decimals="-3" id="Fact-D07355D23D6AE358E01ECC4116D1B83F" unitRef="usd">240256000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-28E26722F64A298B16EBCCA708530651" unitRef="usd">19714000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-1E479715FE853F30A3126B17246B32FF" unitRef="usd">23321000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-9A4A368061BB58FD0CBC6B171BE544E2" unitRef="usd">26421000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-AB219F40944885096B866B172CE0DE90" unitRef="usd">18475000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-2CD3CFB366ED4B6B92806B17137A283C" unitRef="usd">34043000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-F30BE7D5A0172DADFC4FD4978D67886B" unitRef="usd">64134000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-EBC451BF2B105EBA17D3CCA78D9D68A0" unitRef="usd">141121000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-8CAD20E8728B7F708B6FCCA79344F2C4" unitRef="usd">4715000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-CB84A684D76DED96ECCECCA7997BDC4C" unitRef="usd">145836000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-3A77D2B3D406FF826F4ACCAB1EE8A5F3" unitRef="usd">150079000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-2899D6384BFEFD484C7CCCAB2CF1C957" unitRef="usd">1986000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2018Q2Q2QTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-9500E531758AEC70644DCCAB2594FC2E" unitRef="usd">34043000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-3" id="Fact-0C4752157770A3815B9ACA7B311312F2" unitRef="usd">99008000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="-3" id="Fact-2EE5FA7AC50A2BF15DACCCA7083B6B48" unitRef="usd">13619000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="-3" id="Fact-AD1785FA4FE047313A696B1728FC4F9C" unitRef="usd">12846000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="-3" id="Fact-7670B520A71B436FAF176B1720825924" unitRef="usd">18435000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="-3" id="Fact-DED7EE51AEFC1FAD84736B17316C7046" unitRef="usd">22599000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="-3" id="Fact-6126ADF7345766754C346B1718081643" unitRef="usd">5494000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_MajorCustomersAxis_exel_OtherCustomersMember" decimals="-3" id="Fact-0D6A9B4E21941306DFD4D497935CAEB9" unitRef="usd">26015000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-368C79F50D7AD8E603C6CCA79036F4AF" unitRef="usd">80861000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-E0C6478D35D21E1AB5ACCCA796F707A5" unitRef="usd">7143000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-6DDFECF091357B4125BECCA79D9B114A" unitRef="usd">88004000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-459CF6A24CE7D701BC3CCCAB227A9BA3" unitRef="usd">89371000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_StatementGeographicalAxis_exel_OtherGeographicalAreasMember" decimals="-3" id="Fact-D5AC6555EE8AA04595D2CCAB3075EDED" unitRef="usd">4143000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-9773C1C801D907625D28CCAB2A330656" unitRef="usd">5494000</us-gaap:Revenues>
	<us-gaap:RoyaltyExpense contextRef="D2017Q2DEC31-JUN30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-A69AE8E6C2B25AF1846B4FA4BAC4CC43" unitRef="usd">5363000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-CC61B4B1002F55A6A6F8986D73FCF661" unitRef="usd">10753000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-AA3F28B49543520884CB0F73BA779B46" unitRef="usd">5628000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-3226B37D510B5D8A9009E29C7C5AA2F2" unitRef="usd">2962000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyRevenue contextRef="D2017Q2DEC31-JUN30_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-69F888B5DE3F93D3B82ECD1CE45EF46B" unitRef="usd">3665000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="D2018Q2DEC30-JUN29_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-AC2ECA7BCB3AE9B74AA2CD1D80EFE478" unitRef="usd">2895000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="D2018Q2Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-89862CED20B9820C516BCD1D4F9E824F" unitRef="usd">1546000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2QTD_exel_PeriodGeneratedAxis_exel_Q416Member_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-50D3EF3DA3705F108908BB498CC6CF28" unitRef="usd">1100000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-146D27FC7096DD2A3AD6CD1D5397F60F" unitRef="usd">1367000</us-gaap:RoyaltyRevenue>
	<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-6ED25D90987D5552B9885B0B2F400966" unitRef="usd">21336000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
	<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-C547A347FAFC5C18959C36D0D5070D21" unitRef="usd">51974000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
	<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-0B94CD4D2AFB86D8452FCCA469C048A2" unitRef="usd">26810000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
	<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="FD2017Q2QTD" decimals="-3" id="Fact-966414AD80D24E0DD903CCA46BC84B90" unitRef="usd">12254000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
	<us-gaap:SalesRevenueGoodsGross contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-201EA8F9907A52178F43AA0440CA731D" unitRef="usd">178217000</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueGoodsGross contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-81EF8A00B4ED563BBF69444429F55A42" unitRef="usd">332082000</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueGoodsGross contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-A73B23CEAAA1F124ECC0CCA4670EE68C" unitRef="usd">172646000</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueGoodsGross contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9226A3228CA69EDF7ACDCCA468A62821" unitRef="usd">100258000</us-gaap:SalesRevenueGoodsGross>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-CD14B08443DD5C07AAC7CACEF221B856" unitRef="usd">156881000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-F6A5A30F5C3957C69A5D0608A13FA904" unitRef="usd">280108000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-1CC579F1285904C42FFDCA7B2A43B682" unitRef="usd">145836000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-02744EABB70791B131A1CA7B2BDF1C96" unitRef="usd">88004000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-9283EC4DD8265EC78C7B0E21E5A8B51A" unitRef="usd">74955000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q1Fiscal" decimals="-5" id="Fact-EF291F2789B97EA5629FCC30C004C588" unitRef="usd">54000000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-5" id="Fact-90D2CEEA493F7E69376ECC22AB701487" unitRef="usd">1400000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q1Fiscal_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-5" id="Fact-9813498C00A2A24D375FCC30BFE6EAAC" unitRef="usd">52600000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-23428B51A46B510D9E8BE26D44F8FA0E" unitRef="usd">105869000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-D0DD5C1402294221E81DCA7B38B48C3D" unitRef="usd">51853000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-F717A9B76175F6E3BF64CA7B3A524A25" unitRef="usd">40667000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-3F36D598675C5D9EB4EB1520180B0060" unitRef="usd">9740000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-FA105B3D719C5C7E855864D9C8E375E6" unitRef="usd">18588000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-271C9CCDBB18583C9764F82AF9ABD52A" unitRef="shares">120886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-D455BFC795065608920FBA039551D4DF" unitRef="usdPerShare">19.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-655D75F9A5995C6AA2C7429F9D829B8B" unitRef="shares">300670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-4D521E5C45AD54BE9C6B390ABF53A064" unitRef="usdPerShare">23.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-16B2A57F97DC5D7BA29E3010895EEE4A" unitRef="shares">3762990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-59BD769048985B96BE89FEDC8DC7EB37" unitRef="shares">3601202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-271D026DCAA55F84BF3564F3E6F06CAA" unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="I2018Q2Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-E15CD983777B543192EA5817B60193EB" unitRef="usdPerShare">19.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-B8578BE0F8DF5622AD0A6252C8068DBF">P1Y7M27D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-E5D0859884FA53709135138E86C2A5B1" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-4C2F54BB3F0F5DF9A753B254A10027BE" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-C2C1D1F5F1FD51E99DBAFA1A99687FFE" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-7364270E153053BE87667DA9EC17091E" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-60AD0A4603EF5508AA50CD92FAE17FEF" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5D99446004676CA5A113CD92CB0636D9" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-1D7C4EE5710171E843EDCD9300DF490C" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-0071BA60DAAFA644428DCD92CF3A3B98" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-E3BAAF3E86475BB0A50A883F87B326C5" unitRef="number">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-DB6096674C8C50B0BEFF3A0AC08C643B" unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-DA26C25D79A9555C89CC1697618D5BEA" unitRef="number">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-447C7AA645285CF9B442940D71754440" unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-A6C5AA2856C51FBB38A1CD92ECE26783" unitRef="number">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-F9E1CA4C07D8DDBC099CCD92C39D4F1D" unitRef="number">0.0266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-85E6A1E9EBD963E05DC0CD92F768C25B" unitRef="number">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-E8ADCE1151B9AE3C3B6ACD92C6EC8CC2" unitRef="number">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-2BE8B2A955C454E2873538F452D1DB7E" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-3647F9F83BB45B27A641EA0F5F7090B2" unitRef="number">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-374156D63AAE50F2BC6D8E72F40C1E38" unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-0B15C451411A57448510B18DA86AFB92" unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-0D346078BEBC17D8444BCD93038A9BC6" unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-83D6335988E8034A5BCACD92D5207B64" unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-6CE08D22D0FA7052D20ECD930692E18C" unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2C630C26FC1D816DA883CD92DA056BE8" unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2018Q2Q2" decimals="INF" id="Fact-72A843A06D665A6DBDA2CEEF97B3F7F0" unitRef="shares">19509911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="I2018Q2Q2" decimals="INF" id="Fact-02CF5F46472A573AAEB38E6D74B4E048" unitRef="shares">16249965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="I2018Q2Q2" decimals="2" id="Fact-7362D959039957A18FDFCB67FD2BF68F" unitRef="usdPerShare">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-0147FBECDA095A0AB31077756C284E54" unitRef="shares">102177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-AA3D6FCFC11A570692048F7844E1D5EC" unitRef="shares">818842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-C256B2B8AFE351A499074FCF6517D0E9" unitRef="usdPerShare">4.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-EB679EFE08865A5F9FFFA85892094997" unitRef="usdPerShare">10.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-8F862FA1F70658C8AC693E72607F7C74" unitRef="usdPerShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-9D898B2401F959BB9CEF60D656A27FF7" unitRef="usdPerShare">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-BC44AA7D176950F387BBD8C0336B819B" unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-E62F38336F3350118DF68EAC84A51ACF" unitRef="usdPerShare">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-23FF191AAEA753A29F63478A3E80E8AD" unitRef="usdPerShare">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-88362826EF805B92840BA93B63E9BDC5" unitRef="usdPerShare">10.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="I2018Q2Q2" decimals="-3" id="Fact-DD00BD3090925AD3A598F7D89EDE919E" unitRef="usd">312900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2017Q4Dec29" decimals="INF" id="Fact-4FABC330A16A50F69C537A5BBB76B83C" unitRef="shares">22208446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2018Q2Q2" decimals="INF" id="Fact-B9DEE2FC03075BF48913CD424C196ABF" unitRef="shares">21783471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2017Q4Dec29" decimals="2" id="Fact-6A4625E57E0F5D07B57C3CF82C81B4E5" unitRef="usdPerShare">6.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2018Q2Q2" decimals="2" id="Fact-6A691EA0B08958289E5AFCE31B572FA8" unitRef="usdPerShare">7.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="D2018Q2DEC30-JUN29" decimals="2" id="Fact-D6EC394051C6561586ADB2D8AB0438BC" unitRef="usdPerShare">5.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="D2018Q2DEC30-JUN29" decimals="2" id="Fact-5A520C8ADC74534790CDB9DE7F793179" unitRef="usdPerShare">15.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2018Q2DEC30-JUN29" decimals="2" id="Fact-C0300258EABC5777A21166C743D7D7CF" unitRef="usdPerShare">22.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-9EA9D3D3D83157D78C832D9FD99704EF">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q2DEC31-JUN30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-F19E0D2FE5AF5B59B99126143AD63DF9">P4Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-9CD8818179E55E9B85439F8EAAEA565F">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-34BF2A8822E857C28C661519AE83A07D">P4Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-24F245F1DE4549CAFB8DCD930A2C9A01">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-7CEFEDD03B5737354398CD92DD1FBFFA">P4Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-9CF2DCA050A0B2424B99CD930D6BCD00">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-358DF3C50A69810EDEEDCD92E29187B8">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="I2018Q2Q2" decimals="-3" id="Fact-B7F28CDB39385770BB965C1098708283" unitRef="usd">271709000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="D2018Q2DEC30-JUN29" id="Fact-6B5449AD00435EF58426D7A2DBE61AA5">P3Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2018Q2DEC30-JUN29" id="Fact-3BB0AE97CC51553ABE02036D9AE7A6D9">P3Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:ShortTermInvestments contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B615F1E0D0C95704ACF511C3E189C16D" unitRef="usd">204607000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="I2018Q2Q2" decimals="-3" id="Fact-A2D555D8FB0F57159123A9AB7C2D8CDB" unitRef="usd">251516000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2018Q2DEC30-JUN29" decimals="INF" id="Fact-F778FE8FB4125E0E9394D38A2C00D9D0" unitRef="shares">1141640</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5E9A8F98EB2F50E1B66B5367A5E12075" unitRef="usd">284961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2018Q2Q2" decimals="-3" id="Fact-BCE99BE9EE42568E8E4125FDB416A8B4" unitRef="usd">774968000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-36B5FD6CF2945CBDBB3A8DE16871F45C" unitRef="usd">117000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-4FBCA14BC28855108C86E86D94F6EECA" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-95F0996916C95ED0A298D940D0035656" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-CD3FDEC6C2205B6B9D39E3CBD3D1B648" unitRef="usd">60000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-9ED2C60281855731AB2746C9A9C6EA12" unitRef="usd">-7000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-6FFA3B804A3F5BDEA5B75BF00A5EE228" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-3ADA95A987BF55848E7622E6F0AECD09" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9573C6B493BD5F83BD8EEA15271B55E0" unitRef="usd">-4000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6795312D32D05902B235CFAE3B5FEDD1" unitRef="usd">9493000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-ABA99C1D00DD586EA9F15FC8804AC71E" unitRef="usd">1795000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-05A724B99AFD5131AA8D678F201ED0CB" unitRef="usd">5770000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-51819D94CD3A52F2B5D6D898D0D5A179" unitRef="usd">1928000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2018Q2Q2" decimals="-3" id="Fact-23678278B36D5ED3B9BA8392E32EDFD4" unitRef="usd">13747000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2018Q2Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-C16C4FA27D1954FE9C91B0D9AFF1714F" unitRef="usd">1281000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2018Q2Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-162E4B2BBC9659CA84563BE2141F8BCC" unitRef="usd">9862000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="I2018Q2Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-CB2AA58BF57E5B78848126ACFB40A618" unitRef="usd">2604000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-7204CDCE44DC5AD1AF97C9AE6B5CE769" unitRef="usd">47719000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" decimals="-3" id="Fact-BF8FC24CD73A557EA2880D8ACDF0762B" unitRef="usd">6850000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" decimals="-3" id="Fact-A41A1B216D8A5FBDB5A6299487CCCD41" unitRef="usd">10194000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:ValuationAllowancesAndReservesDeductions contextRef="D2018Q2DEC30-JUN29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-3" id="Fact-FE70E95C5CE25D14925C3177E9AFFC38" unitRef="usd">30675000</us-gaap:ValuationAllowancesAndReservesDeductions>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-B1271CDACD9E502688BC6E46A2DF4C8C" unitRef="shares">18730000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-E585E43BAFB856FBB85458BE212148B2" unitRef="shares">16150000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-15A925600D7B530FB07E43431B8757B1" unitRef="shares">14905000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q2QTD" decimals="-3" id="Fact-466266ABE7865E6DA0F1A8198A6C0347" unitRef="shares">18031000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-D78F706B20B15B09B4D2A40C06363B74" unitRef="shares">310759000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-A474A6C8A33953B2A5BE1E95901F2825" unitRef="shares">313024000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-3305E7CB4D8BA30E2F2CCA7B52372D6E" unitRef="shares">312241000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q2QTD" decimals="-3" id="Fact-15E7EA9DF30E4D8E2A3ECA7B53134273" unitRef="shares">311219000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2017Q2DEC31-JUN30" decimals="-3" id="Fact-7CC3D22B008352CAB794DAD4BDFB04DF" unitRef="shares">292029000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2018Q2DEC30-JUN29" decimals="-3" id="Fact-7016328DC5FA54DA899495DB06605E64" unitRef="shares">296874000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2018Q2Q2QTD" decimals="-3" id="Fact-87C6EEA4401758AAADC7251B88D7253B" unitRef="shares">297336000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-2FA05ABA021782E2A072CA7B51C3139B" unitRef="shares">293188000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<exel:CashCashEquivalentsAndInvestmentsTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-A51B7371F43357CDAEECD5184EC50113">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;CASH AND INVESTMENTS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;248,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;183,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;188,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;139,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Investments Available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Investments by security type were as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;595,607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;594,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investments available-for-sale were nominal during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;195,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;200,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross unrealized losses on commercial paper in an unrealized loss position 12 months or greater were less than $1 thousand.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;160,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;149&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;134&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;500,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;377,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;94,396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;594,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</exel:CashCashEquivalentsAndInvestmentsTextBlock>
	<exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-BB79FB50ADDB5BFF8B6127CBE4FB645D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;32,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(30,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(47,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-557ADF892764567B924B1A2176CAFEE4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;195,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;200,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross unrealized losses on commercial paper in an unrealized loss position 12 months or greater were less than $1 thousand.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;160,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-3E51258523D2529BAF1FAA28B89D90DC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="D2018Q2DEC30-JUN29" id="Fact-94AF2448A8B05A53950BB6855726E811">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2016-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-18&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;etrospective transition method in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the accompanying Condensed Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASU 2016-18, we no longer include purchases &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;of restricted cash and proceeds from maturities of restricted cash &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in our cash flows from investing activities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CollaborativeArrangementAccountingPolicy contextRef="D2018Q2DEC30-JUN29" id="Fact-EC38D3C7599B5BF7A30ECCABC9EBE256">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Collaboration Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for product supply; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Except for profit sharing arrangements and payments for product supply, each of these payment types are within the scope of Topic 606. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&amp;#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit Sharing Arrangements: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accounting Standards Codification Topic 808, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;Topic 808&amp;#8221;). &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We expect to recognize an annual profit under the agreement for the year ended December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues on the accompanying Condensed Consolidated Statements of Operations. Historically, we had not recognized a profit for any annual period from the commercialization of cobimetinib in the U.S. and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses on the accompanying Condensed Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Sales-based Milestone Payments and Royalties:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-06737EEB70805683A63C94D67D081613">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COLLABORATION AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;From time to time, we enter into collaborative arrangements for the development, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for non-refundable up-front license fees, development and commercial performance milestone payments, payments for product supply, development cost reimbursements, royalty payments and/or profit sharing. See &amp;#8220;Note 2. Revenues&amp;#8221; for information on collaboration revenues recognized during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&amp;#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&amp;#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&amp;#8217;s ongoing development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we had achieved various milestones totaling &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$125.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we achieved an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone upon the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;EMA&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;approval of cabozantinib &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;first-line treatment of advanced RCC&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone upon Ipsen&amp;#8217;s filing with the EMA for cabozantinib &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced HCC&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; commercial milestone upon &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Ipsen&amp;#8217;s achievement of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales cumulatively over four consecutive quarters&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The timing and amount of revenue recognized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for those milestones is described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$199.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, including a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone upon the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;EMA&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;approval of cabozantinib &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC, and additional milestone payments for other future indications and/or jurisdictions. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;T&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;he collaboration agreement also provides that we will be eligible to receive contingent payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$519.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; associated with sales volume milestones. We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We were entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, which was reached in the second quarter of 2018. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we are entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of annual net sales, with separate tiers for Canada and the remainder of Ipsen&amp;#8217;s sales territory. These tiers will reset each calendar year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with BMS; CheckMate 040, the phase 1/2 study evaluating the combination of cabozantinib with nivolumab in patients with both previously treated and previously untreated advanced HCC being conducted in collaboration with BMS (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with the Roche Group. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product will be supplied&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;at our cost, as defined in the agreement, which excludes the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GSK on Ipsen&amp;#8217;s net sales of any product incorporating cabozantinib.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;U.S. Food and Drug Administration &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&amp;#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We identified the following performance obligations under the collaboration agreement with Ipsen: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib, as described above; and (2) r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;esearch and development services, which includes certain committed studies for the development of cabozantinib, p&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;harmacovigilance services and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;participation on the joint steering and development committees (as defined in the collaboration agreement).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We evaluated the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;collaboration agreement with Ipsen&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; under Topic 606 as of January 1, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Based on the evaluation as of that date, the up-front, nonrefundable fees, the milestones earned and royalties earned as of December 31, 2017, the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone we expected to achieve in the first quarter of 2018 upon Ipsen&amp;#8217;s filing with the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;EMA&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for cabozantinib &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC, and the estimated reimbursements for our research and development services performance obligation &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. The transaction price was allocated to the performance obligations identified based on our best estimate of the relative standalone selling price: for our license, the estimate was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate and for r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;esearch and development&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; services the estimate was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. Other than the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; HCC filing milestone discussed above, variable consideration related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate to the license transferred to Ipsen and therefore is recognized at the later of when the performance obligation is satisfied or the related sales occur. We re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Revenues related to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time, upon execution of the collaboration agreement in February 2016. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues for our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;research and development services performance obligation are being recognized using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union, which is early 2030. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$51.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenue for a commercial milestone from Ipsen that we earned in the second quarter of 2018 upon Ipsen&amp;#8217;s achievement of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in net sales cumulatively over four consecutive quarters. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that sales-based milestones relate entirely to the previously satisfied performance obligations for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the transfer of an&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; intellectual property license and therefore recognized the entire milestone in the quarter the milestone was achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenue of a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC by the European Commission (&amp;#8220;EC&amp;#8221;), of which &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$45.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was recognized in the first quarter of 2018. We determined recognition of the milestone during the first quarter of 2018 was appropriate following the Committee for Medicinal Products for Human Use&amp;#8217;s (&amp;#8220;CHMP&amp;#8221;) positive opinion of cabozantinib for the first-line treatment of advanced RCC. The positive CHMP opinion was reviewed by the EC as part of their approval process. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our determination that we expected to achieve the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone resulted in a change in the overall &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;transaction price of the collaboration agreement, as it was probable that a significant reversal of cumulative revenue would not occur. We recognized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$45.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in revenue in the first quarter of 2018 which represents &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the portion of the milestone that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license and research and development services. The remainder &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;of the milestone &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;was allocated to research and development services to be recognized in future periods as those services are delivered through early 2030, which included an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; recognized in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the second quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Ipsen was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$15.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was included in Current portion of deferred revenue and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$9.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was included in Long-term deferred revenue on the accompanying Condensed Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&amp;#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; upfront nonrefundable payment from Takeda. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2018, we amended the collaboration agreement to modify the milestones we are eligible to receive under the agreement. As of June 30, 2018, we were eligible to receive development, regulatory and first-sale milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; related to second-line RCC, first-line RCC and second-line HCC, as well as additional development,  regulatory and first-sale milestone payments for potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$83.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; associated with sales volume milestones. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, and after the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, we are then entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;on annual net sales. These tiers will reset each calendar year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Takeda is responsible for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the costs associated with the global cabozantinib development plan&amp;#8217;s current and future trials, provided Takeda opts into such trials, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In accordance with the collaboration agreement, Takeda has opted into and is co-funding&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with BMS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda, as well as a quality agreement setting forth, in detail, the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;respective responsibilities pertaining to the quality requirements of the aforementioned supply to Takeda. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&amp;#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; years of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&amp;#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&amp;#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We identified the following performance obligations under the collaboration agreement with Takeda: (1) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the transfer of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;an exclusive license for the commercialization and further development of cabozantinib, as described above; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, p&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;harmacovigilance services and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;participation on the joint executive and development committees (as defined in the collaboration agreement).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We evaluated the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;collaboration agreement with Takeda&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; under Topic 606 as of January 1, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Based on the evaluation as of that date, the up-front, nonrefundable fee &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and the estimated reimbursements for our research and development services performance obligation &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. The transaction price was allocated to the performance obligations identified based on our best estimate of the relative standalone selling price: for our license, the estimate was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate and for r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;esearch and development &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;services the estimate was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. Variable consideration related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license transferred to Takeda and therefore is recognized at the later of when the performance obligation is satisfied or the related sales occur. We re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues related to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time, upon execution of the collaboration agreement in January 2017. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues for our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;research and development services performance obligation are being recognized using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in Japan, which is early 2030. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$28.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Takeda was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which was included in Long-term deferred revenue on the accompanying Condensed Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Genentech Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalty revenues on ex-U.S. sales and our share of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the profits and losses recognized in connection with COTELLIC&amp;#8217;s commercialization in the U.S. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits and losses on U.S. commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The royalty revenues &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;on ex-U.S. sales were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;included in Collaboration revenues. Prior to the adoption of topic 606, royalty revenues from the collaboration agreement with Genentech were based on amounts reported to us by our collaboration partner and were recorded when such information becomes available to us; beginning in the first quarter of 2017 such information became available in the current quarter and for 2016 such information was not available until the following quarter, meaning that through December 31, 2016 we recorded royalty revenues on a one quarter lag. As a result of this change, royalty revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in royalty revenues for sales in the fourth quarter of 2016 in addition to the royalty revenues for sales in the first half of 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Losses on the U.S. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;commercialization of COTELLIC for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations; Selling, general and administrative expenses also included the profit for the first quarter of 2018 in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 2, 2018 as we were not expecting an overall profit for the year ended December 31, 2018. During the second quarter of 2018, we determined that we now expect an overall profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;on the U.S. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;commercialization of COTELLIC for the year ended December 31, 2018 and therefore we have included the profit for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in Collaboration revenues for those periods; accordingly, we have also reclassified the profit for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;first quarter of 2018 from Selling, general and administrative expenses to Collaboration revenue for that period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;GSK Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,628&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;StemSynergy Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we entered into an exclusive collaboration and license agreement with&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;StemSynergy Therapeutics, Inc. (&amp;#8220;StemSynergy&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (&amp;#8220;CK1&amp;#945;&amp;#8221;) a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of the agreement,&amp;#160;we&amp;#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&amp;#945;. We paid&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; StemSynergy an upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for initial research and development funding and StemSynergy is eligible to receive up to an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of such funding. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; payment we made during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; is included in Research and development expenses in the accompanying Condensed Consolidated Statements of Operations. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;StemSynergy will also be eligible for up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$56.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Invenra Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we entered into a collaboration and license agreement with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Invenra, Inc. (&amp;#8220;Invenra&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which is &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(the &amp;#8220;lead preclinical asset&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and that we and Invenra intend to pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and second project initiation fee of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of total payments we made during the six months ended June&amp;#160;30, 2018 are included in Research and development expenses in the accompanying Condensed Consolidated Statements of Operations. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Invenra is eligible to receive payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$131.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; based on the achievement of specific development and regulatory milestones for a product containing the lead preclinical asset in the first indication. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$325.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product. We also have the right to initiate five additional discovery projects for development subject to an upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project basis at any time prior to commercialization, for any or no reason, upon thirty days&amp;#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For a description of our other existing collaboration agreements, see &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&amp;#160;26, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that each of our other &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;existing collaboration agreements &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;have one performance obligation, the delivery of an intellectual property license to each collaboration partner, which was satisfied for all such agreements prior to the adoption of Topic 606. As a result, any consideration earned and received from these collaborations will be recognized immediately as the licenses we provided represent functional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;intellectual property &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;that was transferred at a point in time prior to the adoption of Topic 606, when the agreements were executed. Potential v&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ariable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;upon Daiichi Sankyo&amp;#8217;s submission of a regulatory application to the Japanese Pharmaceutical and Medical Devices Agency for esaxerenone as a treatment for patients with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;essential &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;hypertension, we earned a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone, which is included in Collaboration revenues during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-606181C84335583FAD9274C343310ADF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-DD3B69E937BC5B78873DE86CA36C960C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets: Unbilled Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Liabilities: Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of a change in transaction price and recognition of revenues as services are performed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Transfer to receivables from contract assets recognized at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other adjustments &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(17,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
	<us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-F173B023F0A450279448DDCB778407A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;172,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;332,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;178,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(26,810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(12,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(51,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(21,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;145,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;156,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development services revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included revenues related to the portion of three milestones that were allocated to the transfer of intellectual property licenses and were recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; also included a milestone payment from Bristol-Myers Squibb Company (&amp;#8220;BMS&amp;#8221;). Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and License revenues no longer includes revenues related to the amortization of deferred revenue.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development services revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development services performance obligation which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore Research and development services revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only development cost reimbursements earned on our collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included net product supply revenues from Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Losses on the U.S. commercialization of COTELLIC for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and therefore Other collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only net product supply revenues.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Duri&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ng the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, Net product revenues and License revenues related to goods transferred at a point in time and Research and development services revenues related to services performed over time.  License revenues and Research and development services revenues were recorded in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included the p&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net product supply revenues, were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 for all periods presented&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;141,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,861&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;270,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;143,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;145,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;156,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,619&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;32,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;44,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;42,449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;137,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;150,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;89,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;287,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;163,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Rest of the world&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24,903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-232BC8D3A9055056819366B6F76DC46A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;) as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have several equity incentive plans under which we have granted stock options and restricted stock units (&amp;#8220;RSUs&amp;#8221;) to employees, directors and consultants. At &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;19,509,911&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under our equity incentive plans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value per share of our stock options and ESPP purchases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Stock option activity for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,208,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;818,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,141,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(102,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,783,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.8 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,249,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;271,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$39.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to unvested stock options will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2.3 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;RSU activity for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&amp;#160;Value Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,762,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;300,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(341,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(120,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,601,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;77,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$56.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to unvested RSUs will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2.8 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-C43B8F11D60A5BC5A671C6169F7D1CF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NET INCOME PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The computation of basic and diluted net income per share was as follows (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for basic net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for diluted net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;297,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;293,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;296,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;292,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;311,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;313,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;310,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of our common stock issued in January 2014 (&amp;#8220;2014 Warrants&amp;#8221;) were participating securities. The warrant holders did not have a contractual obligation to share in our losses. The 2014 Warrants were fully exercised in September 2017. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For a description of the 2014 Warrants, see &amp;#8220;Note 7. Common Stock and Warrants&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&amp;#160;26, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Potentially dilutive shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-292AE5EE69C354EC8A38EB33F251BBB3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;540,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;594,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;394,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-31656C9B134C54E2A70225DF8A3A7191">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;540,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;594,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;394,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and there were no transfers of financial assets or liabilities classified as Level 3 during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our remaining financial assets and liabilities include Cash, Trade and other receivables, Unbilled collaboration revenue, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers, and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FiscalPeriod contextRef="D2018Q2DEC30-JUN29" id="Fact-6E1F4E0F7A71512BAE037994A899AF26">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2018 will end on December 28, 2018 and fiscal year 2017 ended on December 29, 2017. For convenience, references in this report as of and for the fiscal periods ended June 29, 2018, March 30, 2018 and June 30, 2017, and as of and for the fiscal years ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2018, March 31, 2018 and June 30, 2017, and the years ended December&amp;#160;31, 2018 and December&amp;#160;31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended December 28, 2018 and the first day of the fiscal quarter ended June 29, 2018 are indicated as being as of January 1, 2018 and April 1, 2018, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-9F8C47C7544C52BE850FE33212DEFA48">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Provision for income taxes was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Provision for income taxes for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; primarily relates to state taxes for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset our federal taxable income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law. The Tax Cuts and Jobs Act contained significant changes to corporate taxation, included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. Further guidance may be forthcoming from the FASB and the&amp;#160;SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts. The Provision for income taxes for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; did not reflect any adjustment to the impact of the Tax Cuts and Jobs Act enactment that we recorded during the year ended December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-439F239AE3E75E1CBCB946EB744DA6F8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INVENTORY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other long-term assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for both the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory expected to be used in production or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Condensed Consolidated Balance Sheets. As of both &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the non-current portion of inventory consisted of a portion of our finished goods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-C97196BB12055BCA8AAE2F9358325D3A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;500,480&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;377,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;94,396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;594,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-67FAB63E667B51E1BF4FAE0D94F009F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No.&amp;#160;2016-02,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Leases (Topic 842),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-02&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require a right-of-use asset to be recognized on the balance sheet for both types of leases. ASU 2016-02 also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU No. 2018-11&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; In issuing ASU No. 2018-11, the FASB is permitting another transition method for ASU 2016-02, which allows the transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are currently considering the potential of an early adoption of this standard in the second half of 2018 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using the transition method permitted by ASU 2018-11&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Based on our initial evaluation of the impact of ASU 2016-02 on our build-to-suit lease of office and research facilities located in Alameda, California, we expect that the amount we have capitalized as Property and equipment related to the building shells and related financing liabilities, will be derecognized upon the adoption of ASU 2016-02. Upon adoption of ASU 2016-02 we will also be required to recognize a right-of-use asset and lease liability related to this lease. The adoption of ASU 2016-02 could also change the nature of future expenses related to the build-to-suit lease, reducing future depreciation and interest expense, which would be offset by an increase in lease expense. We are continuing to assess the impact of ASU No. 2016-02 on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-FD1E1C5B6063587C8AE332C15C456DED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (&amp;#8220;Exelixis,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our&amp;#8221; or &amp;#8220;us&amp;#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products discovered at&amp;#160;Exelixis&amp;#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors, and RET: CABOMETYX&amp;#174;&amp;#160;(cabozantinib) tablets approved for advanced renal cell carcinoma (&amp;#8220;RCC&amp;#8221;); and COMETRIQ&amp;#174;&amp;#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&amp;#174; (cobimetinib) tablets, is an inhibitor of MEK, marketed under a collaboration agreement with Genentech, Inc. (a member of the Roche Group) (&amp;#8220;Genentech&amp;#8221;), and is approved as part of a combination regimen to treat advanced melanoma.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2018 will end on December 28, 2018 and fiscal year 2017 ended on December 29, 2017. For convenience, references in this report as of and for the fiscal periods ended June 29, 2018, March 30, 2018 and June 30, 2017, and as of and for the fiscal years ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2018, March 31, 2018 and June 30, 2017, and the years ended December&amp;#160;31, 2018 and December&amp;#160;31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended December 28, 2018 and the first day of the fiscal quarter ended June 29, 2018 are indicated as being as of January 1, 2018 and April 1, 2018, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, included in our Annual Report on Form 10-K filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&amp;#160;26, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. See &amp;#8220;Note 2. Revenues&amp;#8221; for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain prior period amounts on the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to current period presentation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In addition, as a result of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;new information received during &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the six months ended June 30, 2018, as described further in &amp;#8220;Note 3. Collaboration Revenues - Genentech Collaboration&amp;#8221;, we have reclassified the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in profit on the U.S. commercialization of COTELLIC for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenue in preparing our Condensed Consolidated Statements of Operations for the six months ended June 30, 2018. As a result of this reclassification, for the three months ended March 31, 2018, Collaboration revenues increased from &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$78.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$79.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, Net revenues increased from &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$212.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$213.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, Selling, general and administrative expenses increased from &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$52.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$54.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and Operating expenses increased from &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$96.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$97.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. There was no impact on Net income or Net income per share as a result of this reclassification.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2018, we adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2016-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-18&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;etrospective transition method in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the accompanying Condensed Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASU 2016-18, we no longer include purchases &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;of restricted cash and proceeds from maturities of restricted cash &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; increase in Net cash provided by investing activities for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 4. Cash and Investments - Cash, Cash Equivalents and Restricted Cash&amp;#8221; for a reconciliation of cash and cash equivalents presented in our previously published Condensed Consolidated Statement of Cash Flows for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and Cash, cash equivalents and restricted cash reported in the accompanying Condensed Consolidated Statement of Cash Flows for the same period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2018, we adopted ASU &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(&amp;#8220;Topic 606&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 605: Revenue Recognition (&amp;#8220;Topic 605&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded a net reduction of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$258.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to opening accumulated deficit as of January 1, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (&amp;#8220;Ipsen&amp;#8221;) and Takeda Pharmaceutical Company Ltd. (&amp;#8220;Takeda&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Balance Sheet &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as of January 1, 2018 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Adjustments Due to the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract assets: unbilled collaboration revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract liabilities: deferred revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,829,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;258,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,570,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone from Ipsen&amp;#8217;s filing with the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;European Medicines Agency (&amp;#8220;EMA&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for cabozantinib, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced hepatocellular carcinoma (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC&amp;#8221;),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; that was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;deemed probable under Topic 606 prior to January 1, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. D&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;eferred revenue as of January 1, 2018 is related to the up-front, nonrefundable, fees and milestones achieved &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;that were allocated to our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;esearch and development services performance obligation that had not been satisfied as of that date&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Contract assets and liabilities are netted by collaboration agreement in our Condensed Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Statements of Operations as of and for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Balances Without the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Effect of Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;94,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;240,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;142,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(53,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Balances Without the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Effect of Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;142,469&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;422,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;206,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;229,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;225,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; recognized in accordance with Topic 606 included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenue, respectively, for a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC. We recognized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$45.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenue for this milestone in the first quarter of 2018 when we deemed achievement of the milestone was probable in accordance with Topic 606. If we had not adopted &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606, we would have recognized the e&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ntire &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;milestone as revenue in the second quarter of 2018 upon achievement of the milestone. If we had not adopted &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606, we would also have recognized a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone in the first quarter of 2018 upon the validation of Ipsen&amp;#8217;s filing with the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;EMA&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for cabozantinib &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&amp;#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&amp;#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&amp;#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.&amp;#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&amp;#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Customers in the U.S. receive a discount of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect our Customers will earn &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to our customers, plus an accrual balance for known prior quarters&amp;#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also include amounts related to the Medicare Part&amp;#160;D Coverage Gap Discount Program. In the U.S., the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&amp;#160;D prescription drug benefit mandates participating manufacturers to fund 50% of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&amp;#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to patients, plus an accrual balance for known prior quarters&amp;#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&amp;#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Collaboration Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for product supply; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Except for profit sharing arrangements and payments for product supply, each of these payment types are within the scope of Topic 606. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&amp;#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit Sharing Arrangements: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accounting Standards Codification Topic 808, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;Topic 808&amp;#8221;). &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We expect to recognize an annual profit under the agreement for the year ended December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues on the accompanying Condensed Consolidated Statements of Operations. Historically, we had not recognized a profit for any annual period from the commercialization of cobimetinib in the U.S. and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses on the accompanying Condensed Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Sales-based Milestone Payments and Royalties:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No.&amp;#160;2016-02,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Leases (Topic 842),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-02&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require a right-of-use asset to be recognized on the balance sheet for both types of leases. ASU 2016-02 also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU No. 2018-11&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; In issuing ASU No. 2018-11, the FASB is permitting another transition method for ASU 2016-02, which allows the transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are currently considering the potential of an early adoption of this standard in the second half of 2018 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using the transition method permitted by ASU 2018-11&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Based on our initial evaluation of the impact of ASU 2016-02 on our build-to-suit lease of office and research facilities located in Alameda, California, we expect that the amount we have capitalized as Property and equipment related to the building shells and related financing liabilities, will be derecognized upon the adoption of ASU 2016-02. Upon adoption of ASU 2016-02 we will also be required to recognize a right-of-use asset and lease liability related to this lease. The adoption of ASU 2016-02 could also change the nature of future expenses related to the build-to-suit lease, reducing future depreciation and interest expense, which would be offset by an increase in lease expense. We are continuing to assess the impact of ASU No. 2016-02 on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="D2018Q2DEC30-JUN29" id="Fact-F4F552E95FCD5F0EBCB9936FAAFF4976">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain prior period amounts on the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-65958A775C2B53908DA7147F067E61BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;PROPERTY AND EQUIPMENT &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;41,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;78,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leased Premises Placed in Service&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into a Lease Agreement (the &amp;#8220;Lease&amp;#8221;) with Ascentris 105, LLC (&amp;#8220;Ascentris&amp;#8221;) for office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the &amp;#8220;Premises&amp;#8221;). The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;134,765&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. For a description of the Lease, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;see &amp;#8220;Note 12. Commitments&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&amp;#160;26, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; In June 2018, we relocated our offices and research facilities to the Premises. Accordingly, we placed into service &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$59.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in related Leasehold improvements, Buildings, Furniture and fixtures and Computer equipment and software, portions of which were included in Construction in progress at prior period ends. We are continuing to review the allocation of these additions between Leasehold improvements and Furniture and fixtures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises, including the building shells, did not qualify as &amp;#8220;normal tenant improvements&amp;#8221; under Accounting Standards Codification Topic 840, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;Topic 840&amp;#8221;). Accordingly, for accounting purposes, we were deemed to be the owner of such portions of the Premises during the construction period. As such, we capitalized the construction costs as a build-to-suit property within Property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. Accordingly, we capitalized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs related to the Lease in construction in progress as of May 2, 2017, with a corresponding build-to-suit financing obligation in Other long-term liabilities. In June 2018, upon placing of the assets in service and in accordance with Topic 840, due to our continuing involvement in the Premises the Lease did not qualify for sale-leaseback accounting. Accordingly, the assets placed into service include the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; estimated fair value of the building shells that we are deemed to own. We have also recorded a related financing obligation of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in Other current liabilities and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$20.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in Financing obligation for build-to-suit lease in the accompanying Condensed Consolidated Balance Sheets for the buildings and related landlord allowance earned in the second quarter of 2018. Buildings are depreciated over their estimated &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;40&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year useful life.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-341CC28CA5885259BA034CD34E586E01">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;41,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;78,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-1F275BC5EA82568EA9389AAA98308C55">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;REVENUES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;172,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;332,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;178,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(26,810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(12,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(51,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(21,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;145,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;156,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development services revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,904&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included revenues related to the portion of three milestones that were allocated to the transfer of intellectual property licenses and were recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. License revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; also included a milestone payment from Bristol-Myers Squibb Company (&amp;#8220;BMS&amp;#8221;). Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and License revenues no longer includes revenues related to the amortization of deferred revenue.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development services revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development services performance obligation which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore Research and development services revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only development cost reimbursements earned on our collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included net product supply revenues from Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Losses on the U.S. commercialization of COTELLIC for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and therefore Other collaboration revenues for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; included only net product supply revenues.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Duri&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ng the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, Net product revenues and License revenues related to goods transferred at a point in time and Research and development services revenues related to services performed over time.  License revenues and Research and development services revenues were recorded in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included the p&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net product supply revenues, were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 for all periods presented&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;141,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,861&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;270,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;143,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;145,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;156,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19,714&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,619&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;32,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;44,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;42,449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;137,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;47,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;150,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;89,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;287,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;163,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Rest of the world&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24,903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;399,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to regions based on the ship-to location. Collaboration revenues are attributed to regions based on the location of our collaboration partners&amp;#8217; headquarters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Sales Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;32,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(30,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(47,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets: Unbilled Collaboration Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Liabilities: Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of a change in transaction price and recognition of revenues as services are performed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Transfer to receivables from contract assets recognized at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other adjustments &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(17,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$32.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$103.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Daiichi Sankyo Company, Limited (&amp;#8220;Daiichi Sankyo&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-E62256D2FBBE5CC7A5493BE14FCF2E9A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2018, we adopted ASU &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(&amp;#8220;Topic 606&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Results for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 605: Revenue Recognition (&amp;#8220;Topic 605&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone from Ipsen&amp;#8217;s filing with the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;European Medicines Agency (&amp;#8220;EMA&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for cabozantinib, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced hepatocellular carcinoma (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC&amp;#8221;),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; that was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;deemed probable under Topic 606 prior to January 1, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. D&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;eferred revenue as of January 1, 2018 is related to the up-front, nonrefundable, fees and milestones achieved &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;that were allocated to our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;r&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;esearch and development services performance obligation that had not been satisfied as of that date&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Contract assets and liabilities are netted by collaboration agreement in our Condensed Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:RevenueRecognitionRevenueReductions contextRef="D2018Q2DEC30-JUN29" id="Fact-2098C1EDA0295A6DBE3420C71FF28CB3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&amp;#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&amp;#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&amp;#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.&amp;#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&amp;#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our Customers in the U.S. receive a discount of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect our Customers will earn &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to our customers, plus an accrual balance for known prior quarters&amp;#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also include amounts related to the Medicare Part&amp;#160;D Coverage Gap Discount Program. In the U.S., the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&amp;#160;D prescription drug benefit mandates participating manufacturers to fund 50% of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&amp;#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to patients, plus an accrual balance for known prior quarters&amp;#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&amp;#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionRevenueReductions>
	<us-gaap:RevenueRecognitionSalesOfGoods contextRef="D2018Q2DEC30-JUN29" id="Fact-A4814FCCB2895E63A182C315970FEABC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionSalesOfGoods>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-9C0A05A715C95935A3B4A48012603AF6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Potentially dilutive shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-7497D2F49A7C5D31B94A64FD8A4C5C58">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;248,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;183,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;188,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;139,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;155,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-10C8B50BFE0553C49BD0B78297A1D12B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,628&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalty revenues on ex-U.S. sales and our share of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the profits and losses recognized in connection with COTELLIC&amp;#8217;s commercialization in the U.S. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits and losses on U.S. commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-8457584AEF3D5DC6A1785558758E44BB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Provision for income taxes was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-1DF42EF8BD3150C4A13D863448A140A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The computation of basic and diluted net income per share was as follows (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for basic net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for diluted net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;203,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;297,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;293,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;296,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;292,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;311,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;313,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;310,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-90EFE633EAD658EE9B88715D6976FCB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;) as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-8D3B208DBA91543FB5988F18C6AC374A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other long-term assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-C6D296DC80DC5EC7BB7E087E05676071">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Balance Sheet &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as of January 1, 2018 &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Adjustments Due to the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract assets: unbilled collaboration revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Contract liabilities: deferred revenue, gross:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;31,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;238,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(213,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accumulated deficit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,829,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;258,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,570,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Statements of Operations as of and for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;As Reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Balances Without the Adoption of Topic 606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Effect of Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Higher / (Lower)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;94,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;186,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;240,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;142,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;87,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(53,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-7DCE603F64B45D788370D96B80B21659">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;RSU activity for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&amp;#160;Value Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,762,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;300,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(341,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(120,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,601,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;77,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-DF1F1FC4B872568CAA4E3ED4574F1256">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Stock option activity for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,208,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;818,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,141,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(102,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,783,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.8 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at June 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,249,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;271,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-A96028D47733561286A849D6C186315B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-485D8D66A9C05BB796ED76D432998DE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-7C1F82F73D065DC0859024051C2FE1BC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value per share of our stock options and ESPP purchases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
	<us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="D2018Q2DEC30-JUN29" id="Fact-D2F937B339365DAC8A635A176DC661AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Investments by security type were as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,095&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;280,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;218,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;595,607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;594,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="D2018Q2DEC30-JUN29" id="Fact-39760C9405DA523DB7880646C14ACFFE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-0E2F73243A29562AB215799306DCDEEC" xlink:label="Fact-0E2F73243A29562AB215799306DCDEEC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-204B1901855A5FB7A1AC94E521439556" xlink:label="Fact-204B1901855A5FB7A1AC94E521439556_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-243084626BAA5FC3856C42BDFB34488C" xlink:label="Fact-243084626BAA5FC3856C42BDFB34488C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2930D2E22DC3578DB678C600F3796D06" xlink:label="Fact-2930D2E22DC3578DB678C600F3796D06_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2B5C5E5F17BF577B9592EE42E5707AD8" xlink:label="Fact-2B5C5E5F17BF577B9592EE42E5707AD8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2B6F65C36FD257B1A2783FB83483ADA0" xlink:label="Fact-2B6F65C36FD257B1A2783FB83483ADA0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2DA2A2CBBD1D5D558663EA68EFA9C02B" xlink:label="Fact-2DA2A2CBBD1D5D558663EA68EFA9C02B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2DC56BC4102E58438C6A58949E8DEE57" xlink:label="Fact-2DC56BC4102E58438C6A58949E8DEE57_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2F9A92AF2A0F538DAD8E99D3FA5A4D6A" xlink:label="Fact-2F9A92AF2A0F538DAD8E99D3FA5A4D6A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-328533F3A3835D2F97473D03FF3388D6" xlink:label="Fact-328533F3A3835D2F97473D03FF3388D6_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3B8983E2C88C5EF48A7C2E2F7E28A37B" xlink:label="Fact-3B8983E2C88C5EF48A7C2E2F7E28A37B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3CFD1261A32A5D4F9771139B5495ACBF" xlink:label="Fact-3CFD1261A32A5D4F9771139B5495ACBF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-42F4C651A10853E48C7843EAC7477F0B" xlink:label="Fact-42F4C651A10853E48C7843EAC7477F0B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4492ED1CFCA2523DA94F38574EA767FA" xlink:label="Fact-4492ED1CFCA2523DA94F38574EA767FA_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-5141754A7D0256C0A63A8E8635EC72C8" xlink:label="Fact-5141754A7D0256C0A63A8E8635EC72C8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-54F19A7181DD527E8418DCDC1A908FAE" xlink:label="Fact-54F19A7181DD527E8418DCDC1A908FAE_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-5E9A8F98EB2F50E1B66B5367A5E12075" xlink:label="Fact-5E9A8F98EB2F50E1B66B5367A5E12075_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-69D1A75663AA5E58B98A7BBB86EEDF5F" xlink:label="Fact-69D1A75663AA5E58B98A7BBB86EEDF5F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6C8E3165ED2E542AAA62864DB3D22DDF" xlink:label="Fact-6C8E3165ED2E542AAA62864DB3D22DDF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-701A26EEBC0C5EF78E5246CD25EF014B" xlink:label="Fact-701A26EEBC0C5EF78E5246CD25EF014B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7363991F1FFC58B5B81CF6969CBD0D5D" xlink:label="Fact-7363991F1FFC58B5B81CF6969CBD0D5D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-79840E9FBDDE5A23AC57AF5EE5774CFB" xlink:label="Fact-79840E9FBDDE5A23AC57AF5EE5774CFB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-832123DC7112596F87C72C67F4AE6634" xlink:label="Fact-832123DC7112596F87C72C67F4AE6634_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8B53E46E72F95E26BAE0D95E17161693" xlink:label="Fact-8B53E46E72F95E26BAE0D95E17161693_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8C4772BEA2605E5A82B78E7D696FCF52" xlink:label="Fact-8C4772BEA2605E5A82B78E7D696FCF52_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8DC4F7CA191A568D8D6B4528340C4C7B" xlink:label="Fact-8DC4F7CA191A568D8D6B4528340C4C7B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-907F8E039D1552278B21DD91FEB3A7C7" xlink:label="Fact-907F8E039D1552278B21DD91FEB3A7C7_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-922BC016423853B89E782868043322CC" xlink:label="Fact-922BC016423853B89E782868043322CC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9A435F27A2A654D2BE42D4C637872605" xlink:label="Fact-9A435F27A2A654D2BE42D4C637872605_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9F639AE6CBA250F096722B570C741CCD" xlink:label="Fact-9F639AE6CBA250F096722B570C741CCD_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A290675A84665F72BDFC21AE9EBC94D3" xlink:label="Fact-A290675A84665F72BDFC21AE9EBC94D3_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A4B116F682245F3FA60645658899F938" xlink:label="Fact-A4B116F682245F3FA60645658899F938_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A91A163F98D55C448399F51DFE3FF68F" xlink:label="Fact-A91A163F98D55C448399F51DFE3FF68F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A95B889141605E8DA059CC25F4AE920F" xlink:label="Fact-A95B889141605E8DA059CC25F4AE920F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B615F1E0D0C95704ACF511C3E189C16D" xlink:label="Fact-B615F1E0D0C95704ACF511C3E189C16D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BF183A7CEB115A28A1BB628289733006" xlink:label="Fact-BF183A7CEB115A28A1BB628289733006_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C04AA68F6D2A5B4EA0E928F0EC2BE435" xlink:label="Fact-C04AA68F6D2A5B4EA0E928F0EC2BE435_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C46098D6E8BC59E4BACB8C206AB43465" xlink:label="Fact-C46098D6E8BC59E4BACB8C206AB43465_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C8263A8402A05DC3980B5C06A1BA3E38" xlink:label="Fact-C8263A8402A05DC3980B5C06A1BA3E38_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-CF534C239BC7510F8839A97EBD213A4D" xlink:label="Fact-CF534C239BC7510F8839A97EBD213A4D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E77231C565015324B9AD647CE2816AB8" xlink:label="Fact-E77231C565015324B9AD647CE2816AB8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F177983F35E7570CBE3831EFD2EBDCED" xlink:label="Fact-F177983F35E7570CBE3831EFD2EBDCED_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FDA6B7665BAD5D818EAB3BD2BDB66005" xlink:label="Fact-FDA6B7665BAD5D818EAB3BD2BDB66005_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-0E2F73243A29562AB215799306DCDEEC_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-204B1901855A5FB7A1AC94E521439556_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-243084626BAA5FC3856C42BDFB34488C_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2930D2E22DC3578DB678C600F3796D06_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2B5C5E5F17BF577B9592EE42E5707AD8_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2B6F65C36FD257B1A2783FB83483ADA0_lbl" xlink:to="Footnote-8855190DA6285C268CE63CE258D7219C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2DA2A2CBBD1D5D558663EA68EFA9C02B_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2DC56BC4102E58438C6A58949E8DEE57_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2F9A92AF2A0F538DAD8E99D3FA5A4D6A_lbl" xlink:to="Footnote-8855190DA6285C268CE63CE258D7219C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-328533F3A3835D2F97473D03FF3388D6_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3B8983E2C88C5EF48A7C2E2F7E28A37B_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3CFD1261A32A5D4F9771139B5495ACBF_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-42F4C651A10853E48C7843EAC7477F0B_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4492ED1CFCA2523DA94F38574EA767FA_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-5141754A7D0256C0A63A8E8635EC72C8_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-54F19A7181DD527E8418DCDC1A908FAE_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-5E9A8F98EB2F50E1B66B5367A5E12075_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-69D1A75663AA5E58B98A7BBB86EEDF5F_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6C8E3165ED2E542AAA62864DB3D22DDF_lbl" xlink:to="Footnote-8855190DA6285C268CE63CE258D7219C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-701A26EEBC0C5EF78E5246CD25EF014B_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7363991F1FFC58B5B81CF6969CBD0D5D_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-79840E9FBDDE5A23AC57AF5EE5774CFB_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-832123DC7112596F87C72C67F4AE6634_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8B53E46E72F95E26BAE0D95E17161693_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8C4772BEA2605E5A82B78E7D696FCF52_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8DC4F7CA191A568D8D6B4528340C4C7B_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-907F8E039D1552278B21DD91FEB3A7C7_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-922BC016423853B89E782868043322CC_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9A435F27A2A654D2BE42D4C637872605_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9F639AE6CBA250F096722B570C741CCD_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A290675A84665F72BDFC21AE9EBC94D3_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A4B116F682245F3FA60645658899F938_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A91A163F98D55C448399F51DFE3FF68F_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A95B889141605E8DA059CC25F4AE920F_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B615F1E0D0C95704ACF511C3E189C16D_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BF183A7CEB115A28A1BB628289733006_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C04AA68F6D2A5B4EA0E928F0EC2BE435_lbl" xlink:to="Footnote-8855190DA6285C268CE63CE258D7219C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C46098D6E8BC59E4BACB8C206AB43465_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C8263A8402A05DC3980B5C06A1BA3E38_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-CF534C239BC7510F8839A97EBD213A4D_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E77231C565015324B9AD647CE2816AB8_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F177983F35E7570CBE3831EFD2EBDCED_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FDA6B7665BAD5D818EAB3BD2BDB66005_lbl" xlink:to="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-8855190DA6285C268CE63CE258D7219C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities were nominal and there was no income tax expense related to other comprehensive income during those periods.</link:footnote>
		<link:footnote xlink:label="Footnote-8986CDFF79485EEC9A707B990A47B994_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>exel-20180629.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20180629" xmlns:exel="http://www.exelixis.com/20180629" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20180629_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20180629_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20180629_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20180629_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2104100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails">
        <link:definition>2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails">
        <link:definition>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInvestmentsBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails">
        <link:definition>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2404405 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2304301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsGenentechCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements - Genentech Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInvenraCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails">
        <link:definition>2403410 - Disclosure - Collaboration Agreements - Invenra Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails">
        <link:definition>2403411 - Disclosure - Collaboration Agreements - Other Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GlaxoSmithKline (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsStemsynergyCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails">
        <link:definition>2403409 - Disclosure - Collaboration Agreements - StemSynergy Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2111100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2411402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2311301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesDetails">
        <link:definition>2408402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exelixis.com/role/IncomeTaxesTables">
        <link:definition>2308301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2105100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2405402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2305301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare">
        <link:definition>2110100 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails">
        <link:definition>2410402 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareNarrativeDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails">
        <link:definition>2410403 - Disclosure - Net Income (Loss) Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails">
        <link:definition>2410404 - Disclosure - Net Income (Loss) Per Share - Potentially Dilutive Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables">
        <link:definition>2310301 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails">
        <link:definition>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on the Consolidated Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails">
        <link:definition>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on Contract Assets, Contract Liabilities and Accumulated Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2106100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails">
        <link:definition>2406402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2406403 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2306301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2102100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails">
        <link:definition>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details">
        <link:definition>2402407 - Disclosure - Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedByProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails">
        <link:definition>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails">
        <link:definition>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails">
        <link:definition>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails">
        <link:definition>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2302301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRsuActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails">
        <link:definition>2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails">
        <link:definition>2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails">
        <link:definition>2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AlamedaCaliforniaMember" name="AlamedaCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForProductRebatesMember" name="AllowanceForProductRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CaremarkL.L.C.Member" name="CaremarkL.L.C.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsAndInvestmentsTextBlock" name="CashCashEquivalentsAndInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeInContractWithCustomerAssetCurrentRollForward" name="ChangeInContractWithCustomerAssetCurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" name="ChangeinContractwithCustomerAssetNoncurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" name="ChangeinContractwithCustomerLiabilityCurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" name="ChangeinContractwithCustomerLiabilityNoncurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ClassofWarrantorRightPeriod" name="ClassofWarrantorRightPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationRevenuesAbstract" name="CollaborationRevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossfromAgreement" name="CollaborativeArrangementIncomeLossfromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementWithInvenraMember" name="CollaborativeArrangementWithInvenraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementWithStemSynergyMember" name="CollaborativeArrangementWithStemSynergyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithDaiichiSankyoMember" name="CollaborativeArrangementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" name="ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetCurrentOtherAdjustments" name="ContractWithCustomerAssetCurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" name="ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" name="ContractWithCustomerAssetNoncurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityCurrentDeductions" name="ContractWithCustomerLiabilityCurrentDeductions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" name="ContractWithCustomerLiabilityCurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityNoncurrentDeductions" name="ContractWithCustomerLiabilityNoncurrentDeductions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" name="ContractWithCustomerLiabilityNoncurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" name="ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" name="ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CotellicMember" name="CotellicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleRealizedGainLoss" name="DebtSecuritiesAvailableForSaleRealizedGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" name="DebtSecuritiesAvailableForSaleUnrealizedLossPosition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_DevelopmentAndRegulatoryMilestoneMember" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiplomatSpecialtyPharmacyMember" name="DiplomatSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiscoveryProjectMember" name="DiscoveryProjectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EMAApproval1LRCCMember" name="EMAApproval1LRCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EMAApprovalHCCMember" name="EMAApprovalHCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EMAApprovalMember" name="EMAApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EMAFilingAcceptanceHCCMember" name="EMAFilingAcceptanceHCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareDenominatorAbstract" name="EarningsPerShareDenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareNumeratorAbstract" name="EarningsPerShareNumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_FinalTierMember" name="FinalTierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FirstProductToReachMarketMember" name="FirstProductToReachMarketMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlobalMember" name="GlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseAccruedClinicalLiabilities" name="IncreaseDecreaseAccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseinAccruedCollaborationLiability" name="IncreaseDecreaseinAccruedCollaborationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InitialMember" name="InitialMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" name="LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveAxis" name="MilestoneObjectiveAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveDomain" name="MilestoneObjectiveDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MilestonePaymentsEarned" name="MilestonePaymentsEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_MilestonePaymentsMinimumNetSalesAchievementAmount" name="MilestonePaymentsMinimumNetSalesAchievementAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseandOtherFinancingLeaseMember" name="OperatingLeaseandOtherFinancingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCustomersMember" name="OtherCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherGeographicalAreasMember" name="OtherGeographicalAreasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PercentOfRoyaltyOnNetSale" name="PercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PeriodGeneratedAxis" name="PeriodGeneratedAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PeriodGeneratedDomain" name="PeriodGeneratedDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PeriodOfSpecificSalesVolumeThreshold" name="PeriodOfSpecificSalesVolumeThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductCommercializationMember" name="ProductCommercializationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductRevenuesAbstract" name="ProductRevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedfromCabozantinibMember" name="ProductsDerivedfromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProjectInitiationFeePayment" name="ProjectInitiationFeePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_PropertyPlantAndEquipmentAdditionsAndTransfers" name="PropertyPlantAndEquipmentAdditionsAndTransfers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_Q416Member" name="Q416Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ResearchAndDevelopmentServiceRevenue" name="ResearchAndDevelopmentServiceRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RevenueAchievementsMember" name="RevenueAchievementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RoyaltyTier" name="RoyaltyTier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierAxis" name="RoyaltytierAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierDomain" name="RoyaltytierDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenuePercentDiscountForPromptPayment" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SecondMember" name="SecondMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontAndMilestonePayments" name="UpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontPayments" name="UpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontPaymentsAndProjectInitiationFeesPayments" name="UpfrontPaymentsAndProjectInitiationFeesPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" name="WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>exel-20180629_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20180629.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20180629.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20180629.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsGenentechCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsInvenraCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsStemsynergyCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20180629.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20180629.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20180629.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20180629.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20180629.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20180629.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20180629.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20180629.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20180629.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20180629.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20180629.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20180629.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20180629.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20180629.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20180629.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20180629.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20180629.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20180629.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20180629.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20180629.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20180629.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20180629.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20180629.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20180629.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20180629.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3E57556A059C64356027149A9D44AD4D" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_4DD2D279BAA6C8D0223A149925BD488A" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3E57556A059C64356027149A9D44AD4D" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_4DD2D279BAA6C8D0223A149925BD488A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_055358AFAABC58F4BBA61499F88FB9E4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3E57556A059C64356027149A9D44AD4D" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_055358AFAABC58F4BBA61499F88FB9E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A59C809D2A74C3597611149581B8BF07" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_C9B3A9D3AAB03D1882C31493817F55ED" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A59C809D2A74C3597611149581B8BF07" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_C9B3A9D3AAB03D1882C31493817F55ED" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_FE780D708C5C79E12488149487843595" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_A59C809D2A74C3597611149581B8BF07" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_FE780D708C5C79E12488149487843595" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bb34ca49-0ca6-d513-414f-31e205fa11cc" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bb34ca49-0ca6-d513-414f-31e205fa11cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa6902f3-9ec3-0632-57ef-52a27e57695e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa6902f3-9ec3-0632-57ef-52a27e57695e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_742238c6-99b5-ec8f-811f-240c929f1974" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_742238c6-99b5-ec8f-811f-240c929f1974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3ec21982-5910-da92-94e7-46475f11e9f6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3ec21982-5910-da92-94e7-46475f11e9f6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c7f7eb62-cfa0-f151-36ae-c1d591e39819" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c7f7eb62-cfa0-f151-36ae-c1d591e39819" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_3d7a448c-a43d-5ed6-40e5-a4d7b1565e4b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_3d7a448c-a43d-5ed6-40e5-a4d7b1565e4b" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_4262322a-2489-b411-eb38-a4d7b1a2b4b6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_4262322a-2489-b411-eb38-a4d7b1a2b4b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_734add4d-1361-7540-71cd-3913f8eb4085" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_734add4d-1361-7540-71cd-3913f8eb4085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06a8bc6d-0a67-7d01-441e-cd6865c4697c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06a8bc6d-0a67-7d01-441e-cd6865c4697c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ba1d46a8-6ebe-b4b5-e10e-899fee502d4f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ba1d46a8-6ebe-b4b5-e10e-899fee502d4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_efe2512e-d4d4-64d6-9c0d-99078496415f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_efe2512e-d4d4-64d6-9c0d-99078496415f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_4261eb63-a0fe-7be1-e8a2-dcf5644ff056" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ReceivablesNetCurrent_4261eb63-a0fe-7be1-e8a2-dcf5644ff056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_742238c6-99b5-ec8f-811f-240c929f1974" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_742238c6-99b5-ec8f-811f-240c929f1974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3ec21982-5910-da92-94e7-46475f11e9f6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3ec21982-5910-da92-94e7-46475f11e9f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_d3d89aab-5be8-f6a4-66e9-41f55e0839cd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_d3d89aab-5be8-f6a4-66e9-41f55e0839cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b49c7a2f-2986-824d-e7cb-bc082ac0e888" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b49c7a2f-2986-824d-e7cb-bc082ac0e888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_15394837-f38b-15ac-34b9-3c880d46492b" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_15394837-f38b-15ac-34b9-3c880d46492b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e6d6486e-82d1-24a8-4687-2a4e31bd898e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e6d6486e-82d1-24a8-4687-2a4e31bd898e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_262bbab1-3375-1d39-9ff3-0d0cca3a4b11" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_262bbab1-3375-1d39-9ff3-0d0cca3a4b11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e9a2cdf1-6f49-806b-7b55-b9320bcfa87f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e9a2cdf1-6f49-806b-7b55-b9320bcfa87f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_a475da0e-33d6-3035-9745-df51106bd7f7" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_PaidInKindInterest_a475da0e-33d6-3035-9745-df51106bd7f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_df77eda3-f4a4-736d-7f34-64539d78db5d" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_df77eda3-f4a4-736d-7f34-64539d78db5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_20f1ed35-6a0e-5b11-130c-ae721712c4a7" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_20f1ed35-6a0e-5b11-130c-ae721712c4a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c014c8e-ef65-6055-d342-3e048173d471" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c014c8e-ef65-6055-d342-3e048173d471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1db3941a-7187-c2ca-9a11-6155b0a4bd72" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1db3941a-7187-c2ca-9a11-6155b0a4bd72" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_bb173832-ab89-e3c6-b629-a4d7b19177ae" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_bb173832-ab89-e3c6-b629-a4d7b19177ae" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_c46af164-63f2-fbd2-b7ff-a4d7b168f873" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_c46af164-63f2-fbd2-b7ff-a4d7b168f873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_8f563464-80d3-5024-06bd-d0b7c03ce96e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_8f563464-80d3-5024-06bd-d0b7c03ce96e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f3731d81-24aa-7428-8853-34b405ade4d0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f3731d81-24aa-7428-8853-34b405ade4d0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_b1917564-9f69-b82f-0545-2b32cc97d9dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestIncomeOther_b1917564-9f69-b82f-0545-2b32cc97d9dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_79bdd473-22d2-ef01-683b-1be9d9655f97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:to="loc_us-gaap_InventoryRawMaterials_79bdd473-22d2-ef01-683b-1be9d9655f97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1f11a0f3-903b-2881-9953-5b32589e626c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:to="loc_us-gaap_InventoryWorkInProcess_1f11a0f3-903b-2881-9953-5b32589e626c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_608e386b-8c6f-7cfc-fabb-123ca6d40239" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:to="loc_us-gaap_InventoryFinishedGoods_608e386b-8c6f-7cfc-fabb-123ca6d40239" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba98cf3d-8c3a-45da-49f9-ba76e12862c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba98cf3d-8c3a-45da-49f9-ba76e12862c3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_f2848904-ead3-76a0-9187-ba604c43301c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_f2848904-ead3-76a0-9187-ba604c43301c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_d3f78da4-19db-929a-6aac-efc5b007a9e1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba98cf3d-8c3a-45da-49f9-ba76e12862c3" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_d3f78da4-19db-929a-6aac-efc5b007a9e1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="loc_us-gaap_SalesRevenueGoodsGross_30435c4f-c7a6-5eb2-bbc8-38b6a218b868" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:to="loc_us-gaap_SalesRevenueGoodsGross_30435c4f-c7a6-5eb2-bbc8-38b6a218b868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_64ddbe5a-d6b7-2170-35fd-04d321629d73" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:to="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_64ddbe5a-d6b7-2170-35fd-04d321629d73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_76304021-cc4c-b83e-0c43-ed738e4c3281" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_LicensesRevenue_76304021-cc4c-b83e-0c43-ed738e4c3281" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchAndDevelopmentServiceRevenue" xlink:label="loc_exel_ResearchAndDevelopmentServiceRevenue_5F7CBDCA5A2FE038A3AC02F1A097FE80" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_exel_ResearchAndDevelopmentServiceRevenue_5F7CBDCA5A2FE038A3AC02F1A097FE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>exel-20180629_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20180629.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20180629.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20180629.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsGenentechCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsInvenraCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsStemsynergyCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20180629.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20180629.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20180629.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20180629.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20180629.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20180629.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20180629.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20180629.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20180629.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20180629.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20180629.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20180629.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20180629.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20180629.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20180629.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20180629.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20180629.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20180629.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20180629.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20180629.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20180629.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20180629.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20180629.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20180629.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20180629.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:to="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_04302821D9AC9F959F5EEE33174FE42B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_04302821D9AC9F959F5EEE33174FE42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_534F469CB3DFCCBD46B9EE331750B7DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_534F469CB3DFCCBD46B9EE331750B7DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:to="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E8E2EBCC696B8DABDC45EE3317683E26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E8E2EBCC696B8DABDC45EE3317683E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0F21703BD2EB677BEDB7EE331768D077" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0F21703BD2EB677BEDB7EE331768D077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_0FF369FD8CA57F9F4D94EE33176870EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_CommercialPaperMember_0FF369FD8CA57F9F4D94EE33176870EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_AF84DAF3222D1149C18CEE33176916DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_AF84DAF3222D1149C18CEE33176916DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8D32BC68AABEA5C792B0EE331769172D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8D32BC68AABEA5C792B0EE331769172D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_561C76335799E19AFB11EE331861A8D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_561C76335799E19AFB11EE331861A8D9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_F413DD9B2639DFC6A7DBEE3318619457" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_F413DD9B2639DFC6A7DBEE3318619457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_F51208CC29F69930B6E4EE33186197C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_561C76335799E19AFB11EE331861A8D9" xlink:to="loc_us-gaap_ContractsRevenue_F51208CC29F69930B6E4EE33186197C5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ECFBFDFB380851BF7B47EE33180C086E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ECFBFDFB380851BF7B47EE33180C086E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_40A5EC1E0A28F4342D15EE33180C4DB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ECFBFDFB380851BF7B47EE33180C086E" xlink:to="loc_us-gaap_ContractsRevenue_40A5EC1E0A28F4342D15EE33180C4DB6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_867EBD95DB7B0E5B94B4EE3317EB84D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_867EBD95DB7B0E5B94B4EE3317EB84D8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6" xlink:to="loc_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedAxis" xlink:label="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:to="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:to="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_Q416Member" xlink:label="loc_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:to="loc_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_867EBD95DB7B0E5B94B4EE3317EB84D8" xlink:to="loc_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:to="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:to="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:to="loc_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:to="loc_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E8CC11C9CE1AC13C9A3EE3317B23407_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2E8CC11C9CE1AC13C9A3EE3317B23407_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E8CC11C9CE1AC13C9A3EE3317B23407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2E8CC11C9CE1AC13C9A3EE3317B23407" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_1DD01163E30EDB339BF0EE3317B221B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_UpfrontAndMilestonePayments_1DD01163E30EDB339BF0EE3317B221B6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPaymentsAndProjectInitiationFeesPayments" xlink:label="loc_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_E7F7BC8F76205281B5A9EE3317B3C04D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_E7F7BC8F76205281B5A9EE3317B3C04D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:to="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:to="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApproval1LRCCMember" xlink:label="loc_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RevenueAchievementsMember" xlink:label="loc_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalHCCMember" xlink:label="loc_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalMember" xlink:label="loc_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:to="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:to="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:to="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:to="loc_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:to="loc_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:to="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:to="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:to="loc_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:to="loc_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:to="loc_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsMinimumNetSalesAchievementAmount" xlink:label="loc_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA04BF60FBAC16425C4EE33179BFD03" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA04BF60FBAC16425C4EE33179BFD03" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA04BF60FBAC16425C4EE33179BFD03" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:to="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_4130F35D9380ED3998F9EE3317FB1B93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_4130F35D9380ED3998F9EE3317FB1B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:to="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_BEA30C459EAA1DF8AD3AEE3317FB676C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7" xlink:to="loc_exel_CotellicMember_BEA30C459EAA1DF8AD3AEE3317FB676C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:to="loc_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B5C232E41FFA741EA63AEE3317D5156E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B5C232E41FFA741EA63AEE3317D5156E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B5C232E41FFA741EA63AEE3317D5156E" xlink:to="loc_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:to="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:to="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:to="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9" xlink:to="loc_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:to="loc_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1B912FD1D09FC0FE7061EE3317CA92A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1B912FD1D09FC0FE7061EE3317CA92A5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_313DBD9927A58D8AE63FEE331845C79D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_313DBD9927A58D8AE63FEE331845C79D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:to="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:to="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_E68D6A34840C8FC60686EE3318450558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:to="loc_exel_InitialMember_E68D6A34840C8FC60686EE3318450558" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:to="loc_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:to="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:to="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:to="loc_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:to="loc_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:to="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:to="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E36AAF163423742263F0EE33184CAC17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:to="loc_us-gaap_MinimumMember_E36AAF163423742263F0EE33184CAC17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A162185B061CFFEA8FB3EE33184DF82D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:to="loc_us-gaap_MaximumMember_A162185B061CFFEA8FB3EE33184DF82D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_DDCBA90FB8AEC626ACDFEE33184D1FAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_UpfrontPayments_DDCBA90FB8AEC626ACDFEE33184D1FAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_A2303E24DB6DBB4CDA27EE33184E5A2C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_A2303E24DB6DBB4CDA27EE33184E5A2C" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_350E70B26CE918C65BF6EE33184E79AD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_350E70B26CE918C65BF6EE33184E79AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_8DCF02E4F69D1118F650EE33184FDB16" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_8DCF02E4F69D1118F650EE33184FDB16" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6ADA97206FF1ACE9F0F3EE33184FD704" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6ADA97206FF1ACE9F0F3EE33184FD704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_355A7BBE8E39409B438EEE33184F0A5C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_355A7BBE8E39409B438EEE33184F0A5C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:to="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:to="loc_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:to="loc_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ClassofWarrantorRightPeriod" xlink:label="loc_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:to="loc_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:to="loc_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_2E14B462532C553A4894EE331972280E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_2E14B462532C553A4894EE331972280E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_A7B7BFA46FD16BF8ED3AEE331974CB2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_A7B7BFA46FD16BF8ED3AEE331974CB2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_4798E5A5BF022F8227F9EE33197446BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_4798E5A5BF022F8227F9EE33197446BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_2CEBB0FE86B05FB326B1EE3319754B04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_ContractsRevenue_2CEBB0FE86B05FB326B1EE3319754B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_69D0A683A97EA3F03681EE331975C13B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_Revenues_69D0A683A97EA3F03681EE331975C13B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_11BE4B93203CAAD8ED99EE33198C00BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_11BE4B93203CAAD8ED99EE33198C00BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_54EAB9928A457F89C650EE33198DDB11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_54EAB9928A457F89C650EE33198DDB11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_7C6066F8CEB538C52217EE33198D3CD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_7C6066F8CEB538C52217EE33198D3CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20180629.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:to="loc_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:to="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:to="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:to="loc_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_3B3647AE9FA33E6EBC16EE3319B75EB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_3B3647AE9FA33E6EBC16EE3319B75EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_0AEAF585C3BF3D1A78F4EE3319B843C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_0AEAF585C3BF3D1A78F4EE3319B843C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_A8AE68B769CB8499F760EE3319B9E554" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_A8AE68B769CB8499F760EE3319B9E554" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:to="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:to="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_446745A42AC426081097EE3319BF4FA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_446745A42AC426081097EE3319BF4FA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApproval1LRCCMember" xlink:label="loc_exel_EMAApproval1LRCCMember_E02C5036233DACB63EACEE3319BF4825" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:to="loc_exel_EMAApproval1LRCCMember_E02C5036233DACB63EACEE3319BF4825" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalMember" xlink:label="loc_exel_EMAApprovalMember_3A3DBBF006506A68D951EE3319C0B98A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:to="loc_exel_EMAApprovalMember_3A3DBBF006506A68D951EE3319C0B98A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_5BB0EACC6278EE46632FEE3319C2F722" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_MilestonePaymentsEarned_5BB0EACC6278EE46632FEE3319C2F722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_8E8DC2FD29C0FE4E5B95EE3319C3EDE1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_8E8DC2FD29C0FE4E5B95EE3319C3EDE1" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:to="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:to="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C" xlink:to="loc_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:to="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:to="loc_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_5FCACA42DEBA22CEEF63F0DC249502A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:to="loc_us-gaap_BuildingMember_5FCACA42DEBA22CEEF63F0DC249502A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PropertyPlantAndEquipmentAdditionsAndTransfers" xlink:label="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_E5681BC01E5F2F43B38BF0DB60B307E5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_E5681BC01E5F2F43B38BF0DB60B307E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="loc_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityCurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityNoncurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:to="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:to="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:to="loc_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:to="loc_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:to="loc_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_51E83860A5CF6FC1F1B4EE3319038C14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_51E83860A5CF6FC1F1B4EE3319038C14" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:to="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:to="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:to="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:to="loc_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:to="loc_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherGeographicalAreasMember" xlink:label="loc_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:to="loc_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9F357B9AEC5ABA25E78FEE331903B064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_51E83860A5CF6FC1F1B4EE3319038C14" xlink:to="loc_us-gaap_Revenues_9F357B9AEC5ABA25E78FEE331903B064" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_EF7AC0910A13C672CFD9EE3319222E65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:to="loc_us-gaap_Revenues_EF7AC0910A13C672CFD9EE3319222E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:to="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:to="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5B65F58F399ED1F7338BEE3316D012A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5B65F58F399ED1F7338BEE3316D012A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:to="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:to="loc_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE2BB0C261028D0C8EA3EE3316EC4DB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE2BB0C261028D0C8EA3EE3316EC4DB0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:to="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5830789FFB5C7D950832EE3316EB4324" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5830789FFB5C7D950832EE3316EB4324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_C517EEB91322BB874D1FEE3316EC579C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:to="loc_us-gaap_EmployeeStockMember_C517EEB91322BB874D1FEE3316EC579C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE2BB0C261028D0C8EA3EE3316EC4DB0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>exel-20180629_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:to="lab_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:to="lab_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:to="lab_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:to="lab_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454_label_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Axis]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:to="lab_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20_label_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for MilestoneObjective [Axis]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="lab_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:type="arc" />
    <link:label id="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7_terseLabel_en-US" xlink:label="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EMA Approval - RCC</link:label>
    <link:label id="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7_label_en-US" xlink:label="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMA Approval - 1L RCC [Member]</link:label>
    <link:label id="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7_documentation_en-US" xlink:label="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EMA Approval - 1L RCC [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApproval1LRCCMember" xlink:label="loc_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:to="lab_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:type="arc" />
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4_terseLabel_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HCC Filing</link:label>
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4_label_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC [Member]</link:label>
    <link:label id="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4_documentation_en-US" xlink:label="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EMA Filing Acceptance - HCC</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:to="lab_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:type="arc" />
    <link:label id="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517_terseLabel_en-US" xlink:label="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales Achievements</link:label>
    <link:label id="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517_label_en-US" xlink:label="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Achievements [Member]</link:label>
    <link:label id="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517_documentation_en-US" xlink:label="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Achievements [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_RevenueAchievementsMember" xlink:label="loc_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:to="lab_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:type="arc" />
    <link:label id="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743_terseLabel_en-US" xlink:label="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HCC Acceptance</link:label>
    <link:label id="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743_label_en-US" xlink:label="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMA Approval - HCC [Member]</link:label>
    <link:label id="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743_documentation_en-US" xlink:label="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EMA Approval - HCC[Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalHCCMember" xlink:label="loc_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:to="lab_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:type="arc" />
    <link:label id="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638_terseLabel_en-US" xlink:label="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EMA Approval</link:label>
    <link:label id="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638_label_en-US" xlink:label="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMA Approval [Member]</link:label>
    <link:label id="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638_documentation_en-US" xlink:label="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EMA Approval [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalMember" xlink:label="loc_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:to="lab_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707_label_en-US" xlink:label="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707_documentation_en-US" xlink:label="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:to="lab_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB_label_en-US" xlink:label="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:to="lab_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial and Second</link:label>
    <link:label id="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834_label_en-US" xlink:label="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834_documentation_en-US" xlink:label="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:to="lab_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:type="arc" />
    <link:label id="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D_terseLabel_en-US" xlink:label="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial</link:label>
    <link:label id="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D_label_en-US" xlink:label="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D_documentation_en-US" xlink:label="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:to="lab_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:type="arc" />
    <link:label id="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA_terseLabel_en-US" xlink:label="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second</link:label>
    <link:label id="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA_label_en-US" xlink:label="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:label id="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA_documentation_en-US" xlink:label="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:to="lab_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833_label_en-US" xlink:label="lab_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:to="lab_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_6018FE56724871725519EE3318893D47_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_6018FE56724871725519EE3318893D47_label_en-US" xlink:label="lab_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:to="lab_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7_label_en-US" xlink:label="lab_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:to="lab_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348_label_en-US" xlink:label="lab_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:to="lab_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:to="lab_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:to="lab_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F_terseLabel_en-US" xlink:label="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F_label_en-US" xlink:label="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F_documentation_en-US" xlink:label="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:to="lab_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:type="arc" />
    <link:label id="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:to="lab_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:type="arc" />
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone achievement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:type="arc" />
    <link:label id="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales achievement level</link:label>
    <link:label id="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9_label_en-US" xlink:label="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments, Minimum Net Sales Achievement Amount</link:label>
    <link:label id="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments, Minimum Net Sales Achievement Amount</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsMinimumNetSalesAchievementAmount" xlink:label="loc_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:to="lab_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent cash receipts (up to)</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2_label_en-US" xlink:label="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2_documentation_en-US" xlink:label="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:to="lab_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:to="lab_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:to="lab_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:to="lab_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:to="lab_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:to="lab_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances Without the Adoption of Topic 606</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments Due to the Adoption of Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:to="lab_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:type="arc" />
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E_terseLabel_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets - Current Portion</link:label>
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E_label_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Asset, Current [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E_documentation_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Asset, Current [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of a change in transaction price and recognition of revenues as services are performed</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:to="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transfer to receivables from contract assets recognized at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Reclassified to Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:to="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:to="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets - Long-term Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of a change in transaction price and recognition of revenues as services are performed</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:to="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:to="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities - Current Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:type="arc" />
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022_terseLabel_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022_label_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022_documentation_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:to="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9_negatedTerseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was included in the contract liability balance at the beginning of the period</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Deductions</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Deductions</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityCurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:to="lab_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:to="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities - Long-term Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:type="arc" />
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166_terseLabel_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166_label_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166_documentation_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:to="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619_negatedTerseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was included in the contract liability balance at the beginning of the period</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Deductions</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Deductions</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityNoncurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:to="lab_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:to="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:type="arc" />
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets and Liabilities under Topic 606</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties accruing to GSK</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:to="lab_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Revenues and Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:to="lab_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:to="lab_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:to="lab_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="lab_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:to="lab_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:to="lab_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:to="lab_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE_label_en-US" xlink:label="lab_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:to="lab_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:to="lab_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3" xlink:to="lab_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:to="lab_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2_terseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:to="lab_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Deductions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets: unbilled collaboration revenue, gross:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities: deferred revenue, gross:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Adoption of Topic 606</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:to="lab_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:to="lab_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8_label_en-US" xlink:label="lab_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:to="lab_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9_label_en-US" xlink:label="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9_documentation_en-US" xlink:label="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:to="lab_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E_label_en-US" xlink:label="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E_documentation_en-US" xlink:label="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:to="lab_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F_label_en-US" xlink:label="lab_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:to="lab_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:to="lab_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D_terseLabel_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D_label_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:to="lab_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">As Previously Reported</link:label>
    <link:label id="lab_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611_label_en-US" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:to="lab_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU 2016-18</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-18 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:to="lab_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB_label_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB_documentation_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:to="lab_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:to="lab_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:to="lab_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70_terseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70_label_en-US" xlink:label="lab_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:to="lab_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:to="lab_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:to="lab_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reduction to accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:to="lab_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prompt payment discount rate</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total available discounts expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:to="lab_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:to="lab_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Sales of Goods [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="loc_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:to="lab_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Sales Discounts and Allowances</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Revenue Reductions [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionRevenueReductions" xlink:label="loc_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:to="lab_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Revenues</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:to="lab_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:to="lab_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:to="lab_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:to="lab_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:to="lab_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:to="lab_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:to="lab_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:to="lab_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) matching contributions made in common stock</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid in kind</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:to="lab_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on other equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE_label_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Accrued Clinical Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) accrued clinical liabilities</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:to="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35_label_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:to="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible notes and term loan payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:to="lab_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on financing lease obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure - non-cash investing and financing activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment deemed to have been acquired under build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:to="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred to acquire Property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="lab_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="lab_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:to="lab_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:to="lab_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42_label_en-US" xlink:label="lab_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:to="lab_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:to="lab_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:to="lab_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1_label_en-US" xlink:label="lab_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:to="lab_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B_label_en-US" xlink:label="lab_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:to="lab_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:to="lab_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:to="lab_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing obligation for build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:to="lab_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E_label_en-US" xlink:label="lab_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:to="lab_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:to="lab_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:to="lab_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 295,700,576 and 289,923,798 at September 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:to="lab_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:to="lab_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:to="lab_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average cost recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in short-term restricted cash and investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in long-term restricted cash and investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:type="arc" />
    <link:label id="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35_terseLabel_en-US" xlink:label="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COTELLIC</link:label>
    <link:label id="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35_label_en-US" xlink:label="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35_documentation_en-US" xlink:label="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:to="lab_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:type="arc" />
    <link:label id="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096_terseLabel_en-US" xlink:label="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Generated [Axis]</link:label>
    <link:label id="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096_label_en-US" xlink:label="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Generated [Axis]</link:label>
    <link:label id="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096_documentation_en-US" xlink:label="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Generated [Axis]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedAxis" xlink:label="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:to="lab_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:type="arc" />
    <link:label id="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3_terseLabel_en-US" xlink:label="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Generated [Domain]</link:label>
    <link:label id="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3_label_en-US" xlink:label="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Generated [Domain]</link:label>
    <link:label id="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3_documentation_en-US" xlink:label="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Period Generated [Axis]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:to="lab_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:type="arc" />
    <link:label id="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A_terseLabel_en-US" xlink:label="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Q4 2016</link:label>
    <link:label id="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A_label_en-US" xlink:label="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Q4 '16 [Member]</link:label>
    <link:label id="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A_documentation_en-US" xlink:label="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Q4 '16 [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_Q416Member" xlink:label="loc_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:to="lab_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:to="lab_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B_periodEndLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84_label_en-US" xlink:label="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84_documentation_en-US" xlink:label="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:to="lab_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:type="arc" />
    <link:label id="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E_terseLabel_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark L.L.C.</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E_label_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E_documentation_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:to="lab_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:type="arc" />
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4_terseLabel_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4_label_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4_documentation_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:to="lab_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:to="lab_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:type="arc" />
    <link:label id="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E_terseLabel_en-US" xlink:label="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others, individually less than 10% of Total revenues for all periods presented</link:label>
    <link:label id="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E_label_en-US" xlink:label="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:label id="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E_documentation_en-US" xlink:label="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:to="lab_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with StemSynergy</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:to="lab_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:type="arc" />
    <link:label id="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8_terseLabel_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Products to Reach Market</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8_label_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8_documentation_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:to="lab_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80_verboseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80_label_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80_documentation_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments.</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:to="lab_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially Dilutive Shares of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323_verboseLabel_en-US" xlink:label="lab_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Final</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:to="lab_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:to="lab_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:to="lab_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:type="arc" />
    <link:label id="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2_terseLabel_en-US" xlink:label="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global</link:label>
    <link:label id="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2_label_en-US" xlink:label="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2_documentation_en-US" xlink:label="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:to="lab_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:type="arc" />
    <link:label id="lab_country_JP_C4F575089B4C38897B13EE3318479F69_terseLabel_en-US" xlink:label="lab_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_C4F575089B4C38897B13EE3318479F69_label_en-US" xlink:label="lab_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:to="lab_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5_terseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront nonrefundable payment</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:to="lab_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B_verboseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum pre-specified payments</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9_netLabel_en-US" xlink:label="lab_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Cumulative net sales</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:to="lab_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:type="arc" />
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A_terseLabel_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales volume period</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A_label_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A_documentation_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:to="lab_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation Assumptions Used to Estimate Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:type="arc" />
    <link:label id="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7_terseLabel_en-US" xlink:label="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues:</link:label>
    <link:label id="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7_label_en-US" xlink:label="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:label id="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7_documentation_en-US" xlink:label="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductRevenuesAbstract" xlink:label="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:to="lab_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="loc_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:to="lab_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190_totalLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354_terseLabel_en-US" xlink:label="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues:</link:label>
    <link:label id="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354_label_en-US" xlink:label="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Revenues [Abstract]</link:label>
    <link:label id="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354_documentation_en-US" xlink:label="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Revenues [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborationRevenuesAbstract" xlink:label="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:to="lab_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:type="arc" />
    <link:label id="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F_terseLabel_en-US" xlink:label="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services revenues</link:label>
    <link:label id="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F_label_en-US" xlink:label="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Service Revenue</link:label>
    <link:label id="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F_documentation_en-US" xlink:label="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Service Revenue</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchAndDevelopmentServiceRevenue" xlink:label="loc_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:to="lab_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration revenues</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:to="lab_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B_totalLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B" xlink:to="lab_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_215F464AF977F7706337EE331946503C_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_215F464AF977F7706337EE331946503C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_215F464AF977F7706337EE331946503C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_215F464AF977F7706337EE331946503C" xlink:to="lab_us-gaap_Revenues_215F464AF977F7706337EE331946503C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB_label_en-US" xlink:label="lab_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:to="lab_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:to="lab_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:to="lab_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F_terseLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments available-for-sale</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Realized Gain (Loss)</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases and Other Financing Leases</link:label>
    <link:label id="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33_label_en-US" xlink:label="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease and Other Financing Lease [Member]</link:label>
    <link:label id="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33_documentation_en-US" xlink:label="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease and Other Financing Lease [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:to="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:type="arc" />
    <link:label id="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5_terseLabel_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alameda, California</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5_label_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5_documentation_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:to="lab_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:type="arc" />
    <link:label id="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E_terseLabel_en-US" xlink:label="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Buildings, Furniture and Fixtures, Computer Equipment and Software</link:label>
    <link:label id="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E_label_en-US" xlink:label="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Buildings, Furniture And Fixtures, Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E_documentation_en-US" xlink:label="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Buildings, Furniture And Fixtures, Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:to="lab_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A_verboseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Construction in Progress</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:to="lab_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC_label_en-US" xlink:label="lab_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:to="lab_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of lease property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:type="arc" />
    <link:label id="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC_terseLabel_en-US" xlink:label="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress capitalized</link:label>
    <link:label id="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC_label_en-US" xlink:label="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment, Additions And Transfers</link:label>
    <link:label id="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC_documentation_en-US" xlink:label="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment, Additions And Transfers</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_PropertyPlantAndEquipmentAdditionsAndTransfers" xlink:label="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:to="lab_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of buildings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing obligations included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="lab_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:to="lab_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:to="lab_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:to="lab_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773" xlink:to="lab_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:to="lab_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:to="lab_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A_label_en-US" xlink:label="lab_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:to="lab_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607" xlink:to="lab_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C_label_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:to="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:type="arc" />
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED_terseLabel_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Warrants</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED_label_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED_documentation_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:to="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:type="arc" />
    <link:label id="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E_terseLabel_en-US" xlink:label="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of warrants</link:label>
    <link:label id="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E_label_en-US" xlink:label="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period</link:label>
    <link:label id="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E_documentation_en-US" xlink:label="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ClassofWarrantorRightPeriod" xlink:label="loc_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:to="lab_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments to net income resulting from realized gains or losses on sale of securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense related to other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:type="arc" />
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC_label_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC_documentation_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="lab_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E_terseLabel_en-US" xlink:label="lab_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E_label_en-US" xlink:label="lab_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:to="lab_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A_label_en-US" xlink:label="lab_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:to="lab_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:to="lab_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:to="lab_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:to="lab_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C_label_en-US" xlink:label="lab_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:to="lab_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D_label_en-US" xlink:label="lab_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:to="lab_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:to="lab_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924_label_en-US" xlink:label="lab_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:to="lab_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:to="lab_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Invenra</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement With Invenra [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement With Invenra [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:to="lab_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:type="arc" />
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9_terseLabel_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9_label_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9_documentation_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:to="lab_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:type="arc" />
    <link:label id="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329_terseLabel_en-US" xlink:label="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Commercialization</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329_label_en-US" xlink:label="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329_documentation_en-US" xlink:label="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:to="lab_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:type="arc" />
    <link:label id="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F_terseLabel_en-US" xlink:label="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery Projects</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F_label_en-US" xlink:label="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F_documentation_en-US" xlink:label="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:to="lab_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:type="arc" />
    <link:label id="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8_terseLabel_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project initiation fee</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8_label_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8_documentation_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:to="lab_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654_terseLabel_en-US" xlink:label="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total upfront payments and project initiation fees</link:label>
    <link:label id="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654_label_en-US" xlink:label="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payments And Project Initiation Fees Payments</link:label>
    <link:label id="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654_documentation_en-US" xlink:label="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payments And Project Initiation Fees Payments</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPaymentsAndProjectInitiationFeesPayments" xlink:label="loc_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:to="lab_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60_label_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60_documentation_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:to="lab_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock for basic net income per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock for diluted net income per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3_label_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3_documentation_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:to="lab_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:type="arc" />
    <link:label id="lab_country_US_7718B05CAA1FD23128C1EE331902BEEF_terseLabel_en-US" xlink:label="lab_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_7718B05CAA1FD23128C1EE331902BEEF_label_en-US" xlink:label="lab_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:to="lab_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038_label_en-US" xlink:label="lab_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:to="lab_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:type="arc" />
    <link:label id="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D_terseLabel_en-US" xlink:label="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
    <link:label id="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D_label_en-US" xlink:label="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Geographical Areas [Member]</link:label>
    <link:label id="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D_documentation_en-US" xlink:label="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Geographical Areas [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherGeographicalAreasMember" xlink:label="loc_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:to="lab_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41_terseLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762_terseLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76_totalLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5_negatedLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Accumulated Loss</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257_negatedLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Accumulated Loss</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:type="arc" />
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A_negatedTotalLabel_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A_label_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:label id="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A_documentation_en-US" xlink:label="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:to="lab_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B_terseLabel_en-US" xlink:label="lab_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B_label_en-US" xlink:label="lab_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:to="lab_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621_terseLabel_en-US" xlink:label="lab_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621_label_en-US" xlink:label="lab_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="lab_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:to="lab_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profits and losses on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:to="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:to="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>exel-20180629_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20180629.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20180629.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20180629.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20180629.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsGenentechCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsInvenraCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsStemsynergyCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20180629.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20180629.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20180629.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20180629.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="exel-20180629.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20180629.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20180629.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20180629.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20180629.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20180629.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20180629.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20180629.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20180629.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20180629.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20180629.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20180629.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20180629.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20180629.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20180629.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20180629.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20180629.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20180629.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20180629.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20180629.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20180629.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20180629.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20180629.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20180629.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20180629.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20180629.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20180629.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20180629.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_77EF3B96B4996439A671EE33178B8509" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_77EF3B96B4996439A671EE33178B8509" xlink:to="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_C43D942D7246B177A37CEE331791183C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C1E943384C84DC9B1282EE33174E9975" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C1E943384C84DC9B1282EE33174E9975" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:to="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5733394E920754AD604FEE33174F0FDF" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_04302821D9AC9F959F5EEE33174FE42B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_04302821D9AC9F959F5EEE33174FE42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_534F469CB3DFCCBD46B9EE331750B7DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7E17D54FDF8B734ADB3DEE33174FA064" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_534F469CB3DFCCBD46B9EE331750B7DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_28034C8492B22CCB2F03EE33174EB23E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_56B6A4AE1F0504BB73C9EE331750AD41" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_D7FFF499FA68E35C0769EE331750C762" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_78ABF76270B80F8477BCEE3317506106" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_298760EF02B13282A61DEE3317518A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EAC9E94CF9AA7D929B8EE331750464A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_265D7227846AC4229B77EE33175106C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3E5D29BEE8A14FACC39BEE3317518257" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract_918BD0347DEA159C7BB2EE331751F552" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_F31A83B4133FA99C07B3EE331752846A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2144D53FC1102995F640EE3317266939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D928AE8B174B980621CCEE3317260703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C8EFC6C3220706C8202EE331726C262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06F7E3C440316AC0B6DDEE3317263E70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_61A40F1FA4AD66058A62EE331767C3B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_61A40F1FA4AD66058A62EE331767C3B4" xlink:to="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:to="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_C5062F7568227EA044DBEE3317675F00" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E8E2EBCC696B8DABDC45EE3317683E26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E8E2EBCC696B8DABDC45EE3317683E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0F21703BD2EB677BEDB7EE331768D077" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0F21703BD2EB677BEDB7EE331768D077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_0FF369FD8CA57F9F4D94EE33176870EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_CommercialPaperMember_0FF369FD8CA57F9F4D94EE33176870EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_AF84DAF3222D1149C18CEE33176916DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_AF84DAF3222D1149C18CEE33176916DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8D32BC68AABEA5C792B0EE331769172D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_DD7646CABD4E14E28C91EE331768A1DB" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8D32BC68AABEA5C792B0EE331769172D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_B5EDA7760C59F0986164EE3317675F8B" xlink:to="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94AB5CEE349AF8EF5EFCEE331769EC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3F1BC5611F5EE75D8D63EE331769BFD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3AD56C934E570F001538EE33176A9CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_980B3B32562E6D505241EE331769D621" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1CCF8DA262F7C11B777AEE33176A18E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9FF7727E2EEFB0D8DCD0EE331729749C" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9FF7727E2EEFB0D8DCD0EE331729749C" xlink:to="loc_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss_DD955D40EBF9A4196503EE331729395F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9FF7727E2EEFB0D8DCD0EE331729749C" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_B6AA5CF8824A26A54F37EE331729C7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9FF7727E2EEFB0D8DCD0EE331729749C" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_B59051238C18C7353FD3EE331729D6FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1D058EF7F4E1F60F341AEE33177958AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_F4915D19F76AABE101A4EE331779DE12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_650773AB7D2CF944CBE1EE3317797413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_DAE2AA4ABD29EC91B024EE3317792BCA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F596A89C393B98771CB0EE33177A61CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_168038FAAEABA992AAECEE331783E276" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_168038FAAEABA992AAECEE331783E276" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79305803BB7A73CB3D65EE3317835C7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_168038FAAEABA992AAECEE331783E276" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_19E7984F74C5183204DAEE3317830083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_168038FAAEABA992AAECEE331783E276" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_19F73949EA9BBDB6A043EE3317836954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_168038FAAEABA992AAECEE331783E276" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_EA046B89C0D2C2212266EE331783E6EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2B57576015D16802364AEE3318A6D118" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2B57576015D16802364AEE3318A6D118" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_A394553A2A0DEB001296EE3318A76057" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26B82F767AC15DD652BBEE33185FB70B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26B82F767AC15DD652BBEE33185FB70B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E91628B1D2CF4702E8BEEE3318605D02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_F413DD9B2639DFC6A7DBEE3318619457" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6619827C06435E047D3EEE33186089D5" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_F413DD9B2639DFC6A7DBEE3318619457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_561C76335799E19AFB11EE331861A8D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_BAF511BA0ED1D53DB284EE331860B401" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_561C76335799E19AFB11EE331861A8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_F51208CC29F69930B6E4EE33186197C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_561C76335799E19AFB11EE331861A8D9" xlink:to="loc_us-gaap_ContractsRevenue_F51208CC29F69930B6E4EE33186197C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0B15B6EB30764BF57C92EE33180A8DF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0B15B6EB30764BF57C92EE33180A8DF7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7E7446CD95E2422A0C7BEE33180B4B11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ACF21203DB60F51DB8A0EE33180BF30E" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_A2F976819F01C14EF2ADEE33180C8E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ECFBFDFB380851BF7B47EE33180C086E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3BC3F4E3DDC8BDA2C940EE33180B55F4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ECFBFDFB380851BF7B47EE33180C086E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_40A5EC1E0A28F4342D15EE33180C4DB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ECFBFDFB380851BF7B47EE33180C086E" xlink:to="loc_us-gaap_ContractsRevenue_40A5EC1E0A28F4342D15EE33180C4DB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93C36FA8A5699929A590EE3317E94089" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93C36FA8A5699929A590EE3317E94089" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_66E25837FF7BBFC3AAEEEE3317EAC286" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA4BBB45C8E31A0E0BE4EE3317EABD40" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_D4FCF558BE671F99DBCDEE3317EA49AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_7184497C5EDA0A05697AEE3317EA8A22" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A8D197E450AFE3B15D67EE3317EA4DA6" xlink:to="loc_exel_CotellicMember_B8811B8589E38A83E8D7EE3317EBBC35" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedAxis" xlink:label="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_PeriodGeneratedAxis_958AD02EB13384979EA0EE3317EBA096" xlink:to="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_Q416Member" xlink:label="loc_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_PeriodGeneratedDomain_BEE44296212EE9FC5710EE3317EBF8E3" xlink:to="loc_exel_Q416Member_ED4545E74D7E01C107F4EE3317EB063A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_867EBD95DB7B0E5B94B4EE3317EB84D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9745B357EF2E245F6D78EE3317E9E8C1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_867EBD95DB7B0E5B94B4EE3317EB84D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_867EBD95DB7B0E5B94B4EE3317EB84D8" xlink:to="loc_us-gaap_RoyaltyRevenue_E0FCBD990369DBC961AAEE3317EB17F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1E9777155405F899D7A0EE3317AFFBE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1E9777155405F899D7A0EE3317AFFBE9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39ED6132D06E9579EB8AEE3317B0F2E9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementWithInvenraMember" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0221160203A5CB0DCD07EE3317B02D0D" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_75BC125D551ED43D27C1EE3317B0AF18" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_DF506E7CF9FC21AD8255EE3317B0BA84" xlink:to="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_CB4999D75F47131B6843EE3317B1E5B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductCommercializationMember" xlink:label="loc_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:to="loc_exel_ProductCommercializationMember_EACEB199600CE6B6521AEE3317B16329" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DiscoveryProjectMember" xlink:label="loc_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_481BDDD8E9723DC27837EE3317B17889" xlink:to="loc_exel_DiscoveryProjectMember_1C711C66EEB2DFFBE95FEE3317B1DC0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E8CC11C9CE1AC13C9A3EE3317B23407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06397BFB9AD614B8348CEE3317B2A767" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2E8CC11C9CE1AC13C9A3EE3317B23407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1960C2AD0C6B01E27F8FEE3317AF9F43" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_1DD01163E30EDB339BF0EE3317B221B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_UpfrontAndMilestonePayments_1DD01163E30EDB339BF0EE3317B221B6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProjectInitiationFeePayment" xlink:label="loc_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_ProjectInitiationFeePayment_ADFFF2ECD75B606061D7EE3317B307D8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPaymentsAndProjectInitiationFeesPayments" xlink:label="loc_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_UpfrontPaymentsAndProjectInitiationFeesPayments_705124C960A068E5C355EE3317B31654" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_E7F7BC8F76205281B5A9EE3317B3C04D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83E48DB04B94A41A3F3AEE3317B20D6F" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_E7F7BC8F76205281B5A9EE3317B3C04D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68FF5466FFEF40BA482EEE331884977B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_844AA28B4050DAEE9AF6EE331884CD3F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E9C8891BB2A406B4D1CCEE33188589BB" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_55CC04E301D044E0BE99EE3318855354" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_AA109BC6FA6D1ED8FBAFEE331885A454" xlink:to="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApproval1LRCCMember" xlink:label="loc_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAApproval1LRCCMember_422306919EF3D23434F6EE331886ADC7" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_DF66FAC50BA97298B879EE33188603F4" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RevenueAchievementsMember" xlink:label="loc_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_RevenueAchievementsMember_ACC81D43F42ABDA20C5DEE3318868517" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalHCCMember" xlink:label="loc_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAApprovalHCCMember_E8CF98A66EE799764817EE3318861743" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalMember" xlink:label="loc_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_1EDE3311B3F1D21C9E24EE3318858F20" xlink:to="loc_exel_EMAApprovalMember_8DEAC07A75072FF97918EE3318873638" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierAxis_E3D0F6DF2C4E0A3E02E9EE3318870707" xlink:to="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_3D0013853407ABC0B597EE3318875BCB" xlink:to="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:to="loc_exel_InitialMember_222E4C6F7855A55D2818EE331888450D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinalTierMember_3BDF87BFC021BCBD5FF4EE3318878834" xlink:to="loc_exel_SecondMember_0D1591C40344C6E10AF2EE33188873CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_4029140A872E5C4E60E4EE331888B833" xlink:to="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:to="loc_us-gaap_MinimumMember_92BEE9440A583BC7368AEE331889EEC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6018FE56724871725519EE3318893D47" xlink:to="loc_us-gaap_MaximumMember_CB2D16B31AB085293FD0EE33188F4348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_5D0357C17E7A1789CA47EE33188FF0D9" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_FCDE1BDF0B1AD159FD27EE33188F11DA" xlink:to="loc_exel_GlaxoSmithKlineMember_81C6570A4155FC441BDCEE33188F011E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_582A3B4E192260CCE0CFEE3318841D9B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_UpfrontPayments_7A9EBD93027EA2D8D43FEE3318904A9F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_MilestonePaymentsEarned_ED3D70BB3C55A5DD357CEE331890180D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_44A24C4987C2FB062C07EE3318903F9B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsMinimumNetSalesAchievementAmount" xlink:label="loc_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_MilestonePaymentsMinimumNetSalesAchievementAmount_617377B81E07D53D17B6EE3318907EE9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_C50201B6B430416DE9AEEE331891B9D6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_833D9B76757806328495EE331891D1D3" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_RoyaltyTier_2D5943F6C09C9B8CF4BFEE33189146D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_LicensesRevenue_5FC5A32EA8E432113A5FEE331891433D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_44B3FC73E70515B97000EE3318918A4F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_EDBACD542DAAE5B382F4EE3318913576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1FFF9C98807E60398835EE3318928989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_61EA0664F96F584B0115EE331892E33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0A5FCC4D451FD0F95DD5EE331892F63B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A730AFA914A52C2046E7EE3318906DE7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E65F0DDA9A5F2E359EB1EE331892876D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8C72DC20EA6DF7531E1EE3317992FC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8C72DC20EA6DF7531E1EE3317992FC3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5B09930E9882A9CAF801EE33179AFA73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9061F3E26B8563F6B967EE33179ADD53" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_8EF23F30EA7380B5172BEE33179A2C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA04BF60FBAC16425C4EE33179BFD03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_93B0498B2105EBD0AEF0EE33179906B9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA04BF60FBAC16425C4EE33179BFD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA04BF60FBAC16425C4EE33179BFD03" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05B570FED5320F6EFD87EE33179BEA83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D5DE4FDF7F45795C966DEE3317FAAF1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D5DE4FDF7F45795C966DEE3317FAAF1B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:to="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_085D130F64DD223A3F47EE3317FAC483" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_4130F35D9380ED3998F9EE3317FB1B93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01680B8CA4ACE79CBDFEEE3317FA95FB" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_4130F35D9380ED3998F9EE3317FB1B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:to="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_3A9D80590A72B43686ECEE3317FB504D" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_BEA30C459EAA1DF8AD3AEE3317FB676C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C5553338C3DC004A5962EE3317FB74B7" xlink:to="loc_exel_CotellicMember_BEA30C459EAA1DF8AD3AEE3317FB676C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FB63CF1DEAE8946ED730EE3317FA2C79" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:to="loc_us-gaap_RoyaltyRevenue_BDF26601610445BFF734EE3317FC1B0F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0C8D63C973F77082ADC3EE3317FC4AE7" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_251290D312A2189BA463EE3317FCA021" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1434457DDBB55DFF2E0EEE3317D30831" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1434457DDBB55DFF2E0EEE3317D30831" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8BA057B73B0362183015EE3317D46AEA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FD0D52819FC12802711AEE3317D402CE" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_224B276EBEAB1804387BEE3317D48A23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B5C232E41FFA741EA63AEE3317D5156E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1725750CC98528602FAFEE3317D3570C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B5C232E41FFA741EA63AEE3317D5156E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B5C232E41FFA741EA63AEE3317D5156E" xlink:to="loc_us-gaap_RoyaltyExpense_0A47888282302D9DC60AEE3317D59BF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0323F8EE8CF9923BA13EE3317C27C8B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0323F8EE8CF9923BA13EE3317C27C8B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4F7CB8466393C291BC90EE3317C3EB02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementWithStemSynergyMember" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F7CBBC5922DD4211F33BEE3317C33244" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_C9A17E8883E619C85F38EE3317C3DC0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:to="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_9CE92A8F401267B4D6EBEE3317C9970A" xlink:to="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_FirstProductToReachMarketMember" xlink:label="loc_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_75E4943F0038C4838727EE3317C911C9" xlink:to="loc_exel_FirstProductToReachMarketMember_79BE4D84669B6C0BDC2CEE3317C96FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_29997085DC16D1BFC786EE3317C258B8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:to="loc_exel_UpfrontAndMilestonePayments_9CF7891EE2FF3CCC7D22EE3317CA2C80" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1B912FD1D09FC0FE7061EE3317CA92A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D9AE11EF9CAC85A9E2AEEE3317C928B6" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1B912FD1D09FC0FE7061EE3317CA92A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A3F6AEACF640ACE190B9EE33189FFC5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A3F6AEACF640ACE190B9EE33189FFC5F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3C6B6BD3961907CD4481EE33189F4594" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41783FD516A07318332CEE331843C592" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41783FD516A07318332CEE331843C592" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_218F5688BB9533A9408DEE331844A55B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_313DBD9927A58D8AE63FEE331845C79D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_648D59CBF28FF6646BC7EE33184409B0" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_313DBD9927A58D8AE63FEE331845C79D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierAxis_703B1D378BBF94770B38EE3318454367" xlink:to="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_E68D6A34840C8FC60686EE3318450558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:to="loc_exel_InitialMember_E68D6A34840C8FC60686EE3318450558" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4CD1113FD4C9EA8DE2ECEE33184563A8" xlink:to="loc_exel_FinalTierMember_839C8458FFC4D4F7A33BEE331846C323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_6838790F0F22253BAC77EE331846CB94" xlink:to="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:to="loc_exel_GlobalMember_371DCFF29D3639B996E6EE33184653E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_9CCDF64D965FF2785778EE3318468C3F" xlink:to="loc_country_JP_C4F575089B4C38897B13EE3318479F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6E9D04B97C10450CAB4CEE33184747C5" xlink:to="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E36AAF163423742263F0EE33184CAC17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:to="loc_us-gaap_MinimumMember_E36AAF163423742263F0EE33184CAC17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A162185B061CFFEA8FB3EE33184DF82D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_48969B604BEA74B8D15FEE33184793D9" xlink:to="loc_us-gaap_MaximumMember_A162185B061CFFEA8FB3EE33184DF82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52458B49F0486B2FDD35EE33184393F0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontPayments" xlink:label="loc_exel_UpfrontPayments_DDCBA90FB8AEC626ACDFEE33184D1FAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_UpfrontPayments_DDCBA90FB8AEC626ACDFEE33184D1FAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_UpfrontAndMilestonePayments_986B015F1F4BFE3B8641EE33184D4AD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCDCD81204EC3FB7B375EE33184E5670" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_46C5C921B32F8230E5ACEE33184EB62B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_A2303E24DB6DBB4CDA27EE33184E5A2C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_A2303E24DB6DBB4CDA27EE33184E5A2C" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_RoyaltyTier_BA7B231558E007BF3AFDEE33184ECAA9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_350E70B26CE918C65BF6EE33184E79AD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_350E70B26CE918C65BF6EE33184E79AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_8DCF02E4F69D1118F650EE33184FDB16" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_8DCF02E4F69D1118F650EE33184FDB16" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_7682132DF5E6218B128BEE33184F0B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6ADA97206FF1ACE9F0F3EE33184FD704" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6ADA97206FF1ACE9F0F3EE33184FD704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_355A7BBE8E39409B438EEE33184F0A5C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D30AE53FDD6831047246EE33184D12CF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_355A7BBE8E39409B438EEE33184F0A5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CD50089172E80EA9C55DEE331ABFC43F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD50089172E80EA9C55DEE331ABFC43F" xlink:to="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AB9E1FAF7697FA61DB00EE331AC0E7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_ShortTermInvestments_2AEB75382A6C0F47461EEE331AC1928D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_C1A805DA2A44EA2817B8EE331AC121A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_ReceivablesNetCurrent_961EC54EE1B6F3FFC6C5EE331AC1BECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_InventoryNet_7757CC26E0601D39E72BEE331AC17B42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42A99CEEBF9B987D584BEE331AC2024A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F8D2073B4A3548083E8CEE331AC08C32" xlink:to="loc_us-gaap_AssetsCurrent_B73EEF9756CB338C7936EE331AC2E786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_LongTermInvestments_634E6D9A293094B46157EE331AC326B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_25B0F78ABC949D51D5F2EE331AC3F674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_F47D049986B4518E4239EE331AC32CB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_Goodwill_4C5B33A7C5959C6F5D68EE331AC315D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D68DA776FAD064DDECBCEE331AC398E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDF69F2572FC50219EDFEE331ABF01BA" xlink:to="loc_us-gaap_Assets_1B556A003343DF874C4FEE331AC4696B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD50089172E80EA9C55DEE331ABFC43F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_us-gaap_AccountsPayableCurrent_2C3CBDA98FFB677ECB92EE331AC4CC9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_93F556C325144465DFDCEE331AC5BD44" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_89FAA331D8A1881FCFAFEE331AC5419F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_1D94A03C8A211DFF6668EE331AC5C105" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_E6BB7FFB982ABF3386C6EE331AC5D387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_EBD2995610AC043D08E4EE331AC63C73" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_EBD2995610AC043D08E4EE331AC63C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8711563D8B3638D7A36DEE331AC69A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9B01F2AAF8940333AAFBEE331AC45C4E" xlink:to="loc_us-gaap_LiabilitiesCurrent_79CA6D7E3D6F700DD39BEE331AC6ED3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_F08955CA149030EB33F7EE331AC624AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_F08955CA149030EB33F7EE331AC624AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_5D5DB6CE737FB70EC054EE331AC636E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8990B4A1B0284961082EEE331AC7ED4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_Liabilities_0FF40977EA1FC74C907AEE331ACC8F3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_23EB9B12E03C327B2625EE331ACC8732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:to="loc_us-gaap_PreferredStockValue_B5A8087DE0F0CD7A94E2EE331ACD40AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:to="loc_us-gaap_CommonStockValue_3E2B3E9D4C9D12ADDA83EE331ACD0C7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:to="loc_us-gaap_AdditionalPaidInCapital_EFC9418C60AD0C2CEC8AEE331ACD6F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E375E8FC3C8530AAEEACEE331ACD32BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C0F68BB4F01549961490EE331ACDE488" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C0F68BB4F01549961490EE331ACDE488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33418071A3E28DAD90FEEE331ACCA1CC" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565CE8ABFFD86450DD74EE331ACD5A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7E385F9767BF332C55EEEE331AC4CFC5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF4542FF157BBC00980DEE331ACED1AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F0E01717513C472D0EE7EE331A874F00" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_F578349FFF3FDDCA4F4DEE331A87F112" xlink:to="loc_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_778D93A3A4D8AC5115EDEE331A88210A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_06BE40FAC2A224DEECC6EE331A88CA71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_06477712A9E2E40E46DDEE331A8844C1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_BEAB7767F930579FBBBEEE331A884B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_860B172CE6F0E450F578EE331A876E33" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_E7371632BB207CCC2309EE331A89EACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6A3638C4753EF8A15D5BEE331A89FC98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:to="loc_us-gaap_CommonStockSharesIssued_281FEFF283471BCF0FAEEE331A895362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7FC2940C4FC7D104B1E3EE331A894141" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A6C8546EC54B19CD8C5AEE331A8F1686" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2CEAAA104724AD2E57A1EE331A203847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_NetIncomeLoss_2CEAAA104724AD2E57A1EE331A203847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_696230013AC398B97FA9EE331A211893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_ShareBasedCompensation_E741AE0852950549809CEE331A21ECC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_45AF231A2A2410BC7876EE331A211000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7BE5F70447E8157C472AEE331A211673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C0973E7E7090ABB6E00DEE331A212D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_PaidInKindInterest_FBF35CB32629EBB42859EE331A2702ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9DB9BB9F32A2CFBF7A90EE331A275AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_C84831EFB1685E61C4C7EE331A27FA57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7DA9D7FC0B84B457B8E9EE331A2068FB" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4DF504AD0F5C76B21E44EE331A27F389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0217FE317D510D95CD7CEE331A29B482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1F96A872F821D805B1F6EE331A29860D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2F0B945F94476679BE77EE331A29E969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8086FBDE664914954207EE331A2A829A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_D87B94D093DCE89D779FEE331A2A04AC" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_F698AA4515DD9811B185EE331A2B4FCE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_62597A4A7C32872E0229EE331A2B8A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CB73AF1FB4F7175B73B2EE331A2B3022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2E9D5FD1D483A7541635EE331A27A55E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7E1A6623A5B072D247EAEE331A2C7968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_084C0015B32653D0F86EEE331A2C7A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E2112A5711E4BF3C7D9EE331A2CD9EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4E79A4F226924D05F9AAEE331A2CD2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_53D112B8D28C14FBEDFAEE331A2D2C45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_199B264B2A1B62165045EE331A2DD7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_262625253DDCDDA605CAEE331A2D2584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C25B186E0A6BEBC4A833EE331A2CF4CE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9D1A01140DB6B8860297EE331A2DD5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4A952E9755B066B8F5E5EE331A2ED88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3B7E8DEAC8C816D7B8A2EE331A2E1876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="loc_us-gaap_ProceedsFromStockPlans_CF81C1832A92CB35926BEE331A2E662B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D27E08974ECDED2F1276EE331A2EF515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_00B3978F0D8F459BF5A2EE331A2F0CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7F815AF2EF38F2F53970EE331A2DAB37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43FAAD5141677346688FEE331A2F0C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_EF7A1A4BD8191756E176EE331A2FE4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6EC52785D6FC73090A14EE331A2FFE02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0AE6E307951175AEBB48EE331A2FBA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9BA57989FECC331629B7EE331A201D26" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_6C688E43F00D64574FA8EE331A350319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9B619E565623EE3C21B4EE331A354E30" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_267FB8A5FF47FA9B6977EE331A35C6B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_106B1EAB5D26AADD3E8FEE331A4D4702" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FC152CDAE0DE03F3752AEE331A52C405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_106B1EAB5D26AADD3E8FEE331A4D4702" xlink:to="loc_us-gaap_NetIncomeLoss_FC152CDAE0DE03F3752AEE331A52C405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_106B1EAB5D26AADD3E8FEE331A4D4702" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2C00BD8696FB9D8B4B71EE331A52EA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_106B1EAB5D26AADD3E8FEE331A4D4702" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_27A91E3577334191CDFDEE331A528F32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8A361BF10EC1BEC90A6FEE331A434F88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_93BFA2F2F3B0DE778FB8EE331A43A149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_2FCBC98B78E95E7E419BEE331A433B01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7DB5CBA3E9FFFDCDEC79EE331A6D39CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_53BE6649BEF7ABF5F714EE331A6D05C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:to="loc_us-gaap_ContractsRevenue_53BE6649BEF7ABF5F714EE331A6D05C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DE0E0EB4F671515113BAEE331A6DA1C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_D5D07C839D169259EEA1EE331A6C060B" xlink:to="loc_us-gaap_Revenues_DE0E0EB4F671515113BAEE331A6DA1C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:to="loc_us-gaap_CostOfGoodsSold_EF68F9D66660CA2512E0EE331A72BA63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_BA814CF68A88BFA1CED6EE331A73BF81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_957D1C4692A2EA492F7EEE331A736225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_622448590816A2369B6DEE331A6D425C" xlink:to="loc_us-gaap_OperatingExpenses_A9A665A66614A6DF40AEEE331A739773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_OperatingIncomeLoss_25CD1E51D51890D6DC44EE331A73AEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:to="loc_us-gaap_InterestIncomeOther_42BBD320AA09FE0636DEEE331A74A484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:to="loc_us-gaap_InterestExpense_449273075982F91568D1EE331A747F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3C225B588D7490346762EE331A74541F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_C3C5AE1570B37C8896B2EE331A74F1C2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_56F7C53849FCBE94ECDFEE331A74CF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1F1E33CF330100D69D6AEE331A75EDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_172C5D120C5A2933E6FDEE331A7545A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_NetIncomeLoss_CEAB877E0DFDEAE547D9EE331A756607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8C20DEC16BB6F714B57CEE331A757A6A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_EarningsPerShareBasic_8C20DEC16BB6F714B57CEE331A757A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7DB63886403C499323C3EE331A7552E9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7DB63886403C499323C3EE331A7552E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_B564478A11630AFB23B3EE331A756314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F342E5158C3719C9B74EE331A6C2672" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BD7A1698A3C473FD2EC6EE331A761DA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="exel-20180629.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_DocumentType_40A8F2A624EFF955FD4AEE331AE3074E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_AmendmentFlag_8DBDACFA90B1EFD1D2F3EE331AE3F16A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_DocumentPeriodEndDate_D872F3BC8671774D992DEE331AE39DD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_DocumentFiscalYearFocus_33F10DE1EEF22AF7A9A1EE331AE32AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_DocumentFiscalPeriodFocus_F610F4863A4EF8D00A60EE331AE433E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_TradingSymbol_3D371D1BCBCC019B7284EE331AE4C82C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_EntityRegistrantName_D998F4651E2662CF257FEE331AE5EA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_EntityCentralIndexKey_6FE989A33070A6B169A5EE331AE55FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_EntityFilerCategory_C66E4C452D3C8AFEB586EE331AE5C924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_CurrentFiscalYearEndDate_FE5664ED357C7C67F3EFEE331AE5D963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_7AB1D68A5FC688DD3142EE331AE224AC" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_C9469171517F230A672CEE331AEB4F2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C73A7A5361DB9C626F74EE3316AA8A54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C73A7A5361DB9C626F74EE3316AA8A54" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_DD00D2F2B17CCE5086C3EE3316AA06B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99FF97F829E4ACD52D9EEE33169CB008" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:to="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_FD15BD4A962A8927A3BAEE33169DF48D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8D6AC6C9C017C34468E0EE33169ED682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_CertificatesOfDepositMember_F0E1A25613444AD5FE47EE33169EB44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_CommercialPaperMember_6808DF880DD916EA8AC3EE33169E4EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_E59E403F2CF2C3808FADEE33169F0FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_38BFC8650D8D952389B4EE33169D9B75" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F356D7A30EA706285C4FEE33169FC538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E42FBC5B3D507C46CD7EEE33169F8DC7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_212E3D5FE5BED826B965EE3316A0D0AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_352BFCE4BA4F9FF0442CEE33169FB093" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F89AD4352B036D840685EE3316A0517B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_C6CEF319E63195E8D807EE33169D38FF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D5ED920411110B6DBAC2EE3316A0A57A" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_69A4EF8027066C1B15C9EE3316A0C118" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8F22E316C66891A74118EE3316A7B6E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8F22E316C66891A74118EE3316A7B6E0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_C80E2BD97F3D9FD2714DEE3316A7B387" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FAE0B7B3CB82B9D197C3EE3316CAA509" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_FCD1E4DE94EEA0510479EE3316CA74FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_54E273EBCBC7F1BEDB75EE3316C40801" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9D13EB99D0413C1D2006EE3316C4D05C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_54E273EBCBC7F1BEDB75EE3316C40801" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9D13EB99D0413C1D2006EE3316C4D05C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_88D5E0D2D91B0C5E4BFEEE3316C72D0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88D5E0D2D91B0C5E4BFEEE3316C72D0D" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_61C96ACCFC88880A1782EE3316C76DB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B10EA737FBEECE613F78EE331722126B" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_09B4C87E1EC3E64B4B7DEE331722E2D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2BF4490D363CDD20ADA4EE33171A3343" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2BF4490D363CDD20ADA4EE33171A3343" xlink:to="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8484CBE4F8495004AF99EE33171B438C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:to="loc_us-gaap_InventoriesMember_A2FB0563B4AC448102CBEE33171BDFBA" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9C69A2FAB8603D58A7E9EE33171B5CC7" xlink:to="loc_exel_OtherLongtermAssetsMember_467283813D1310ED34B6EE33171C698C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_8C5FFFA54F4048A8CB83EE33171AE39E" xlink:to="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryRawMaterials_8CD601F9F862653A15A7EE33171C63FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryWorkInProcess_17F50A09C5F6AE7829FDEE33171CB2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryFinishedGoods_774DE7E09B3F5FB60AC5EE33171D5EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryGross_A8338C200DADA7B5098AEE33171D46EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A503A1B795A3288121E0EE33171CE69E" xlink:to="loc_us-gaap_InventoryWriteDown_035B6E84727A5B3590FEEE33171DCE1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_493A6445E7DB36F2C1A8EE3317204048" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_493A6445E7DB36F2C1A8EE3317204048" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1999D07CA0044ED8B443EE331720BCD0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_EFBB0621A800F7C073ECEE3316C2A44D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EFBB0621A800F7C073ECEE3316C2A44D" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_382E7BBCE48A191AF07BEE3316C2B3D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2396113E82DD7D60702CEE3316B9C989" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2396113E82DD7D60702CEE3316B9C989" xlink:to="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A1DA0BB018575D2F05F0EE3316BAA19F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:to="loc_us-gaap_NetIncomeLoss_A1DA0BB018575D2F05F0EE3316BAA19F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4B18187213605E435766EE3316BA2372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AF251F19E7434F7143B3EE3316BA8D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_0717E0237A6BAF6E2AA7EE3316BA40D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D61F8C2E8EC23287F97AEE3316BA8C60" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_A8706D63214FD1765C1FEE3316BB53ED" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2396113E82DD7D60702CEE3316B9C989" xlink:to="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1E2759D3D346D80E8ABAEE3316BB67A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_CA4176DBC7B3E952508FEE3316BB465A" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FEDFE3029BF18D61438EEE3316BBA4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_3BB358A7C700A63458A2EE3316BB7AF3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_941F5F9EB0A5CF20F7E8EE3316BC9EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_360B0C1996F1D2BBD663EE3316BC0C8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2396113E82DD7D60702CEE3316B9C989" xlink:to="loc_us-gaap_EarningsPerShareBasic_360B0C1996F1D2BBD663EE3316BC0C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C0665F9AB765282E8ACAEE3316BC1C70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2396113E82DD7D60702CEE3316B9C989" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C0665F9AB765282E8ACAEE3316BC1C70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BD0B230091D86269E7DBEE3316B27A89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BD0B230091D86269E7DBEE3316B27A89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B0DF16A73379DDB05CEE3316B300B8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_437FEA9567FB29CCE9C6EE3316B35762" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_7E75358A807F8FFE088FEE3316B39AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_ED57597EC6889A6F24ECEE3316B2DB87" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ClassofWarrantorRightPeriod" xlink:label="loc_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:to="loc_exel_ClassofWarrantorRightPeriod_60CCF428DA999263DF76EE3316B41B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D7689DE4D6314AB59E86EE3316B33AB2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_675B83471F95D51F1990EE3316B43FB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_72691FC125615A4CD44AEE3316AD5EC3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_79CA560DFC665DC5220AEE3316AEEF67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D65F9F7BEDDC2DA89B52EE3316AEB537" xlink:to="loc_us-gaap_StockCompensationPlanMember_6786D9E95622E7B5967FEE3316AE81BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58C297E775E81E85D3D3EE3316AD3784" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5509673FB1FDD3804D6EE3316AF8A43" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DA0709F30B5BC8165BC1EE3316AFD51D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C82D6511682E1C4C201AEE3316BF5B12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C82D6511682E1C4C201AEE3316BF5B12" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_197CEAE1DFFBDD660124EE3316BF29B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C82D6511682E1C4C201AEE3316BF5B12" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_D42151254DF8CD22D91EEE3316C0205C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79BE350DE03E5579925AEE3319F26AFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79BE350DE03E5579925AEE3319F26AFB" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_B55432B4C5C9F6BDB91EEE3319F23ED8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C68C53DEC0AD01D96D5BEE33196C9B42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C68C53DEC0AD01D96D5BEE33196C9B42" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2A73039905C3EED1898AEE33196C873B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_2E14B462532C553A4894EE331972280E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_42460DA247D89B69725BEE3319714B9E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_2E14B462532C553A4894EE331972280E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_E7801D03E19012A86989EE331973511F" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_A7B7BFA46FD16BF8ED3AEE331974CB2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_A7B7BFA46FD16BF8ED3AEE331974CB2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_4798E5A5BF022F8227F9EE33197446BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_12E959C472FB97F668F4EE331973B1C3" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_4798E5A5BF022F8227F9EE33197446BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_2A4416A7ABB7BD3EAC61EE33196CD2B0" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_2CEBB0FE86B05FB326B1EE3319754B04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_ContractsRevenue_2CEBB0FE86B05FB326B1EE3319754B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_69D0A683A97EA3F03681EE331975C13B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_Revenues_69D0A683A97EA3F03681EE331975C13B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_47E13C0B1B167F5FA06CEE331975B40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9FB1305781747FF4169FEE3319752194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_NetIncomeLoss_0E8C1CDC97AC1149F679EE3319754172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_EarningsPerShareBasic_F758A2CC550697F0B074EE331975FE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3DD23B892E8ADBE54194EE3319748F5C" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C470B7669A90A1E20EDBEE3319754A88" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F65FF62A6C834B9E04DBEE3319861A0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F65FF62A6C834B9E04DBEE3319861A0E" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ACD9A6F3A0744A7405EBEE33198C5AF8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_11BE4B93203CAAD8ED99EE33198C00BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_DFB4CA6BCFCCD5D0F8A8EE33198CC8C9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_11BE4B93203CAAD8ED99EE33198C00BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9D3BDD536DAAC6398B3DEE33198CB6BB" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_54EAB9928A457F89C650EE33198DDB11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_54EAB9928A457F89C650EE33198DDB11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_7C6066F8CEB538C52217EE33198D3CD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_BBDB41900590A679C166EE33198DA01A" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_7C6066F8CEB538C52217EE33198D3CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_19B2D63792A0694562F7EE331986F81E" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_78B0078B1ABCDF27BEBDEE33198E4FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_E4873E02C8760B8EF146EE33198EEB20" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1935CA1244357116FFE2EE33198E1853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_FE8104B1C7E63599A445EE33198FFF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_05C82C5FC375C23F1607EE33198FDDB6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6801D9602FF5D3FFF935EE33198F5283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_7AED2912188CC0643132EE33198EC8E7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AA986D1A91A539D2430AEE33198F37F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E4E3FA206E2815204890EE3319B3B496" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E4E3FA206E2815204890EE3319B3B496" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_8F64C63F53517107868EEE3319B4D055" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:to="loc_us-gaap_RestatementAdjustmentMember_BDEA03F3662D31DAE0F5EE3319B41F6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7499CB625254DDCFC3E3EE3319B422B5" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_631AE1B2DB538FED3F85EE3319B5A611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F3C86CA125330B292E60EE3319B54346" xlink:to="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:to="loc_us-gaap_AccountingStandardsUpdate201618Member_16C0DF727CF285887834EE3319B65C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_3B3647AE9FA33E6EBC16EE3319B75EB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_34A9DE34D98D4484F265EE3319B56485" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_3B3647AE9FA33E6EBC16EE3319B75EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_AB09EC8C4A7F9011069AEE3319B738BC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_0AEAF585C3BF3D1A78F4EE3319B843C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_25CBA30050FB92FB24DCEE3319B8A3D1" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_0AEAF585C3BF3D1A78F4EE3319B843C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D28DA741163E8EE5B5FFEE3319B89D6E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_A8AE68B769CB8499F760EE3319B9E554" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_275D51A15D8E621F097AEE3319B98E42" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_A8AE68B769CB8499F760EE3319B9E554" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_EB4CAFA4FE7A474218DBEE3319BACA5A" xlink:to="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAFilingAcceptanceHCCMember" xlink:label="loc_exel_EMAFilingAcceptanceHCCMember_446745A42AC426081097EE3319BF4FA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:to="loc_exel_EMAFilingAcceptanceHCCMember_446745A42AC426081097EE3319BF4FA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApproval1LRCCMember" xlink:label="loc_exel_EMAApproval1LRCCMember_E02C5036233DACB63EACEE3319BF4825" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:to="loc_exel_EMAApproval1LRCCMember_E02C5036233DACB63EACEE3319BF4825" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EMAApprovalMember" xlink:label="loc_exel_EMAApprovalMember_3A3DBBF006506A68D951EE3319C0B98A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_DE38A383D9CF6409CCC5EE3319BA5F99" xlink:to="loc_exel_EMAApprovalMember_3A3DBBF006506A68D951EE3319C0B98A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_5BE1A58783AEEB6433BAEE3319C0B042" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AD6DD6769E3514410BC3EE3319C0F629" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_315FF34BC53D01324CE6EE3319C0F5EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_C5B30D5FCC57EDE37529EE3319B3DB4D" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_NumberofProductsinCommercialMarket_B6CA684E07C8453AAE0AEE3319C1BA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2C67BD16CD520E0F50DAEE3319C19FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3286446F2F8BCAE75EA4EE3319C1F46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_ContractsRevenue_2DB279333D535B8CFD08EE3319C15E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_Revenues_524BDBE86E0CD8ED6C4BEE3319C246B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_OperatingExpenses_C2B71AD003A08527A282EE3319C2D129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56BF3A5CFE9C26C0AF0EEE3319C22A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65457901600DA7EE7A1EEE3319C29896" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_5BB0EACC6278EE46632FEE3319C2F722" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_MilestonePaymentsEarned_5BB0EACC6278EE46632FEE3319C2F722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_us-gaap_LicensesRevenue_AF893D266DEB230E390DEE3319C2A9AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_8E8DC2FD29C0FE4E5B95EE3319C3EDE1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_8E8DC2FD29C0FE4E5B95EE3319C3EDE1" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_ECCE3374E8B829609573EE3319C3B038" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_0685B2AFCE063A396BB1EE3319C11D55" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_35111CB786F841C904FAEE3319C3A2BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4324A31CFFB16E59FEA4EE3319E00064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55B06E31998DE81B084BEE3319E1D5B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_FiscalPeriod_AD0A5AC150BF6B107377EE3319E631A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A2176C682F5516CC1507EE3319E60768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_UseOfEstimates_6114D70348150554DDCCEE3319E75A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_280A1CE4B285E1B3D530EE3319E78FA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03634818F14AE94DFA41EE3319E7124C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3EF7E07AC66FC59C1DD0EE3319E8ECBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="loc_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_RevenueRecognitionSalesOfGoods_A576E2F811CA2DBF6EEDEE3319E8E3E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionRevenueReductions" xlink:label="loc_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_RevenueRecognitionRevenueReductions_62532543A578CE345D43EE3319E8E937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A888A49F0358FF634245EE3319E8DE9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A0EF806CD4FBBA15EEDEEE3319E0F051" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18E78255BF2B67923C0AEE3319E8CD9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82874EEFEA53344C9F1FEE3319CFD9EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82874EEFEA53344C9F1FEE3319CFD9EA" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_AF7AA54BB0C4A2366AD3EE3319D09989" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F6021C36365804ECA940EE33171688A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F6021C36365804ECA940EE33171688A9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8B8C0426F52E209352BFEE33171670A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7FB01CBC03EB566B91BCEE33170DAB60" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9DE33167E9EB17810D22EE33170D7C55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_743BA785F113EA9515B6EE33170EE5E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_1934DDA75652B45A29B0EE33170E9ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_BuildingMember_C3613AFB21C9DD6C5DECEE33170E27DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4DBDAAF1B09020FD527DEE33170F7612" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_exel_LaboratoryEquipmentMember_7AE670AA5D426DDF2C0EEE33170F081B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4A5BC68C8FB688E64E46EE33170E3F38" xlink:to="loc_us-gaap_ConstructionInProgressMember_077EB763AD7FAADE2CADEE33170F284E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_AE954B696DAC0241EFA6EE33170DEF27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34A34144410F540036FFEE3317104DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3352892EB7032FBEFAE4EE33171069C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12E45191F7C261B1D21FEE33170F7605" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_871B7DCB19D04661E1A7EE3317100F34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_94AA3E6F5FD9E0AADA99F0DB609AF0E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_94AA3E6F5FD9E0AADA99F0DB609AF0E0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_E483BF61204D6A881C71F0DB609F947F" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_618AF7871AAA479EDFA0F0DB609F1C6D" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_58E8600303BA2A2C1FAFF0DB60A0FF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_B42BDAC275E9C3C20AC6F0DB60A0AA56" xlink:to="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DB3A62A4EDE2EF2B6B98F0DB60A1AE3C" xlink:to="loc_exel_AlamedaCaliforniaMember_3901D77B8DBFABB8B7A7F0DB60A1B8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_FE125F31B1BFB0F310AFF0DC2457F712" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:to="loc_exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember_B42AB5DE47DCC46E0E9BF0DC2472254E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:to="loc_us-gaap_ConstructionInProgressMember_FA609174CB067C776FBBF0DC2482F55A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_5FCACA42DEBA22CEEF63F0DC249502A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7C5B9493B79C36C5058FF0DC261B7F44" xlink:to="loc_us-gaap_BuildingMember_5FCACA42DEBA22CEEF63F0DC249502A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B75B0271AFD65178F3FDF0DB609DB852" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_Depreciation_2F50FB24398076249AABF0DB60B2EBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_0A7FCD8076AF6CD9274DF0DB60B2FB7D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_PropertyPlantAndEquipmentAdditionsAndTransfers" xlink:label="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_exel_PropertyPlantAndEquipmentAdditionsAndTransfers_1F0973A6ECBA1FE130E1F0DB60B2DFCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6295FC2A3A43806C70A3F0DB60B33E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_12D86AFFB4E3F4BFE575F0DB60B3D6D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_E5681BC01E5F2F43B38BF0DB60B307E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_E5681BC01E5F2F43B38BF0DB60B307E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_56FBDBC907BA56F9EBBDF0DB60B1F39F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8223BD061F9C40945C5BF0DB60B398C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B5FDAE756AD075A0B306EE3317131423" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B5FDAE756AD075A0B306EE3317131423" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_AD40C89C2186C7960FEFEE331713A386" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F53CC28C53B09D7EBD69EE33195C75EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F53CC28C53B09D7EBD69EE33195C75EE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_43D98A7115885217F32EEE33195C98E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB41B190E3AEE70C767CEE3318E9AAFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FB41B190E3AEE70C767CEE3318E9AAFE" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_B615E7687651B8CED981EE3318EAFEDA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_EB4E989B2FB61BD9AEAEEE3318F04DD2" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_BEFF35B5187F0B02D074EE3318F0DD18" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_521EC0A99F0E969BB952EE3318EFD0F8" xlink:to="loc_exel_AllowanceForProductRebatesMember_1E42F53C5149E7E81664EE3318F090E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_641124998CEC56E2B6B5EE3318EA146C" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_0005F9A556DCF4C6DF87EE3318F1C1D2" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_D9591785ECBC3383EA55EE3318F18DFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_DB370E5E72C91D9F7591EE3318F2F554" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_878593666BDFC4D76EAAEE3318F1408D" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2C5D547CF7C588FD7A83EE3318F2BE22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_94444EB5791C3428959AEE3318F2F278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_E2A0ED565F220B4D476AEE3318F13506" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4E49E7FCEEF938215308EE3318F2946F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_DD0B39801ED7474DE972EE3318CB7A7C" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_E81AE69545AB08DE01B4EE3318CC0DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_CF36D1644B6E5AEB04E2EE3318CB657A" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_24DD2A47EF68E739D91CEE3318CC19A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F454EEBCD24530D9665EEE3318CC8F64" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8FC71CBC07A0E0417292EE3318CDC120" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_DEE80A029F6020101E9FEE3318CDE730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_54AC40859961AA8817C4EE3318CA3D3F" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_46E14FE3C3FC06FC3B97EE3318CE9364" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_CC99EF239E315C58C796EE3318CE698F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_5295E8114CD7B34A9C74EE3318CE0DFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_475A82C016FF867020D9EE3318CF0C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_5F6A8E350DB741B66D85EE3318CE419E" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3B9D513E1D2B3C301136EE3318CF535A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B1C6D2621D053A7832EBEE3318CF6957" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_4BF6912B172635B4E32FEE3318CFBE77" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_D04FE7944302E193DDF6EE3318D00CB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_7A72E988726BF183DA18EE3318CF22CA" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_F6169483D015557AAF24EE3318D02C3B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B0182DE049A294974A52EE3318D07C8B" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_06D10E4926533921813EEE3318D51022" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityCurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentDeductions_CF69C48E136B67D1EA5FEE3318D63FB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_96D024510B5D3561F364EE3318D62407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_927F759835089EB1B10CEE3318D00FAA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_EC79A49D7EE408C02A63EE3318D6FA39" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_AD0FCDF2156F4CCDA727EE3318CDC379" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_134B86008F92E4FA2658EE3318D7B5AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_4E12910BFA2CEB2B3B7BEE3318D70166" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityNoncurrentDeductions" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentDeductions_005068CB340C31EF928DEE3318D74619" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_589A84EC619B9C7A63F8EE3318D7DFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_32CB2D051DEFFD29D49FEE3318D6E5EB" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_007BB733301AA054FA16EE3318D7ECC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7AE02A8CC07B8B1489DDEE3318CA9698" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_08A6E35C0C363AF20FF8EE3318D7A848" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5AD133A03FF7108D7154EE33192C5859" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5AD133A03FF7108D7154EE33192C5859" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:to="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_0FE7BEAAEB1446A1D80AEE331932A9A8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_03677739224EC9CC1233EE331932E18D" xlink:to="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:to="loc_exel_CabometyxMember_8B9F8D610A186784404BEE33193310B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7F078F2000EBEA3E693EEE331933A0F8" xlink:to="loc_exel_CometriqMember_6A7E040EDA2B4C99D051EE331933D93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_406FA0906C9EF6FE4639EE331931B1B1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CD82A417C161B3C34B2AEE3319332ED4" xlink:to="loc_us-gaap_Revenues_3D4D3BD815F401CF3439EE331934698F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E92B8D8BE7208F3B9CB3EE331943BCB1" xlink:type="locator" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ProductRevenuesAbstract" xlink:label="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E92B8D8BE7208F3B9CB3EE331943BCB1" xlink:to="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="loc_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:to="loc_us-gaap_SalesRevenueGoodsGross_2917C89F0F02859A69BBEE331944673B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:to="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_70C456A8CFDFF503DCC8EE3319440807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductRevenuesAbstract_33FB48634FD13726F7E7EE3319447AF7" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_79ECB9ABB4FFB17E0572EE331945B190" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CollaborationRevenuesAbstract" xlink:label="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E92B8D8BE7208F3B9CB3EE331943BCB1" xlink:to="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_DED646DBE43735552EBDEE33194575A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:to="loc_us-gaap_LicensesRevenue_DED646DBE43735552EBDEE33194575A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ResearchAndDevelopmentServiceRevenue" xlink:label="loc_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:to="loc_exel_ResearchAndDevelopmentServiceRevenue_244C890B6F8E2544B04DEE331945030F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:to="loc_us-gaap_OtherSalesRevenueNet_CABAA179CF0D39198DC1EE3319454191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationRevenuesAbstract_FFC9654B8B7669BDAB3BEE331945F354" xlink:to="loc_us-gaap_ContractsRevenue_88FFD229DCCA24B488AFEE331946F12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_215F464AF977F7706337EE331946503C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E92B8D8BE7208F3B9CB3EE331943BCB1" xlink:to="loc_us-gaap_Revenues_215F464AF977F7706337EE331946503C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6324D9862EA67970168EEE331901E833" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6324D9862EA67970168EEE331901E833" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:to="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_126740263F2C129F05A6EE331902C939" xlink:to="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:to="loc_country_US_7718B05CAA1FD23128C1EE331902BEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:to="loc_us-gaap_EuropeMember_F0B0E0AA05DEED088450EE331902B038" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherGeographicalAreasMember" xlink:label="loc_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2E8460B4378D959B8BB9EE3319021679" xlink:to="loc_exel_OtherGeographicalAreasMember_C1584F3046A68CC16CBAEE331903527D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_51E83860A5CF6FC1F1B4EE3319038C14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2648EA58F49300358607EE3319013B95" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_51E83860A5CF6FC1F1B4EE3319038C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9F357B9AEC5ABA25E78FEE331903B064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_51E83860A5CF6FC1F1B4EE3319038C14" xlink:to="loc_us-gaap_Revenues_9F357B9AEC5ABA25E78FEE331903B064" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C9A23BEC3817DCC2580DEE33191877B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C9A23BEC3817DCC2580DEE33191877B8" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_0090FA281B9D5A8BED77EE3319191C3D" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_IpsenMember_222B22F46EDB036B7E70EE331919CD84" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_CaremarkL.L.C.Member_840489AD2B1F504706DCEE33191A899E" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_3B3351A80C4D58CE6CCDEE33191AA992" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_B22C9A8001999C58BD84EE33191AB2B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_AccredoHealthIncorporatedMember_B8AC0377790ECE90FC25EE33191AFEA9" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_639188909B56804563B3EE3319192DC1" xlink:to="loc_exel_OtherCustomersMember_A26E09D6C48B9BE5204FEE33191A661E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_31B0B07CE279BC77D4BCEE33191BA82D" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_623CFCCA2E3A16649341EE33191BE66A" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_EC20C0C068CAF2E379D1EE33191BB6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A18A349D2F8E04D538BCEE33192107AE" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7C6DC505F7D166443AF0EE331921F5A7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_29D993A9268651254F1BEE3319219E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_3B1E7949C8600A0AD793EE331919CEC4" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_EF7AC0910A13C672CFD9EE3319222E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:to="loc_us-gaap_Revenues_EF7AC0910A13C672CFD9EE3319222E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_5FB17959B6D059F0BD8EEE331922DB2D" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9C2EBA4FAF9962AE057BEE331922628E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E848577D010C346F37E9EE331954FB01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E848577D010C346F37E9EE331954FB01" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_F37EEB515514D1E7844AEE3319540E0C" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E848577D010C346F37E9EE331954FB01" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2EC641804DC8F0A1F84AEE33195414AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E848577D010C346F37E9EE331954FB01" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9E20A75397316E764673EE331954405F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3B27D66CD714C8F9307EEE3316FE1954" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3B27D66CD714C8F9307EEE3316FE1954" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B253D3ABEEF63622A1BFEE3316FE831B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E16C3C207C139F092C0EE3316F5FE76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E16C3C207C139F092C0EE3316F5FE76" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D866C3B456477D82447FEE3316F6005B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FB5165BE23D76C85FBE5EE3316F66DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10E08B541BD46CF3DE63EE3316F61667" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3AF93B830DF92B78DA10EE3316F754BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_BA65AD9CB0A0A640D83DEE3316F5FBF5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FB980887992BE29313B6EE3316F75DF8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C0E3CAB960CFF3CC5B35EE3316F7767C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3373206780C1EF81B4FEEE3316F07212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3373206780C1EF81B4FEEE3316F07212" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:to="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_FA7E5651EB66041EA4E3EE3316F0CF34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E5E0A867FD90EF77DAE4EE3316F14B44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6C7D473907A00266388BEE3316F1AE77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B758BA0440EDFA44A742EE3316F1B332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2A4E3D6F261FF4695AD6EE3316F0CBE3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2BC09A9F8617A487267EEE3316F1E08A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4BB8C5B0590643A42B62EE3316F23297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E18A91721281502106B7EE3316F17327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95A83FCB5E752C56983FEE3316F26066" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B534865C9272F938DA5BEE3316CF6C6C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B534865C9272F938DA5BEE3316CF6C6C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:to="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_863DDDC209C4AF0369FFEE3316CFF20A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5B65F58F399ED1F7338BEE3316D012A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639749DA14B67F4EBAFFEE3316D0C0C2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5B65F58F399ED1F7338BEE3316D012A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE3BFEA7A90B5C26E91BEE3316CFF66D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BD849D280EEA8F42A54DEE3316D15B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_549FAD00954E6F5A0928EE3316D140DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6C3DF97B68715DDAE318EE3316D18EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74288E1E7BFDB3195BEBEE3316D13FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_760123AAD51DE7980F1DEE3316D0E49E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16E77020ECA0BCE6420EEE3316D17570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_594F2DA7CD608AE57EC0EE3316D3EE12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5771948DCD50EA31F19DEE3316D3C679" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_95FD7C4CBE7161F1A317EE3316D38E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7A4F2B8FFCF8DA8621D7EE3316D3B60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_CC0EA118AC91E5F91308EE3316D3B6DC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0174F125F7DFF1C3ED9EEE3316D3069C" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_946E44A9CFA091EC62E5EE3316D3D51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8DD9955FF8CE5E505E53EE3316D32EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2D2EF0C5D0EF5B6107D3EE3316D0F433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_820524203ADBD4C4CA1BEE3316D3389A" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_A864F0283CFB1E041206EE3316D5A06B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D7352A24208103312D9EE3316DBE8FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5050D97D3CBE989D4BA5EE3316DB5263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_555F644EE58CB1196B24EE3316DB0020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B8338F869A2B162AF4C3EE3316DB38DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3EC079641FA859B33B74EE3316DB08C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FF15AD81432628931BC9EE3316DBB7DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C54A3DFF75A08BB57A4BEE3316DC84FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F489D25B326CE326CBAFEE3316DC9D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CB5B3E81783AAF54530CEE3316DC1B03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_231B89862716517A2F6DEE3316DCAD22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_014ABF5784AFAE5F2E27EE3316DE61E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7DD163FDD6FC8F0F0F49EE3316DC3F88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96B5619B7B091F66B192EE3316DE018C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7DC7AF6ABB644DB91FB1EE3316DE64AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20180629.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AC3E22D41AA156EF8876EE3316DEABE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_50D59E69D0EB72DC31A5EE3316DEDFA9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_CC2808A52E5A8601DAAEEE3316DF5C8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260F7738C825142AE1F5EE3316DBFAA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9F8144F8C2F71688D261EE3316DFB364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2E2956DFCE818F7F8912EE3316DF43F8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F40AC8D26B9C082104B9EE3316DF75B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_779C2A158E1FED6AC9CEEE3316FAE400" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_779C2A158E1FED6AC9CEEE3316FAE400" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7426CCD362B2BB5327EBEE3316FA2895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_779C2A158E1FED6AC9CEEE3316FAE400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_2775FC416E2691B83B58EE3316FB7172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_779C2A158E1FED6AC9CEEE3316FAE400" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CC76F259B2EC9CE75597EE3316FBFB4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_779C2A158E1FED6AC9CEEE3316FAE400" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9A263AFF5A253F52357EE3316FBAEFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_779C2A158E1FED6AC9CEEE3316FAE400" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_D8F8CC9F22DFFF4C0A53EE3316FBBB62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62D5715A3D937124581EEE3316E4AAFF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:to="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3ABAC7D87BAD952F5CD4EE3316E542E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_DB45470EAFC46BC78441EE3316E5E8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CE149447FB85D50E63A1EE3316E506F8" xlink:to="loc_us-gaap_EmployeeStockMember_09476000D4B196954038EE3316E6A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CA35C1FC325D412EDC0EE3316E599EE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6A32F2B94D34F7223631EE3316E6206A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_204E01A77EC4B7C975D9EE3316E68C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ACD468F33AC3A00D6011EE3316E7E452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557DDE55946746918F58EE3316E6DDED" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_046BDC1C08378743F9D6EE3316E7751B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A5C2C2022CC7F107D5E8EE3316EA47C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A5C2C2022CC7F107D5E8EE3316EA47C4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:to="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B431A75FD3D33A726100EE3316EBDD88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5830789FFB5C7D950832EE3316EB4324" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5830789FFB5C7D950832EE3316EB4324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_C517EEB91322BB874D1FEE3316EC579C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E21951A9C11CB8A96F2EE3316EBDDB2" xlink:to="loc_us-gaap_EmployeeStockMember_C517EEB91322BB874D1FEE3316EC579C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE2BB0C261028D0C8EA3EE3316EC4DB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7679A119C8AD0AF87316EE3316EB3023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE2BB0C261028D0C8EA3EE3316EC4DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AE2BB0C261028D0C8EA3EE3316EC4DB0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0C039E0B905D0D2943E7EE3316EC15C0" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exellogo2017aa02.jpg
<TEXT>
begin 644 exellogo2017aa02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#\U_\ @OU^TS-INF^&?A3IMPT:Z@G]N:TJ'[\:N4MHCCL725RI
M[I$:_,+YO:OHS_@K-XRG\:_\% /B#),6$>GW,&G0H?X$AMXD./JP9O\ @7;I
M7SG\WM71#8QEN'S>U'S>U'S>U'S>U62'S>U'S>U'S>U'S>U !\WM1\WM1\WM
M1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-
M[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^A?_!O1_R67XB?
M]@6W_P#1YK\]/F]J_1__ (-X/#[S^,?BAJVQ_+M;/3[0/_"3(\[D>Y_=#Z?B
M*BIL5'<_4:BBBN<V"BBB@ KX[_X*S?\ !/1/VKOAU_PEGA>S!^(7AFW/E)&/
MFUFU&6-N?61<LT9]25_B!7[$HIIV=PW/YFY8F@E9'5D=&*LK#!4CJ"/6D^;V
MK]&_^"TG_!/#_A&M2O/C%X,L?^)??2;_ !/90)_Q[S,?^/U0/X7) DQT8[N=
MS$?G)\WM73&5U<P:L'S>U'S>U'S>U'S>U,0?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U %WPUXEU#P;XAL=6TJ\N-/U+39TN;6Y@<K)!(A#*RD="" :_<W_@
MF_\ MVZ?^VQ\&EGNFM[7QMH*K;ZY8KA0S8^6YC7_ )Y28/'\+!EY 5F_"7YO
M:O0?V7OVD_$/[*'QETOQEX<E_P!)L6V7-JS$0ZA;L1YD$G^RP'7&5(5AR!43
MC=%1E8_HDHKB?V>/C]X>_:;^$6C^,O#-SYVFZM%EHWQYUG,.)()!_"Z-D'L>
M""5()[:N<V"BBB@ HHHH **** "BBB@ HHHH **** ,?Q[X\TCX8>#-3\0Z]
M?P:9HVCV[75W=3'"Q1J,D^I/8 9))  )(%?A'^WU^VIJW[;'QMGUR=9K/P[I
MI:UT+3G/_'K;Y^^X!(\V3 9R"<<*"0HKW#_@L#_P41_X:&\:3?#SP??;_ _A
M^XQ>W4+_ +O6[M">01PT$9X7LS OR-A'P]\WM6U.-M3.4N@?-[4?-[4?-[4?
M-[5J9A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U>Q_L._L=
M:U^VG\;;7PWIYDL])M<7.LZELRMA;9P2.QD?[J+W//0,0M@/:_\ @D;_ ,$\
MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
MTYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'
MS>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z
M/J***Y3H"BBB@ HHHH **** "BBB@ HHHH **** "OS:_P""RW[(7_"/Z[#\
M5]!M=MEJ;):Z_'&N!#<<+%<?2081N -RJ>2YK]):QO'_ ($TOXG>"M4\.ZU:
MK>:5K%L]K<PM_$C#''HPZ@CD$ CI7S'&'#=+/,LG@:FDMX/^62V?IT?DV?;^
M'O&E?A?.Z69TKN'PU(_S0?Q+U6CC_>2Z'\_E%>A?M1?L^:I^S#\;-8\(ZGND
M6RD\RSN2N%O;9^8Y1]1P0.C*P[5Y[7\18O"U<+6GAZ\>6<6TT^C6C/\ 37+\
M?0QN&IXS"R4J=1*46MFFKIA1117.=@4444 %%%% &EX/\7:CX!\5Z=K>DW4E
MEJFDW"75K/&?FBD1@RG\QTZ$5^WG[(O[26G_ +5/P-TGQ59^7#>2+]GU.T4Y
M^QW: >8G^Z<AE/=77OD5^&->F? 3]K+QG^S;H'BK3_"NHFRB\660M9V_BMG!
MXGB/\,H4NH;MOSU52/T7P[XX?#^+FJ]Y49KWDM^9+W6O/H_)WZ(_'O&#PQ7%
MN IO"M1Q-)KED]$XMI2BVM;)>\M]59?$SZL_X*S_ +>__"3WUY\*_!]XW]G6
MLGE^(;Z%^+J53S:*1_ I WG^)AMZ*=WP/3B=QR?F+=33:^9XEXBQ6=X^6.Q3
MU>B72,>D5Z?B[OJ?;<%\'X'AK*J>5X%:1UE+K.3WD_-]%T226B"BBBO /JPH
MHHH **** "OL_P#X(Z?LJ_\ "T/BQ-\0M6M]^A^#90MB'7Y;G4",J1_UQ4A_
M9FC/8U\D?#_P)J7Q.\;Z5X=T:W:ZU36;I+2VB'\3N<#/HHZD]  3VK]S/V=/
M@=IG[.7P8T/P?I2JT.DVX6:<+@W<[?-+,WNSDG'88 X K]9\)>%/[2S/Z]75
MZ5"S\G/[*^7Q/T2>Y^!^/_'G]BY)_9>%E:OBDXZ;QI_;?ES?"O636L3N****
M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !63X\\"Z3\3?!FJ>']>L8=2
MT?6+=[6[MI1E9HV&"/4'N",$$ C! -:U>0_ML?M>Z'^QA\$;[Q1JGEW6I2YM
MM'TW?M?4;H@E5]0B_>=NRCNQ4$ _%W]O3]DR;]C3]HG4O"/VZ/4=-DC6_P!+
MG\Q3,UI(6""51]V12K*> &V[@ & KQKYO:N@^*WQ2USXU_$35O%7B2^DU+6M
M:N#<7,S^IX"J/X550%51PJJ .E<_\WM74CG#YO:CYO:CYO:CYO:F ?-[4?-[
M4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM3[6W:\N8X4V[Y6"+N8*N2<#). ![D
M@"F?-[4?-[4 ?NW_ ,$W_P!AO3/V+?@I##)]EO?&'B!$NM;U"+#*6QE;>)N\
M4>3@_P 3%FXR /HJOSK_ ."+W_!1#_A-=)M?@_XTOLZQI\6WPU>S/S>P*,FT
M8G_EI&H)0_Q("O!0;OT4KFE>^IM';0****DH**** "BBB@ HHHH **** "BB
MB@ HHHH **** "OS?_X.(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z
M_-1_] MZJ.Y,MC\NOF]J/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:
MCYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:
M@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;
MVH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#[3_P""#O\ R>Y=
M_P#8LWG_ *-MZ_9*ORS_ .#>WX4SW?Q!\?>.)(RMK8:?%H<$A'$KS2":0#W4
M019_ZZ+ZFOU,KGJ;FT-@HHHJ"@HHHH **** "BBB@#A?VH/^3:?B)_V+.I?^
MDLM?SJ?-[5_17^U!_P FT_$3_L6=2_\ 266OYU/F]JVI&=0/F]J/F]J/F]J/
MF]JU,P^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J /3?V*?\ D\CX2_\ 8Y:/
M_P"ET-?T,5_//^Q3_P GD?"7_L<M'_\ 2Z&OZ&*PJ;FM/8****S+"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^9?^"Q7_ "CC^(W_ '#?_3G:
M5]-5\R_\%BO^4<?Q&_[AO_ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;VH
M^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_ "6/PE_V&;/_ -'I7,?-[5T_
MP5_Y+'X2_P"PS9_^CTI ?T?4445RG0%%%% !1110 4444 %%%% !1110 444
M4 %%%% 'RK_P5<_91M_CQ\!KCQ-8I#'XD\#P2WT<C$+]IM -T\).>P7>N>ZD
M#&\FOR-K]-/^"SG[59\&^!;/X8Z/<;=2\1*+O5V1OF@LU;Y(CZ&5UR><[8R"
M"'K\RZ_D?Q@KX&IG[6$7OQBE4:V<NGS4;)OY;IW_ - OH[X7-*/"D98]_NY3
MDZ2>ZAU^3ES.*MMK=IJQ1117Y6?NP4444 %%%% !1110 4444 %%%% !1110
M 4444 ?H%_P1*_9QL]5OM;^)VH-;7%QILK:1I4(=6:VD9%::9AU5BCJB].'D
MXP0:_1JOQO\ ^":O[7K?LL_'**'5+CR_"'B@I9:J&/R6C9Q%=?\ ;,DAO]AG
MX)"U^QT<@E565@RL,@CO7]<>#^/P-;(8X?"KEG3;YUU<GJI>C6B[6MT/\_?I
M#97F>'XJEB\<^:G5BO9/HHQ23AZQ=V^_,I:<UAU%%%?JA^$A1110 4444 %%
M%% !1110 4444 %%%% !7S+_ ,%BO^4<?Q&_[AO_ *<[2OIJOF7_ (+%?\HX
M_B-_W#?_ $YVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 'S>U
M'S>U'S>U'S>U !\WM73_  5_Y+'X2_[#-G_Z/2N8^;VKI_@K_P EC\)?]AFS
M_P#1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@#)\<^!M'^)OA#4- U_3[75
MM&U:%K>[M+A-T<R'J".Q'!!'((!!! -?C[_P44_X)*^(/V7[N]\6>"8;SQ%\
M/F+2RA09+S0AG.V4#EX0.DHZ '?MP&;]F*&4.N#R#U'K51DT3*-S^9KYO:CY
MO:OU]_;=_P""*7A7XVSWGB+X;R6?@OQ-)NEET\H1I-^_7[JC-NQ]4!3C[@)+
M5^7/QU_9O\;_ +-/BQM%\;>'=0T.[R?)>5-UO=@=6BE7*2+[J3CH<'BMHR3,
MW%HXCYO:CYO:CYO:CYO:K)#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]
MJ/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J]C_ &/_ -N3QS^Q
M?XR^W^&;[[1I-RX.HZ+=,6LK]?4K_!(!TD7!'?<N5/CGS>U'S>U+<#^@;]CO
M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
M9K]>?^"8G_!*NW_92\GQMXW^RZE\0+B$K;V\>)+?0%8894;D/,1PSCA02JY!
M+-$I6*C&Y[I^PA^R]#^R%^S/H/@_,<FJ*IOM7GCY6>]EP9"#W50%C4]UC6O8
MJ**YS8**** "BBB@ HHHH **** .%_:@_P"3:?B)_P!BSJ7_ *2RU_.I\WM7
M]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:C
MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?S
MS_L4_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK,L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KYE_P""Q7_*./XC?]PW_P!.=I7TU7S+_P %
MBO\ E''\1O\ N&_^G.TJH[H#\-/F]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO
M:@ ^;VH^;VH^;VH^;VH /F]JZ?X*_P#)8_"7_89L_P#T>E<Q\WM73_!7_DL?
MA+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110 4444 %%%% !1110 5SOQ
M5^)>E_!SX<:UXHUJ;R=+T.U>ZG(^\P X1?5F8A5'<L!715^;_P#P6D_:J_MC
M6K'X5:-=9MM.*:AKIC;AYB,PP'']U3YC \9>/NM?+\8<1T\DRNICI?%M!=Y/
M9>BW?DF?<>'?!U7B;/:.5PNH-\U1K[,%\3]7\*_O-'Q?\;_B_JOQZ^*^N>+M
M:?=?ZW=-.4#%EMTZ)$I/\*(%4>RBN3HHK^(<17J5JDJU5WE)MMOJWJW\S_3C
M"X6EAJ,,-0BHP@E&*6R25DEY)!1116)T!1110 4444 %?7_P?_X)0^(OB+^R
M/K'C>Z-U:^*KN%;_ ,.Z0%Q]JMU!9O,!&=\R_P"K QC"DD[_ )9?^"6_[!'_
M  OSQ1'XY\5V;?\ "&:+/_HEO*GRZS<J?NX(^:%"/F[,PV\_/C]5PH5<#@"O
MW/PW\,Z>8X:68YM%\DTU36SU5N?Y?9[O7:U_Y>\9?&RMD^-AD^0R3JTY*566
MZ5FG[+Y_;MLO=O=NW\\SHT;E64JRG!!'(--K[$_X*Z?L@_\ "F?BPOCK1;7R
M_#?C&=FN5C7Y+&_.6=?99?FD'^T)!P !7QW7Y)G^2XC*<?4P&)^*#WZ-=&O)
MK7\-S]_X3XFPG$&54<VP;]VHKM=8R6DHOSB[KSW6C04445XY]$%%%% !1110
M 5^K'_!(S]KW_A<WPH/@76[K?XD\&P*MLTC?/?6&=J'W:+B,_P"R8SR2:_*>
MNO\ @1\9]8_9\^+&B^+M#DVWVCSB0QEL)<QGB2)_]EU)4^F<CD"OL.!^**F1
M9I'%?\NW[LUWB^OJMU]VS9^=^)_ M+BK(ZF!T5:/O4Y/I-=+]I+W7ZWW2/WM
MHKF?@_\ %;2/CA\,]&\5Z%-]HTO6K<3Q$_>C/1XV]&1@RD>JFNFK^V*-:%:G
M&K2=XR2::V:>J:]3_-'$X>KAZTJ%>+C.+::>C33LT_-/0****T,0HHHH ***
M* "BBB@ HHHH **** "OF7_@L5_RCC^(W_<-_P#3G:5]-5\R_P#!8K_E''\1
MO^X;_P"G.TJH[H#\-/F]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;
MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\N_;"_:-L_V6?@)K7BNX:-[Z-/
MLNEV[G_CZO) 1&N.X&"[8YV(QKU&OR1_X*S?M5_\+V^/+>&=+N/,\->"&>T0
MHV4NKP\3R^X4@1KU'R,0</7P_B!Q0LCRF=>#_>S]V'^)]?\ MU:^MEU/T[PE
MX'EQ/Q!3PM1?N*?OU7_=3^'UF[1[VNUL?+NO:[>>)]<O-2U"XEO+_4)WN;F>
M0Y>:1V+,Q/J22?QJG117\6RDY/FEJS_2B,8QBHQ5DMD@K[:_X)2_L#?\+:UV
MW^)'B^RW>%]+GSI-G,ORZK<(?]8P/WH8V'3H[C!R%93Y+_P3]_8GOOVO?BA_
MIBSVO@W0W235[M?E\W/*VT9_YZ/W/\"Y/4J#^Q_A[P]8^$]"L]+TRU@L=/T^
M%;>VMX4VQPQJ %51V  Q7[5X4\ _7ZJSC'Q_<Q?N)_;DNK_NQ?WO39-/^:?'
MCQ7_ +*H2X=RF?\ M%1?O)+>G%K9/I.2^<8Z[M-7:***_J _A\**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CFF6WA:
M21E1$4L[,<*H'4DT >"?\%&_VIQ^RY^SO?7%C<>5XG\1;M-T<*<-$[#]Y./^
MN2'(/]\Q@]:_&1W:1RS$LS'))/)->[?\%$/VI6_:E_:(U"^LYVD\,Z'G3=&7
M/RO$K?//CIF5\MGKMV _=KP>OXU\2N*O[:S:7LG>C2O&'9]Y?]O/;R2/]&_!
M?@3_ %:X?A[>-L17M.IW5U[L/^W4]?[SD%=]^S7^SMKW[4/Q8T_PKX?C_>W!
M\R[NF7,6GVX(WS/[#(P,@LQ51R:Y7P5X+U3XB^+=/T+1+*;4=6U6=;:UMX1E
MI78X ] .Y)P  22 ":_9O]AG]CK2_P!C_P"%$>GKY-WXEU0)/K6H ?ZZ4 XB
M0]?+CR0OJ<L<%L"?#_@FKG^-_>75"&LWW_NKS?X+7>R=^+7B91X3RW]RU+%5
M4U3CV[SDOY8]%]IZ;7:[SX$_!'0?V=OA?I?A/PY;^1I^FQX:1L&:[E/WYI#_
M !.QY/8<  * !V-%%?V-A\/3H4HT:,5&,4DDMDELD?YTXS%UL57GB<3)RG-M
MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit102image1.jpg
<TEXT>
begin 644 exhibit102image1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (/ G # 2(  A$! Q$!_\0
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M-X.NF'Y&U-3?\/>=:_Z&+Q9_X1-S_P#(M?/>>*,\5A&A76BQ57_P-_Y'K?\
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M\-VNN^'?@WH^KZ+J0,EG>V/@&^FMKA Q7,;B<AAD$9SVKV;]D#_@LQ_P4/\
M'_Q(U"Q\>?"?PAX;TI-+EGM[K7/ 6N0V[W*O&$C#6C22;B&;JNW"GG( /T)_
MP2+O!<?\$UOA"\;[E_LB7!!_Z>YZ^C/-.[JWYUFL.MSBHY+2E%2<GJ>#1?\
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M %Z+_P"AO7'U^(Y+_N</0_JSPU_Y)K"?X5^84445Z1]P0:O_ ,@2^_Z]I?\
MT UXA_P3)_Y,1^'O_7M=?^EL]>WZN,Z+??\ 7M+_ .@&O$/^"8[!_P!A#X>_
M]>UT/_)R>NZ/^ZR_Q1_)GBUO^1M2_P $_P X'NU%%%<)[1X;\8?^3_/@;_V!
MO$G_ *3PU[E7AGQC_P"3^_@;_P!@;Q)_Z3Q5[G7;BO@I?X?U9XN5_P ?%?XU
M_P"D0"G=OP/\J:>M.[GZ'^5<D=T>O4^!^A\__P#!+G_DR3PK_P!?FJ?^G"XK
MWZO ?^"71S^Q'X6_Z_=4'_E0GKWZNS'?[S/U?YGE\/\ _(MH?X(_D%>'_M3?
M\G"?L]_]C9=?^D4E>X5X?^U0?^,AOV>_^QMN?_2)J,#_ !?E+\F&>?[K_P!O
MP_\ 2XGN%%%%<)ZY+:_\?,?^\*\"_P"">?\ R2WQI_V/VN?^E KWRU_X^H?]
MX?SKP3_@GG_R2WQI_P!C[KG_ *4"NZC_ +M4]8_J>+B_^1EA_2?_ +:>[T44
M5PGM$EI_Q]1_]=!_.NR\87FK:)^T1I.J:3#?K+8^'KMS>6EY/:O;GSX0/GBM
MY\<%N2HP>AZBN-B/[]?]X5VGQ",>E_%ZQOVBM)IQH=S#;I>6UO<VXD\^$AGC
MECD!"D@D@#Y0W///M<$_\E9@O2?_ *2?R[](Q:X)_P"/\XGC?QT\6^)(?V7O
MCPL;^*/.TW5=1?3-/EO;Z2>S$DJI)YJ"U19A(QQ@R1'JN!E@?1O@7\:-2_X9
M8\"FZAL=2DL[718VOH8M32XMK5;N,QRHR@H%E=3EE/'\/0&O)?BQ/IVL_LI?
M%[[<UG&JOJ*&YM;/3483)*?,?SXXU98N@# +C"#!P:@^$F@>)O'/[+W@70;?
MX2_$98?#NDVDUY=:5H6GWAFNHCYC(\WV9WDAD08VRNW.QB<+M']<2O9Z:76N
MNG_#O^MS^6/=LOGIIK_PR_K8]Q\&:W#\3/\ @J]\(K'Q#?77AVSA\*ZO%=16
M]K+:1662R(IDG57CF4I\LJ<#>2-A6OT*O[:T\2Z-::3KETNB^&=%5Y-#U=(!
M'_;)3@ KC&T#AHL8N1R!MRM?G+^S1H*>*OV]/A[XYU#X5^.?#WPYT7P_J%EK
M>I:IH\4=O<F9)25<VD4<;H'VAPX=B/D!(^0_H[J#V^FZ58W7BZ.ZN?!MVRKX
M7M5FWW%G.W,'F,#S*>#"^[$(X9MWSU\[GTG[:"=[V^YW>W]ZVZ>EO.Q[N2V]
ME)JUK_>K+>W2^SWOIL?DQ_P71\=>,-5_X*V_LSPZEX76QM[BPM(Y9 C@PQKJ
MDA617SB'=\I*=<-Y;%BM?I;?'-[)_OM_.OS4_P""Z&B_$*T_X*R_LVMK6H6,
MUC'8V1OPNW:83JTGD)( H,D@; W#(\P,X$:G%?I7??\ 'Y+_ +[?SKYW&?P8
M=M;6VMIMU>O?J?JW!?Q5N_NWOOUWZ)V[=+$1.32Y.Z@L<T;CFO-/N@R=U(#@
MTNXYH#'- 'PE_P %+/$/BSQG\.OCDD6IZ'9Z/X>\ >*=.2V;2WDN)H%M=.ED
MS+YH =C-@';A0O1LU]<?LSD_\,S_  V_[%'2/_2&"ODW]NX_\6D_:5_[$[Q?
MQ_VX:17UC^S.3_PS/\-O^Q1TC_TA@K./QG%0_C29VV?EK@OVJR3^RO\ $[_L
M4-7_ /2*:N\K@_VJSC]E?XG?]BAJ_P#Z135<MCJJ? SYI_X)M?MZ? _P+_P3
MZ^#&BZW\8OACH^L:5X2LK:^L;WQ+:07%I*L>&CD1G#*P[@C(KZP^%WQD\(_'
M+PRVM>"_%'A_Q=H\<[6K7VC7\5[;K,H4M&7C)7< RDC.1N'K7@G_  2_^#_A
M'5/^"<?P/NKKPCX5NKJX\'V,DLTVCV\DDK&/)9F*$L3W)-?1WAWPGI7@VQ>U
MT?2M,T>UDD,SPV-I';1O(0 7*H "Q &3C/ ]*B-[&.&Y_9QO:UD:!8YKCOC)
M^T)X#^ &F6UQX\\:^%?!<.I"6.RDUO5(;%;MT7++&9&&\@,N0.F1ZUV))K(\
M7^ =#\?VJPZYHND:PL2R+#]OL8KK[/O7:Q3S%.TD=<=<5?H;RO;W3PG_ ()%
M727O_!-3X/RQ.LL;Z-(593D$?:IZ^C <&OG?]F?X%^,?V _V</#_ (/L[ZP^
M(?A/P9#-&8H-.-CK4=L9I)?,BQ(\5PZJ^3$1&S8(5B< ^_:#KEKXGT6SU/3K
MF.]T_48$NK6XB.4GB=0RL/8@@TH[6,Z-U",9;I(MACFDS@4H)I*HV#.!3D)R
M/K2 G%*A.X?6@#Y7_P""8C9\1?M-_P#9:]:_]$6M?4V<BOEG_@F%_P C)^TU
M_P!EJUK_ -$6M?4U3'8PP_P+^NHI8YI"<FE)-!8YJC<,_-1D[J-QS1N.: $!
MP:,X%*&.:2@ S@4N?EH!.*-QQ0 9^6OF3_@L+;P7G[ 7BJ.ZN#9V[:AIN^81
M&39_I2$?*.3S@<>M?35?+_\ P64O[/2_^">?B^YU*.XFL;>\T^69('"2,JW*
M'Y6((!Z=0:Z<';VT;]UOM^&MCRL\_P"1?6M>_*]M]NE]#[=T^;_A%'NKCPZ4
M\07&O1%O$"/8DKH:'(>18.JJ"6S:?><[GZ[RTMG:6>@Z=)X9TV^-_P"![R9'
MOO$;GS9;&5L$1^=T9B0FV;I;C:O&$VNT>"ZU:XOH?!2WMCJUGA/%XGG7SKJ0
MJ,HLGW3=%1\DX^14PI_A$=>VN=,N?#4VIZ'&T?P@C+'5;(#:TS GSFC0_,(
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M\QS.\\6Z(S#B4*N",?ZM<)T"@?L43Q7XZ_\ !<"[T?4?$'[(=UX4B:W\(O\
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M_P"RUXZ76+J:!]:\-:O9V216LMPTTHT^=R,1JQ "JQ+'"@#DUZWCY<U\[?\
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MC*48R<W=KR_R/F$?'W]K8?\ -M7P[_\ #JQ?_(M ^/G[6P_YMJ^'?_AU(O\
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MZ,5)=:=^U7?"*%O'7P7AL[5O+AAM?"US"7MB6+V\Q\\^:C$@L#C)!)^\:]T
MR:55W57U^:=U%;M[=7N:OA'+VK/FV2W>R_K<_)#_ (*:_M2?%.[_ ."C'[,_
MPA^*E[X.UK5(_'7AGQ7;ZCX;TI],M?+?4OLRQR1M(Y:11$1NX^4J.V*_HTY_
MPK^:+_@LI_RL#?LO_P#77PI_Z?9J_I=W<UXV*Q$JL_>^RK+T/$J8.EA:DJ=+
M:]]2KI?_ !]ZA_U\#_T5'5RJ>F?\?FH?]? _]%1U<KF$%%%% !1110 4444
M4=4_X_\ 3O\ KX/_ **DKE/VC[1+_P" 'C2-\[3HMV>#@Y$+D?J*ZO5/^/\
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MB_X*"Z-\!?%'QS\ ZCX=NKQO$6G:UX;AOH-2@!AN=0TO37B=[<_O!&OEXW'
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M-]G,3%GB5K0(S;,E06 )QD@<UPYE_NE3_"_R,JW\.7HSX(^,QQXR7_KRB_\
M0YJ\S^+/@-?BI\+O$GAA[IK)/$&F7&G-<JF\P"6,IO"Y&<9SC(S7IWQJ_P"1
MI@_Z]%_]#>N/K\5R.3CA*<H]#^J/#JG&KPOA:<U=.%G\[GE/[*_[*&D?LW_
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M9BX3:951(DRZD*1D]B!C->G/;ND>YD8+ZD<&F$A.I ^IQ6DL97D_>;9A3R;
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M&!P-L*X &=JUY)^S?XYTF7QYXG^%O@WQYH_B;3=-MK36_P"W8-7BU#4K6RN
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M-=H_^-?4ZMBDSBCE0OJ\//[W_F?*\O[)'[3A3Y/VP)E;_:^%FCG_ -F%>/\
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M@YXGT;P_<:1K_P /X])NEMK+5+F6WU+P_!Y3?NH9E21;F&,9$<<@1E4!?-8
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MO4!_"/\ @HGX7L[GX&7VGZM#9^*?$6HI=WFI+/&_V2WACTO4'1/ER8HU*DQ
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M.)OV7Q_S(.K?^%7JG_Q^OKPYQ0<XKGY(]CZ?ZM2_E7W(_.'Q/^PU\-?V(?\
M@JS^R@OPST;4O#\?BQ_%"ZJDFLW=ZEWY&G(8@1-(P&/-?IUSST%?H]D[J^2O
MVT;?/_!3?]C:7^);_P 5H/H=*4_TKZUYW>]**M=(SP\5&4HI65_T09^:D!P:
M7G=[T#.:LZ@#'-)G I1G- SB@!,X%+GY:!G%'.WVH 3.11G(I3G%!SB@ +'-
M(3DTISF@YS0 9^:C)W4<[O>CG=[T (#@T9P*49S0,XH 3.!2Y^6@9Q1SM]J
M#/RTF<BEYV^U!SB@ 9LFL3XG<_##Q1_V!+[_ -)I*VVSWJKKNG0ZQH5_9WA8
M6EY:36]P5;:1$Z,KX/8[2>>U!,MCYT_X(YG'_!+KX(_]BX/_ $=+7TKD[J^?
MO^"7,WAG2OV%/AGX>\-ZQ:ZA_8.@Q1SV_P!K66ZM&9W9EE3ADPS$891C@5]
M\[O>IALC/#JU-+R0@.#2JV#0,YH7/:J-CY _;!DD3]MOX+[(PZM\5/ 0=MV/
M+'GZG@X[\X'XU^PA^Y7X]_M@3B+]MKX+J0_[SXI^ @"%) Q/J9Y/;IWK]A#]
MRN"MN?'YM_'_ *[E73/^/S4/^O@?^BHZN53TS_C\U#_KX'_HJ.KE9'EA1110
M 4444 %%%% %'5!F\T__ *^#_P"BI*XW]J*X>V_9T\;.C;7_ +&NAGT!C(/Z
M&NRU4_Z=I_\ U\'_ -%25P7[8&HKHW[+'Q"O90YBL?#][=2A/O%(X6=L?\!4
MURXRE.K0G2IJ\FFDN[:T,<1)1I2E+9)_D?C[^T#\,=<O/VC;SQ#IOB"VTFSU
M+PS8:1,JV7G7<1AN[Z4R1,S>6I83@99&QLSBCPUX;M/"&AVVFV$;1VMJI"[F
M+NY)+,[L>6=F)8L>2237H7P_O=)_:KTN?Q)HG]KI:VLO]FN)+8 [T'F'H3VF
M'?M74C]ER\QS:Z]^%HW_ ,37X?+$5<O7]GX^$HU:?NM<KNK='H?L'A]XF<,8
M#(</1G5?.EK92>[;=G:UGY'D(ZUX3_P4'_Y)3X/_ .Q\T/\ ]**^U?\ AENZ
MS_QZ:]_X"-_\37*?&G_@F[-^T!X2TW3KNV\96T.FZQ::S#-9V.6:6W?<JG=&
M1M)X/>ML'GF'A6C*2EH_Y7_D?19MXM<.U\'4I4ZDG)JR7)+_ "./NO\ C[D_
MWS_.HZ]NE_9$U:65F_L7Q7\Q)Q]A?C_QRG0?L<:Q/]W0O%TFWKML)./_ "'6
M/]K4V](3_P# 7_D=R\9.'+)*4_\ P!_Y'A]>!_MX_P#(2^"'_93]*_\ 0)Z^
M\/\ AC#6O^A<\:?^ #__ !JN1^+'_!,:;XRS^%7U+1?B';MX2UVW\06?V6SV
M"6XA#A5DW0-F,[CD#:>GS"NK!YM&%52E3G_X"^QY>;>+N18C#.E34[NWV7T:
M9YW)]YOK33UKWP_L7ZVW_,K^+O\ P!D_^(H_X8NUK_H5?%W_ (!2_P#Q%<_]
MH3_Y\S_\!9V+QHR&UN6I_P" ?\$\#KQ']L/_ )*'\!,?]%%M?_1$M?=Z?L5Z
MX@Q_PB?BL^YM)?\ XFN>\??\$V)?B5JWAB\U/P=XR:;PCJR:UIYCAF0+<*K*
M"PV_,N&/%=&%S*I3J<SH5+:_8?8\W,_&+)J^']G3IU;WC]GM)/OV1Y!_'^-)
M7T/#^Q1K@Y_X0[Q.WLUM*/Z"I?\ ABG7/^A+\2?]^)JP^N5^F&J_^ ,[/^(V
M9*O^7-5_]N+_ .2/G.OK;_@G1'_Q=3PG_LQ73?\ D*7_ !KE8_V)]<+?\B3X
MB^A@F&:]H_8Z^!/B7P!\9-(GNO#FI:;IEE%-NEN(F18PT;J.6Y)+$#')Y]!3
MP]/%8G'8:V'J14:BDW*+223[GY[XA>(&#X@PU#"8*E4BXU%)N225DFMTWKJ?
M9@HHHK]V/A0HHHH **** "BB@G% '*>%O%FI>,X]9@U/POK'AR*UD:""2]GM
M9!J"$$&2/R99"J_[X4\CBORW_P"#>#4=0M+OXOV^D6:S:M>IH\<5Q*A,-E&#
M?;WD;K@97" Y<@= "R_K?.<P/_NU^2?_  ;Y6VKZAK_QCTG3YEL;>Z_LHWE^
MK?OK=$:]&V(?WWW$!CPH!/)P#]UPWKD>8IV_Y=/R^-_U;KL?GO$^F?9:]?\
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M\4>*KVPT[_@Y)^"<^IP_:+6'X97C^4(3,TD@N+KRPJ $EC)MV^^*]*O?V_\
MQ#IVH103_LN_M51"XFCMXIG\%1B"1W("@.;C!R37A?P@^,.O?%C_ (.$/A+X
MF?X6?$[P/<:7X!O-/CT;QCH_]DWU\'DNL7$0+.GD!F +%@?E?"G;6E&G-S5E
MWZVV6NO0\;/LSPM3!RA"2;NNE]VK:=3Z<_;1_P""]_PS_8/_ &F/$WA+XD>
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M74KB.VM;QGDN(Q);&6:)2T'FOB0,$*AB,_Q'^W;X7\$_%+XJ^%_$&DZYX?\
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M\2+$NT!I,R._!!_,S_@IA_P7;F\(?$__ (5G^S_\4/&7PA3X=W&H:'XLGOO
M*:AJ6L7MONA65=[-MMXTMV"_)&R9&5"@;?J'_@DQ_P %)_@?\$/^"9?PC\"Z
MQ\2_!/@+Q!INA^5XF:6ZVS:0ZRR Q<AO](VE?OG" YY.%/T!J'_!4O\ 92U"
MWCT^/XQ?#?2O!L*A+JZ>] DUEG!S$)",^6<MYCDEY#N7IN)WJ83$-?"[;O1[
M+K_DOFR(8JA&6K3>RU6[Z>=^K^XXG_@C+_P4=TO_ (*/?LJ0Z69]>^R_#+3;
M6T\:>)[S3$TNU\57CB7<8=LC,H98O-G)"DM-M'!8U]C7=[;ZE8PZUK4,FG^&
MK!XQI&D"'$M[(,")WB')8G'E0XXX9ANP$^#_ -OK_@KE\+'^ DD/PU^+O@W2
MM3OM1M=,TBUTP13WEK \@674$@DV1-)&N#"&)2+<)6#,JHOP%\&OBY\1/'/[
M;WQ(U[0?VD/%7@N;1? UD8]?$\?B>&]O7NHH_P"S8;C40S?9XQ+*XF,:2'$Q
M(Q\M..#KQC><7IN[/=_KW?1$_6J$I>Y)6>RNGMIMV[+JS]H?B[XI\5WOQOT+
M2IM8D\*ZIJ&DSZEID5K;V]S<%Q(L?V6!KA7@5T1O,N9BK$(RK'M&YF^);KQ1
MXO\ B!_P7<^ 6KW.K:;K&I2> ->L1?(Y72[R2'4KRW%W;0!B?+,48< '!)^_
MA@U<-\9?#?Q$\2PWSZE^VE?^*/L<6K++;W7AKPW<0G^S)X$AD'FPMM^T)-,P
M\M,L0  5R:^+O%OQX^+WPY_X+*^,EL?B1XA\?:]\/-+N])\&^(;'3]%M1<Z<
M=DDD2*_EV_'G,L>&.-H &W@/#RC"=Y.UTUY:JRTW2_,JM3E*'N*_7SNO/;F_
M)']&5A8.9[KP]X=NIO-,N_7]?8AIA(0,HIQ@SD8  &V%=O'W5J.**Q\2:#)8
MV,D>E> -*5Q=W8DV?VKMR757SGR<Y\R7.9#D X+,?R!UG]L_XI#X<W9T?]I;
MQ!>_#ZZL%TM)YM&\-6NK6FJ3VR3I!+IZN+MD,TJ6\K@'EWDW%5).U^SCXN_;
MG_:,_9L\$>,M9^+FHZ/8>(;K2KVQMK'X;VM]&UI/]G"RQR)BWD53*\B*2<^4
M@PK=*E0II_Q%OV?^6_9;(SC4J.-^3IW5O^&_%GT]_P %(-5N=<_;:_8\N/L*
MZ;H_]O\ B2/3;=D,<[1KH4O[QEX$:L,;8\9  )P3M'J&.*_/_P#:U^&7[2_B
M77M4\::U^T1INI?\,^K+?:5J$W@^SCOKB>YCNK2[FMXD80F.$Q-;ONX)60J^
M0H;SWQM\8_VE]#U28Q_M 7#6NB^(M)\*^)],'@F&VU+PO<7N(,7+R)L6Y:X)
MDA5-R-  [%"1&:]A";C",EV6]MWU^>K[['T62YVL'1E&K!N[O^"5K=&^B^\_
M4,KBDZ5\MO\ L-?')'Q_PV7\3?E./^1.T;_XFD_X8;^.7_1Y7Q-_\([1O_B:
M\[FEV/O(UIM7Y'^'^93_ &T./^"EG[''/_,3\4C_ ,I(KZRQSUKY8\&?\$X_
M%B_M'_#WXC>/OV@O&WQ,G^&EQ>7.D:;J&@6%A KW5NUO(2]N V-I4XP?N#ID
MU]3_ ,7M3C?5L='FNY25KO\ 1+H)CF@#)I>_MFD'6J-Q0,TG6E&.])0 H7-)
MCBBE[>^:  KBDZ444 *1BD(P:4X[4AZT &.:7'/6CO[9H_B]J $ R:.M ZT4
M *%S28XHI>WOF@!*4KBDHH "-M4_$.J6^@>'M2O[O+6>GV<UU<!5W$Q1QL[@
M#N=JGCO5RL3XH()/A;XJ4\JVAWX/T-M)03+8\<_X);P^&;S]@OX7ZSX9T>RT
MBWUKP_#+*T5E';S7+!G!,I7ESN!.6)KW_'/6OFK_ ((YG_C5U\$?^Q<'_HZ6
MOI7^+VJ8_"C/#RO3B_)" 9- &Z@=:*HV/D']L"!9OVVO@NQSF+XI^ F7#$<F
M?4QR._7O7["$_)7X]_M@QO)^VU\%RLA15^*G@(NNT'S!Y^IC&>W//'I7["'[
ME<%;<^/S;^/_ %W*NF?\?FH?]? _]%1U<JGIG_'YJ'_7P/\ T5'5RLCRPHHH
MH **** "BBB@"EJG_']I_P#U\'_T5)7F'[>;B/\ 8A^+S,RJ/^$+U@9)P!FR
MFQ7I^J?\?VG_ /7P?_14E>1_\%%?^3"OC%_V)VJ_^DLE=F7*^*IK^]'\T<.:
M:8.J_P"Z_P CYF_X-SSG]C7Q7_V.ER3[?Z#85^@)^\*_/G_@W+_Y-$\7?]CA
M/_Z16=?H,?O"O8XPTSK$_P")_H>%P/\ \B/#?X1:***^;/JPHHHH :5KD/CA
MX$UCXE_"3Q!H.@ZOIFA:MJ]H]K;WNHZ0FKV<6[AA-9N\:SQ,NY6CWKE6.&!Y
MKL32$86IDKII[#B[.Z/SL\5_\$*=2U#PAX-L]!^)/@WPG<:#>:A-?6FF> 9H
M]"6"YU[2M;6UTRQ&J Z=$EQI,8*F:X4_:)RJQY4+I>,O^"*>O?$/2_$5OK'Q
M=T^-O$5AXUT^673?"<]G);IXAU.UU5&1O[19@UK>6JY.[]]"Q3$3?O:^>_B!
M\%QX>_X*2?M)>,-#\"^+/"FOZA?(_P /_%.B_ '5-3U6#7VTS3K<W\.JMI\M
MDU@9QJ"3I(T:2>;)+YDF])(Y/CW\:OVDOVA?A9XH\,>)/"?C[5?A[XM^"=[<
M3:-K7PYU&34M1UZYL[XFW6&UT79#=6FH1V\,2S7, :W$<JQW+R"X#C4?LE)=
MGIVYEJOG;Y?,IQ]]4_LMIM^::W]+_AY(^RO&?_!-_P 07W["?@WX-^&/&WA/
MPW>>&=?LO$%SJMSX;U36+:[EM=5&J@1PW.L-=(9+E$+M->SDJ90-I93')\:_
M^">_C3XR_%[XM>)&^(G@:ST_XF>!;+P9%IUS\.UU46#6DL\\5Q<+>7TMM>1M
M)=W(>!K9 T;1*'5D,C_-=Q\:OBQX1\8>*+SPJ?CQH6G2?$'0S>#3?@FPNM5\
M.W.BZ;:74WFRZ-OFFT^Y9S&S^;-Y=JT;K-&HV=-^S?\ &[XR>%_C/\,])MK/
MXBMX1UCXA>---\3Z?+\)+C1);NUDU&>YTW6[F\&F0VB(8Q&)#F"2<WDDFZ:5
M"JVXW=K[W?S<5?\ !I>J,U+EI<RVLM/*[?SLU?[O0^POV+_V3-)_8Z^$+>&=
M+M?"ME)?:A/JU_%X8T1M"T5;F;:&^QZ>9YQ:1;43]VLK#=O;JYKUY%P*!S^5
M(.M2VWN*,4MOZN/HHHS04%%%% !117CW[)_[2/B?]H1_'*>*/A7XL^%\WA'Q
M%<:+9#6B&C\0VT?W+^V<*H,,G..N,=>: /8:*,T4 %%%% #)!^Z;Z&OQV_X(
MJ:Q!X;_;6^*7_$M?4M4^R7":=;(!DR_;%4_-T0!2=SG[J[NN<']B9>8V^AK\
M<O\ @C5J.IZ=_P %"?BI9Z-#%-?76G:A'$T_^KM\:C!F63HQ51_"OWF91P#N
M'W/">N6YA%_R1ZV^UW[=S\_XPTS++Y?WY=+[K\^Q^H:)>^'=:>WMW@UCQUK$
M0:XN&4_9M*M\G''585.=J9W2L"2?O,N!XZ\ :/XP\):KX6CL+'7XX=UWKFJZ
MG:17NVY6,D;5D4HUQ@C QMA4CC[JG>TS3F$]UX?\/74SS-)OU_7WPTPD(&44
MXP9B,  #;"N./NJ?+?VK_%-U!\%?[-\(W5QH'A9I+JRDU*TD59[]EL;R<B%W
M5LIYL*[Y#DRDL >K'YZG\2^7]-?E'YL^BE?E:7GU_)_G+[CY%TG_ ():?#+]
MGSX):'X9EOO'EMXRUR"6+P9I>E7\$\=Y-=+NVX> G%LSF21YOE1<LIQ\HQ_^
M"B?[4?P__P""8GA#P/I;? K2/BKX^D#6WB2ZT_2K&:VTQ46WC2XGMU@;Y+DN
MQCXC</&VXDDAY/\ @FUX@FM/V2/@+/I-Q:Z;=>/H3/KMX-.COKF%S?O$HO;I
MW$MLB+&S0F/;NDR#@+\W'_\ !5#_ ((L_#G]IW2?&VJ?#OP;X5\4?M%:Q?VU
MS+XHU_QA>6UCJZJT7G_NA.L"W0@ WQJJHH.Y<$[5]7%^TU=/S>VEKZZ?R_W>
MKUVT/.P:IW2J>F]]>EVNO][HM#MO^"<7[5?P[_X*&V_B:SM?V?=)^$VM>%[R
MWL+_ $WQ/8V$][KR2++(WV R6T06\78V41=JJRY S&1UO[*^E^#M%_X+;?%N
M#X5Z'I]O%J7POT5XVBM?)T^$&Z<>>Z'#-C:0 H!8C:2 =P\8_P""87_!&_X8
M^#;+2?B!X\^&OP\^&/Q@^&FKS:E%<:)XWOK[1]=@"GR9%22YD6.WVF6-SEBS
MQ$XV?*WIFE_M7^"_A]_P63^+'B+Q)KF@_"O0]0^'.@6$^M:S<Q6KPO+=N$@4
MXV><VT[=S-M&&[;:RH^T=*7M=[.]_P +]W;:VRTZEUE3C52HWM=6MZZV\K[W
MW>O0_033]!C-S<>'_#[[KGS=^O:\\:-*DI RJ'&TSD8  &V)<<?=4_DG^V%X
M9TG_ ()4?&3XT?&[QA\&]'^/GPO^-GC&TDTB*RL5DDT VEMLQ+/<P2)'%/+(
M4WQG,C0J S XKZP_:[O/&7C;_@G9\5/B5H.L>)_"^F:!X5U+5?"FDZ5<R6(D
M:-':W,^W$EQ)(5#RM(VW,FQ5^5Y'^>?B5_P4P^!O[:G[,'P!^''[6'A^YU:3
MXP>'_P#A*(]%\(W(L]&M[FUEFCC,UR+N)XR=C+'"KLH(RY)9 /-ES+5;^>]_
M\_+9>IZ5.S>NWEM;K\O/JSH/^"<W[;OPW_X*/?M :A_;?[%>F_#GPSH>CRWJ
M:Y=:)8WD-W?[H8EL9"MFC-/)'<@QP[LE59BK#!3W;_@H'\(])^!/[-&E^(?"
MCW'@?XW:-9MX?^#6F>'(C-=P7+*S1Z9%:(1%=)(H;SA(I@B0%OD6/>?)_P!C
M+3_V8_\ @G/;>-K[X-^$=2\,^+/$VD7UW8Z1)XDBUVSCET^RN;E=Z#49RLH0
M2EY?D&'\L,-PW]Q^R-_P5Y^'?QP^%'PU\6ZY#:W'Q8\966G127T_V 6V@7-\
M+>)XX8FN?M,=NKW" JB;Y!EB6 ++G]FW7;^O+N^O0VT4N9)I;_UW?9=#X?\
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M^S3XR\>:3X=F\6:CX7L1>PZ-&[I)J'[U$**45V!PY;A3]VJO[&7[0]Q^U?\
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MA'J&E^%;B769=!0V=MKHNI%DW/;2LRA0D>\RD9D:=OX0*],_X)Q?\$3?#?\
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MK#E4$UIV9W .#0&Q7+CXZ>!@?^1Z\$?^%!9__'*$^.G@9?\ F>O!'_A06?\
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M$3 ?\^JO_@#/V'VBDVBOQX_X? ?M=?\ 1,6_\(C4_P#XJC_A\!^UU_T3%O\
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MY9_^/4IU?)_U?_CU4:* NR[_ &OSGR__ !ZE_MC_ *9G_OJJ-% 79>&KX/\
MJ_\ QZFKJ^/^6?\ X]5.B@+LNC5L#_5_^/4?VOQCR_\ QZJ5% 79<_M?Y?\
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M4/\ /D_O-^=+Y\G]^3\ZC3K1'1[27<7*/\YO^>C?G1Y\G]Y_^^J9_P LZ/\
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M+,8@G;Q1>Q/$,., QNO&)9 1WW&NK+\=@XP4<724K7UUO;IU1I"4$K21\O\
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M1"PFOQ#<2\M?W::3J+J\;-U42+\TIR9&+8/5C[E!!8>(=!DL;%UTOP!I:O\
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M452" TD@PQS\P\U3_@M?\$W\,6.G:7^Q3\:IYKB5XM7U"3P3:RW5H[9<K%_
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MR1_?K^AQA[5PU?B/D,P_CREW*FF?\?FH?]? _P#14=7*IZ9_Q^:A_P!? _\
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M3_9_*C[?)_L_E4-% $WV^3_9_*C[?)_L_E4-% $_]H2?[/Y4GV^3_9_*H:*
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M\<=5A4YVK]^5P2>Y3YWR7]+KKV[OKLCZ#;5^7K?T[]ETW/RQ_P""EG_!+KX
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MLK74-;D&C0VL#YN(8)Y5\^:6YDB^5050'D'> TG_  3J_P"#>;P+^U%^S/\
M#/XI>*IH9&URVT[Q%K6N3:OJ%O=1J$C-UI\-N&6&,1%)4\T_<<X4 )@?HU^P
M5_P3P\ _LM?"KP];V'AWX>VFK^&/#R>'O$OC_0?#L6B77BZ.$@NNY69UB8QH
MT\GF$22*VW Z<'_P4_\ B)XF_8Y^#]Y\:/A_X@\/^$]&AU%+J3P)KENGV+QG
M.4,:W2J2K6TBDI*50A66 22#>-I(RE;7?KZ_YV^Y"O%R]W;].OR_,^1?%_\
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MO@?^BHZN5D>6%%%% !1110 4444 4M4_X_M/_P"O@_\ HJ2O%O\ @I[XLN?
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M5=P157.,D 5H_#WX5:-\,)=4DTL:D\^M2Q37L]]J$][-,T<8CC^>5F("H,
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MWXD6R@<NL:ZVPWN?XV.W+-C@$YP.!4RITG&W,OQ^[;[WN:1R'&Q=U%?>OO\
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M:D&HVNJ1F:TN;:\A+$>;;S+*A/<;E)%/KRW]CG]COP=^PO\ !2/P#X$_M?\
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M^X6D+$D\D\DGO2;OEKY3'[-7[7>?^3K/!A_[I+9__'Z7_AFK]KK'_)U7@O\
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MI^A?M4V/[0OA3PGXR^(L5S<W=H_P_M;Q(=DDME@YG53\D0((5<9QSC)^J/\
MAGK]K+?_ ,G:>!?K_P *ILO_ )(KS?:-J]CZ.GB925^1V>VVWWGUCGGI2 X-
M?)__  SU^UEO_P"3M/ OU_X539?_ "10O[/?[6(;_D[+P)_X:JR_^2*.:78K
MVTOY7^'^9]8JV* V*^3Q^SY^UC_T=AX#_P##4V7_ ,D5XY^VUXS_ &KOV,OA
MAH7BB;]I#P3XBM]9\4:=X<EAB^&5I UHMX[(;GB5R_EXSL RV>HH]I97L3+%
M.*YI0=OE_F?HE1GBOAKX-0?M)?'#4_$%CHO[6G@R2]\/7DMO/!)\'8H9&A60
MQI/B21/E=E;@9P1@UW?_  S=^USL_P"3J?!?_AI;3_Y(HY_(J.(;5U!_A_F?
M59;-)G-?G[^W+?\ [67[%W[+'BCXGW'[1W@_Q%#X5-G*^F1_#*TLC>"6\@M]
MOG><^T?O<GY3D#'&<U^@;'('T!_2J3OH7"KS-Q:::[V_1L&;-&>>E!;-&[FJ
M-A,\T X-+NYH5L&@ 5L4F<4H;%)G% "AL4F>*4-@4;N*  MFDSFE+9%)G- "
MLV:0G)I2V:&;)H 3/-+GGI1NYHW<T (#@T9Q2JV#29Q0 H;%)GBE#8%&[B@!
M*4MFDI2V10 A;-9?CW4I](\ ^(+VT817=EI5W<6[E=P25('9&(Z'# ''M6J6
MS6%\4LR?"SQ6 =I;0[\ ^A^S2<T$RV/ _P#@FX-0_:3_ &1?A1\5/B!K&K^,
M/%FKZ8NJ WTB)8V-SYDB>;!:Q(D2R!1@.RLPR<$9KZ9_BZ5^57_!$;]CZ\_:
M9_X)W>&?$FI?&S]H+PZUOJ5_I5MIOA[QG)I^FV=O!( BQ0[&"_>8G!ZFOH7P
M+\ ];B^*7C[P.OQF^.$EKX*ETV+2YCXE%UJ.J-?1;C%/-*H42>87$1[*F2-J
ML:[LIR]XR3AS<ME>^_5+]3Y7-N(EE>$AB*D')2:6C5[V;OKZ'VAC!Z4*<=J^
M//VJ_AOJ'[-7[-WB3Q<GQ:^-FGW?AW2UFBFUG6XIK>]NA=01&-52( KME?>W
MW@P'W=K =O\ %GXI:Y\1M'^#>M>&=:U?PI(VK66IZQIUQI=ZUMKUDT0-U:QR
MQIB5XSN*D91BK9XZ=F+R6M2BG2O/?9/2WW_TF<N4\<8/&.2JVIVM\32O?M?M
MU.M_:C\/:;XC^)'P M]:L+&_TF7XGV$=Q'?0)+;NIM[G<K!P5(QU!KW[Q3\'
MOA/\;/'.E>%? /@7P!=0Z7JMMJ/B'Q!INA6GV?2H[:5)UMH[A$P;J62.-=J,
M3&GF,VT[ WXC_P#!5SQ+X@^*G_!:[X#M';ZU_P *[TSQ#X3TN:VO2Z6EQ=OJ
M;.Y>TDQAB':,DIA@F,D<5_2EHVC6?A[2X;+3[6WL;.W79#!;Q+%'$OHJJ  /
MI7S6,HU*=3EJ)Q?FK&>-QU'%574H-2CM=--?@.TS_C\U#_KX'_HJ.KE4],_X
M_-0_Z^!_Z*CJY7,<H4444 %%%% !1110!YM^U;H7B;Q/\!_$.G>#8[>;Q3?V
M%S;Z;%/=FSCEE>WE4*9@K&+() ?:VTD'!Q7S)^T7\:/VBO#'[(7CS2_^&:?!
M.C^']/\ !^H6O^C?%-)/L-JEE(OR1_V:N[8@X7<,X R.M?:^J?\ ']I__7P?
M_14E>$?\%9+V;3_^"7G[1,]O-+;S1?#?7V22)RCH?[/GY!'(-)JZL!XE^S5X
MF_X65^SA\/\ Q#:V=Y;V^M>&]/NXX9E!DB#6T9VMM)&1[$BNU^P3[?\ 4R_]
M\&OR&_X-P/V5_"/Q_P#V*O$WB+Q1)XONM3M_%<NE1-9>+=3TZ)+:.TMI$016
M]Q&G#2OSC/.,X K[_F_X)R?"NXNH9FB^('F6V[RS_P +"U_C<,'_ )?/2OP#
M-,#A\-C*E!S?NO\ E7^9X=2*C)JY[U]AN,?ZF7_O@T?8;C'^IE_[X->"W_\
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MKQ;_ (*?^%+KQS_P3;^/FCV/E?;-2^'FNV\/F-M3<VGS@9/85[3JG_']I_\
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M2J L9_B-CPI_P3&_9J^'?Q'L?C#'\+='A\,6<HN]-OI)[RYN89RGEK<M"\K
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MUNG_ &[?X7NWN?CW_P &SEE:Z'^T=XPL-)N6U70E\-O/%J+ KYTQGA$B!/\
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M-6^'WCZP\<:KHW]KWDUU%>V%W_9J1FX-Q#>EA%N#E2"K1C VAL?>W6=9\*>
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M(Y(W(3_Q\Y;.?N'I(JMJ">,8Y->:UM?#\7AV.WC;0W4K%XA13B)F7 +0D_\
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M<$\_)QTZFBZ_X*V?LTVELTK_ !D\([$&3M>9C^03-?II_P (-H?_ $!])_\
M 1/\*/\ A!=#_P"@/I7_ (")_A7D_P#$/<)_S\E^'^1C]1AW9^#?[2G_  =
M?#/X&?&K6_"NA> ]4^(&EZ2\:0Z_IVNQV]KJ.Z)'+1H\#, I8KR>2IK$^%7_
M  =7_#_QS\3O#VBZC\*]<\.Z?JVI6UG<ZM<^(HI(=,CDE5&G=1 "R1@EB <D
M*<5^YGC#]D'X2_$37I-4U_X7_#O7-4F54>\U#PW9W,[JHPH+O&6( X SQ532
M/V(O@OX>UBUO]/\ A#\+['4+"9;BVNK?PK8Q36\B\JZ.L0*L.Q!R*].'!>5Q
MA9P;=M[O[]S3ZG3M:Q^,O_!+;_@H5\%_A*?V@XO%'Q(\/:+'KWQ>UG6=&-TT
MB?VA8S"'9<1_*<HQ#8/M7U(O_!6O]FE[EXO^%R>$-Z ,?GEQ@YQSLQVK]-#X
M&T4_\P?2_P#P$C_PH/@;1?\ H#Z7_P" D?\ A7)B^",-B*KJN;3?IZ$RP49.
M]S\Q-:_X*[_LVZ3IUQ*GQ=\*W4T5O+/%!')+NG*(6V [, MP!GN:_,#Q+_P<
MA^%=>_;M\(_%X?"G7H]/\,^#=0\+2:9_;L+2W#W5RLXF$GD@!5VX*E3G/45_
M3Q_P@NBE<?V/I6#U_P!$CY_2O/3^P7\#78Y^"_PGR3DD^$=/Y/\ WZKHP'!N
M!PW,Y7E=6U=M'H]K;CIX.$=]3\AOV.?^#D/X0?M,^,]8TWQ5I4GPEL],TTW\
M6H:QJRW<=\XD1# BQPA@VUBV>>$(ZXKZ.@_X*P_LUSLG_%YO!RAR.3)+P#W^
MY7Z"^ _V5_AC\*]0N+SPS\.? ?AN[NHQ#/-I?A^TLY)D!W!6:.-25!YP>,UU
M1\$:*#_R!]+_ / 2/_"N7$<!X"<^:FW%=EK^>I,L#!['\[,/_!6/PO\ MD?\
M%"_V?_'VJ:38_"_P3\*;O7C>ZIK'B2WN'O4N;1[>/;;HBS)EU7&5.0P.<#)^
MJOVJ?^"[OP$_9[^#]YXD\.>)M+^)FK6=Y!:C0=*O&MKB429W2"22(KM0<G@]
M<5^OG_"$:+_T!]+_ / 2/_"LKQ?\%/!OQ!T";2=>\)>&=:TN<JTEG?Z5!<P2
M%3E24=2IP0",C@UTUN#<'5G!R;48*RBNUV]7ONV4\'!M=D?SR:=_P=M:*/$V
MI?;/@IJ!T7;%_9P@\1(+I6V_O?.)A*$;ON[0..N:[+Q?_P %B?A/^V)J/[*_
MC>XU"U\#S>&_BE->:YI%[>&ZFT:SCLI8UNI72-1Y;LZXP.,U^W(_8(^!9_YH
MO\)O_"1T_P#^-5UO@KX&^"?AQH$>D^'?!_A?0=+C=W2ST[28+6W1G.YB$1 H
M))R>.373_JCET7S48N+UU3;W375OO<KZK3Z'YQW/_!6O]FJUB+O\9/"&T8SA
MY6/)QT"9I[_\%8_V;4!)^,G@_@9.)9?_ (BOTQ_X0?1O^@/I7_@)'_A1_P (
M+HO_ $!M*_\  2/_  KQ_P#B'N$_Y^2_#_(R^H1[GX8_M5?\'+_PM_9M^*=O
MHOAOPO-\4M+DL8;^/6='UP6T!WEAY3)+;E@Z[>>2/F%>T?\ !)+]O+X2Z9^R
M6UUXR\6>&YO[;\1:QJ=MH%U-':2:5_:%[)/'+V697\S#7&=\6#P,MC]-OB3^
MR9\+/C%>6MQXN^&?@#Q5<62-';R:OX>M+UX%8Y*H9(V*@GD@5<\'?LV?#OX>
M:)'IN@^ _!NBZ=&2R6MAHMM;PH2<DA$0 <GTK[?AO+\'D\)1I1;YK7=]7:_W
M;]+'+BLK<^5TY6:OOJM;;KJ?*-M^W[\$U6^T[4?C!X"\1^()/+^P:S'K:A-"
M4#<B._5/+^\''S7'1P,XJ1OV]O@VT:Z?#\9? 5CXO7-S+XP.IQM%<QM\N0F<
M,6QM^SD[(L!@3A-WV ?A#X4!_P"19\/X_P"P?#_\31_PJ'PI_P!"SX?]/^0=
M#S_X[7TO]J4OY7?Y6OZ6M:VZV?4Y_P"R:M_B5OG>WK?>_7='R1IO[:OP?\9:
MU8:3X8^)'@G1=0D865[:G7U!\5/@N8(YB03N&YOM1P_)7'+[>SA^,G@S6+!O
M%%AJ^@V_@6)PUSX:^WPI-?R)A?.$(;"LI  MQQ-PQ^;:&N_\%"_AGX=T[X)>
M'6M?#VBQR2?$#PG&=FGQ LK:]8JR\+T(.".X)'0TG[77PN\(_'SPOJWP9\,:
M;HD/B3Q9:M9ZOJ%C8PL_A2P<?O+F1@N$E8#9"A(9F?<!M1R#^TJ/2+^_IUZ;
M]GNNG2Q_9-;^9?=UZ:7V[K9]>I3N_BYX-\/:?;ZQK&K^'=9\,ZMF/2-#3589
M/[%:0?*3E\%6&2S=+89"_)DC@;?]O3X+QV$EO??%OP'XCUC4.-+UN/7$\O0Q
M'R(VD^\HCZB0#=<'AP*](\5:AX2\>?LL?$73]0\,^&]%^(&@>%M0CUS2/L,*
M7%G.MI(/.B&W+V\A^>*5?E96'(8,HZC]A_X6^&;_ /8N^$,T_A[0YII_!6C2
M22/8Q,SLUA"2Q.W))/4T?VI2>\7]_P!W_!_FZZB_LFKTDON^_P#X';H>&VO[
M??P8O[22SM?C-X#M?%5K*7N?&7]IQF*8'Y3A"<,S8V_9ON1XW G"Y\Z_;+_;
M(^$_Q._90^)7AKP5\3?!/A[Q%=>$]0T^6)=4CNW\1SR0/Y<40?'G%F;(F;Y\
MOLQ\S8_0D_"'PIC_ )%GP^>,?\@^+_XFC_A4?A7_ *%G0.N?^0?%U_[YIK-J
M5OA?WK?TMMV6RZ68_P"R*M]9+[GMZ]^[W?4_D5_97^/OQO\ V"O$-Q<?#G2?
M^$H^)FKAM,.=&;6#<V !GD2)5R\XC98V:7!$?F% >N/=!_P6>_X*$8_Y)7>Y
M_P"R87/_ ,17I_[-#'3O^#L;XN6MN?(M;'4/$L<$,?RQP+]E;Y44<*/85^Q)
MOY^TTW_?9K#$5E7ESPO%+1)N[^;TN?:Y!EU98?\ B-.[O967397T/PG_ .'S
MG_!0G_HE=Y_X;&Y_^(H_X?._\%"O^B5WG_AL;G_XBOW8_M";/^NF_P"^S1_:
M$V[_ %TV/]\US^SE_,>W]0K?\_9'X+Z]_P %ROV\O"LVG1ZG\/X].FUBZ6QL
M$NOAU-"U]<,"5AB#*-\A"L0JY) /'%: _P""SG_!0G_HE=Y_X;&Y_P#B*_2[
M_@IG>RM\4OV2LR2''QNTLC+'C_1+NOJK^T)L_P"NF_[[-)0E>W,9QPM9R<?:
MRT/PI'_!9W_@H03_ ,DKO/\ PV-S_P#$5Y7^V#_P4[_;*^./POTO0_B)X#O-
M'T5?$&GWUG/_ ,()/I[2:A!+YEM&LC+AF9QQ&.6QC%?T5#4)C_RVF_[[-?)/
M_!9N9KK]F?P&9'D<P_%3PK(F6)P?MV,_D32E3=MR:V!JJFVZC9^:LW_!8K_@
MHA)*[/\ #C6=S,2W_%L9AS_WZK)\;?\ !5C_ (* ?$#P7JVA:E\-]>;3=:LY
M;&Y$7PWN(G,<BE6VNL8*G!/(.17[]W^H3?;9OWTW^L;^,^M1?VA-M_UTV?\
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MFCM;.S^)GA>>XFD.$AC2^#,S'L  2?I7;?%;_@J/\'_@IKL.G>(+KQY!=7$
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M(1F.#G&*^@\<]:(;!A]*:79+\A ,FE5=U(!DT ;JHV/B7]MOX8:#XC_X*$_
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M;_P87/\ \<H_X8O^''_0O-_X,+G_ ..4O]5>(?YJ7WR_R"7BQQ.U;DH_=/\
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M$G.,=K_=^I6_X+&?\HLOCI_V+1_]*8*Q_P!A3QUKOPL_88^%NN7EMH5Q\/\
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M,<99X]K,47).!7J@7%6^6VGG_P  E<REKM9??U'4444%!1110 4444 %%%%
M!1110!^7?[-P;_AOS]LXE_D;XB:>%3;]TC1;3)SWSQ^5>^9S7SQ^SAXBLO\
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M_P#PHU#PG^TMHGA/PW=Z()-/T>;X:66HOIT7FR?NS</*&EYR=Q /..U>Z?\
M#+O[6G_1VWAW_P -'I__ ,?K:_X(YG_C5U\$?^Q<'_HZ6OI7)W5G&*LCCP]!
M.G%W>RZO_,^4#^R[^UJ!Q^UQX=_\-'I__P ?IG_#+G[7'_1V_AK_ ,-%8?\
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MH ,?+FC'RYI*,<4 *5Q05Q05Q2=* %((-&#NH(Q1CGK0 8^;%(!DT8YH R:
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MM;!&JW+E:M]QZOCYL48.ZDQS2XYZU1L(!DTH7-(!DT=: %"YHQ\N: N:3'%
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M4=7*DY HHHH **** (;R18H?F 9694(/?<0O]:FK-\2SBUTM78JJK<0%F8X
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M_P ]-0_\#Y__ (N@#0HK/_X1FW_YZ:A_X'S_ /Q='_",V_\ STU#_P #Y_\
MXN@#0HK/_P"$9M_^>FH?^!\__P 71_PC-O\ \]-0_P# ^?\ ^+H T**S_P#A
M&;?_ )Z:A_X'S_\ Q='_  C-O_STU#_P/G_^+H T**S_ /A&;?\ YZ:A_P"!
M\_\ \71_PC-O_P ]-0_\#Y__ (N@#0HK/_X1FW_YZ:A_X'S_ /Q='_",V_\
MSTU#_P #Y_\ XN@#0HK/_P"$9M_^>FH?^!\__P 71_PC-O\ \]-0_P# ^?\
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M (NC_A&;?_GIJ'_@?/\ _%T :&*,5G_\(S;_ //34/\ P/G_ /BZ/^$9M_\
MGIJ'_@?/_P#%T :&**S_ /A&;?\ YZ:A_P"!\_\ \71_PC-O_P ]-0_\#Y__
M (N@#0HK/_X1FW_YZ:A_X'S_ /Q='_",V_\ STU#_P #Y_\ XN@"33/^/S4/
M^O@?^BHZN55L=/CTZ/;'O^9MS%Y&=F/ Y+$D\ =^U6J "BBB@ HHHH ****
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M7_\ !SJ]G\"/%W@WP;XT;X&0O-?>)M->_LWLQJ3>9$(TY$A?RB&[!6]:M_\
M!>GPE\;?!O\ P04\:VOQ[\7>"O&7C)O&NDRV]]X7TN33[2.R-U;A(V1SEI X
ME)8 ##*.Q) /UULM/M=2LH;B*2\,<Z+(A-W,,@C(_BKX=_:!_P""_O[.GP%^
M+VO^"[=_B=\1-2\'NT7B2Z\$Z-=:Q8>'G5MKK<SK(J J0=VS=M*L#A@17UE\
M0KK5M1_9KUVV\(W5O_PE4WABXCT8B0'%X;1O(/'_ $TVU\)_\&L/BGP%9?\
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M;_V7]3TZQU.[L_C;HWAV\*'^WK[PG?C3($8X$CRH[_)GNH:ODKXZZOHGC/\
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MB+3S9R?%3PM\9-)\)W\.KEUB37=/BG@3[7M^=1)M@E?'S 3''- 'Z5?L[_\
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M#X<^*["XT_6;&UGF6XU1)XO)E>:Y+F=Y63C>7W   $  #H;/]B+X:V7[&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4[K1X;NX,S><LC*$)CF>/(!)&=I'J?SJY10!1_L*W_OW?_@9
M+_\ %4?V%;_W[O\ \#)?_BJO44 4?["M_P"_=_\ @9+_ /%4?V%;_P!^[_\
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M&_ARW>97\R^W1@@8O9L<^HWX/3O6E10!1_L*W_OW?_@9+_\ %4?V%;_W[O\
M\#)?_BJO44 4?["M_P"_=_\ @9+_ /%4?V%;_P!^[_\  R7_ .*J]10!1_L*
MW_OW?_@9+_\ %4?V%;_W[O\ \#)?_BJO44 4?["M_P"_=_\ @9+_ /%4?V%;
M_P!^[_\  R7_ .*J]10!1_L*W_OW?_@9+_\ %4?V%;_W[O\ \#)?_BJO44 4
M?["M_P"_=_\ @9+_ /%4?V%;_P!^[_\  R7_ .*J]10!1_L*W_OW?_@9+_\
M%4?V%;_W[O\ \#)?_BJO44 4?["M_P"_=_\ @9+_ /%4W2!Y,UY'ND9(I@J[
MW+D QH>I)/4G\ZT*Y^Z\7Z=X<U2^CO;CR7>97'[MFX\M!V![@_E0!T%%<_\
M\+2T+_G^_P#(,G_Q-'_"TM"_Y_O_ "#)_P#$T =!17/_ /"TM"_Y_O\ R#)_
M\31_PM+0O^?[_P @R?\ Q- '045S_P#PM+0O^?[_ ,@R?_$T?\+2T+_G^_\
M(,G_ ,30!L:K_P @JZ_ZY/\ R-6*Y?4?B;H<NGW"K>\M&R@>3)U(_P!VNHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit102image2.jpg
<TEXT>
begin 644 exhibit102image2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" '" G # 2(  A$! Q$!_\0
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M3NX!YQ?\<_\ !3;X??#7P9JGB'6K+Q)::/HML]Y>SQQ6URT,*#<S".*=Y'(
M/RHK,>@!/%=_J'['/PPU>XAEN_!FCW4ML&$+SJTC1!L;MI).,X&<=<"O./VB
MOV%?V?M;\.6J>+;:T\'VJN_ES6?B&?0S<C;\Z,8Y4$RX_A8-CMC- #X/^"JW
MPCN9)5C_ .%E,86V/_Q;CQ -IP#WLO0CIZT0_P#!5;X1W$TJ(/B47@8+(/\
MA7'B ;20&'_+GSP1TK+_ &4_V-O!45]XEUJ"S\6ZGX3U,VT&AIXGUN_OII5B
M$AENXUN)"\4<K2*J@XW+;J^,.*]B_P"&5_A^?^9:M/\ OY+_ /%4 >37G_!6
MWX/6VJV>GJWCXZAJ-['I]M#<^"=6TY)9WC:14\^[@A@7Y$=OFD'3'7 KL?"G
M[='A/Q=XIL=)@T_7DFOKJ*T#E;69('E<1H9!%.[*I<JN[;@%AG&:Z#4?V/\
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MXUK45MM2L3)!>J+6; DB9D<@!.A*DC&>#WK\J?\ @I;XHL?&?Q>^*FIZ;/\
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M_P $=M_\10!D_P##9WPA_P"BH_#W_P *&T_^.5C^/OV[_A9X4\%ZEJ&G^/O
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M_P %,O#.@7^J6]KK7B-M%BTNS97,E\Z77GNJ8!&1%!,^"1\L3GM0!]MT444
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M/V2!M_98^&_3_D6-.Z'/_+M'7H= !1110 4444 %%%% !1110 4444 %%%%
M!7@'[1G_ "?!^SM_UU\1?^FY:]_KY>_;D\$7WQ&_:D^ .D:;XEUCPA>7%QKS
M)JNE",W4 6Q1BJ^8K)A@-IRIX)Q@\T ?4-%?/?\ PQ=XW_Z.(^+/_?O3?_D:
MC_AB[QO_ -'$?%G_ +]Z;_\ (U 'T)7P5^V.S?\ #T+X"C>X4?$&P.T'Y6/_
M  C'B0<BO<?^&+O&_P#T<1\6?^_>F_\ R-7R?\9O@=KOPN_X*A_ "XU7XE>,
M/&D?_">6T/D:NML$+-X;\0,)#Y4:?,@4A<=I'SGB@#]-**** "BBB@ HHHH
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M/S],UQ'@[]H+6? VG:587_PVU_3;>YN8;>ZU"XG"AYI7"M*Q*C<S,<]<G.*
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M0&)!! J_X$T*\\+^"-'TW4=3FUK4-/LH;:YU"5-DE]*B!6F89."Y!8C)Z]:
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M)9Y&.O\ Q3'B+O0!]WT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;_%3P)J&@W=Q=6D%^JJ9K<KYD95@P(W CJ!U%>0Z'^S1%9_$2UL#XU\6Z]!
MCRZE"]YY:0*5(C!>/:RN7((7/*JV1TIB/?J_/#X30-<?\%HK!5ZCQ?*WX!')
M_05]F_\ #,_AW_GY\2?^#NZ_^+KXM_9XT6'PY_P61TFQMS,T-KXHGC0S2M*Y
M ADZLQ))]S7IX'^%7_P,\[&?Q:/^-'[.5\R_\%-_$<_@'P'X/\6I->6UIX*U
MI]>O9H-&CU94BAM)\&2%YH,HLC1O\LZ-NC3AQE:^FJ^=/^"J/PX'CS]B/Q]<
M#49].DT70[ZZS%!%*;A/(<-$2ZDJ&XRR8;T-?GI]X<]^R1^U?\2?BE^T4GAG
MQ%I=\?"]]X9FUJVU'4/!5QX<G:9)X(PL>Z[N$DC*3 D_*V2,<9KZLKQKX=MN
M^+WPZ]_AY<'_ ,C:;7LM !1110 4444 %%%% 'FLMTW_  V%!#YIV?\ "'2O
MY7FG&?ML8W;/-Q[9\KVW_P )]*KSB6;_ (RZ@CW-_P BA(VW<V/^/V/G&[&?
M?;GW[5Z/0 4444 %<-^T[_R;7\0O^Q9U+_TEDKN:X;]IW_DVOXA?]BSJ7_I+
M)0!0_8Y_Y-)^&'_8J:9_Z2QUZ17F_P"QS_R:3\,/^Q4TS_TECKTB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KP']HMB/VW_P!G?WE\19]_^)<M>_5\M_MS
MP>,+G]JC]GQ? MSX>M/$?VK7C%)K<,LUD(_L"^8&6(A]Q'W<$8/6@#ZDHKY^
M_L7]J/\ Z#WP-_\ !5J?_P >H_L7]J/_ *#WP-_\%6I__'J /H&O@+]M#7U_
MX>I? 73H[?4YI;/QI8ZI=O#IT\UO:VS:%KEFLDLZJ8XP;BY@C 9@295XQS7O
MG]B_M1_]![X&_P#@JU/_ ./5XO+9^.[;]LZ >/KGPW>ZV)]$/F:!;SPV:P?;
MH-@9969M^[?DYQ@KCH: /NFBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *H>*O\ D6-1_P"O67_T U?JAXJ_Y%C4?^O67_T T 7Z_'/]K%Q)_P %
MKY2I!'_"4:,,@]Q;V@-?L97XU_M._P#*::?_ +&W2_\ T5;5]3PI_'J_X'^:
M/FN)OX-/_&OR9^AE%%%;F CH)$*L 5(P01P17#7^IZM\(-*MH_L\&L:(MY;6
M4#_:/)NK2.:9(5# @K($+KSE3M'0GD]U7 _M'7\^G^ ;,P&(,^N:6&\Q2P*B
M]A8@8(Y.W&>V>E '?4444 <?\??#]]XJ^#?B#3M,MFO+^[M2D$"LJF1LCC+$
M ?B:R[?XI>*X;=$_X5SK/RJ%_P"0C:]O^!UZ)5>35[6&0JUS;JRG!!D (H X
M;_A:_BO_ *)SK/\ X,+7_P"+KG-<U[Q?JWQ)T+75\ :JD6CP7,+Q&_MMTIE"
M@$?/CC;SGUKUK^W++=C[9:YZX\U?\:#KED!_Q]VO_?U?\: .(_X6OXK_ .B<
MZS_X,+7_ .+H_P"%K^*_^B<ZS_X,+7_XNNW&MV9'_'W;?]_5_P :/[<LL_\
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M HHHH **** "BBB@ HHHH **** "BBB@ JAXJ_Y%C4?^O67_ - -7ZH>*O\
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M\):);.[0OMETFS99HVGCB< QDE6'F CB@#U@^-M&'_,6TS_P*3_&A?&NCLP
MU;3"2< "Z3D_G7D/[+GPAT+Q'\(+*ZUOPOH,]P\LHCF>SC:25 YSN.6Z/O4'
M/*JIP,XKN==_9S\&ZMHMU;1>&]"M9IXF2.=+&/="^/E<<=0<'\* /GG_ (+(
M?\D,\+_]AT?^D\M>Z_\ !-C]CKX5_$G]B+P%K>O_  ^\)ZQJ]_;7#7-Y=Z='
M+-.1=3*"S$9.%4#Z 5\T_P#!6GQ+<:M\'_"5K?V=Q8ZC;ZL_VA#&Q@<^2PWQ
MR8VLIYQSN'< YK[@_P""4?\ RCZ^&_\ UZ7/_I9/6^:U9T\KIN#:?/T]&8Y9
M3A/,IJ:3]WKZH7XO?\$W?A;XE\%R)X=^'?@>PUJTFCN[7?IZQ0711@6MYF0;
MA'(NY"P!*[@P!*@5S7P)^'OP$\,_M&:5X;L_A?\ \()\5;'3GUVVM+G3I/W<
M*-Y+RPW2%[>1=S$##[B.=HYQ]5U\L^*_^4R'A3_LEMW_ .G&OD7C<0U9U)6]
M6?5?5*"=U!7]$?4U>(?\% /VB_$W[,7[.NN>)_">GZ+?ZK86-U=*=4DF$$"Q
M0L^[9&I\QMVW"%XP>?G%>WU\O_\ !6NU-_\ LB>*(%_UD^BZC&GR[B28".!U
M[]!UKF.@]3^#7PTNM5&B>-/%6NW/B?Q#)IR-:%[=+6RTH3(K2?9X$SAFSM,C
ML[[?E#!20?3:_-GP'_P6DU'P[XCLX)_"_AY_!]GX?M;.&U'B.%-0%^AQ)([%
M=OEF/: N,AE/K7:?\/RM'_Z$BU_\*RU_^(H ]V_X*:ZO9VG[$OCZUGNK6*XN
M].40PR2JKS8GBR%4G+=>WK7>^'/V>? $_AVP9_ O@YF-M&23HMMU*_[GN?S-
M?B%^VU\1=9_:\_:$\1^+;O1_!]U;ZIJ^F/HSW?B9;VZT6RMC:OMB@%N2LR2Q
MW)3R98XV%Y(9ED8(T?ZY_"WXI^%_VY-?FT_P_P")3K'@/P?8VBZE%ITLUL-5
MU"97(AF<;',442*QC!P[3#?D)M(!R'QT_P""3/@GX]_MI^"_'^L:-X/E\!^&
M?#5]I=WX6.E;$U&^FF1X;H["L>8E#@$J6!;@C)KLXO\ @D_^S?!-'(GP:\#*
M\1!0BP P02P/7KDDY]3FOG__ ()X?MW^&/@CHOC_ ,'?$OQI9^'K7PSXIOM/
M\.Z=?6[1O:6L=S,KH&";F D# ;R<8P/EQ7NWCO\ X*A?!2'P/K+:/\3=!.KK
M8SFQ"QR.3/Y;>7A2A!^;'!H \ _X*96NK?LI? 36_!?PG\7ZE-I^J:'<)K?@
MJ[875MX6\-%##=:C;W(7S[".",L(U=I$<@I%&"A9/%/%-QXS\3>#? ^C^-WO
M%\&Q^)!9VF@RV5M9:9XBCN1)!,DLB7VZXMP\A\]6?*Q*P:+8Q<_07[//[47[
M.5C^QU+X6\9_$;18/%?Q#\/>3X\O-0F9M5U*]N+7RKE[B1DY==[*JX\M  J*
M$ %?/OC?]L7P?\3_ -C#1/A9_:^@M+;^+&T[4M6O+626$V[W5Q!'?VB>60T0
M@>.Y:X.U8PV$$CC  /I__@F99W.A_M4_&G1KF(68\.6.C:3;6$%O''8Z3;PB
MY"6=JR2R;X827C&XCR]AC&1&#7VU7Y(+^V7?_L*>%T\6?#6ZT'XA:--XF\,?
M!:*YU,R[M3 LYY;74S<;XP99&E5+C> /-\V3?CK].?\ #0_[:G_1"?!/_@XM
M_P#Y.H ^TZ^?/V(_^1G\<_\ 7:/_ -+=1KQCX3_MQ?M(?$W]J+5_A!=^#/A7
MX5\9:'X=B\3W<6IW5Q-$MI+.8(@'M9IAO9E<[3@A0#_$*L_LZ_M51?LW?$[X
MB^%_'NC:Y>>(]*NK6WNIO">BWNKV$S.LMV7#)%NB_P"/K:$?YL)G)!H ^X:X
M;]IW_DVOXA?]BSJ7_I+)7FG_  \J\#?]"Y\5_P#PA=3_ /C5>1_M'?\ !9/X
M%7GPG\<^&9=>U:PUNXT>^T[[)>Z5+;2PSO Z!)%< H=Q&=V,=Z /IC]CG_DT
MGX8?]BIIG_I+'7I%><?L=KM_9+^&(R#_ ,4KIG(.0?\ 18^A[BO1Z "BN9^,
M.I>)](^&VJ7'@RPLM3\31HIL;:[($4K;U#9R\8)";B 70$@ L,YK0\!W>L7W
M@?1YO$-K;66O364+ZE;VS[H8+DH#*B')RH?<!R>!U/6@#6HHHH **** "FAF
M\TC'RX&#GJ><_P!/SIU% !117"?L^^(?'OB7P;=3_$30=+\/:TE])'!;6$XF
MC>V"H5<D2/SO,@Z@D*K%4+;0 =W1110 5\V_\%(/B3\>_AQX.\,R_ GPU;^(
M+NZO94UEVT^.^EM(0@,92-[F 89MP)&_&!P,YKZ2KQW]H3XX>)_!/QR^%W@7
MPQ!H"3?$)]4$^HZHLLPL$L[99ALAC9/,9BV,&10 ,\T ?+G[&OQ>_:OUCXD>
M/;CQ'\._#4VO3VNER7,&KL/#JI'_ *6D<J"%KH3.X1E9F*E5@B&",5]!?\+)
M_:7_ .B6_#'_ ,+*?_Y$KUGX5_"]?AQ8WTEQJ%QK>N:U<?:]5U2X14DO)=H1
M0$7Y8XT155(QPH')9BS-U5 'SY_PLG]I?_HEOPQ_\+*?_P"1*^0OCI\4_'=[
M_P %6OV>-'\?Z)X'\-7<WC:WO5@TWQ"][=,!X?UV&-A&T2'RV>0J7XPYC49+
MU^H%?'WQN'_&P.TX'W="[?\ 40BH ^P:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JAXJ_Y%C4?^O67_P! -7ZH>*O^18U'_KUE_P#0#0!?K\:_
MV@[@W7_!::Z8C&/%MBG'^S% O]*_92OQG^/7_*:&[_['"S_] AKZKA7^+5_P
M/\T?-<3?PJ7^-?J?HA1116Q@(1D5PFNR:M\(M+MVT][/4-$^W6MHMK=%HY[.
M.:XCAPD@R&5/,RJLH.!C=TKO*X#]I&[GM/ %D8)?)+:YI>X[ VY1>PL5YZ9V
MXS0!W]%%% !7B/@>66_O/C!)/--*+.2YM;=6;Y(8R)I"JCW=B2?>O;J\5\,6
MT>@2?%AI;N';J0N+M$;"&/YKN(C)//\ JLYP/O8[9H ]@T/_ ) MG_UP3_T$
M5:JIH3!M#LR""# A!'?Y15N@ HHHH \^^!?_ "&?'O\ V,T__HJ&NXU'1[35
MS;FZM;>Y-I,MQ!YL8?R9%R ZYZ,,G!'/)KA_@7_R&?'O_8S3_P#HJ&I/CI.\
M$_@O9))'N\3V:ML<KN!$F0<=0?0\4 =[7#^._P#DH6G?]<(?_2ZVKN*X?QU_
MR4+3N<?N(?\ TNMJ (?V8/\ DANB?6X_]*):[ZN!_9@.?@;HGUN/_2B6N^H
M^0?^"R'_ "0SPO\ ]AT?^D\M?7__  2C_P"4?7PW_P"O2Y_]+)Z^1O\ @L9&
M#^SYX<;'S#Q#& ?0&VN,_P A7I/_  3>_P""BWP;^$7[&_@WPKXG\;V^D^(-
M%BN4O+6:PNSY6^[GD0!UB*-\C*?E8XSS@UTYG0JU<K@J47)J?17Z,Y\NKTZ6
M93=622Y>KMU1][U\L^*_^4R'A3_LEMW_ .G&NB_X>K?L_?\ 12=,_P# *[_^
M-5XIHG[7WPX^+7_!6KP9K'AWQ1:ZGIMWX&F\/Q3I!,H>_DO?,2##(#DKSG&W
MWKY)Y?BDKNE*W^%_Y'U*Q^&;LJD;^J/N^OF/_@J^@E_92\0IG]X^E7X1-PRY
M\GTW#/\ WRWX=1].5\]?\%)O!GB#Q[^SY>Z5X<\/ZSXBO]2@N+-+?3D1F1I(
MCM9]\L:A,C&2'P2.!]X<9UG3_LD_&3X?_&CX1>'4\+:UH&MRVFD6XFCMROF*
M$18V;80&VAU*[L8R",UZ5>'1M/U&TM)_[,@N[\LMK#)L62Y*C<P13RV!R<=!
M7R]\ ?@#XN^$7_!.'X=QS^%YI/BG\.[$:E8Z=!<1"[\WSVEEL1,6"?OH&:%P
M6V9;/501\_?\%!OVK+31/VH/V:?'?Q4^'/C_ .'NG^"_$UZNEHRV-_<ZY?7=
MND,-K"L<IV$R; 69D^5R,]< 'Z6'1+,C_CTMO^_2_P"%5-=\2:+X!L(I]2OM
M,T6UN;F*TBDN9DMXY9Y7$<48+$ N[D*J]22 *\B^#'[<UI\>=*U:ZT#X<_$P
MC0]1;2;^*YL[&"2WN1%%,4(-W@_NYXFRI(^;&<@BOEO]JW_@IUX&_:%?X6^"
M;+PWX^T74O%/Q"TW^R+C6=*B@M;]K#4$^TA669V4KM.-RKGM0!^ATFDVLTA=
MK:W9F.2QC!)_2J5[+HFG:I9V-PVE07NH[Q:6\AC66ZV+N?RU/+;5Y. <#DU.
M/$VG&WAE_M"R\JY!:%_/7;* "Q*G/. I/'8'TKY3_P""@VC:3XQ^.7PMF.O>
M(-%U#2M/\01Z?J/A?RI-8ANI7TRV>VMMX91+-%/+%S@IY@<,K(& !-\0?@I\
M$],^+OCKQ3XG^&_PX^(&@7DXN];UA-"LM8O_  M=0P+%-%>)M>40&. ." 3&
MWFAE"D&OHKX22^#_ !9\*?#.J>#K;1V\(ZEI-K=:&;*S6"V-B\*-;^5'M79'
MY13:N!@8&!C%?FAX/^"O@71M!^-^N6WA^[T;P_J6OSQZ=X8TNUWZ-XLTZPT+
M36TF]UA'8NT,,UWNERZ^?+<J9UDVG'VY^Q=XZB^&O_!,SX+ZSK,5RS6GP]\.
MK);VL7F33W#V%K&D,: \N\KJBC.,L.0.: /DW_@HO<:#\7?VE/#WA":P8V5K
M\<_!.@ZK&R*B7 N-$U*1MF"3_J[A1D@$,#V )^WOV6_B3<:U^S]:R>)KR(:W
MX.-QH7B*XDDX%U8.T,T[$]!(L8G'^S*IK\[/C7XW_P"%C?MK)K,22QV-Y^TM
M\/&LUFB\J5(QX7E#(ZY)#K+YJL#C!4CMD_6/[35C>>'?CCJGPWLOM<=E^TC]
MDC1X?NVLEJJQ:TQ.,(9-*2':>[QGN: .,_9'CN-:_P""C=EXPOX'@U/XC_#&
M_P#%$JR',D=O/K,"V,3>GEV4=LA'9@_K7LG[)I_XRF_:._[&;3?_ $U6U9CV
MT=G_ ,%<=,BB18XHO@_.B(HPJ*-8A  '85B?!;X^>!_@U^UG^T);^+O&'AGP
MQ/?>(=.FMH]5U*&S:X0:7;J602,-P!!!([T ?6%>%>*?#J_LYZGXIURY\%1>
M+_!UW-<^())K"UMY-4TB5LRW*M'(5\^)GWR*R,9%+LNPJ%-=%_PW%\&/^BL?
M#G_PH[3_ ..5QW[1'[:/PEUC]G_QS::;\5/ 4NHW7AZ_AM4MM>M))GE:VD"!
M%WG<Q8C P<G'!H ]M\ >,;/XB> ]$\0::LZ:?KMA!J%JL\1BE6*:-9$#(>5;
M:PR.QXK7KS?]CD3+^R1\+UN999[A/">EI++*H5Y&%I$"S   $D9. !GL*](H
M **** "BBB@ HHHH **** "BBB@ HHHH *^>OVD].M[K]NO]FZ>6"*2>UF\2
M&&1D!:$MIJJVT]L@D'':OH6OEO\ ;G\8:WX$_:H_9\U'P]X5O/&>J1W6O(FE
M6MW%:22JU@H9_,E(0!1R03SVYH ^I**^??\ AJ;XO?\ 1N/BC_PJ-*_^.4?\
M-3?%[_HW'Q1_X5&E?_'* /H*O@;]LBQN;/\ X*H? N]MM5UNVAU7Q?8Z-J%E
M!>F.ROK==%UF^02Q ?.PN;2W<$GCRAQR:]W_ .&IOB]_T;CXH_\ "HTK_P".
M5\H_&KXK>,?'_P#P4[_9]C\1_#/5_!,1\?6\AGN]6M+M0Z^&M?"1XA8G+AF(
M/0>6<]10!^F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50\5?\
MBQJ/_7K+_P"@&K]4/%7_ "+&H_\ 7K+_ .@&@"_7XN_M*7D^G_\ !8O4Y[:U
M>^N(O%EH\=NCJC3,$APH9N!GU-?M%7XV?&Y!)_P6GO 1G_BK;4_B(HB*^IX5
M_BUO\#_0^:XF_A4O\:_4^R_^%I>+O^B<:K_X-+3_ .+H_P"%I>+O^B<:K_X-
M+3_XNO0**W,#S_\ X6EXN_Z)QJO_ (-+3_XNN0^-'CGQ!KWAK3K?4?!U_HMJ
MVLZ>6NI;Z"54(N4(&U&+<GC\:]OKSK]IR=(/A]8%W1 ==TU06;&2;N, ?4F@
M#T6BBB@ KR#XG?!6RLI[[5;CQ;K]LMW-(]O81V]A/NDD8MY,(DMV<[G8X7)Y
M8]J]?KY_\->&_B3\*_'GB^ZL/ 7A_P 3QZQKMSJ-EJ5SXC^S7$5O*%"PA6@<
MHHVG@-CYNE 'M'P]T"7PKX"T73)FW3:?8P6TC<<LD:J>G'4=N*V*\C_X69\8
MMW_)*_#F/^QR'_R+0?B9\8L<?"OPYGW\9#_Y%H ]<HKR,?$SXQ?]$K\.?^%D
M/_D6KND?$'XJ71D^V_#G0[,#&SR_% GW]<Y_<+CMZT 7O@7_ ,AGQ[_V,T__
M **AK7^+WPPTGXL>%5T[6;B[M;6&X2Z66VN/(='7./F].35#X'^&M9T&W\0W
M.N6=O87>LZO)?K!#<"=8T9(U W8'=3VK#_:1\1:']J\(V.H7VE;H_$MF\]O<
M3QY5-LARRL>G(ZCO32;V!M+<P/A]^S)X/N_%MV]K+K&N:+;V_E-+=ZC(\4EP
M6!_=,FW.Q5(8@D9D ZJ<=G)^RQX#E<,V@AF' )O+@D<Y_P">GJ ?PKHHOB9X
M7@B5$\0: B( JJM]$ H'8#=3O^%H^&?^ABT+_P #XO\ XJGR2[$\\>YY;\!/
M@#X2\5?"K3;Z_P!*,]U,TV]_M<R9VS.HX5P.@':NQ_X9@\#_ /0%;_P.N/\
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M%_'KQ?\ %S_@G+\,GD\520_%;XCZ7;V=KJ5O:Q-=>:9-L]^("I3$4(>5B5V
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M+_PL?_@FU\&]'U6>XL+F;P)X=E>XL65)+2ZBL[65)(\@KE)45@"I4[0"".*
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M)2[HL\;',13G&[.0.;M/%7Q"N2\=K^U?H-YY&$D^RZ]HUR(SZ,8]%8 ^QYH
MG_9)_P"4UWQY_P"O)_\ T1H]?>[P)+(C,BLT9RC$9*]N/2ORPM[:^_9@^.GB
M7XB_\+9U#7?$7B_1;L/J&AV\.N7,U^'L52.:-=.CBBB,,/RX3):)LMV/HMU^
MW_J*:JZQ_$[XDFV%U,H;_A!H?]2-7CBC8?Z!R3IYDD_WAGK\M 'VY?\ Q_\
M"&E_'6P^&EQK447CC5-(DUZTTMH9-T]E')Y3RB3;Y?#\;=V[@G& 378U^+/[
M3OQ0\:?$7]J'P=\3?#_Q!^(/VCP[X>N],U.2'1GTC5+^%]0FV6=I*ED\$+^4
M89V>:!]P5D5T9N*/BKXZ?'?^POLNE?&_XH-K%_:I>6]],UPUCHP&XR:=<P+I
M:2W5R5 1;F*6&/?*'VJL9W 'UK_P6:NXI/AIXW_X59;W%S\6(-"$7C!["5H]
M/@\-.#]J&LLH*L/LQG,"_P#'R"2T6$\S/@^MZOXMU:T\ >'_ !C:R0:?K7C&
MU3PT]Y:V\6D++$IFEB#QWFS;,R/ \DG^D!9@L:JA9Z].T7_@L-:W?P13PAXG
M^"GQ5U>>\T9=(UN\%J2VIN;<6\TQ?R\L7 )W'L17R_XE_:D\1?$KX0>&/AEX
ME^'WQ F\ :)K=_\ VD8+"5M6U_2)XKJ%4DF,06&X,,L43&( Y\R19%;:M 'W
M9_P3_P!0O+W]N?XR7VJQ_8[FYTZUF=(45-+4>:P=[-O-D9HFG%P7+$#S?,V@
MJ03]N*X=00001D$=Z_%7Q=^UBOB3PC\0O#\W@3XBP)X^T/2OAWX+LQH%Q=7#
MQ03(T:WK*H2-520Q>:?E=8LGYBPK]+?B3XT\.?L*^,]&U!VU/3? /BMY[*ZT
M^SL;F^MM,OE0S130Q0H[0I(B3(ZJ!&6$9 5MQ8 ]^KY\_9,_Y.G_ &CO^QFT
MW_TU6U/_ .'GOP<_Z#?B'_PE-6_^1J\>_9Z_;H^'7@;X^?&K6]4O/$5KIGB[
M7+*\TF8^&=2;[7%'I\,+MM6 LN)$888 G&1P<T ?<-</^TTI?]F[X@@#)/AK
M40 ._P#HLE>;_P##SWX.?]!OQ#_X2FK?_(U<[\7?^"A/PN^)?PK\2^&=$U/Q
M!?:[XCTF\TW3+,>&=2C>\N9;>18XD+P*NYCTR: /2_V%?%&G>,?V-?AC>Z5?
M6VH6@\-V5L9H'W()885AE3/]Y)(W1AV9".U>HZCJ,&D:?/=W4J06UK&TTTKG
M"QHHRS$^@ )KYZ_X).20R?\ !/SX>>0T31I!=QGRB"H9;VX5AQQD,"#[@U[=
M\49%B^&?B)G(5%TRY+%N@'E-G- 'E7_!._XN:I\<?V:XO$FJ:T_B%KW7-7%G
M?LJ+Y]FM_.+;;L504$/EA3C)4#))YKI/VISCPEX</(_XJC2^1_U\"O@_]C"X
MN_A[^R)H$<U]JNC'7X+K5=&>+6Y;:"XMYW9X)XE75H$V'<IXA'/4$Y)\-_8Y
M_P"&G='_ &B=(OOB]KGVGP9HVZY1[GXJ)XC2YN4M%BB=[![Z-,_:0UQG?\C-
MM **!0!^AW_!/YMWQ@^,F"2-_AO&>N/["M:^HJ^6O^">EW'J/Q6^,=S =UK-
M<Z&EN[36\CRI#I<5N7802RHFYX7(7>2!C/45]2T %%%% 'SY_P %'P3\(_!_
MMX]T GV_TU*^@Z^ OVP_!M@_@_PQXG9;M]<E^/5G8O<O>SMF!=4DC6/87V;0
MBJH 7  %??M !116#\,_B-I_Q8\%VNO:7%J<-E=O-'&FHZ?-87 ,4KQ-NAF5
M9%&Y&P2HW*0PR""0#D/VD_@C%\5K30=5CT+P_P")-4\)WCWEOINLP));:A%)
M&T<T&YU81NRD,CX.'C0'Y2U<_P# ?XU_#6U^,.I_#?1O"H^'OCB+3TU>YT67
M1HK%KNWW;#+')!F&8(Q .USC>OK7MM?'FES1)_P6]U)&*":3X;*4!^\P%RF[
M'TR,_4>M 'V'7RS^TUK-KJ'_  4__9DTJ/4IEO\ 3K'Q3J4]C#*5#0R644,;
MRKCE=WF!<G[RY[5]35\#?MI?%#1?@]_P6:^!GB#79+J+3;#P-K*SO:V4UY*G
MF/L3]W"K2$%B!PIQU/ H ^^:*\"F_P""F?P@ML>9J_B1,]-WA+5AG_R6IG_#
MSWX.?]!OQ#_X2FK?_(U 'T!7PC^V:2/^"F/[/WRN0?B)9C<%^4?\4QXBZGM7
MMW_#SWX.?]!OQ#_X2FK?_(U?-WBWQ?\ #K]JS_@HOX4\8:1+?ZC?>#[G2)],
M>=;[3GM96N/LTDOV>3RPX,-W-%O9",2N >N #]$:*** "BBB@ HHHH ****
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ME;27$N.YVH"<?A57XM_%W3OB/H.GZ7I=CXA>[?5[&4"72+B) J7",Q+,@ P
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M_!LT<4$:C+.[%L*H ))/  K5^$'[>/ASXR^,_#^CV7A7XC:6GBA))-,U/5-
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MRYM#;-_8NN.%?S8UVL4D1@#U!R,@&@#]-:*** "BBB@ HHHH **** "BBB@
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MBE_S_>!?_ 6Z_P#BZPO$?PP^(7BKQ%8:E>7W@MWL+>XM5A%M<B*6.=560/\
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MT!:-L?2O,XKIRA'#J6_*U]UCTN&*D9RKN.W-?[[GNU%%%?'GU84444 ?/?\
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MVBKWXXV/Q ;QO\)1KFGZ+-H,<8T&]^SFWEFCF8E?/W;]T:X.[&,\<YKZPHH
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M %%(3@5G^%_%^D^.-)%_HNJ:=J]B7:,7%E<I<1%E.&7<A(R#P1GB@#1HHHH
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MUNK.'4?%>O7L*7%J]M(T<NI3R*QC<!@6# \C/-?1=%% !1110 4444 %%%%
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M_L^6W@5?$M]XM>.]GOI=0N;9;;>\I!*K$I8(HQTR>23GFO9Z "BBB@ HHHH
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M:UJ<>HZU:R2I;/INHZ7&RI$6$FZ?48SPV0(I,@?+D _1^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *H>*O^18U'_KUE_\ 0#5^J'BK_D6-1_Z]
M9?\ T T 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /BO_@E;\0="\>?$#QU_8FKZ?JW]GZ9I-K=?99A)]GF
MC@\F2-L=&26*1&'4-&X/*FOM2O@[_@B(2?!GBW))_P"*B\5'GM_Q6?B"OO&@
M K*\9^!M'^(N@R:7KNF66K:?*0S0740D4,/NL,]&!Y##!!Y!%:M% 'S_ /\
M!/34S=>#_B79)-KLEGH?Q'UW3+)-5O)KJ2""*90B1O*[MY(R2@S@ \ =*^@*
M^??^"?'_ " _BU_V5#7_ /T;'7T%0 4444 <)\6_@W>_$SQAX.U2U\5ZWX>B
M\+:A]MGM+&0K%JZ[HV\J8!AE?D*\AAMED&,D$=W110 4444 %%%% !1110!\
MG?MS_"&/X^?M5_"CP?+KOB'PO'K.C:\#JV@70M-5L=D=NV;>?:QB8]"P!..*
M[&/]@.VCC5?^%D?$EMH RVI1DGZGR^M-^-?_ "D*^!__ &!_$/\ Z)MZ^@J
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M8?$[P!XA\5>,M032=*73]8M=0EMR=[3W'D*Y9O)ABG?:1@M& W!->K_\*?\
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MX*7_ /DJC_AT_J__ $5S4O\ P4O_ /)5'^J^5_\ 0?\ ^4I_YA_;N*_Z!O\
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MNKWP^_92\!> O .AZ$/"7A>]&BZ?;V N)M(@:2<11JF]B5)+';DY)Y/6M?\
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MHKY,V_MJ?]"+;?\ ?JR_^/4;?VU/^A%MO^_5E_\ 'J/[#7_031_\&(/KDO\
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M%%% !1110 4444 %%%% !5#Q5_R+&H_]>LO_ * :OU0\5?\ (L:C_P!>LO\
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M^XZ* /BV?_@IOXN@V?\ %L_'\F]PG[OX9^(SLS_$?W'"CN:6?_@IMXO@"?\
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MP_:8U;XX6WA/Q+J/V2U-['X<6RCUFXN1"(A'_P >DRQ!A&.$;G/S5Z%^T/\
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M)+S^Q/#EWXKELM4W:KI%[X:DTM+)D.IM+I=G<L LQ:W@M9(KEF=#(T2LX6X
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MW]I#]G?QNNMZ;8:?\$_$UWKU]IUW8FY_MA)K<0B)3D*A!&<L#^E-_P""E_[
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M);JO_02U#_P(?_&BB@ _X2W5?^@EJ'_@0_\ C1_PENJ_]!+4/_ A_P#&BB@
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1<C!71IV*L"<$$9Y%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit102image3.jpg
<TEXT>
begin 644 exhibit102image3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &L B8# 2(  A$! Q$!_\0
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M?Y!]>QO\D?O9]Z?\-.?#;_HH7@?_ ,'MK_\ %T?\-.?#;_HH7@?_ ,'MK_\
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M+U\$?]#CX5_\&UO_ /%U^1?C7]C#XW>#)5#R^!KF*20QQ3)=2*'PI;.UE!'
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M5+Q'_P $[M+DT.[&D^(-0BU(QG[,]Y&DD"OV+JH5BOL"#[T?ZPYG_P! \?\
MP/\ X ?VCBO^?:_\"_X!][?\+.\-_P#0PZ'_ .!\7_Q5+'\2O#LTBHFOZ*S,
M<*HOHB2?0?-7YG1?\$XO&ZJ=_C'PJQ[;=*G7'_D8UNV7_!.[4$M(A<:_9R3A
M0)&C1D1F[D @D#V)/UI?ZQ9G_P! T?\ P/\ X ?VCB_^?2_\"_X!^D/_  D^
MF_\ 00L?^_Z_XT?\)/IO_00L?^_Z_P"-?G'_ ,.\+K/_ "'+?\C_ /$U'=?\
M$[[]K>3R=>M$E*$1ET9E5NQ("@D>V1]:K_6/,?\ H%7_ ('_ /:C_M+$_P#/
MI?\ @7_ /T@_X2?3?^@A8_\ ?]?\:/\ A)]-_P"@A8_]_P!?\:_,/_AW'XTQ
M_P C?X8_\%<__P =K8TO_@G;JD=C&+WQ#I\MR,^8\$3QHW)QA3N(XQW-'^L>
M8_\ 0*O_  /_ .U#^TL3_P ^E_X%_P  _23_ (2?3?\ H(6/_?\ 7_&I[/4K
M?45)MYX9PO#&-PV/RK\V?^'=]]_T'[3_ +X;_"D/_!.Z_P <:_:9_P!QO\*2
MXDS'KA%_X,7_ ,B+^T\3_P ^?_)O^ ?I=17Y=_\ #N;Q9C_D:O#W_@!-_P#%
MUH:=_P $[-82VQ=^(M-DFW'YH8'1<=N#DY_&J_UEQ_\ T"+_ ,&+_P"1'_:>
M)_Y\_P#DR_R/TTHK\TO^'=]]_P!!ZT_[X;_"FO\ \$[M0.,>(+,>N8V/]*7^
MLN8?] G_ )47_P B']IXG_GS_P"3+_(_2^BORI\5?L">.M*OM,73+O0]5@N[
MQ8;N3>T)L(#G,Q#?ZS']U>3FNF'["'C8?\SM8_\ ?$__ ,50N)L?UP?_ )47
M^0?VIB.M'_R9?Y'Z845^4O@/]G+Q!XX^'HUE?&#6]P=;FT7[.8963='>-:F3
M?Y@.#MW8V]\>]=?_ ,,'>,/^AZMO^_,__P <JO\ 67'?] G_ )4C_D']J8C_
M )\_^3+_ "/TKHK\U/\ A@[QA_T/5M_WYG_^.4OA7]BG6?$-O=F7QS<6\EI=
MR6K*EM)(#L.,Y,J]?I^=)\38[_H#_P#*D?\ (/[4Q'_/G_R9'Z545^:7@[]C
MSQ=J>AVNHVOCF2T%["L@"-.I"GD D,*UO^&./'?_ $4:[_[_ %Q_\737$V-Z
MX1_^!Q'_ &I7ZT?_ "9'Z+T5^:'B7]F[Q?X2%XUW\0]2V6NE76J QR3G<(-F
M4.9!C._KSC'2OI+_ ()0^(+[Q'^SKK$NH7EU?2Q^(IXU>XE:1E7[-:G&22<9
M)/XFNK+N(JF(Q:PE:@X-IN_,GMZ&N&S*=2LJ,Z?+=7W3/IVBBBOJ#U0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IP?\A^Y_Z]X?
M_0I:^)O^"ND*W/CWX<1ORLB7*L/8R0"OMF#_ )#]S_U[P_\ H4M?%/\ P5M_
MY*)\-?I<_P#HV"OF>+_^17/UA_Z6CR\Y_P!TEZK\T>O4445YISA1110!Y-J*
M?\9S:.W_ %(UZ/\ R?M*]9KRK4?^3V](_P"Q)O?_ $NM:]5H **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110!3@_Y#]S_U[P_^A2U\3_\
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MM^);Z*>:ST*REOIXX0#(Z1J6(7) S@=S0!Q@_8\\"AR?L_B+D8Q_PDVIX_\
M2B@?L>>!0Q/V?Q%SV/B;4L#Z?OZSM/\ VJ=3U'0K75E^%_CI=)NH8[H7C-8[
M$A<!A(1]HW8"G<>,X[5Z#\5?B+:?"3X=:OXDOH+FYM='MS<20VRAI90. J@D
M#))'4T >7^)/^"=/PE\7:H;W4=!U.ZNF0(99->OV8J,X&3-G R?S-<_XU_X)
MK?#'3_!VH2:%HNL6.J11>;;S6VLW;3(RG=\@>1EWX! R#R17L?P3^+MK\;O
MD>N6EAJ&EJT\ML]K>JHFB>-BISM9EYX(P>AKCO&7[4VI>%-8NH+?X7?$37;2
M"ZEM8[W3+6WN(;@QL59E EWA<@@%E&<&@#@+7_@FQX+\9:-#,_CCXDZKIEZJ
MRF.77C)%<)D-AE*=..G;ZU]. ;17RG\1_P!H/Q3>>'=2?P7\*_C'X=U^Y(DB
M?^S(OL;2;U+,\3,ZY*ALD*"2>3WKN1^V7K!_YHO\6_\ P5Q?_'* /=**\.7]
ML366'_)&?BN/KIL7_P <H?\ ;%UA!_R1KXL'Z:9'_P#'* -[X;C'[5WQ./\
MU#=$_P#0;JO4Z\%_9?\ B%<?$W]H7XFZG<^']<\,2&RT:+[#J\(BN1M6Z^<J
M"1M.>.>QKWJ@ HHHH **** /+&_Y/87_ +$@_P#I>*]3KRH_\GN#_L1S_P"E
MXKU6@ HHHH **** /)_C+'N_:7^#9_NW6K_^F]Z]8KRKXPG_ (R2^#__ %\Z
MM_Z0/7JM 'S!XU^*'Q"^-WA_7KOP)\-+FVNA<7>DV/B*#Q5;VKL]O.\)=HL
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MSH?[]'_"_P!#ZLHHHK[T^@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;?>8[=<;G.7D).69CW9B22?4FO.?V(O^31?AU_V ;;_T 5ZG0 4444 %%%%
M'E/PV_Y.U^*'_8+T/_T&[KU:OG?4?&GC#P=^UK\0CX5\#_\ "8BXTO1OM)_M
MF#3_ +(56ZVC$@._=D].FWWKH_\ A=?Q=_Z(E_Y>-E_\30![+17C7_"Z_B[_
M -$2_P#+QLO_ (FC_A=?Q=_Z(E_Y>-E_\30![+17C7_"Z_B[_P!$2_\ +QLO
M_B:/^%U_%W_HB7_EXV7_ ,30!H_\WM?]R/\ ^W]>J5\W?V_\8#\<_P#A,?\
MA3R>7_8/]C?9/^$ML]V[[1YWF;MN,=L8KKA\:?BW_P!$3_\ +PLO_B: /8Z*
M\<_X73\6_P#HBG_EX67_ ,31_P +I^+?_1%/_+PLO_B: /8Z*\ \4_M5?$WP
M==0PWGP,U-VG4LC6_B:SE4XX(R!P>1^=4;O]LGXD66A1ZB_P&\0&UED6*/R]
M>MI9)68D *BJ6/(/;B@#M/C-)M_:8^#0_O76K_\ IO>O6:^9/!GQ*\<_'_\
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M444 %%%% %.#_D/W/_7O#_Z%+7Q5_P %@(1<>(_AM&3@/]N4D=LM;5]JP?\
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MU_X>Z[8_\*V^*]E]MTZX@^T76@"."#=$R[Y&\P[4&<DXX ->P?\ !):U%O\
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MG:1!U_<#A1U,8;JV* .6FL[?3/VYM MH(DA2#P#=QQ(@PJ(+ZV  ]AQ7LM>
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M%%% !1110 4444 %%%% !1110 4444 %%%% %.#_ )#]S_U[P_\ H4M?&O\
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M_P"%_FCZ8HHHK[T]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRD^V6PTF\%A<74ULRVJS%(Y-OF?='RRIRV!DXSFN>/[2+C_FGWQ+_P#!,O\
M\<JQ\"K>YUJS\8:AJ&C:AI=OX@UR2YAM-3@5)GA^RVT)+QY8 %HWX)Y&#WH
M]#HKRZS^+5U\-Y+C09O!WCO5(],G>&VN[+3A<0S09W1;7,@)VJ0IR,Y6I_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IP?\A^Y_Z]X?\
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M="WEJ&\P+R#OW9SWS7J22Z3%J<EZK:<MY+&L,DX*"5T4DJI;J0"S$#H-Q]:
M/--<_9$T_P 0>'=+TJ?Q)XA6STBQDTVW""WW&WD"!U8M$<D[%^88(QP:X_\
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M\,:7J$/B363+;7FJ0031[M0N",HS C(((XZ&O1?^&H_AI_T4'P3_ .#NV_\
MBZZ.X^'F@7<[RRZ'H\DDC%G=[*,LQ/4DXY-,_P"%:>'/^A?T3_P!B_\ B: /
M$_VD_P!H3P%K[_#[[#XU\*7GV3QGI]S/Y&K02>3$HEW2-AN%&1DG@9%>H?\
M#2WPZ/\ S/O@S_P=6W_Q=;@^&OAP?\P#1?\ P!B_^)H_X5IX<_Z%_1/_  !B
M_P#B: ,9?VCOA\ZY'CKP>1ZC6;?_ .+I'_:3^'<38;QYX-4^AUJV'_L]<WX^
M^"WP?N_$$\^L>'/"\^L%462&*W4W<O'R#RH_F8XZ<5K_  G^!'AOPCX7>/\
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MDCV6G0R0D23,ZX+3*>C#/'6M;X\_&[Q-\5M&318O@K\0[K1GD9[M;NSMQ]J
MB81KM\TX E*L<]1'CO7U#10!\.:A9:JVC+9:?\ ?&5K#%-&T2FWML1QK<F7;
M]_/W"%_^M7">!I]7N+.>.W^#7C'43ISMIUR]O8QR+'<10V\,B$@XR'ADS_O#
MWK]'J\O^&.A:Q\$8/$HU6R%]IVJ>(;_64N["3S6MX;B8NHDB(#?*#SLW=.E
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MQN,D<9QZG.*^\_V>/AQJ'PN^&YTS56LWO9=4U#4&^S,7C47-Y-.J[BH)(60
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MK4-8O#X)FGD_M.% ][>J=K2:>25693VDDVM&<?=99&' 7(!XK\/OASJ?@/\
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MET%>(H)5B*<.,$YP*ZKP]^V'X6T_0+&"32OB )(+>.-Q_P (=J9P0H!_Y84
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MU^7?_H,-?84'_(?N?^O>'_T*6OC;_@L=?BRT7P 6'"W%]*3[*L'^-?-\7_\
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M^DU>C^'?#UOX8TQ;6W\QAN:2221MTD\C'+.[=V)Z_I@ "KU=AN>6?VO\:?\
MH!?#3_P<WG_R/1_:_P :?^@%\-?_  <WG_R/7J=% 'EG]K_&G_H!?#7_ ,'-
MY_\ (]']K_&K_H!?#3_P<WG_ ,CUZG10!XE^S;-KUQ\??BJWB6VTJTU<C2/,
MCTV=Y[8+]GEVD,ZJQ..ORU[;7E?PJ;/[4'Q8'I%HN?\ P'EKU2@ HHHH ***
M* "BBB@ KSC]G^0/K_Q*P",>+Y@?<_8[.O1Z\V_9\0IK_P 3,]_&$Q'_ (!V
M= 'I-%%% 'DGQH7=^TW\&/:ZU<_^4]Z];KR7XSC/[3?P9_Z^M7_]-[UZU0!\
M^_$7QO\ &[79M5TVV^%&C7&G"X=;&\_X2.%9"J/F&<*2"K\*^.QXKL$^+_Q$
M*\_"+4A]?$6G_P#Q=>I44 >%>-F^('Q?\6^!H;CX>7/A^PT+Q);ZQ=WD^M6<
MZK%'%,A 2-RQ),@Z#M7NM%% !1110!Q'[2/_ "0CQ5_V#Y/Y5V'_  2VC*?L
MFV1_O:E=D?\ ?8']*X_]I'_DA'BK_L'R?RKIO^"4^MIJO[*_D(CJVFZQ<VSE
ML8<D1RY'MB0#GN#495_R.E_UZ?\ Z4B<+_OW_;C_ #1]*T445]V>\%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.#_D/W/\ U[P_
M^A2U<JG!_P A^Y_Z]X?_ $*6KE !1110 4444 %%%% !1110 4444 %%%% !
M1110 5X[^W]_R9_XV_Z]H?\ THBKV*O'?V_O^3/_ !M_U[0_^E$5>;G/_(OK
M_P""7_I+.;&_[O4_PO\ (^?_ -AJ-H_V<]*RK+FZNR,C&1]HDYJ7QS<"#]L?
MP%O944^&]9.6..?.L:T?V1O^3=?#7_7*7_T?)6Y\2_@5X.^,LEF_BKPWI.O-
MIX<6QO(!(8 ^-VW/3.U<_05\;E_^ZTO\,?R1XN&_@P]%^1TW]HV__/>'_OL4
M?VC;_P#/>'_OL5YA_P ,/?"'_HG?A;_P"6I%_8H^$R=/A_X8'TLUKL-STK^T
MK?\ Y[P_]]BE_M&W/_+>'_OL5YM_PQ=\*?\ H0?#7_@(*1OV*OA._7X?^&3_
M -N:T >E?VC;_P#/>'_OL4?VC;_\]X?^^Q7F+?L0?")CS\//"W_@$M)_PP]\
M(?\ HG?A;_P"6@!GPCE6;]J#XMLC*P\O1>5.?^7:6O6*\3_9N^'FB?"[X^?%
M32/#VF6>CZ7&ND2):VL>R-6:WE+$#U)KVR@ HHHH **** "BBB@ KP?X:_M&
M> ?AYXT^(]AKOC+PSH][_P )7._D7FHQ0R8%K:H3M8@XW*P^JGTKWBOFSX ^
M'-.TW7_B-KU]IMA>6<WCW5+746N+=)#"NZ,13@L"0%)VMVVL&_@H ]+'[8?P
MI89'Q&\%D>HU>#_XJM;P1^T/X#^)6N#3?#WC#PWK>H,C2"VLM0BGE*KU.U23
M@5HZIX.\+Z'ID]W<Z-HD-M;1M+*YLH\*H&2?NUX3>:+:^'/VX?A=J$UG:Z1>
M>(-&UE$M8X5B\I%$+Q0D*/OA/,9B?XBPS@"@#O/C3_R<Y\&/^OO6/_3>]>MU
MY%\9;J%OVI?@U;^8OVCSM9F6/N4%B5+?0%U'XBO7: "BBB@ HHHH **** .(
M_:1_Y(1XJ_[!\G\JV/\ @DC;O!^S/J;,CJ)O$5PZ%E(#C[/;+D'N,@C([@CM
M6)^TO(8_@+XI(_Y\7'YD"NV_X)=G_C$K3O\ L(7?_HRHRK_D=?\ <)_^E1)P
MO^_?]N/\T?1%%%%?=GO!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!3@_Y#]S_P!>\/\ Z%+5RJ<'_(?N?^O>'_T*6KE !1110 44
M44 %%%% !1110 4444 %%%% !1110 5XM_P4../V./&G_7*V_P#2N"O::\6_
MX*'_ /)G'C3_ *Y6O_I7!7F9U_R+J_\ @E_Z2SEQW^[5/\+_ "/'/V1O^3=?
M#7_7*7_T?)5WXX? [PK\7-&-SXCTB+4YM*MIS:,\LB>3N7+8V,.NU>OI65^Q
MKJD6J?LYZ 8MQ\@W$#Y&/F6XD!KT'Q5_R+&H_P#7K+_Z :^.R_\ W6E_AC^2
M/&PW\&'HOR.+_9)=I/V7OA\SN\C-X?LBS.Q9F/DKU)Y->AUYW^R-_P FM_#S
M_L7K'_T0E>B5V&X4444 %%%% 'E7PI?=^U%\6A_=BT7_ -)I:]5KRKX4 C]J
M+XM\?\L]%Q[_ .C2UZK0 4444 %%%% !1110 5Y%^RQ:Q7MG\3(9466*;QSJ
MR2(PRK@F,$$>E>NUX-^SQXBGTG3/B/;V6R35=1^(>K6UDC<A6S&3(P_N(H+'
MUP!U(H [#PZ[ZSXS;PG<S>=IOAHK<I(Q).H $&*(G^(P$J7]28">K"O+_P!J
MOPQ=>+OVU?@Q:VMNESY=EK,\@D*A$40QC+%DD Y8#[IY(Z=:]QU#P!_9_A>S
MCTMO^)II#FYM9YCS<2G)D$A[B7+!O=LCE17DGQ#\;VLO[6?PTUS9,((O#.NN
M\17]ZCJULK1$?WPX*8]: ,K6_ =YX-_;2^#\T]I;0PW%MK</F0-&RE_LJ,%.
MR"+G 8C.>AZ=_IBN$?X67GC#Q]X8\4Z[?"&\\,M<RVFGVB#R8S/"86$DARTA
M"GJ-HSVQ7=T %%%% !1110 4444 <)^TW_R0/Q3_ ->3?S%=O_P2Z_Y-*T[_
M +"%W_Z,KB/VF_\ D@?BG_KR;^8KK?\ @E7K$.I_LJI#%OWZ?J]U;S;EP-YV
M2#'J-LB_CGTJ,J_Y'?\ W"?_ *4B,)_O_P#VX_S1])4445]V>^%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.#_D/W/_ %[P_P#H
M4M7*IP?\A^Y_Z]X?_0I:N4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7BW_!0__DSCQI_URM?_ $K@KVFO%/\ @HI*(?V-?&9/39:+^)O( /YUYF=?
M\BZO_@E_Z2SEQW^[5/\ "_R/!/V$>/V;],_Z_+W_ -*9*]3\5?\ (L:C_P!>
MLO\ Z :XG]DT;?V>?#.!C]Q)T_ZZO7;>*O\ D6-1_P"O67_T U\?@/\ =:?^
M%?D>/A_X4?1?D?/O[-'Q<^(&F?L\^"+>Q^$NIZE9P:':)#=KX@T^(7*"%0)
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MXC_!/_TEG)C_ /=:G^%_D>3_ +)W_)O/AG_K@_\ Z->NU\4C/AG4?^O67_T
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MBBB@ HHHH \H^,B;OVEO@X?[MUJ__IO>O5Z\J^,)Q^TE\'_^OG5O_2!Z]5H
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M<RO^$VE_Z/7\1_\ A,>'?_E=1_PFTO\ T>OXC_\ "8\._P#RNK5_X9C\ _\
M0K:7_P!\'_&C_AF/P#_T*VE_]\'_ !J?[8S;^6G_ .3"^N8SM'\3*_X3:7_H
M]?Q'_P"$QX=_^5U;_P .]$\2?%G6GT[PY^V+XJU:_CC,QMX?#/ASS-@(!8 Z
M>"0,C./6JO\ PS'X!_Z%;2_^^#_C7-?LY>#M,\"_\%%HK#2+*&PLUT*1Q%$,
M*&*<FB&>YC&M2A7C#EG)1TYKZ^H+'XF,XJHHV;2TOU/9/^&5_B[_ -'.^/\
M_P )3PW_ /(%'_#*_P 7?^CG?'__ (2GAO\ ^0*^@**^U/</G_\ X97^+O\
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M;#PC\3KNQOHEGMYX?"MU)'-&PRK*P!!!&""#SFK?_#6VG_\ 0D_%3_PD;O\
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MV'RTO/(N)(514%HL94"V&Q2.R_X;[_ZHK^T!_P"$A_\ ;J/^&^_^J*_M ?\
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MQ_S#^R\1_P _O_)5_F?G?_PWI>?]"#J7_@6W_P 9H_X;TO/^A!U+_P "V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .$"?!GQMJU_JFCWWBZWO3K_ ,._MKF6XBM5A!AND#N[1&0@ACEAUS=^&?\
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M,\ :=>:7H&G:#:W2S7DRHZ,\U_*B"%=ZA0DDN7^8!?>_V=?^"(GA_P#X)_\
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MVC6.Z,PEG5=T>(C]]23C)KVOXM_\'!WBCX"?MO?&CX3ZEX:LM<\73Q>#]/\
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' /%44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit102image4.jpg
<TEXT>
begin 644 exhibit102image4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &> B8# 2(  A$! Q$!_\0
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ML_\ I(M')C_^@J?_ )+_ )!R8C_G\_P*?_#P+X\?]$ST_P#\$U]_\=K'U_\
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M*]HJCJ/B:PTC5M/L;F[A@O-6=X[.%VPURR(78*.Y"J2?84<F/_Z"I_\ DO\
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MX+B$Y20 E3CZ$$?A1R8__H*G_P"2_P"0<F(_Y_/\#S+_ (;\^/7_ $333?\
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MJ]?-?P0_:/T'X9W_ ,0-+U.T\4SW*^-M7DW:?X>O;Z':TYQ^\AB9,^HSD=Z
M/I2BO)?^&S_"/_0-\>_^$=JG_P 8JOJ'[<_@;23 +J#QK;&ZF%O!YOA+4D\Z
M0Y(1<P<L<' '/!H T/A#G_AH[XNY9B/M.DX4GA?]!7IZ5ZE7S1\./VEM%\/_
M !J^(VL7>C^/$T_Q!/I[V$@\):DWFB*T6.3@0Y7#@CD#/:N]_P"&S_"/_0-\
M>_\ A':I_P#&* /6J\P_;*_Y-M\1_P#;K_Z50U4_X;/\(_\ 0-\>_P#A':I_
M\8KA_P!I']IOP[\0O@MK.CV%EXNBNKOR-CWOAJ_LX!MGC<[I98E1>%.,D9.
M.2*XLR_W.K_AE^3,,5_ GZ/\CZG_ ."<7_)F/@WZ7O\ Z77%>WUXA_P3C&/V
M,O!GTO?_ $NN*]OK[?+/]SI?X8_DCW,+_ AZ+\@HHHKN-PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#DOC)_R+$'_ %]+_P"@/11\9/\
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MCW<+_ AZ+\@HHHKN-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)7 "-A0#_P!]5R'Q/\1^-_"'B#P!XNU+QIX'\3)IVMV]H-/M-/:WE_T[%HS
MB9]VU92<8'3//2NB_9ZM%\-^)_B=KKPQR6<GCV_MM2#(&V1;(/+GY_N%B&_V
M&)/W!4'[7-E;>)O"FBZK%;P1Z?IOC+1;>P:- OG2B_C66;@<CK&OT<]&% 'T
M?1110 4444 %%%% !1110 4444 %>3_M#KO^*OP<_P"QIE/7_J&WE>L5Y/\
MM$()/BK\',]O%4I_\IMY0!ZQ7D_[4IQJ/PN_['JQ_P#1%S7K%>3_ +4W_(1^
M%W_8]6/_ *(N: /6**** "BBB@ KRO\ ;2_Y-RUS_?MO_2B.O5*\K_;2_P"3
M<M<_W[;_ -*(ZX<T_P!SJ_X7^1SXO^!/T9[3_P $XO\ DS'P;]+W_P!+KBO;
MZ\0_X)Q?\F8^#?I>_P#I=<5[?7W&6?[G2_PQ_)'NX7^!#T7Y!1117<;A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')?&3_D6(/^OI?_0'
MHH^,G_(L0?\ 7TO_ * ]% '6U\#>#6+_ /!17XG9_P">-R/_ "-;"OOFO@CP
M@GE_\%%OB</^F-P?SFMC7R/%>^&_Z^?^VL\;-]Z7^+]&>YT445RD!1110 44
M44 %>4?%_P#Y.=^#_P#OZQ_Z1"O5ZXOXN_ G1_C/-I,VI76N6%WHDDLEG=:3
MJ4MA/$9%".-\9#8*C&,T =I17D7_  QQI'_0Y_%?_P +2_\ _CE.3]CW2(_^
M9R^*A^OC*^/_ +4H ];HKR@?LB:2/^9O^*'_ (5][_\ %TUOV0M);_F</BD/
MIXPOA_[/0!W?B77;UM9@TC2S;Q7<T1N)KB=2Z6L0.T$*"-SL<A1D#Y6)Z8-7
MX5_#"W^%NEZG!!>75_)K&J7.KW,TX4$S3MN<*%  7/0?J:\S\1_\$^/!/C&Z
M2?5]6\?ZI-$NQ)+OQ/=S,BYS@%F.!GM5W]B#PW!X*^'_ (JT.S>Y>QT7Q?JE
MC:_:)FFD$22@*"S<F@#V>O(O"[_\9Q^,!V_X0_2C_P"35]7KM?,WQI^*'B;X
M$?M::KKFF?#W7_&-AK7AJPLQ-9-Y4<,D5Q=,PW%2&.)%X'3CUH ^F:*^?O#_
M .UG\2?%.E1WMC\"/$$UM*S*K-X@LHSE6*,"KX8$,I!R.U<;JO\ P4TUG0]2
MAM+OX0:_;SW&I'2(Q)J]N%-T':/RRVW:,LC ,3M.UL$X- 'UG17R\O\ P4(\
M2NRC_A4=]\Q '_%3V'.2@'?UD3_OKV-5M7_X*2:SH.CO?W?PIU".UC"$LOB&
MSD/SF)5PJY)R9XN@_B]C@ ^JJ*^7;?\ X*'^(;VWUJ6'X2ZG+'X=(7467Q!:
M8MLDJO;Y@6! *YR1@5F6?_!3;7M3N5BL?@MXMU)WMTN\6%XEWLC=G52QCC;:
M2T;C#8.5/% '<? N_?6;OXEZ!:'%QJGCK4UN''_+M;".W$K_ %.=B_[39Z*:
MH_M0V_\ PB7PQT#PPPVP:9XKT$Z8W_/2T%_"JI[M%PA[XV$\L:\+\#_M1:S\
M)-4\6ZMJ_P )_B;8R^,O$DFH(UO.]L@\T(L4!R@#."&Z==U5_C!^UO%\2?&7
M@GPGJG@GQUX<UE_$^E7ML==OB1&JW:9;RV4$@C</3OVH _0>BBB@ HHHH **
M** "BBB@#F?%GQG\(^ ]6^P:WXGT#2+TQB7[/>7\4,NPY ;:S X.#S[5EO\
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M?^"@WCQ?$_CWX-V5I]I2TM_'$'G^8FQ9F6141UYY7<)E!QU0]!C(!]@4444
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MK2*PN_BO# BQQ1^/M054485 $A  '8  4 >W4444 %>3?LEPK!IGC]54(O\
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M!+;Z3#&EV2\F\@[06"X5<L.<=NE>UZ5H]IH5IY%E:V]G "6$<$0C3)ZG  %
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MZDXK@M#T'2O@M\=/$T2+:3'4?#EC_9=D8<37#P33JXSM"MN>YB'R9QSD  4
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MD'C@@'Z@4 >P5YO\%'TWQS?^(M4=KW4+S2/$FHZ>CWLKR"T:*4KMA5B510.
M5 XS7I%?-_P@_:+\-?!O4_'>D>(%U^ROG\8ZK=(L6@WUPDD4D^4=7CB92".>
M#0!](5Y9^U(^Q/AY[^-],'ZR50/[>'PV4X.H:\"."#X;U'C_ ,@5Y_\ '_\
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MXR?\BQ!_U]+_ .@/11\9/^18@_Z^E_\ 0'HH ZVO@GPI_P I&/B;_P!>\_\
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M**ZS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+XR?\
M(L0?]?2_^@/11\9/^18@_P"OI?\ T!Z* .MK\XM1\?1^!O\ @I%XL>[NK"SL
M=1O;NSNI[N01I&@C\Q<,2 "7BC'/8GUK]':^=?BC_P $S/ ?Q:^(.K>)-1U;
MQ;!?:Q<&YFCMKJW6)6/7:&@8@<=R:^;XCP&)Q,*3PJ3<)7LW;HT>9F>'JU5!
MTE=Q=S$B^+?A69-R>)O#[+ZKJ,)'_H5$GQ;\*1?>\3>'E^NHPC_V:I[;_@DQ
M\,((0K7OBV8CJ[WT0)_*$#]*D_X=/?"[_GX\5?\ @?'_ /&J\?ZCG%OX4/\
MP/\ X!Q^PQO\B^__ (!Y3\8_B5X=U#XQ?"NX@U_1)H++5[Q[F6.^B9+=3I]P
MH9R&PH+$ $]R!WKT;_A=7@[_ *&SPS_X-(/_ (JM#_AT]\+O^?CQ5_X'Q_\
MQJH?^'2GPRS_ ,A#QA_X'0?_ !FE]0SG_GU#_P "?^0O88[^6/W_ / *Z_&3
MP@XR/%7ALCVU.'_XJO,_V3OB;X=T'X131:AK^B6,W]O:Q)LN+Z*-MC:C<,C8
M+#AE((/<$$<&O7;'_@E'\+;16\Q_$]UGH9;]!M^FV-:G_P"'5_PI_P">&O\
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MHH **** "OD;PD,?\%B?%'OX23/M\EK7US7R)X/_ .4Q?BKU_P"$43_T7:4
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MBVD_ /QM=(95>#0;Z13$VUP1;N05/&#[UJ_#K2;'3/!^GM864%DEU;13.L:
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M6V@F\P@?:/-)9E" 9VC/M7N->0_M:_\ 'Q\+O^Q^TW_T">@#UZBBB@ HHHH
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M#VU34/\ TW3UZG7EOQI/_%^?A#_V%-0_]-T] 'J5%%% !1110 4444 %%%%
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MFEEXQ\SLI)X '7M7A=A^R;\,C\0H8/\ A!/#)A_M-X]ALEP5#W0 QTQ\B_\
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M+5\+_P#0R:#_ .#"+_XJC_A:OA?_ *&30?\ P81?_%5SW_#)WPN_Z)QX$_\
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M;"JHR3VKU:@ KQO]H$_\9&_!'_L,:E_Z;IJ]DKQO]H+_ )./^"'_ &&-2_\
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M!G_A Z%_\8KPO]>,'_SZJ?\ @*_^2.#^WJ'\LON_X)^IW_"V?"W_ $,OA_\
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M_P#X=[? /_HA_P (/_"-T[_XS1_P[V^ ?_1#_A!_X1NG?_&: /0/^%L^%O\
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M+XG_  NO](U'QIXIM],\21W.H?VOJ[7D-C HR9=KXP>,9&3SCO0!])V]PEW
MLD3I)'( RNARK ]P:?7!:UJ%W\*O%!_LGPOK>LZ3JD)E>'2A;[+.X5L$[998
MPHD5APN>4)P"23SLW[46NV\#R-\'OB;L12QQ#8DX'L+G)^@H M_L:($^!J ?
M]!O6#_Y4[FO5*\C_ &'I;BZ_9TTZYNK&^TV6^U'4[P6U["89X4EU"XD0.IZ'
M:PKE/@3\$M8^)_PSM=<U[Q[\4K#5+ZZO#+;QZL;9(E6ZF1 L;1Y4;%7'Y]Z
M/H>O&_V@?^3C_@A_V%]2_P#3=-5W_AE7_JI/Q7_\*#_[75*\_8PTW4]=TS4[
MSQQ\2[V]T61Y;&6?7-QM7=#&[+^[X)0D?0T >R45YK_PS?\ ]3[\2?\ P=__
M &%5]6_9S>+2KEH_'OQ+WK"Y7&M\YVG&/DH ]2HKS/X3ZQK5W^R+HE]>SZC+
MK[>&$FEFG5OM37'V?)9@1NW[O49S7(_"#]G:_P#%_P )O#&K:I\1/BO#J>IZ
M3:W=VG]MF+9-)"K.-ACROS$\'D=* />J\S^-DA'Q;^$Z?PG7KEC]1IMW_B:J
M?\,J_P#52?BO_P"%!_\ :ZYG7?@?-\/OCA\,;Z/Q+XZ\1Q_VM=)*FK:@;R"V
M!T^YP^ @"G. &)_BQWH ]]KS#]E>]FO?"WBKSG+^7XQUI$R ,+]MD../J:]/
MKR#0O@/XY\$7NLKH'Q!TVRTW5=5N]52VN/#8N'@:XE:1D\SSUW %N#@4 >OU
MY9^TN0->^%N?^AUML?\ @+=UD>/?#WQ@\.:=:2:?\0O"\\MS>1VI^U>&#'%$
M'R Q*SL>7VJ..K5GVGP0^+?C#QSX5N_&GC#P?>Z/X:U9-7^SZ=I,L$\TB1R1
MJ-S.0!B5NWI0![U1110 5Y#^W%_R;[??]?5O_P"ABO7J\A_;B_Y-]OO^OJW_
M /0Q7GYK_N57_"_R.;&?P)^C/<_^"<?_ "9EX,^E[_Z77%>WUXA_P3C_ .3,
MO!GTO?\ TNN*]OK[[ _[M3_PK\CZ"A_"CZ(****ZC4**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Y+XR?\BQ!_U]+_ .@/11\9/^18@_Z^
ME_\ 0'HH \L_X*/_ /)&/!7_ &57P'_ZE6EU\L?$/_D^WXB_[\O_ *%#7U/_
M ,%'_P#DC'@K_LJO@/\ ]2K2Z\ _:$_9<^+-M^U#XM\2>&?"_P#:ECK,I>"X
M$\)1XV"$\&16# K@Y';N"#7QG&E"K4H472@Y6G=V3?1]CP\]ISE3@X1;L^BO
MT*U%9'_"DOV@?^A%3_ON'_X]1_PI+]H'_H14_P"^X?\ X]7PW)B?^?%3_P
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M^_Z_XTT>+-+/_,2L/_ A/\:X_P#X<\>&_P#H<=<_\!8J/^'/'AO_ *''7/\
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M5'L,W_Z!E_X,7^0<F-_Y]?\ DR.R_P"$GTW_ *"%C_W_ %_QKR/]M?7[&_\
M@)?107MI-(;J#Y(YE9N'&> :ZK_ASQX;_P"AQUS_ ,!8J/\ ASQX;_Z''7/_
M  %BKGQ> S>O1E1^K)<R:^-=?D9UJ&-J4W#V6_\ >1Z'_P $N=0GU/\ 8>\(
MR7&#(MWJ\0Q_<35;Q$_\=5:^@:XWX ?!/3/V=OA)I/@_1Y;J>QTLS.);A]TD
MLDTTD\K'T!DE<@=%! '2NRK] PL)0H0A+=)+\#Z&E%Q@HOH@HHHK<T"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .2^,G_ "+$'_7TO_H#
MT4?&3_D6(/\ KZ7_ - >B@"I^T/\ =%_:7^&;^%]=N=8L;7^T+'5;>[TJ\-I
M>65U97<5W;312 ':R301MR"#C&*\W_X8$_ZK5^T!_P"%?_\ ::^@** /G_\
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M]7^)NA>,O$>IP:K?:K9:K'(9);>9)+91!<"6W5(0GEH%B!V.X8L3NKD/&O\
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?%8WC#QO:^.],2TM([B.2.43$S* N ".Q//S"B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit102image5.jpg
<TEXT>
begin 644 exhibit102image5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &S C\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFUK):Z%;_A[=X(_Z%WQ1^5O_ /'*/^'MW@C_ *%WQ1^5O_\ '*T?^%9>&O\
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M,T>WXE_Z#8_^"HA[#A?_ * 9?^#9'HC?\%</#@''@[Q!^-Q#_C3/^'N/A_\
MZ$S7?_ J&OF\_"G12J_\6YLO]7_SV@YYE_VO8?E4+?"?1/)/_%N;'/E$Y\V#
M_GBI_O>O/XTO;<2_]!L?_!41^QX7_P"@&7_@V1]+'_@KGX?4<^#==_\  J&F
MK_P5Y\..V!X/ULGT%W#_ (UXK\+?A5X>M?&K3R?"_3KE;2"YG"&2U.THT9#
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
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M>:U87!5I;JW\J$1MM0@)DXR&)(']T]*ZZRL8M-LXK>WACM[>!!''%$@1(U'
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MP?\ QBH?V&YFN?V0/A[(XP\FDJS#.<$R.2*]5H \I_X9<N?^BJ?%S_P=Q?\
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M_P"E(^GX4_WFK_UZJ?\ I)^@U%%%?LY^(!1110 4444 %%%% !1110 4444
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MT[&?^^Z5OCU\1 O'P.\3D^AU[3A_[/0!ZY17D3?'KXB#I\#O$QY_Z#^G=/\
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M4-8M](MI+ 7L6NVL27+132([*K?,!N! SZ5Z))\:_B.J_+\&-48Y'_,QV0H
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M*WPWO)+I+FWTS6YKR7RH9G";;.<+N+NP4%F !QUQ7M= !1110 4444 %%%%
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M$)0!Q7B7Q)\5/&/QE\9:5X0USPMIVE>%FL(Q;7VE&>XG,]OYK,)?,5>", $
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M+_W]_P#K4?\ #6OPV_Z'+1?^_O\ ]:O1:*_9C\1/.C^UM\-@/^1RT7_OZ?\
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M<5WLW[8/P]\<3,9?B3X5\/Z0Q.(DU6(:A=K_ +3 _N%/HN7]UZ5[)>Z9;:G
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M? WR!B -MW\JXYPQSQB@#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $P2O/O^"F6GW6J_L4>,(+.WGN[F0VFR&%"[O_I,>< <]*[G]E'5;;7/V:?
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M?#34?$7CN*_U;Q5<>(M4@O[JSU:\LK>5XKID_=PQR*J+P< "O2A^P%\+@?\
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M<9RF-R@$$ <<5ST\1/W'427-M9WZ-]EV.JIA:?OJG)ODWNK=4M-7W.X^&?[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.U"%;BUN83F.>-AE64^A%7* "BBB@ KP64>;_P %*O" ]&M__1$AKWJO!O\
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M^"KJ9_9KLF_NZW ?_(4U?3=?,_\ P5:'_&,=NW]S6[<X]?W<U?+<;:Y#BO\
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M_P ]]7_\ &_QI_ZQ97_T$0_\"0?ZLYM_T#S_ / 6>NT5Y&O[;O@$GFXU<?\
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M0ABD3(R,JS C@@_C0!OT5RW_  O'P5_T-_A?_P &L'_Q5'_"\?!7_0W^%_\
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M2ZGN+I(QU^59)&"_\! K4B_X)^?!:&%HT^''AI(W.618"%8^XS@U[%12_LG
M_P#/F'_@*_R'_;&/_P"?\_\ P*7^9X]!^P!\&+9]T7PY\-Q-C&Y("IQZ9!KG
M-5_X)7? ;6-4EO)/ B0RS-O(MM5OK>-3T^5$F"KT[ 5]"44?V1@/^?$/_ 8_
MY#_MG,/^?\__  *7^9X=X<_X)M?!'PO#*D/@'3[GSGWN]]<W%Z^<8X::1B![
M XK4?]@OX.RD;OA[X>;:,+NA)VCVYKUVBE_8^ _Y\0_\!C_D/^VLQ7_,1/\
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M^*OB=H&E>!/AY\1?A'?>.-3LI()I=9DU:"]DM8;6Q)=5>.X,>^,.F2DBL74
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M_P  A_\ %T?\-U>!?37O_ (?_%UZK_PR)J__ $)WP'_\$-S_ /%T?\,B:O\
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5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit102image6.jpg
<TEXT>
begin 644 exhibit102image6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &3 A@# 2(  A$! Q$!_\0
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MB!A?^@6O_P""_P#@A_Q#K%?]!>'_ /!O_ /NBBOAG_AHG]IK_H#V'_@!!_\
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MC_X:J_:0_P"A/TK_ , /_M]+_P -4?M(?]"?I/\ X __ &^C_B(.!_Y\5O\
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M"&JA_#TC66A6.GZ7"\@ATX/EFDAV_=VA1U)/K0!X;JW/_!7[2/N\> 91CO\
M>;]*^H*^2OB-XOB\$?\ !730&N;:[N&OO!@LH(;>(-+)([2XP"0,?*<\^E?5
M6B:Y;>(K 7-J[,FXQNKH4DB=>&1U/*L.X- %NO-/AT?^,H?BA_UXZ)_Z)GKT
MNO&/#WC^T\+_ +7?Q'L)K?49Y;G2=)O&:VM_-6"&..16=P#NQF1?N@GJ>U '
ML]%1VMU%?6L<\$B30S()(Y$;<KJ1D$'N"*DH \S_ &<_^0U\4/\ L=[S_P!$
M6U>F5YI^SK_R&?B=_P!CM>?^B;>O2Z 'VO\ Q\Q_[P_G7EG[&W_)O6E_]?\
MJ?\ Z<+BNY\3>/++P7\TT=Y=S1PO=FVM(O-E$*<M(1D!5&#RQ&3P,FO(/V'O
MBWI.N_ [3[>-+^!$U2]MA<SP;;=YI+F298]X)PQ65/O  DX!)H ]VK ^*O\
MR2OQ1_V![S_T0];]8/Q4&[X6^)QZZ/>#_P @/0!G_ #_ )(+X(_[%^P_])XZ
MZZO,?V6OB;IWBSX)>"8H8[ZV+Z/!!;M=0;$NV@C$<GEL"0<%&X.&P,XQ7IU
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M/%FN^%?CK\2GT+PG=>+'FU*99D@U&WL_LP%S+@DRD!L\CCIBOT@K\_OV1/\
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MDU6^%/P'\0^%?CIKOCSQ'XETS6-0UC2X=,6#3],:SCA$; A_FD<DD "O5**
M/,[WP!\3-*U*YB\.^,?!^GZ&;N2:TM+OPY+<36T3L7\LR"=0<,QQA1@8%'_"
M)_%__H>O G_A*S?_ "57IE% 'C7@KX+_ !1\"W.N2VGCKP:[^(-4DU:Z\WPS
M*0LSJBL%_P!(X7"#CGOS6Q/X3^,++^[\=> U.1U\*S'CO_R\UZ;10!QW@_P'
MKD7AO7XO$^L:;JNKZ\K0/=Z?8-:10P^3Y<:"-G<_+EV^]@ECP*Y3]G7]EZ3X
M%_ ;5?!MSK<6LSZG/<W!O%M/)2-I$54Q'N)^4JK=>H[5ZY10!Y?#X1^,JL/,
M\>^ G 0 X\*399NY_P"/JHM;^'OQ9\0:#?:?<>.?!'DW]O);2%/"\RL$=2IQ
M_I/7!->JT4 >:^ ?@1?_  W_ &<-'\%Z?K=J^LZ%&CVFJSV1:%;A9C*)#"&!
MV\E2N[)!//-1IX3^,?F/N\=> L$C:!X4FX]?^7JO3J* /'/B!\&_B?\ $WP5
M?Z!JGCGP:-/U1%BN3;^&I4EV!U8[2;@@'Y>N#7L9.3110 4444 %>:?M?_\
M)N^O_P"];_\ H]*]+KRW]LO4H=/_ &?-529]C7D]O!",???S0V/R5C^%>7GG
M_(NK_P""7Y,]?(/^1IA_\</_ $I'O?[#G_)I7@3_ +!J_P#H35ZO7E'[#G_)
MI7@3_L&K_P"A-7J]?H/#_P#R*\-_U[A_Z2C\YXC_ .1MBO\ KY/_ -*84445
MZYXP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
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M*;?AMX1;YAC_ (K C/\ Y+5#^Q9++-^S5X?>>-8IVFOC+&K[UC?[;/N4-@9
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M445ZYXP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M..Y%>1:%8?'N7QG!I6K>,? -HDUI)=&2TT%KAX@K*J[E,BX#%B <_P )XX.
M#WBO-/VO_P#DW?7_ />M_P#T>E'_  @WQ8Q_R4?PO_X2'_W17F7[4_A3XKZ7
M\.5FU'QEX>UOPVLX_M>VM]#73YBAQY15C)(6_>[,@;>,G)Z5Y>>?\BZO_@E^
M3/7R#_D:8?\ QP_]*1]@_L.?\FE>!/\ L&K_ .A-7J]>4?L.?\FE>!/^P:O_
M *$U>KU^@\/_ /(KPW_7N'_I*/SGB/\ Y&V*_P"OD_\ TIA1117KGC!1110
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M1E<JP&"?2N7'[,\P.?\ A9_Q=/UU^/\ ^,4R3U*U_P"/F/\ WA_.O+/V//\
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MH_9(_P"1?\>?]C]KG_H\5ZPGWQ]:\I_9,C\OP_XZ_P!KQ[K;?G.* /5:***
M/,/VRUW_ +-/B4>]I_Z605ZG<J?M#\'[Q[5Y1^VPGG?LN>*TW.OF+:H61MK+
MF[A&0>QYX/8U=G_9?TQ9V'_"7?$_J?\ F;+F@#T?8?0_E7EO[9:D?L]:MQ_R
MWMO_ $:M65_9DTU?^9M^)WX^*[FN"_:;^!UEX,^#FH:E#XA\<W\D$T $&HZ_
M-=6S[I /FC;@XSQZ'!KR\\_Y%U?_  2_])9ZV0?\C/#?]?(?^E(^KOV'/^32
MO G_ &#5_P#0FKU>O*/V'/\ DTKP)_V#5_\ 0FKU>OT'A_\ Y%>&_P"O</\
MTE'YUQ'_ ,C;%?\ 7R?_ *4PHHHKUSQ@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^ /V06W?&#XH?]A!O_ $IGK[_K\_\ ]D 8
M^+_Q0_Z_V_\ 2F>OSKC7_D99=_BJ?^D'Z5P/_P BO,O\-+_TL^@****9(444
M4 %<5^TF<?LZ>/?^Q>O_ /TG>NUKB/VF&V_LX>/SZ>'+_P#])WH Z+P)_P B
M'H/_ &#+7_T2E:M97@,_\4%H/_8,M?\ T2E:M @HHHH&%/M_^/A/]X4RG0MM
MF4^C"@#Q+]FPY^'WA?\ [&S7?_1U]7M=>&?!SX*2^!;SP?J8\5^*+R+4-6U"
M_.F2RQ+I\+3I=2D)&$W  L<9<^M>YT %87BB"^B\1Z'?6>GRZBMF;A9HXY8X
MW421A5(WL >1ZUNU@>/_ (M>&/A#9VMYXHUW3M!M;N8PP2WDFQ97 W%1QUQS
M0!P/[!RE/V2/!H88817((ST/VN:O7:^:/V//VJ/AMX-_9P\,Z7JWC;0-.U*V
M%R);:XG*21EKJ9ER,=PP/XBOI9'$B!AR& (/J#0!7UG6;3P[I-Q?W]S#9V5H
MAEGGE;:D2CJ6/85X+^T[XST#XQ7_ ,,-&\/^(["XO_\ A.].NB;9O,DACB69
MV?!!'8#D8R1FO>M8TB'Q!I-S8W 8P7D30OM.& 88R#ZCJ/<"O)O&?C>^UW7O
M UG/9SWL5OXHMH_[;MPHLKTA)02 Q#;N/FVADSG#'L >C_\ "*W_ )F?^$FU
MKKG_ %5K_P#&J\<_9J\9>'_@W<?$?1-?\2Z?#J \;ZA<YN'\MY4E$3JV  /X
ML<#&0<5[]7D'@_QQ?:%X@\<VD%E/9Q7'BBX3^VKD*;&R)BA +!26W>FX*F<9
M84 >K:-K-IXBTJWOK"YAO+*[0203Q-N253T(/<59JKHNCQ>'='M;"#=Y-G$L
M2;CEC@=3[GJ?<FK5 !1110 4444 %*IP:2D?[C?0T >*_LE?%CPMH_[.'A.U
MO/$FA6EU!;2)+#/?1QR1MY\O#*3D'ZU[4K;E!'((R".]>'? [5H_&GPCT#PX
M^DW&DI?0R1S7NH6R1_;(_-<O';$;M[LH())7:"2 <5[D %&   . !T H ***
M* %3[X^M>6?LI-GP_P"./^QZUK_T>*]33[X^M>4?LDG/A_QY_P!C]KG_ */%
M 'JU%%% 'EO[:C;?V8O$W#-S9\ 9/_'[!7JMR<W#_P"\:YOXJ^%=%\;_  ]U
M/3/$5Q]ET6X16NIOM(MO*".LBMYAX7#*O6LSP5\3=/U;Q<-%M_$^D>)OM-O)
M=6\UM<PR7$80J'258S@C# JX SR#R 2 =I7E?[9\GE_L^:GQ]ZYME^G[P'^E
M>J8_SFO*_P!M&,M^SYJ6/X;JV)Y[>8*\O//^1=7_ ,$OR9Z^0?\ (SP_^.'_
M *4CWW]AS_DTKP)_V#5_]":O5Z\H_8<_Y-*\"?\ 8-7_ -":O5Z_0>'_ /D5
MX;_KW#_TE'YSQ'_R-L5_U\G_ .E,****]<\8**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O@#]D/_DL7Q1_["#?^E,]??]? /[)G
M_);_ (I_]A!__2F:OSKC7_D8Y>_[U3_T@_2N!_\ D69E_AI_^EGOU%%%,D**
M** "N&_:=_Y-L^(/_8MZA_Z3O7<UPW[3O_)M?Q!_[%O4/_2=Z .D\!_\B%H/
M_8,M?_1*5JUE> _^1"T'_L&6O_HE*U:!!1110,*?;_\ 'PG^\*93[?\ X^$_
MWA0!X+^RS?Z)8^ TNKQM9FU"PUW6%ARE[<0P#[;<(-B@&/A"0,=,UU<O[6?A
M"SU'4K>YDU6W:QD:* G3;AO[0=?E98@$^^'RNT\]^G3C?V6_A=JFJ>!Y=4B\
M>^,M-MI->U@KIEJ]K]DC_P!/G'RAX6;WY)YKKHO@MXF9Q&_BV<Q:'>RW^B2S
M6\,LKS2.7+7&$48&YTV@<YW<8 H TK/]I+PU-X'379SJEM"<QM#_ &;<22+,
M&*>2-L>&?<,#'6FVO[1WABZ\#IKET-1AA),;0-ID\LBS!BGDC$9#/N&!CK5:
MQ^#GB*70DGG\9ZS;:T;YM6\A5MI;"*X,A<)M\D.R#."=P/?VI;#X/>(GT-+B
M;QEJ]MK?VYM6\A4MI;".X+LP0KY(=DP<$[ASR!VH$7= ^/GA36/#MAJ,[-IB
M7]REDJW5A(HCN7D\I82_E[=Q?Y1S@Y%=V1M.*\GU?]FV^^('@U;/7_&?BBUN
M9]27698M/DM1#;7*S><GEDP9(5@O7J0>,'%<UXR^'_BK0?C1X(\.1?%KX@_8
M_$T&IS7+N]EYRFVBB=-G^CXP2YW9![=*!GM/C72KW7?!^IV6G7$-K?7=L\,$
MTP8QQLPQEMOS8QGIS7E'Q+F\7Z%XG^&=OJZ^#_[+E\5VEI''I<=RDL/[F8KC
MS"5V@)C'TK<_X9ZU[_HK_P 3?^_EA_\ (U9^N_LGWGBBXTV74?BG\1[M]'O$
MU"R+RV0^SW"JRK(,6XY =ASQSTH ]?KQGX>/XPU?Q1\28='_ .$._LQ?%-S;
M21ZI'<O++^X@W9\LA=I#8QCUKT+X4PW6CV]SH.IZM?ZWJ&E7)/VN_*?:;JVD
M.Z*1MBJIZLF0HYC(ZUYG^PCKMYXG\#>-=1U"X:ZO+SQC?R2R, ,_+$  !Q@
M #V H ]<\$:1>:!X.TRQU">&ZO;.V2&:6$,(W*C'R[B6QC YYXK4HHH ****
M "BBB@ HV[P1Z@BBE3[U 'R+\-/C'\5]>^!6GZ=I'P:FU32RDGV#5$UR",L4
MG<QSJK$%2K#(!QT]Z]F'Q[\9E1N^"WCG=CYL:CIF,]\?OZG_ &-QC]F#P=_U
MZR?^E$M>F4 >7?\ "^O&'_1%O'7_ (,=,_\ C](?CUXP'_-%O'7_ (,=,_\
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MZ]P_])1^<\1_\C;%?]?)_P#I3"BBBO7/&"BBB@ HHHH **** "BBB@ HHHH
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MS\"/!-Y=^!?#-Q=W>@V,\\SV8+RR- C,Q/<DDDGU-=;_ ,,B_"W_ *$#PO\
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M=':0+++]JF!L(R52.-QG)[D8'<@4"/I0ZE;#_EZM?^_R_P"->2_MK^)X]/\
M@-<PQ/;3G4;ZWM6Q*"4&XON !Y^X!^-.\ _L3?#3P]X2M+6[\ >&'N@&>3?!
MYQC+N6$>]B2P0$+DG^&N6_:;_9M^'WP]^#VH:OH7@SP[I&JV\T"Q7=K:".6,
M-(%;#>X)!^M>7GG_ "+J_P#@E_Z2SV,@_P"1GA_\</\ TI'UA^PY_P FE>!/
M^P:O_H35ZO7Q#\#OB)XY\-_"#PQ8Z3XVT_3=/%A:I!;2Z+Y[V_F3V><OL(8[
M9Y%'/\2D\J<=&?C)\3I]!\T?$?2$E\@R;QX<)&6B64<%.B\@>H//(K]!X?\
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MCD#"6/>K,!(@*#>C#:P./< 'I?PQ\8W'C_P)I^KW=B=/GO$),?.R0!BHECW
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MA,K(S*7,>W)!.2,GDUXM!WYM;ZO]#W<0K<FEO=7ZZG2UXS^UC\!-%\9QVGQ
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M!L!OX<<X'6O4J* /,O\ AF.#_H??BK_X4TG_ ,32C]F. ?\ ,^_%3_PI7_\
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M^'T;(T+1P1T(LH^/_':7^J&<?]!Z_P#!4?\ Y(?^N>2?]"Y_^#I?_(GPR/\
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MI\6:9)86AN+:)_M$K:@^<>4F(N&]S7Z;T5I_JAC&G?&/_P  7^9G_KG@4U;
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M4$$JW<<<&O=*_0<E=\OH.]_<C_Z2C\ZSW3,L0K6]^?\ Z4PHHHKTSR@HHHH
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M'\/6=S\.;AV2/1WTTO.+Z#=YJ/RR+Q@G!VYR!FOKG]GNRCN/@OH#W$6DSSM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?F[_P7-^&>J?%KXD?#/1]'6T:]ENK251<
MW"P(52]!/S-QGFOJ6Y;=<.?5C7R?_P %[?!&M?$+QK\,=-\/V5S?ZF][:21Q
MP1^8R 7@^?;D9"Y!(KV2Z^'WQ5-P_P#Q='0S\QY_X0^/G_R/7Y53_P"1KCO\
M:_\ 2$?KE;_D49?_ ()?^EL])I]O_P ?"?[PKS!/A]\5!U^)VAG_ +E",?\
MM>GQ?#[XJ-,F/B=H:G<.?^$0C./_ "/7HGED'[&G_)M^@?\ 7:^_]+KBK'[0
MG@/X;_$MM"T?Q_HUIK]Q++/+H]D\,TMQ(Z(#,8A'@\*5W9..E5/V*H9;?]F3
MPTD\@FG5KP2R!-@D?[9/N8+VR<G';-/^* /_  U'\(SV$&NY_P# 6*@"E\+?
MV-OAOX1TJ\/_  KGPK;"_NC<1VEU8QWCV<>U55"\F\[CMW, VT%B!TR3XX?L
M[^ =+^"/C2ZL_ O@VVO+70+^:":/1;97AD6VD964[."" 0?:O7:YKXSRF#X,
M^,77&Y-!U!AD9&1;2'I4S^%E0^)'QY^Q!X4\,_#K]B_P'\2(SHL_B/4-#%[X
M@@N]1^SZCJ5N)9%<P2>:A#[44JCAD;R\#:37INF_$[X>?M'M)9_;=#T[PG>"
M-;/_ (2"^G6\U"=6):2.!Y@FT'"KO/+*QVD8K@OV!/&SZU^RO\*/[>\-:/J^
MJW.D-_PC]HS(B78264&8DQLJNIW#$C*%'W 22:Z'X5>)O"_PE^&7A\^(?AO8
MRC6K=7TZXN[.S<WEZS',<<O+,CL05SAU.\;<;:B@[THOR7Y&F)5JTTU;5_F:
MW[//@ZW^&O[7?Q$\'^"-0ATW0UT73M6"$+>1W5P55"SL?FVG>W$;*!VZ8K;\
M5ZY::U\6-1U*7QM?>%TDL8K/7(8=3M;+^RIX/-$=O%-*C&1IFW,8_E4*%<D$
M@&_^R-X>CT+XL_% '0FT&\D;29;BW>"*)@[VSLQ58R52,G[JY!  R <U[+J/
M@_2+T3W-UHNF73 &65WT^.5VP,DGY22>/K6I@?$GC.:R;2O&O]GB34K4_#.Z
MD2]>:.=KW=?0YC+K#'N*'(S\X.[CCKZ/+8QIX,O_ #_%&JZ7YMM DFA0R:;#
M%=1NK*Y:%[599# ,D[%).T;,L"*YO]IKXBZ7JVN^/XM%TRTL+;2?A7<7IC6V
MA3S6>^B8;Q$Q&-J+\K889((KZ ^&GA?X??%#28KRT\$>'!,EM;W#E]%M>!*F
MY2K*& Z-\N=P[@9&09SOB;Q?K>E_LKZW?:9XEL]1A\,^'W@_MK8MTVN3I  \
M@9CM$?."<%F;=]W'/G_P4^$_ACX-_L]>%?$.B7?A^Q\0ZUX<LY9+75]8FMC=
MR-$CLJ.D@<!C_"5902,;1Q7T=KWA72],^&FL:5;:9IUMI?\ 9UTILXK9$M\&
M-R1Y8&W!/)XKY4^"^K^"_!/P7\%Z=J_PV@O]6UW1[6309=0TRWEDOYWA0NJM
MN)D0$[U/WMN5(!44 =KIFI> /VS;^+0XM.DCT/2F5]9?7KV99[>Y<%$M;>)Y
ML&7[^Z4@J !M!+ CE/\ @C;JD]_\(OB;!-+)+'IOCV]L[?>VYHXDCC55)/)P
M !D\U:^$FG:+X)T[5HF\%V6GZC;>,KR'0[O4$MTFNKH^439&-4<;F/\ RSW#
M .4(*\5?^"-FMSZU\(/B6;FTMK.>#Q[>QR1P]F\N,MN;^(@Y&[OBL*C_ 'L%
M?O\ ,Z*2O1F[=M>VOZGU_7R+^U1HVB>-/^"GOP4\-:_H=KK%CKWAK4XO,>XF
MMYK%D:2421/$ZL&.PJ03@JYXZ5]0^+?'-GX.MW,T=W=SI;R77V:TB\R;RD!+
M.<D*JC&,L0">!DU\Y?%'Q1H=W_P5(^ \MWI-Q>WFL^$=1?2+CS_+_LUVWR%W
M0</F(.F.Q?/:C$.T5K;5?FAX6SF[J^DOR9T/PW_94\!SP0V>M:/>7:ZJ\\MA
M<R:S?#?LE<-;M^^QN15W*?XD![H2?!OVE_A+X9\'?M=?L[QZ#HZV_A7Q5XID
MTZXM+NXDO[;680H#2/'</(-IW$)A1E06S\PKZQL-'C^)_@6W\+AY8;5&DGU*
M[B.)+7]_(T4<9[2,>3Z1Y'\8KQ3]JKXH:EX<_:]_9IT_[-80WS^)IM*U%&LU
M:,1O#L62!CRJNC%E ^Z1CJE/$:4][;?F@P:O5M:^C_)GOP_9?^&BCCX>>!Q]
M-#MO_B*\_P#&W[&7PH@\5WVI:SX TPZ3>1(RS6%JT<=@R)M=7BAQA6 #!PIY
M+9QQ7O55==)&@:A@X/V2;!]/W;5L<QG?#:+0H/AYH:>%_LI\-I8Q+I9MF+0F
MV"@1[">2NW&,UQ_B#_D\7PK_ -BAJG_I5:58_9(0Q_LL_#M6;>1X>LP6QC/[
ML5S'QD\.^(/$G[57A&'PYXE3PM>IX6U)WNFTR/4!(GVFVRFQV '.#NSGCWH
M]JKQ/_@HYJ]SH'[$/Q#OK.9[:[L]/$T$R?>B=9%(8>X-;:_"SXI <_%^V/\
MW)MI_P#'*\J_;<\.?$7X>_LI>-M<U+XCV?B&TTRP\\Z>_A6VMEG8,NS+JY(
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M&0[E)X/K5>BLJE9S5F;4Z*@[H****Q-@HHHH **** "O-->0R?MD^% H)/\
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M]=>_[\Q?_'*/^&__  1_SZZ]_P!^8O\ XY7T/_PR]K?_ $'_  ;_ .$-:_\
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MGTG5M-UN;4533],T^&.&,31--*LTH6'*B-F+#'S?OA10!^.7_!([]C'XO?\
M!*#]N#PI\/\ XE:-X2U7P5\?_ 3:3<W'A33[V>SBUC2E,XDU9I@R?:9X+FZ1
MI,JDI50!Q@^H_P#!&']A/3/@5^W]^TK=S:;XI_L;X5:NO@[X8Q:SYKV7A[1+
MPOJ5U!IYD&-AN)MI922$15SR<_IY10!\ ?\ !Q?\._$_Q0_9%^&&E^$%UB/6
MS\8/"\L-[ING&_FTG$\H^V&+!!6(E6._Y> #UKRO]N?]B_Q_^R#^S_\ %CQS
M#\0_'/QT_:._:'L=-^#VBZO+HL.GP:)9W<[*=D%E'L@CCC>>5IFX#(O*DG/Z
MIT4 ?SP?'G]D#XS?\$__ -C?]JS]G3Q#X6TG7-,^)W@70/&/A9OA[H^HRZ+%
M>Z?J%CI][ !(K.+N:&&"YD!)#%688!P/I3]I']FKXT?#;]N3X)W'Q.\>^+OC
MWI&I?#/QS;>'+G_A#X=*A\&:NVB$$R?8EVR/<0%X5$W.?NY;&/V+HH _#/\
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit102image7.jpg
<TEXT>
begin 644 exhibit102image7.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %' FT# 2(  A$! Q$!_\0
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M'\7;'^V__?;>II:!H?(FH_\ !9?PUI_Q>U3P-%X%\7:IXDT.2X^VV5EY+3I
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M(XR=H"KR3M !.!6?X$N_A[\0(+6_\/+X4U+[%;P0PR6D4#26<4B+<0Q8 W1
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MT:"T/D70O^"S'ASQ#;:?-;>!/$=Q#=/#<W,L&HV$L=E82KIS+<,PEPTBC4X
M]NN9$*L#_"6^S:R[/P1HNG6YBM](TN"(N\A2.TC52SE6=L =6*J2>Y49Z5J4
MA'#^(_BWK&A:Y<VD'PX\;ZM# ^U+RSDTL07 _O)YMXCX_P!Y >.E4O\ A>6O
M?]$G^(O_ ']T?_Y/KT6B@#SK_A>6O?\ 1)_B+_W]T?\ ^3Z/^%Y:]_T2?XB_
M]_='_P#D^O1:* /.O^%Y:]_T2?XB_P#?W1__ )/H_P"%Y:]_T2?XB_\ ?W1_
M_D^O1:* /.O^%Y:]_P!$G^(O_?W1_P#Y/H_X7EKW_1)_B+_W]T?_ .3Z]%HH
M \Z_X7EKW_1)_B+_ -_='_\ D^O)OVS/"?B']K/X0KX8@\!>/_#-Y#?)?VFL
MK!I<][I$Z)(L=S9O'JT+P74;.&24,1PRLCH[*?IZB@#\]/B'^P1KWC3QW=:I
M9Z5\1]%L[KQ4_BR6.WT+P^+Z:Y?["7,EVNI*S$O9L<A0"MPX*D@-78_"3]D:
M/X*Z7J^GZ%\-/&MG8:Y\.+3P!=>5I>A)<EX/M1-\)AJ6?WINY&>(@AG5&W\<
M_;5% ^9GYH:+_P $U/%T_P#PCT_B.3XE:UJ&E2Z6E]+;>&O#UE'?VFFBV2TA
M11JCM$_EV[I(Y=Q()SE0$0#HO!OP.TW]CKXA_#'QEXGLO'-E:^"=#L_"FF6;
M6NE:?;7,EM!?JK0QPZJ0KR0W#O,A217:#S,(<;?T-KS/XS''QL^$'_8<OA_Y
M2+VG=[BNSSS_ (><^"O^@!XL_P"^]-_^3*/^'G/@K_H >+/^^]-_^3*^CZ*0
M'SA_P\Y\%?\ 0 \6?]]Z;_\ )E'_  \Y\%?] #Q9_P!]Z;_\F5X!\$_VA?VN
M?"VK^&;*?PMKGC/2=7EM9-?U7QEH']G3Z3=G<;O3[..QA1C;B-HC%=31L@DC
MD1G<,&3N_#7[5O[4B>+?#]AK7PJT4PW!AGO);'1[X1W4<]M!(\"RM.5M9+1I
M9-[S;EN# 8XU1SD.P['HG_#SGP5_T /%G_?>F_\ R91_P\Y\%?\ 0 \6?]]Z
M;_\ )E>4:G^TA^US9:%#/>?#O0+J\&;B&#1M(O(5+I;12^5<&6:0F-I+@Q?)
MM;=:.P/S[5B\=_M1?M;'5M:T'3? .B6,^EZ9<'^WH_"=_=6D]W!J:HLUO%]J
MS+#-9;B(=PE5QD,RX!+!8]<_X><^"O\ H >+/^^]-_\ DRC_ (><^"O^@!XL
M_P"^]-_^3*\OD_:J_:OUGX?:I=:;\-?"]EK%M-=3PG4O#VJ"%8TM5D6R$*3&
M6683'RQ<IB&;/RHNUC7V)\--=U'Q1\.= U+5[";2M6U#3;>YO;*:(126<[Q*
MTD3('<*58E2 [8Q]X]:0CPO_ (><^"O^@!XL_P"^]-_^3*]=^"_QZ\,_'S0)
MK[P[?QW+63)%?6ID1I].E9 XBE",RA]K*<!B,$$$@UV5>:_!AB?C)\7AG@>(
M++ ]/^)/84 >E4444 %<9XM^*FK>&M?FL[7X?>,]=AB"[;VPDTT6\N5!.T37
M<<G&<'*#D'&1S79T4 >=?\+RU[_HD_Q%_P"_NC__ "?1_P +RU[_ *)/\1?^
M_NC_ /R?7HM% 'G7_"\M>_Z)/\1?^_NC_P#R?1_PO+7O^B3_ !%_[^Z/_P#)
M]>BT4 >=?\+RU[_HD_Q%_P"_NC__ "?1_P +RU[_ *)/\1?^_NC_ /R?7HM%
M 'G7_"\M>_Z)/\1?^_NC_P#R?1_PO+7O^B3_ !%_[^Z/_P#)]>BT4 >"?M%7
MVK_M _!?7?!UU\)O%QM]<B2*3^T[;2;VVPLB/DQIJD3[OE^5DE1T?:ZL&45\
MMZC_ ,$ZO%&I6%M!*/BI=3MJ6E:OJ>JW>BZ!/K&KW5E:6MMYDMX=3$F6^RHZ
MGDJ7?<9,Y'Z/T4 ?%GP!_94C_9Y^.USX\TGX9>-)=4U>QU:UUB5],T);O4I+
MW4GOEF^T#4MZM&K^200P=$C^[MQ7C5G_ ,$Q_&EWX+\.Z;K%[\3;Z\\,6.F:
M'97=KX:\/VFS2M.,KVD.!JK.+A9)I&-P'&X$#RP!S^G%%.[&Y-[GYY7'[,5E
M\"_C1HGQ(UO2/'&CZ/H.O:CJMGI_V/2+&+S;S4;C4<!X=54O,/.EB=BC"6&.
M-6C_ '>3[]_P\Y\%?] #Q9_WWIO_ ,F5W_[2)QKWPN_['6W_ /2.\KU"ETL+
MK<^</^'G/@K_ * 'BS_OO3?_ ),H_P"'G/@K_H >+/\ OO3?_DROH^OSU\(_
M'[]K;P9\09+>S\-ZYXSTK5]?N(]3N?%V@?8K3PPJZA=^1;V'V*%)[BWELHX
M;B19EAD=&+ON9%!VTN>]_P##SGP5_P! #Q9_WWIO_P F4?\ #SGP5_T /%G_
M 'WIO_R97G^M_M5?M/Z+X:65OA9HT]_/JD4L"VVCWTJFT:*1UL74392=WC\L
MWA/D0^:I>,C&Y?#7Q_\ VI=6\1:&GB#P'H=GI&I:E8"?^QM*NH[O3H7>QFE$
MKS321LJQRW4+E44EHRP*[<$"QW__  \Y\%?] #Q9_P!]Z;_\F4?\/.?!7_0
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M^A<;_P &5W_\=KS35/CQ\6O%7PV>UM_!VOZ3XCM(HDNYH],D3$KB\^YO#1R
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M))0051/,CD0;CA260@*2>,9 2<M_PQA\-?\ H7&_\&5W_P#':/\ AC#X:_\
M0N-_X,KO_P".UY_X2^(_Q+\.6OC71O&J^);>]ATVUM_#VH16-O(NH3QPS+/<
M1&SBN7S(T:2MOML1^<JK%Q@^=:E\6/V@8M;TM63Q6-/N-#%QJ4]MX<#2V5_]
MBC>SMTB-J03+="87#*[JB/&#]G(8@'8]S^%W@32OAM^U'KNDZ+:_8]/A\'Z;
M(D7FO+AFO]1+'<Y+=?>O8Z\K\)27$O[66L-=HL=TW@?2#,BG(5_MFH;@/;.:
M]4H$%%%% !1110 445\@?M[_ !3_ &B?AA^T%X9U/X4:)J_B7P1H^C-=:SHU
MK802QZQ=/-)''$9&A:8$8CSY4L?EJYD82JI2@:5SZ_HKXF\?_M.?M7P_"33K
MO1/AYX0_M^;P^TMZZ:-JMPBZ@[:BL30P.T;A$6UM7>&0E\W:JKD88\YJ?[9G
M[4DVL1WD'PRFDMM)UR2VAAB\):G;Q>(;-K;Y4>-V>2VD,T;;)V?R4$Z>8/D8
M%V86/ORBOE']GW]HKXZ)XHN+#QM\/KA_#7A_P-#JDEZ;.X&M:WJHMXII$B5$
M^S<N\D/D964/$&^97 7R[2?VI?VQ?!WPS:PN/AI9ZSXJTES)?ZAK6C2^5<)>
M7$+6_DKITC1NEK%/)'*$+2D6P8@$M2%8^_Z*\%^ OQZ^*?CO]I[Q5X9\5> U
MT+P7IVB65WINK+9W,?F7Q2(W,'G2?N[B/=*WELBQL!"P=,]/>J "BBB@ KR_
M]LDX_9[U3_K^TS_TXVU>H5Y?^V1S^S[J?_7_ *9WQ_S$;:@!9OV-OAO<3,[^
M'6+.Q9C_ &C=\D_]M:;_ ,,8?#7_ *%QO_!E=_\ QVO,O&_B3XF>*$UJ/0?$
M7CC2;K1]>U+;=R^&5BLWTZ.%)(UV/9223YE811O KLPWOB0K@WM"^*_Q$O=$
MU$"T\9VVHOX N;VRM+S13*(M3BDD6)_M0M(U>:5=CB%D5@-N85;<M*^EQ\IW
M_P#PQA\-?^A<;_P97?\ \=H_X8P^&O\ T+C?^#*[_P#CM>7?##X__%A]%L-&
MU?PIK]]?RZG&L>JMI5Q$)M/\]PTKNUO"JNJB-,/#$[#<XC"D/5C3/BU\7HO%
MW@W2)=%U9K0?9VU>4Z/+YEPDDD8>5KG:8(PFZ13$!YGR;CA3FG8?+I<])_X8
MP^&O_0N-_P"#*[_^.T?\,8?#7_H7&_\ !E=__':\LT_]L#X@Z+\9O 7A#Q7H
MVB:#)XJECGFN/[-NC&(WCBQ:C,N8YA)(R"0AE+1D%$ZU]24":L>7?\,8?#7_
M *%QO_!E=_\ QVC_ (8P^&O_ $+C?^#*[_\ CM=O\1GFB\!:Q);RZO#/%:22
M1MI4:27VY5+ 0JZ.ID., ,I&3TKQ3X<^.?B;X-^)^DZ)XVB\0W&BS>&C"NK)
M9V4\5YJN(YV9OLX\U753/$J^2J,+<M@EP* L=I_PQA\-?^A<;_P97?\ \=KY
M@_X*$_#?1OA3KWA?3M L_L-G);3SM&9I)<N74$Y=F/11WQQ6C;_%?X^#6M(6
MYD\;CP_//<IJM[:>'#+=Z?8+YPM98HGT]&FN9)Q"I;RQ^X<LUO&5,E4_^"AE
MUJE\GPYFUR);?6IM!#ZA$H $=P=AE4 $CA]PZFF(^ZZ*^-X/^"ATGA?X0Z1X
MD\:_%7X8>&;N;1M&U75[)/!&JWO]C'4[5KB!9&BOFPA$<N'8 83)VY&>Q\ ?
MM:W'Q1\6V^A:'\7/AG>:M>ZM>:':V[>!=4A-W>6<;2W,<1DOU$@C1&)=24RI
M&[/%(#Z7HKP'X<?'76_BW!')X?\ BS\)[]+B]GT^U/\ PBE[#]OFAW"7[/OU
M)?/5=K_/%N0[&PQVG%[_ (6OKXTJ.^_X7'\$/L4T#W4=Q_8TGE21),('D#?V
MK@HLS+&6S@.P4\G% 'N%%>=CP[\6#_S.'P\_\)"\_P#EG1_PCOQ8_P"AP^'G
M_A'WG_RSH ]$HKSO_A'?BQ_T.'P\_P#"/O/_ )9T?\([\6/^AP^'G_A'WG_R
MSH ]$HKSO_A'?BQ_T.'P\_\ "/O/_EG1_P ([\6/^AP^'G_A'WG_ ,LZ /1*
M*\[_ .$=^+'_ $.'P\_\(^\_^6=9_@WQEXYTK]H.'PGXDU+PGJNG77AZ?5TE
MTS1KBPGCECN88@I,EU,I4K(QZ Y YH ]4KRWX\79L/BW\)YUAFN6AUC4)!#"
M 9)2-'OCM7) W'H,D#/>O4J\G_:)>UC^)?PO-](\-D-4U(W$B2/&T<?]C7VY
M@Z$,I SRI!'8YH Q+?\ ;NT34]:M=+L/#/BB\U;4--M+^TL1]ECFF:X6-UB.
MZ8!"!)R[$1DQR@,2G-KQ)^W%X;\-_!J_\;RZ5K::79:A;V"I<&VM9+CSX(IX
MY5,DH14*3+C>RL2,;<D9XG3_  S^SG8Z9%;V;:C=*UC:W5H+:]UFZN DHMO*
M:V96:03E&M WE'SA&8P^$(KIM5T'X+^%_ 7B-VFU.VTBWUZWM]06SOM5\ZRU
M&"*,1)"L3^;"4B\L8@"J$7!X4X&5;N=-XC_:_P#"&C?#Z'Q!:W$NI17$(FCM
MHU\N8@^>,8? W;K:9<9SE#VYHU']L3P3I?B[5M*FO;E$T.V>YO+QK600!4:5
M'$7R[IRK0NI\H,-PQG.0,/4OA!\$O W@R?5I-/TQ="OHXIMT-S/<6ZQHDY3R
MD5V6-,27!P@52SN3ECFKJ?#/X.V/Q UJV*:8^N,CW&HQR:A/*+))&EE8'+E+
M="QE?8-@RS'&6R7H5[O8Z3P%\?O!?Q'\?-I6AW,EWK+Z?]KF<:;/&(XD=5,4
MLK(%25&E&86(==Y.T<UWU>-_#'X(^ O!?[2&K^*_#OB-?[<\4Z4MS+H\&I1O
M%<VY=<77E EG3=]U^BM++@G> /9*1#.-^,_QHT_X)Z5I5WJ,6^'5=2CTY9'N
MH+6&W+([[Y)9W1%4!#QG<Q( !)KE/$_[7NF> M"\6WWB+1-3T./PMJEMHZM=
M7=F(=1N+G9Y*QRB;9'D21%O.*;!(I-=/\<K+PKK?AVQTOQ:NIW%AJ]ZMI%9V
M1O2;^1D<F*6.U^:2$H'+K(#%M!+C KB=5E^$_B?2?&DM[=ZA8:=X3EDO]?25
MK_2Q8SM+]I-X&(CD,A,64EB8_*H5#M." 5=)_;[\+:UK45G#8W<8EUF'1OM4
M^H6,-JKR*[!_-:?:<[#M09>0,C(K!P:ZOX,?\EE^+_\ V,%E_P"F>PKSOP9X
M5^ =LK>&M%L-3ACCNK-!I$<6L)'."\TENBP'Y9;0,)Y-H5K=26=@,Y/HGP8_
MY++\7_\ L8++_P!,]A3$>ET444@"BBOE"S_;9U2Q^'IUWQ%\1?AQX=N+?08/
M$U_I:>#=3U&YTVPGG\B*1O)O=T@\PA<J@[DJ!0!]7T5\H_"O]O&Q^-C:=_PC
M'QI^%^IKK&I0Z/82#P)JL,=_=RPO,D4+R7RK(?+C8G:2%QAB"0*[+PM\<M=\
M93:DFG_%CX4.-*U5]#GEE\)WL$+7R2&)[>*234E29UE5HR(RV'4J?F&* /?*
M*\6B^(GBB>/<GQ;^##KFZ&5T.4C-K_Q]?\Q7_EC_ ,M/[G\6*W=)L_B=KVEV
MU]8^.?AI>65Y$L]O<0>%+J2*>-@"KHPU,AE((((."#0!Z917G?\ PCOQ8_Z'
M#X>?^$?>?_+.C_A'?BQ_T.'P\_\ "/O/_EG0!Z)17G?_  COQ8_Z'#X>?^$?
M>?\ RSH_X1WXL?\ 0X?#S_PC[S_Y9T >B45YW_PCOQ8_Z'#X>?\ A'WG_P L
MZ/\ A'?BQ_T.'P\_\(^\_P#EG0!Z)17DS>+_ (@>!OBWX+T?7]6\'ZSI?BJX
MN[60:?H=S87%NT5I+.K!WO)E()CVD;1USGBO6: /+OVE6V:U\,#@G;XTMS@=
M3_H=YP/>N<UW]O+0=$N_"UH?#?BA]2\8(5T^Q(M8YS.9Y($@8--MW&2(AF!*
M1[D+L P-=%^TQM.K?#+>2$_X3*#<0<8'V*]SR.1QZ5YCJ6@_LX6^@^'OM$UY
M=VMQ"MYI#"^UB[E=A<7#PR(0[/\ :!.;HP$_O0WF^5T;!U&CO6_;2T)?AAK_
M (I?1==M+30#9+)'>-;6QG-TR(A5VF\M55W*LSLH!1L9&"=C1_VK_!_B'PMH
M>IV=X['7_LXMK61=DP::*"55;G;N"7,)(#'[_&:Y.U\,_!KP]X8\7&W_ +5M
MK2U;2K76+>"[U;[19RIY3V*1PJWFQ3 O$1Y*J^X_-\V:U-#^#_P?B@T/Q-86
M=C-%Y-N-,FCO;B9""(FCD$>\CS&"PEI"N]@$WL0!0-6%T[]N'P3>VD4TDM]:
MQ#38-3NYI;=E@LTDSN3S/NR/&0P98MV"I'7BMWP;^T;X%^('CZRTW2+N6[UV
M]MI2#_95Q&]O'&QW1S.\8\ELJ2(Y"I.TD ]:X[1/AU\#+UC;VD.FS?VOIUK=
M&T-[<NL-K(,PMY1<BW5MVX\)N)+-DY-6O"?P0^'NF?M/0>/=#\3Q1>(->TZ5
M5TVUU2-HM5A#N9) @):1%=V8XR ^#D8Q0-VZ'ME<S\8/B?:_!SX>7WB*\MY;
MJWL6B5HTEBAR9)4C!:25DC107!9G8  $YKIJYKXNWNBV'P_O7\07&JVNE,T4
M4CZ;-=Q7;,\BJBQFT(GW,Y5<1\G..0300CBO!O[8OACQC;>,9TAO8;;P9'%)
M<S>9!,EUYF\(L/ER-N9V3" XWAXV7*N#5?6OVP+:P\&W&LVOA#Q/?16VC:?K
MC1"2RA>2WO%D*+&7G"O*KQ^64SR[J%+#D8?@GX9?!#3[C7])T_2386/AJR2Z
MUC2=3L[R+3H[0F=DS#=KY1@607$@6,;!(&<C< :K:%J7P(\->(M&BTV"]AFG
MTG39-&L;:SU5K.YL[=HYK/[);*IAD\LS))B)"RDLSXPQ!U'H=SH3F7]L+7V*
MLA;P7I1*MU7_ $W4>#7IU>9Z/_R>/XB_[$S2_P#TNU&O3*!!1110 45\R^*O
MVO\ 5/#&JZTVL>.? 7A."#4-9BTW3KCPKJ&JWUS::9)MGF_<7:F0@88A8QUP
M <5S_P /O^"B&B_%/PKJ.N:%\;_A?>Z+I+V<5U?GP#J\-M')=NL=O&)'O55I
M&=E&Q267/S!: /KJBO W^..NP^-=>\/R_%CX46VI^%VB355G\)WL,%C)*BR1
MQ/,VI"(2F-T?R]^_:ZDK@@UL+XU\7L7Q\5?@Z?*U$Z0^- F^2]"[C:G_ (FG
M$P7GR_O8YQ0![)17EWAX_$CQ=H=KJ>D^/_AAJ>FWT8FMKNT\+74T%PAZ,CKJ
M95@?4'%7?^$=^+'_ $.'P\_\(^\_^6= 'HE%>=_\([\6/^AP^'G_ (1]Y_\
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M?_MF^#/B'X*MM7MKHP2SWR:<UG))&[I.TKQ@"2-FB=3Y;L&5R&5>.H%-T_\
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MI/A:.?[?!874^J:=<7MMI<VHBP-SHU];QR211(Y*[Y%'*[<D ]10);F3I/[
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MX,(?_BJS?^&=OA__ -"+X._\$MM_\11_PSM\/_\ H1?!W_@EMO\ XB@DTO\
MA;'A;_H9= _\&$/_ ,51_P +8\+?]#+H'_@PA_\ BJS?^&=OA_\ ]"+X._\
M!+;?_$4?\,[?#_\ Z$7P=_X);;_XB@#2_P"%L>%O^AET#_P80_\ Q5>27GQ#
MMY?VF=4FEFO5\+WND#2UN;?Q1;M8WTKKYC3&+[6'MFB"&)72)6=IF);A*[?Q
MC\"/ FB^$=4O(/!OP^M)K2TEFCGOM&M_LL#*A(>7"@^6,9;!!P#R*^)OA?\
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MZ;$W*O"C:._$/#347+L/VT;I'V-1117,:!1110 4444 %%%% !1110 4444
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M_9!\9_!*#6(_#^A_#VW37-1FU.Y$FLW3'S97:1@&%F&*;G<@.6(W'G%>Q_\
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MW.&4-L(8\9^:OI[_ (7CX@_Z)+\1?^_^B_\ RPH_X7CX@_Z)+\1?^_\ HO\
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M'?L;:_\ !/XL77BI/ WQ&U>XN;/R0D]SHZ&.XDP;F<8U8H?.;<Y4ID%N&PH
M<:]+1:?\-L-PD^Y[O%&L,2HH"HBA551@*!P !3JSM_C#_HEOCO\ \"]#_P#E
MC1O\8?\ 1+?'?_@7H?\ \L:U^LTOYB?9R[%K4['^U-,N;;S[JU^TQ/#YUM)Y
M<\.Y2-T;_P +C.0W8@&O*[;]F[P1X!O/ ]O=:_KD=QHEX8?#<=_JT2S37A$L
MC["(UDFF:-IM_)W(SE@3\U>E;_&'_1+?'?\ X%Z'_P#+&O-_B'^SWXQ\;_'/
MPCX]A\)_%"PO_"#'R-/>3PY<Z?(K+(CD*U^)(Y&61LNLG.V/(PF#+Q%*Z=UT
M'R3ML97ASPE\(?#WC.^>'QG:7/B2_O;NREDN-?A>X6]F@2&8K& $6X$*! ^S
M< 7!)+MG8^"7PM\!?"_XF>!AX%DM3;ZQXL@OIHK:]6XABC.B:LL)C"\*C .P
MZEB6.>@'EFC?\$XO$6E>*M:U)O"7CF>W\16]M9WNFR0Z1):0V]I/+<VEM;!]
M;9X8!/,9)4W$R$ *T8KT3]F']EWQ3^SUXV\*V%MX3^(,OA\>+UU6274I]*:/
M28O[*O[=Y',6H32R,TL\>2J=-HVY!+<LZT'2:TO;^OZ_X<T4)*6FUS[=HHHK
MRCL"BBB@ HHHH **** "BBB@ HHHH _*CQM\%O&_Q7^%_A)/#&F>)[/3K_P5
MX.\V]A36IXKJ>RTRZ&4CBM9(!$3>0 F-MW[AW0K,(W7N?@)\+_&/PG_:"\.>
M*]2T3QGJ$-CK\U[JDL%IXC9+]9+74()=0-M):%3/-]KM,Q,?D6P&'RPKZ5\!
MMKJ?\$R?A^?#5WJ%EK*^"M",$EC9O=3N!;6V^-5C!<;UW(716:,-O .W%4M<
M^*?QE\3^![^TT_PGJWAS7-.A)6=[=+K9(R7C1A27"76U%M-V JF20C@Y"N[L
M5N?+7PK\/_&[X1_'BVM=!_X6)IW@-=7N-?W7&DZI=-/YMS$\\6HM_9HDOI)(
MS/'$5$31(8FD>5XQG+T_P9^U4W@Z?3K[XD?%%9)75+>YL])U/[58VC7#33Q;
MGTS$UP6,?E3NP"0QM$1\Y-?:OACXJ_$;4E^(\7B/PUK$>CZ)IBR:-+I-J\>K
MZOF'(:%701"9_P"YN)C<A2!BO*-'UGXT+H<:ZA<?%.X@6)DU6:VTR&.Y6+8I
ML#:*T89IO-+)<MMR54LRH"M MSZ[\!:A+JO@C2+BX>\EN)K.)I7N[1K2>1]@
MW,\3*IC8G)*E1C.,"M:LSP4VIMX-TDZT(UUDV4)OQ'C:+C8OF8QQC?GIQ6G2
M$%%%% !117E&MZ?J]O\ M#7EP^H^,8/#U]I7]G);PN)+2:\E5G\R%0A:(PQ6
M[$R%@I>Y P2!0!ZO7E]]_P GHZ9_V)5Y_P"EUK7S_P#:?CIX5?6K&2/QO?6=
MUIT=SIMRTGVBXTJ&>>.1HI3'%B>:,%XB4)F15+*K#!/KGPLFU>X^//@=]?6Y
M77&^&SG4!<A!-Y_VJS\S>$ 4-NSG  ]J >A[I1110 4444 %%%% !1110 44
M44 %%%% !1110 5^:7B[X=>)_B'\.;*#0=+\5)::S\.],T.74+*WU6='EBU.
M"\81QQVLMM_J%E3<2RNS[)49-PK]+:\5_9WN+BU_81T"2TDU.&Z3PT3"^G0+
M/=H^QMIBC96#/G&T%2"<<&B]M1H^'/V;_P!GCXB_!W6O!.I:]IWBO6M5T#6=
M/NM5N[6W\3"+54AFOBUR\4UHVZ2.TN;>T6-B01;%@RC8!M^,M$^,WA#QYKZ?
M#X?$C2-.\6^,KO74O3I&IO=6RM%.ZO>S/II,UH+AH/+M%0R"-6A,^S81]3^!
MOB;\4]=\9>#+2YT[7M/T)(]+;5;FXT',UQYEE,)XIRQ4QN+I4+/$K*BE0<9.
M<JSN_C-\.O#&GZE=+J^IW-]-J4E]LC;5'TZ*2YM1;N+4>46D2,2[8HR5 9VR
M<4T^G]=!KN?-NC:=^T['_P )?]L\;^/_ /B:6]^?#PBT35RFB3W!5I/,#::6
MG0C>ML2X^R\,5?.U?O3]EJVUFQ_9Z\)6_B#4M<UC6K;3TAN[W6;8V^H7#IE=
MTR&.,[^!EMB[OO=\UYUIOQ3^-6N^/M/TYO#%EI%K/+:)J4TE@\T&G1&*-Y)8
M9O-43L[M,A3 \GRT)W9Y^@Z'H2%%%%( HHJOJLYM=+N9 MPQCB9@L"[I6P"<
M(#P6]!ZT 6**^2O@-XS^)^F?$;2=0UMOB#<>%IK>=KBTUC362YTZ*20I;VS@
M0@7%T)6C)F1\",,"I4>8:6C>)/BSJNJ:*LNG?$V7PO=KJ,QAE/V+6[,EW*QR
MRB+RW*1[#'N*JS2E%9S'F@=CW/XR?\EZ^$'_ &%=1_\ 37<UZ?7A*>'M8\*>
M)?@%8>(=2N]7UR"YOOMUU<NKR/,=+N68%E50P4G:#@9"@GFO=J!!1110 444
M4 %%%% !1110 4444 %%%% !1110!PNO?M/_  W\+ZW=:;J/CWP=8ZA8R&&Y
MMI]8MTEMW'5'4ME6'H>:J?\ #7GPJ_Z*/X'_ /!W;_\ Q=?(/[0_QO\ &7PJ
M@O[7P1XCO]+O;_7?&*SVEM]A\H2O*ZVES*9\.I64$*$.#\_RLP45YM\,/VI_
MCM;_  RU^Z\2>/=6AUVWB"16\5WHER+A8M2M/L9M !O/G6/VTW/F 2)^Z!$<
ME-*X['Z#_P##7GPJ_P"BC^!__!W;_P#Q='_#7GPJ_P"BC^!__!W;_P#Q=?&7
M[4'[??Q$^#_[16OGP5XGT'Q+X>\2R6]MH3W/V:YLM'D6Q>0VB6Z7,3W+S31%
MC=>>%A#NCQG;&65?^"D'QX-EKTS:/\.8I+?5+J32[8W=K,]S$MHS06#E;\*$
M>X4@WZEHPI0>7EN%TN%C[,_X:\^%7_11_ __ (.[?_XNC_AKSX5?]%'\#_\
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MN7MI'.9=/!FGBD,;W4;+;'_6CG?PS!N:[I/V9[J- J_$WXG(JC 5=0M0%'H
M+?BFR#U*BO+O^&:;O_HI_P 4/_!E;?\ R/1_PS3=_P#13_BA_P"#*V_^1Z0'
MJ-0ZA="RL)IB\48BC9R\K;8UP,Y8]AZFO-/^&:;O_HI_Q0_\&5M_\CU1\4_
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MR<[CDL37U[7G8J$85+1.BC)N-V%%%%<QJ%%%% !1110 4444 %%%% !1110
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M02 0>A(SUJX?C5J><?\ "/6^<X_Y"7_VJCZM5_E%[6'<7_A&OBO_ -#G\/\
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M8X(-3\3V$/\ 9LZZ"D$<-G;RW)B%LMWY5Q*TL,5P'$JJ9T<*MC0=4_:BT#P
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M^Q%XXF\(7EO_ ,+$N+?4;F>)8X[;4]0^RVUF9I9+FW5YFE<M(K6ZB4H3^Y8
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M9KY)UGXX>#](7PI%_P *=^#4LOBK4K71+>X%O (#+=&Z:VU#!M]PL3':DG<
M^Z9%XP2?L#X"ZOI_B'X,>&=1TK1[/0+#4=/BNXM/M(U2"U\P;RJ!0J[<L2"
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M\&9M7U;5[?7/$$FIZSXI6$O\0M4T@Q/8,3:VD-M#((RC ;<KM(.T ,6R//\
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M_P#\&E]_\CT?;OC1_P! SX7_ /@TOO\ Y'H]M-=0]G'L9G_#+FN_]%2\3_\
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M<$$'@T7N#/7Z***!!1110 4444 %%%% !1110 4444 %%%% !7SG\*O$SO\
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M[/Q8GQ#L=*\5^*?$$K:W8^*M2T_3(;B.]9(K&&*&01O=R<OY7[MF17=?,*L
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M)9("V(T8([X%YG 9@OU(%)82HU=+\4+VL;V/2O\ AF'0O^@Y\1O_  N-7_\
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M67PMT6"SL($MK>(>+P1'&BA57)ML\  <U:_X6-\4O^B9:-_X5R__ "-71_\
M"[/#W_/;4_\ P4W?_P :I1\:O#Y_Y;:E_P""J[_^-4N2787,CF_^%C?%+_HF
M6C?^%<O_ ,C4?\+&^*7_ $3+1O\ PKE_^1JZ3_A=?A[_ )[:E_X*;O\ ^-4G
M_"[/#W_/;4O_  4W?_QJCDEV#F1S%W\4?B;I]I+//\-M"A@A0R222>,$5(U
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MOQ',24VLK $J69217,W_ /P3?O;Z1,> UM8A:Q64L-M\1)(X[F**...)9/\
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M15& H P !V %.KG?^%IZ5_SY^,__  BM;_\ D.C_ (6GI7_/GXS_ /"*UO\
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M:IHVI1,9[BXMHT \V5%1-VU=RA>7(KGJ58.FUY&B@U)6[GWG1117D':%%%%
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M'S,ORDYQQ7/B+>P=G?\ X?<NG\:OW?Y;?Y'U91117C'<%%%% !1110 4444
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MY\V[2>?# '$F0 .![/\ \.W/V=O^B"?!;_PB-,_^,T?\.W/V=O\ H@GP6_\
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M?_ Z+_XJC_A97AW_ *#^B_\ @=%_\57YV_L8Z-\!_P!IKQGIWA_6/V=_V?\
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M_P!%.\?_ /@-HG_ROH_X93N_^BG>/_\ P&T3_P"5]<-_PF/[4O\ SX_L]?\
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit102image8.jpg
<TEXT>
begin 644 exhibit102image8.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &/ F\# 2(  A$! Q$!_\0
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MMMA:"*3<64*WWF'S'(!&,CKMKT!=*BT/4+.6TC\B^#[X3+(F+?)^3*]6PO\
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MA>SUAH[@WT:IIFJ32%2)YXU(B<<YR\*C.0.8FZUT2(/%'@H)$K&_\,$$$?\
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M5>;_  GN]0\*.-16VD_X1YKB*&]NG4_9H2V54[\'!_/I79^++N'6I+U]/N=
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M'1I*O47-+K?9/KIMIW$EGEN$&6SM ZGH .!CMQQ52ZF2U(6>3YI#A5ZNY]%
MY/X4WPCXGLOB/K,VG^';RUN/(?R)IHB)G+XSA%7C./[WY5Q_B;]K7X;_  -^
M*3Z#>6VO:K-;RK#J6I6RQR0VS97*M,S?/@$EQ&"%Y'48J<)E-2H_>^[K_DOZ
MT-<PXFP]%?N_>\^G_!^7WGKWPQ^$6H_%CQ*-+M[FQL)_*-R8'N8OM\L(ZE(F
M.0.V=K8SDU\Z^&/VQ+_3OC%?:7J'@M=-\.&^GTJVG,I^V+="0I#YSR';L9P%
MY^[O7D]*\"^*'B[6/A7^TUXE\3VT]]#XKM-9GNHI(YVD!MRV1 TG#-"\?R8'
M!3'K6CXQ\ 3>,M=MK73-3:W\-ZM:C4M-#RMM,$N6&0!EY4?Y<'HR$]J^HP^4
M4H+E/S_&\0XK$N[>G;I]WZ[GW/IOB_X&_"'0_"?_  IKX4_$_4OB'_8EOXN\
M5_$.Y2XEM8(90#>V=[G=YD/$D?RJJ1R!"I)4U!\=/VZY?$NDG0+70H].TB&\
MB3Q"OFKJ+ZC!*A":="$ #3708, ,^6A5F*D<=]_P1)_:GU+P=H?COP7?Q:7=
M3>-]%FGM-+UN\%I:2ZG;L8;Z-Y9"%CCV/]H*]2LS8SLQ7SS\?=$\&^#OBQ?Z
M!H?C7PPFE^% ;-]6TN]>>&&*6)99(M-*J6GG\QI+4SD'9'$F,<5U>R3:TU1X
MW/*UF=#_ ,$^_@=X+\0?%CXE>$O'7AL:X=(\-S/IDUO;I<ZA-;!P5B0 \L4D
M."IX>/&:Z#PSXIM/AA;C0_&6K:;IOB3PI;C3=3M=5F6%X\#,3N.KN82F=N><
MCK7S?!\<M7\#>*_#^M> ]6U;PKK'ANPFTZVU.PQ92I [';"BKEMBJS#<Y+MO
M)(& *X;Q%/<^+;RZO]0N;G4-1O6>>>[NI3//<2MRSN[99GSU)/-/$T(XF"A4
MZ%T*CHS<EU/;/BE^TYH.M^(_/LX[[7IC"T:7+0B&U(4D JO!E .!N;' QWJC
M^S+\1O&?CO\ :0\,65G')JT5W(UO>644")#';-]^=@!A1%\K;C_= JK\0O%W
MB3]I?PSI&M77AVRT?0O"$4>EO=V>/*,YBC#([86.#S=H=1)M0M\N_M7;_L0_
M&;PO^S9XWU&775EM;/5K1K-]2>,_:+=D;S!'+;D>;"2"%(3?&_RL&XKA644*
M+<Z:NWU9?UR<G>1QG[<VC^+_ -EGX^Z9XLT^0V/AF"[S-9606.TEE="KR.J@
M"1WC+?,^2I  X-?16@:I;ZMHMG=3Q07-O?6Z2^2Z++$X8!@>ZD'AA^!JQ^T)
MKG@[]L/X0ZKI/AW6=,UJ*[1K8RI&Y.GW!&Z(LI4,O((SQC\#7BG[&>KWFG?#
MT>&=?U'2;KQ%H7^C3V%O<I-+8QJ2(!,02!(8PPQDG$7.#Q7EYOAO:8;G^U3_
M "?^1]APYBU3K^S?PU/_ $I?YK\3IM*FU#2]5;[3=6[H\P,D(5?EW!V.S.1A
M5!S@X)8>M<9XT^$%M\0]=75]/U:[TO4%'E3*TA=8HD^^AW<!B>@'&><5U/B6
M_>ZG31H[6WMHKF'S;MG<DJY?='%MSD=55L8 P,\ USFJ:H^AZ4^E3S6MHP*F
M9AEOW8^9H]P.&,><;CP23[5WM=3YN^AEZ/\  +PPWBFS\22Z5+'+:,+B5'D)
MM5D'W'=7)R>C*@...>!7H]G.GBRW@-E=M</?R$/*K[P%/0XX^F<8YKD-0\<-
M8Z*INU;!(=HMFXH&^XC _P"Q@GWKN/AQI@_LNSF&ZVGN9,HVP,RKP5^;'W0!
M]WZBHY4M25HCOM%\#2QZ?!([+!;6L#*BMSO/.&/;W^M8_P 1=='PS\ 7>J+;
MS:CYW[I)(0N^!"/]80>N,$],#O7H3V*:A;HA&9<'?\Q(8'J/3I_6O#/VY_%U
MKHO@BQTA;J6*XOI&00P/A60#!,A'W0-XX_BZ5ESIO4GFOHCX%^*'BE]9UV>6
MZG,C7UQ+<3(6.2Q;&X]LGD_C7M/P&L8/'=GI[6LFV2V*),TB;S;/@#>1W'0^
MVTUXKXM^'\UIXM:&*6>[$DK(QV?< &[<,=L?SKZQ_9)\"0?"SP?>:UJV@F:U
MO=/F:ZF>["0Z?'%$)87*XW,\DN< 8(P >M>A7J4JM**7R,H73U.9\2>+;"^N
M%TW4[1=2T^SC$,<]E+LO+.4,P>5&.4D5B<E&&#QAEZUDW7@>4Z?)?Z5-_;6F
M69$KWEG&T<]E_=-Q#]^$Y_B!*9Z-3!XEM/$0M_[?AD620 G6+2,-<)D#F>,8
M6X'J1MD_VCTJEK=E_8NJO!%?V%]^YREY82-Y4T3]5/ 8'CYD<9!ZBMZ5-1BD
MC"3;=QFKZC=>(+LW5].;BZE"HTLB@O(!P-Q'WF]6/S'')JC+&1<*J':>I8]Z
MDB1EQD9YP/:I#'MC8\XQ@@\XSTKH(?D)! D9!V]0><\BII550OS8'/?J3[U'
MM$<>?FZ?>/0#%4]9UB#1-'>YF($:D+@@@9/_ ->D(L75C#)&H*Q%?5EYJ,YB
M@ P0HZ!1VKS.X^/%VNJM+':1-;[@'A#;MP P?F_7BN_\/:^FOVHDB1R" 2R#
M,8! .,]OI5N+6I5BMJ37*7A6(C9&NXC'WOI6A!.MU#&?NLPSANF?2K#QK-*&
M(4MDD=_K2.2@V@?+N&1C(H%Z#D&Q/FYX_E44ET8YM^XXVXQWX[U8O+&6VTZT
MNI5VP7SRK!*"#O:)@)%]B-RG![,#4?B.VMKKPM97]FC0R6MR=/U-<G$C/NDM
MYQD\;E$D9 [QKZT(1L^ M<GT98GECEMX=53S;:5@ ) '*DY_NDHP/?*X..:[
M6YT"QGE2Y%R\#3 [MDH!WD>@[#\.*\@.IWFH_#S4--BF^?PX[:G:Q 9+VTC!
M;E0?]A_+EQZ-*:V?@=\3=0D\4V6E7$43'4";6"Y8;?)E;B,'L=S83)[L*\7-
MLMG4_?T=^J.BA-+W9'0:QHY:Z@(^T1ZG'\T3P(VY'7##U((.#U["JOQ#TL7^
MH6NK);00VOB")KEK>-,+;7(.VYB _NA_G _NRK6U?W>L>.;.>/1;&XCO+!XY
M+BVGF59)(6!5SN?:%,<F-PSG:W?%:G@[P)&-+?3M8E;5WDNX[V*VLF=8X9E#
M(W[T$.P="%8*J_<7GC-5E-.<*?-4T3%6UERHYD:)>>.[?2IK&&YU778 ND75
ME;Q&2XE1$'V6YVC^$Q@QLQP 802?FKT.S^"F@^$/ ]I-X_U:TMFTVXFE2WLY
MC#LCE"DV\MP?O 2*7 B7(,C@.0:SOB5\7O#?PI\%ZE917=KI-R]M-&NG:8O[
MPNRD R,I^4YZEFW>U?/_ (O\>6OQPNY?%.OZG-':IB"'2]Y$,(10.!G<Q;&?
M<UZ4ZK2TV'&FEON>XWO[=WA3X>Q#3? GANZU+RQADL81;0R$=-\C9=C[MDU?
ML/V_=%M/#2S^)?#-_!XB1W6;2K,CR@A.4;[0_ R,?PG!!KYLT+7KCQW>'3-$
M-KH-G#'YQD\O?<2*#C*CH,51^(W@]O#%Q;/]HN;R*]0J9KAOG:5?O GT(((^
MAK>AEU6K#VTXVC^(2QG*^2)UWC7]O'Q_XH\2"&XO(?#7AY91%<:9I.8UFCZ-
MYDQ)DDX.1R![5V^E^ KV\TZ*\E^S:5I%R<1ZAJ,GD6[CKE."\IQ_SS5NM?.5
MW?RQV>[R86FW>0\KH'(&/E(!! R.,XSQ7K'P*U#5?BW$]G]GU'6M6T6-%>5F
M,ABMCPI>1CMC1<8R2%&*UJ4HQ5XHSE/FU.@FC5+N7RI#-%O*1RE"AE ^ZVT\
MKGK@\^M-@4@]!P,M[FM#5])MM,C41:I;7E^[D216B&2WMT]Y\A78GL@( _B[
M5GLCNV=RK\O)K#T)'!Q&NTXZ]!TI\^!R3E2!E>]0%&!SGJ>/>I%?#-NX!.T9
M_I0'4Q/'7C8^![&VF$0F6Y<J 3C  //YU3^'GQ+'BZXGMIR(9>6A"XP5_NGN
M6].*H_%_0+W7[S2X[""2XE$<N1'R4R1T';/3/O6+\)O!%]8>-K:XNK5[)HHF
M<B4'Y2<C!^O^%.\;6OJ!Z@80L8'SY'([U))']G(\Q)8F:))%5XRN]&&58#T/
M8UHZQ96T/AK3=2MFEPSR6.H+(=WDW()=2I[+)$00/6-Q3]1-UXC^'@N-T;7?
MA)1;1M)]Z6PF<E 1W6&8L">PN%'05C;4S(=8T^U2QTXP3_:H-7L1."1S%*"4
MGAR.,JZG'?:R'O5_QLQUNRTW76#23W:?V=J9X_X^XD&R3 _YZPA3GNT<E<+\
M,-'N_$-]/HAED\NR:;5;*$'#-.J?OXE/??$F<9Y,([FHO"/QEGUCQ_JGA]],
M:/PM>R+I]SJ)!86=T'_T6X9N%1?,^4Y/^KE<FM8)W''5Z'9:VSZM\,K:8,JZ
MCX3NHHW/5KBPEE^0^_DRL4]EG7^[7-V'P07Q-;:J]Q$R1Q3_ &N!]^%0, C,
MRA?NG<!GN<'M7:-X;TK0)KW3_%6L7%O&^;.^M=! N;F%#@3(TW$:D#</EWY8
M#/ S5QQ<^%OB)<>'XYD9(]T2W,B><IA/-M+(=N"KQLC948^?./3/&.I&GS4M
MRXV;U(_A?\';#P-K>H:!K%Y%I=AXAC2VBACB,MQ!=$*]O*&)VHGFX&]F^[(_
M!J3P]\0_^%>>)DN=.TN32;6#?:ZC"91/J%W =T=Q$]P5&QBI;'E*@#*IYQ2?
M$J"*[FMTCFBO8]2M4O8[N-_DD0@HR@8&"DBNI]-@K+\2W,^M26NNM(TCZN&A
MOL)M$=Y$ 'R,8_>1E)!CJ6?IBKP;G*DI35F.22=D17T$_@3Q=BSOA/=:;=I<
MVEX#N$X&)(9">^Y2I.?4BE\8:9:_VD\]J#]@U=/MT"C@1AR=\(]/+D#I]%%6
M+^ ^)_!UM=[B;KP\4L+C( +VSLS02>^QM\1/8-'59]4B;PE_9TT4CW,-V+JT
MF5AMB1QMFC8=PVV-AZ%3_>-=70DTO%]T/$6F:?XC#223ZFS6>JL>2-0B4%I#
M_P!=HMDGNPE]*SK[4[34?"VG6Y5AJ.FR2P1OC*SVDF9 C'/!CEW[1CE93S\H
M%5%#B)X>5C=ED*K)A25!P2.F0"?S-0SGSY,.N<<[O[WO5+R$.T[4KJP3-O>W
MT&!C]U.R +],\CVI+S5KK4K989YWD@A&$ & /TY-1RA2V3N/8C(Q2II<E\PR
MRA<9QCK6,J-+XFE<395%PJE5?.T\@'OG./QIT+O.V[Y%QG.1R/I7F_C'Q<UI
MJ3PI<+,4D/[P<!@...Y^OL:Z[X7_ ! _X22UDM=0DC^UQ<1M@+YB@=./3\^:
MT\POIH=!'9%4P!EL_-D^E<]X\^&-WXUM?/LH_.N].A:8J6X2%>7;/MU/M7>^
M'M"_X237K?3('ABGO4?R?,Z/*J,ZQ CHSE=@/]YE]:ZJZ_9;FT+P1IVK7'CE
MO$GCOQ9IL.OZ?X$T+39;M-&T-CYJWFH7"_)&2BE@F#@#)*XK#$5'3IN<=T-)
M2=F?.G@3]F?Q5\6_%,6F:5##;6ZE3)?73;($1B!N'<C<V.E?6_P=_P"":/@/
MX<C[5XI,OC+6/E.R5FALXB.NV,$%AG^\3_2N&^%OBK3="UZWUZPDT'Q-HHE\
MO5["VG8O+$)U#P/&I#!MVTHRX^<*1Q7U]J5G'IFH%/M0NHYE2:TN5&3>6\BA
MX)%4<DO&RD@#.<CJ*^'Q6>YA5A9+DUL[)W_']+'V7#> P-2<O;KFDM5=Z6ZZ
M=?F95[X$\.>+/#Y\+:QIEI!X3O4-E<VUO L:6\;\>8BC@.G# _[-?F-XS\/7
MWPN^+_BCP;XO*37GAK4)-&%H VT",XC<2!@2KJ493@DJP/%?=WQL_;:\!?!9
MI+*^O)M2UB,$?V?I^RYNU.,X<!A'#_VU<,/[AKXE^-?Q.UG]LSX]+XDMO#AT
MZZN+*WTRV@M"9[FX2!2D<DCA1YTVTA2R(!A%&.,UU93A\5&E)5KI/57WOU?<
MGB6OA*U2'U5WDM';:W3^D=-X5L[?3;8V,\=O)9Q.Q,[8(0$<#?G) S7D_B_Q
M!;V?Q,N=<TEBUG%=8C=P1YQ"@/\ 7=AN.V:^G?@Y_P $Z-?\0);77Q'UF+3[
M-&,O]E6C^;<RMQRS#"(<=LMCTKZ8T3]EGX>:+HMUI=IX:L/L^H6OV.>:Y'VB
M=X\?WVZ<_, H S6=#,Z&"K.;ESMZ:;?><^&X;QN(C>24%Y[_ '?YGP[=^)K"
MQTQ-0FNHEM)HQ)$\C ;U(R,#J3CTJ_\ #J*Y^*^CW^H:1 8],TG+7U[=RK;V
MUG&,'>[,<X/]U0S>@KRWXD?#.\^&GQ'UKPYJ"1?VGHTLUNLT[Y10/FC=5/RA
M60@C.?O"MCX,?%'3?ASXZN3?P'7++6+>?37C>4PV\1FV!7R/F(5@,A<9!(S7
MVZY904XO0^9J4Y0;B]&CZ4T?X*6^EZ9J#V%L_BKQ%IJ7SQF1FM-)M9[0V_S=
M5>13YV07>(?+RM=Y'\6M*UKXJ2M+J^A6^K0ZW_:5A?Z<C?8)@GRQP32X"M(R
MG;YB@K@ $GK7B_B[QUJ_C-I4U"XC-F9C,-/MHA!91R'DL(AP6_VFW'WK'<(B
M[<KSV%<]:E&I'EEL*C5G3DI1W1]/>+OAT?"MIJWCR_?;;Z0MS<:5:+,8C/'*
M4D\ER#CY9@R@GG:#P<U\-?&?X^>*/BQJL-G=QPV-@]PUQ;Z/81L8@SG."I)W
MX[#ISTKVV/QXWC?PS9>'/$-Y+;V]CN33=1<NXL6/195&=\?/# %T[9&17-:A
M\-TF\607%S'#'-;6_D730N)&<@D;T"_*$90-K G(YSFOG9/ZC=U->Q[>-S"6
M+2C&Z757T;]#R73]*\374MRT/]HZ/9P#S;:.PG>!8F3.V7&[+LISG.?RXKI?
MB7IZ_$&31_$]LUNL7BZ)_MT2I@0:A%\MW"%Z*&?]Z!CI*,5ZYHNFI:LD-N&D
MEW+'#+=$,,J"JJIXVI_>)/Y<UR^H>'D\)W/B+29U*6=]-;:U8&-0WV?44RD@
M!'\+ID,1T9%]*[^'<^A6Q7+7CHM=.JZGDXG#N$+Q)_A=+X:\3VVB:QXYTJZU
M2;P_9W/A6^2TD$+F<1%M+NY6.0T8'R.#C<(NO-/\(Q#P;X>M+:*\1K_PM?O=
M:/-#N13%."985;''ERG>I/&'?%4(IY+:&Z@6;]S>JJW$?\,H5@XR/4$ @]?S
MJ3S)"OR#=V /&1Z5[=9P=1NE\-]+]CF6VNX6WB:Y\2^'O+O$!2ZF2\EBD <Q
MSH'0MN]<,P/]["YZ559[>R&TR1QX..6 QD?ITJ.%_L%O<;CAK65_F(SC(#+[
M?Q=:\M\5>++B\NB[2"616+Q$#!P2<!AGD '@?4UERMLKH>I$"3Y%)V.N<YST
MJ2.VQ-PQ/'! ^[TSFO-?AOXROM0U@PO(+MV.]8\@/(JJ<H.@!X)/TKTN$I+;
M/@!QG( /:AZ#.T^#$.K^(M;G\&67B=?#>F^+\V^H-/'YD-T(@[I&5Z;F^=02
M1][!["N$^,.K:;\'?$&KVT][_:HT^Z-I:RQ.&>_^4,G&3@A2 PS\I!%3?8PZ
MG<JD9QM8=*W_ (5:?X$D\:S6_P 09UT;2;K3I[6UU@69NSH,S8*W"PJ"S'<
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MB9OO@X*EB.!P<$>U>B>%=$GOK;3[_4)/[*AN;/RWO;N)]TQ#C;M11N<Y)&0
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M!YJ#Q7X2E3PS<R(//5R)$!(RX!#%RJGY"O/S#[P./>L(:'I?BJX3^P9VT;5
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MQ+-KWPSN].U2+[/KW@:YD:^>1?+EN-/G8;'F#<[X9OW9)YVS)_=K2C_;KM_
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MBW#A8K?VCC7Y(Q[**B\2?!?Q%X6^#EWXOUA;'0K2TN8K:V@U:Y6SN-2)^_\
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M]GG_ ()!>$/AQ:P7WQ"NSXNU+8!_9]E*\%BC9R?,<8DEZ8P-B_6OI'QQ\5O
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M2-TBG< \[%(V'(.X-D'.*^;/AAXJ;1O$.U= @\2:A,0]J%C+SP3X \Q!@]<
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M5C':C'3OT^_^F?,?P^^'>N_$W6OL&AZ5=:I,,,Z11[E1?5VZ*/J17T[\)_\
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M^#];=X;[0KN:QNG13_I$8XW@#JCKM<8ZAA7[E:A;K+;'(48Y.>-I]_6OB/\
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ML$:&PCN0;2[=1LA"MD9V'&<E6[ YS7PUKEOIWA341&+HW=S(J+.JGY?,(&Y
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M1VMG'I\4B3&.$J"8\EW5C]X8(53P>N>:\8\03?$'Q3XLGU^.PLGCOIUNGMW
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MD,IC)15R,<Y8'=TK]._A'\4=$^%?P)\,^';.^E\4:]HL]KX<LK35+OR]0O\
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MY\_#C]OW]L'7M)CG\4CP_P"%KB78PM1%9W#6ZN=J"9_*$:NSD*%#'D\TJ_\
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MU]K3Y9+D>MC=6A\1SG_!-']JCQ%\=/VD?'UCXK;4/$P\0>'UDNM1EME2SL3
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MZ\8Z:EQIDSV9O(I(!$[KC:RJ+AQ&_P!XX&TY(Z5UU(K>Y27<VO$WC_PE\0O
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MOX>?\''/P]^*]E<W>@>"/$=_8V<J03WAG\JVCE<X2/S7C"EV/10<^U>,:MX
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M&]8 E?,7'F1.3QN7<G3*KR:\J\"Z-J<GBRVN-3CN_M883!V.Z&YC)/*R#*L
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MZ\<-W(H2"YG*[G95XRJ)@#WQFOGS7_B%<>,+C^U+C79M3FNF_P!8;DOOXR
M",8'0 < 5QW[5GQ6\7_&A=!O?$T1GT3PU/)H]E>6D9C$TF%<R.-Q&]E7(/3"
MGWKRW2]672=8RDT_]G0WPO!)MV,2HP&(QQP<'CFNN66W@K/;^OO!RN_(_0O]
MCGXOO8MHU_),EQ+HMP+2]$QWK=6K@HZN.ZO"SH<]<&OJOP'I\/A-;GPM;7L]
M]%X82!;&[8[A?Z;<*SV-ROKF(&-CCAX6%?FK^S5\4K6/QK;2)-$MKK3FR96(
M1W?/RG;U/S$=.S&OMGP1XVEM-(T?7Y'DW> )?[*U<QJ6=O#]]*H2=_5;*^*G
MH=L=TW05Y.25'A<;/!3T4O>CZ]4?I7%T/[=X9PF?PUJX?]Q6[M+6G)^JT;ZM
MVZ'N&F7%QX?UB.[AD$MS;L)%9P",9X!'/'8CN*^5O@C>G]E+]O'Q%\.88'TW
MP-\293XA\.C.$LY]KL;2/(PV=KPX&#@0GM7U3J\#:==B(@/L8A]K;C@CM^.#
M]*\K_:+^'47Q \,6\EX)Y[?0YC<W*P2%;FW3@_:K9QS'<V[!)D;H561""'-?
M90=C\;5WH?6_AW6CKVEQ31E)-J^7)M.]MP Z*,* 1S7Y_P#_  6Y^"#VNJ>'
M/B-I3SVUU?E-.O+J-COL=0@ >RGWCA2ZJ4Z]8E[UZ5^Q/_P4 L/%'Q&M_AWX
MK-S8>,8E-G< V^VWUEHES]IA/9I%(D$>/XFVDJ17H'[>?VGXX?#77OASHJWU
MLFL:#<7-I/\ 9E:"XO[:6*2%5<@[3SCC'>M*?-"JK$.+3T/!OA;\1M'_ &NO
M"UI-=[1;_%[2+GP[XEMH_DFL]:MH@_G[>F<#<&Y.1%ZUX!<?\%%?BW^SM/J/
MPXO;/PQ:>*/ 4US86GB-[<RZGI$DBA)Y(#GRF65<2#<C;2V1@UYC^PI\'/C7
MXA^+=I=_#6UE2QT[5%U&XU+7':WTFVGCPL@<M\SDA2A6,%FQCZ?6GQC_ &?_
M (0^"?B?<?$W]H/Q%H&N>(-5@1O[.M(S9Z7F)-B*EH&:>Y.,#?*W/&0,5U.G
M&1LO=EJ>4_L-^)?$'[8'AWXE>#O$VNZ_JZ:M/;:\OBFY#WDEM=1,J?9V=N"K
M@(0@. $/ Q5?]EW0(?CA\#O%O@WPI=G3_%W@&\N=>TK2&L;74#K<TK>7-<"X
M=-T8S'Y8094ATR3GC"^-7_!3+Q3XXTN;PS\,M)TCP)X22/[%'+:6T:WTR2?*
M-JX$<#,,@;06Y^]FOHC_ ()W_P#!(WQQ\%?$U]XP\<_$#3/A!J!TZ;3H=.L4
M35=<$$P'SXSY*$\$ [\$= >:4_=5QRUN? 7PM\,^)/BQXW/AS0-$O-7UZY9Y
M3;64&Z3 )+EP.%P0<@XZ$"OMW]G_ /X('?%/X@^7J7C;4=*\%:6N&ECO929
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M5^TQI.D?"GP7>^%_#UU;_P#"/OXBN;,6=CK%R'+VD/E+_P M,^;M,C[R)""
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M;_=/*G/9C6OX_P!,TFS\9S7.A7,5WX<\0Q#7-$G@^:)[.=BVQ>FWRY"5*D9
M*^M4K*V%OATQG.<GO^->]%IKF1Y1\.Z9XV_X8,_;"UNRU-'B\#^);/S-/CAC
M,DGWF>WW+P R2>;"?9LYP*[_ $C_ ()K1>+/'4VJW+S7%K\4+J\EL;.W"PO=
M3M&9"M[C#QV:LVPHHZC+%LX&O_P5<_9^_P"%M?L^-XLTRVWZSX-S=R1Q];JT
M/^N4]R5_U@_W6]:^/_V6_P!NI?@!\._%WAC4?!]UXYOO$XA.@SKJL]M/I5SO
M4S_.FZ1HI!'%E%')3J,UU.]3WX[]2$K*W0_5W]B/X8Z'X+\&ZWI?AKP?I6BK
MX:U 6]YK]O=K<?VG=B-//<R$#RDB<,H'"J/QKSS]IW_@KU\'OV;Y[W3](O3\
M3_%%O,89;319P+&WDY_U]Z04Z]H@Y^E?-&C_ +)_[3__  4)TFYO_'NN6OPI
M^'\S/,-*GC.EV5PTG61;*(J\S,,9EN&);GK7U5^SC^P'\$OV1A;RZ#X<_P"$
MU\36D8C_ .$@\1QK(J$=X+?&Q,'I@9QCD]:Y6E?47*KGS%)IO[9'_!4NUW)"
MGPI^%M\YC8I)+I&FO Q)WR.<7=[A>"!A#D< 5[E^S1_P2F^"W[,;Q7NKH_QC
M\46VUDGU. 6VAV3C!_=VH)$G/>3=7T'XB\;7OB&Y5]0O9KM8UPBDXBC ' 5!
MQBL.>Z(FC\QU@A+ < %E&>2%_P ::E)>['1%*'<Z#6_'=UKMN+2>95LX0!%:
M6\:PVL0 P $7 KDQJDFG>*XQ;VRK#<1.)I#A5XY  SDG//3H6J"YU$M.WE."
M%. Q7+,.QQT6L35-8DNFG \Z"YL)%=6:)E6;@?,C'AUY*DKD Y!Y!J-.IK9;
M(ZS7+MM5TY%3 N+=Q-"C_P 6/O+@=F4E3_O5^<'QSTZS_84_:#\26L6FC4?
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MQ+\1ZQ\3=?E :[MXI'M-.\TC+'S 3//@DX+,HX&17#^/OVN_!_["_P 0]?\
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MB#Q+\2-9\>V[7>O6-O;?V3+;EA&;6";4?O1QQ!"##&CDABK$9S7@OBS]I_\
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M3TX-8WQ?_94M_A9/;_#W6%FUNX\>75I<Z?JFA6TT^LZ9:1SLDC/8QMFX,H!
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M'E)$<'%?5N5]9/4_*U'H>'RI]_+#!ZD]J<[EGC/)D4?>!Q]>:0I^^PY7.#@
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M6G?M^>,M/AWSKI&H_.%P+/:N,<_,&')ZU],? KXRZ9\3OA-I6O:OJ%CX?O\
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M3]M;X;2:#JFG>(;:5_+U!OL5T#&QV2!2%.0.Z@CZJ*\5BO?L=C]GBA<MW).
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M:'[..L^#=%\6>+O%>BS#2_$=E:P::+PCS9W#.\I5?O*A)0[CUYQ7S-_P4C\
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MBSUVH^",G<2V?\\5Q3R3*Y0Y:E)7\M/R/H:'B5Q3AI?N<=4^;YO_ $NY]Q?
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M-:>2W,Q.U,9X.?Y#K7N'C'XX:_X\\*-IE]JDFH6-U<+&\30H)=RX8-D ';G
M//6O*/B)X1O;2&.X_?RQ-\H#1-B-AT [8QR#Z"OILDA5P6$6&Q4TW%Z6[?.W
MG\CYWQ"SS+<WSB>9953E"-1)R4DD^?9M)-JS5F]=979DRZ9;3WJ1&8/.03),
M\WV>%'!RW8L20>N!T/%>X_"?P=/X,\'V"R:C9WEOJ0>\B2!7_<H<!6\PJ%DW
M_-]W.TH0>M-T[]GZ"T\(:1>1+_:5V;5&/DE2=Q SM4#YV(R>3@YKMO"OABVL
M? MUI5M!B\T)VOU$@,=Q/:N1O'EY(7R\AF&>%#<=:BEQ!2JUU1BGJ['Q?([7
M*,S%R2V5V=_Y5&K .57G?^E3MA01L&P<]*B=?*/OSA1VKVY+L8DVC:5>^(-4
MBM+*V>ZG8$[%(4*HY+,S$*JCJ22 *\Y\5_%J7PYXJOX(YH[R&TF:V:.W<>5E
M3AOWF#NS@X91]#77>+]4FT/PM>7L4"74UO$UPL3J<,!V..>G\J\VU7X<+*;3
M4EO;6TT;5;=9899AF261MQ*<9+.&^7)P.#SQBL9U(4US38U'F/??V2_VGY]9
M\:6<5ZNFZ1X?NC_9EU;VT"PVML[_ .IG)^^S>9C+.Q."W0<5]"?&/P1;^(M+
MO-'O@L;7L31/$S#S(V7H^!SP=IS_ (U\(^$-7O\ X<:5J8L+1+:Y"FX&IO9!
MKR.%0,&.5\I;_,?OJF_+##"LSX=?'W7?!OB:R\57^HR7E_(YC=KV5YRT;_*?
M-).YS@@Y')*"O S; K'T7[!^\M4_-;?Y'VW G$<,FS.-7%+FH33A47>G/26G
M6VCMY6ZGV!XY\#7GASX)7?@7PQHNDZ_8W-V;Y;G4DC$D;LX+CY^Y 4!A@@*1
MZ5XMX1_9Q^(/A6V6WM]$\.01PR^9$ZRQ[NA!W?-\Q.>]?2=QXT\#:QX0T*Y;
MXB:=;O/9PS7%QIH<&67:K,#$Z,54\\'!'KD4[X*_$WX?> ?'VLZAXY\9IXBT
M&^A9M)L;>PNIA;EI#]X^4A.Q5 !SR2WI7E?5\XY>3E@UZ2/H:M;P\3MR8NWK
M1/#[CX/>/-4\(W$4VEZ%#J#QD;$DCV3%EPP)W8Z' _.NG_9D\%>,_AWYNGZ[
M96=MII@4Q&">)C',I]%Y((/4\\5]&ZW\8O@IX]T:[T_08O$=E=W%H\B:E:::
M?^);@[1(WF2; ,\ -U)XYQ7EGA+X]_#/PSX-6Q-UX_\ %&NSS*/[0U"R@@7T
MV)&LGRY/)))KGK9-FM:DZ,HP47Y/[SU,@XFX'R;'T\RP<,7SPO:[I-.Z:::T
MNFGW/:M*M)8;"'S-KNP(<JPX'%6K".&TNB'D54<['8-G(->06_[9WA1;L0QZ
M-XH9MZHS/Y,2H2P7/WCG'-5?%_[9]IH^JW]A%X2O9Y+.YD@+2ZFJ@B-F7(VQ
MD\[>![BOI%A*MK6/R6IB82FY[7[;?(V-?U[6)7G?Q+:Q:#;I,T=K#)>1.DL*
MX D9U."S8S@GBN+\5?&7P=IL!CO/%EA;!>&6VN@9/I\@)'X5P'[8G@'QG\<;
M2_\ &%T?#WA7PUHE[<Z-H^EWUU--=7KPC,L[#: K'&.1@8'K7R)=ZO-'*DMN
MNZV=$D&P?("5&>>IP<UYF(X15:K[?$U6K[+33T;O^1^JY#XR2RC*XY9@,%3N
ME:4FW[[[R45%[::R9^C?PX^#>B^.M(L]6TJPL[BUU,":"YNF8F92<;SOR?7K
MZ&O0_#_[.<\UO(]JMI"RD(HAM/O,0=O(&<<=:^1?V2OVE_'OAW1M!T9]>U06
M%IJ\4,]LT,8!ADD4%%DV;F!4D_>.,]JUM2^.OCZ76B^H>-O%<_\ 9U\':,ZG
M*%0Q39.5! _AZ8HCPEAY:RDY+SD_TL>;_P 1>SBGI@:='#_]>Z4%_P"E<Q@Z
MO^V3XKT;QEY5YH.F6VEVMY)!.C.RSS(CLA*;V#9XSPIZ5]BZQ?>!_";JUUJ?
MABVBDC65#<:K%*Q1@"& #$]^F,UY3X*^/&A6GA?QA\&? _[-OP[U+XF:A9ZI
M8:UXZU:Y>>_N5N&D(NHE9-T3K$PZR (4STS7SFW@V7P';W>BW\:?VCHV_3[H
MHRLK/& ,Y4D'(P>"1S7=3R3+N;EIPBFO*_YW/ Q?B)Q/BDY8C&5&GVDXK[HV
M1]>?$;XP?":TAN]*\07MK?0VLC?:+2PTZ>5HV4$=0$&1S_%WS7.VG[1/PT_9
MQ.IZ%X6\*^(KG=,LTDJ7,4$5PY0,,NS2.1@@#CN:\,^(\,=YXSN[S 8ZE#;W
M@8G&[S;:-R/S)J+QT%O-6T^YCR3?:18S$'NRQ"%R/;=$:]"GEU&.D4?*XC'X
MBO+GK2<GW;N_O9ZG^T%^TM9^+/!VL>'O^$*LBNKV5O)!)_:DH9%EB2978JHW
M8SM(R!\IKY,'A!!K%S/"+9$$&5_>G9"&8)M7."S*QZG( QUYKUWQ0TM]IOA>
MY+Q[KS2ELSM'3R)Y8OF/;Y0II)/" TVZMS=64X,:C#Q+O@ +=&W8+?Q/P20,
MYS7!F^*6$A%PZF--2J/4\3T[PIJW@/QWHMRVH2QW=E=)?QM(A^4Q/O <*<8P
MN#]<5Z_\0M)71O%VL0VR1 1W<CQ,G(PS>;&0?3#"KVG^$U9M1>+?+#> &<W$
MK8N 6+",,!D]OH3UJ3X@1PKKMHMJ496TRV+CC=#*%*.C =&!3ZX(Y.<T9/FW
MUN;A+="K4N74A^)ML=2\>:K+M,/]KE=23YL_+<1+,<'KU<_E1X\#7.NPWH4>
M7J^G6EYA<8,AB$<G3OYD;YJ+7K^WU2#1Y4>8SVVG1V5P&7@/&\@3![CRS'],
M8[51U/Q&JZ9IL$R#S+".2%'0\RJTKR >VW>1]*]\P9I>+5CN8O#]WAS]JTB*
M%P5_Y:P.\#?^.HGYU)K5K'=^"O"]X[%V2*ZTZ10 ,+%-YB<^NV8@_P"Z*R;;
M4VUC2;<;I/*M3(L,9'^KW$,WUR<&H)?M$5S@1IY &#N;+'/7BE9VY6!T6B:G
M#J<:1P1K)?P2.D+HIWPQF,EI"H^5P<*K*=Q&0W&2:S_ MM+:>(K=[59UO+MQ
ML=0(F+,<-"RCY&5E9L@9!&:AT^632;5H(# T+S?:XP\*[K:; #,K_> 8  J<
MJ<#(XS6K:^);W2-,DMH/LMN)B&<QVZ^8.,?*Q&4XZ;2*^2Q>18F5:]%I1\SI
MC5BHZD_B_5YM-N+W0+%+2QTB*5HWM[$.([HH2 \CNS22=. S%1V KFIK%'==
MR'!/W0<9X_S^5.5#$QZ;=V0N,%AZ?7FJ/B3Q'!X1T.34;L[;:$JN]1N().T#
M'XU]=3AR121SMMGFOA2^?2[RV1]0:^@E_=JDL0W6CJV "1]TL,XSR<>];.M7
M3V4FZWT[4[N5)HX)(H(CYL;')X!P25 )8=@*E\(Z-J'A_1(,?9_[1CC&U2X8
MR-]X.XQQM..I))%=;HEN^BVMO!)=DLC/=-(&^=P5R=Q[EB3D]\U\A7J1IIS>
MOZG3=V///%.^UMW-O;RR7O61F;;/'N&<,OIM)XZ\5B:7:P7-G%(C?N@GEPH6
MQY8'&"._]ZM"75;J]\;)K7V=(_M5PQ,.T[&7: 0>H48P,GV[5H>+[K0= BM(
M+")FUZ[8/);B R_9D;NQ^Z.W'YUVP<E%)[LE:L@U+P9HLFE632M=WD\Q=W>)
ML0KQR23_ '<[>!@\5YGXZ,DBQP"&#[%:1K KQQ[=S%?XCW8=\<9KW3P;HAM8
M[ZYAN?*BNX&0$*&-Q@ -)&IX5B<]/I7)Z]\#]=M=0ADLBMX;?_2(DR#@L.=R
M'U] >Q%:T*T8S:DQ2C?8\0^$6JW'A#XKP/,OF6UJYFGMV<IYJGC@CN>OH<5]
M ZY\2O#3>&S:61CNK?#%#Y31-%(3G&[(.5SUQ@X]J\RN?#+S:HUU?PV8U*S4
MJ$2'R\ $XY'4Y#8![\5O>&?#MHUO&M_&YA^79'$H#;P<@,W P1G\:Z,1*G5D
MG+=$QO'8Q(K1].B:W33C>W%^N+9MI+8R2V!C!8^_2N<U/P5XBTO0Y-1ECG%G
MYI4VI;.S_@)_(_2O3?$5S!?R;UNVGU&* K9F,%?*3'!&/J<GM6O#;RR6PGU&
MY@DOKVV0.]Z_[^(CG=QPPXZMV('%$L9*"NA<EWJ>-:/=RS669X'3("QE6^4#
M_=QUS[UJ6^FS,IFN!) @7C" OMQQA>.#ZUOP0QWMY<W%I [:?;81,CY%8_+Y
MC-TYQV[=JO-X/O-3O8G$BQ12JC-%+)L6;C!(]AZ?2NAXE)>Z"A8Y--B>0;,2
M-+@YWKP<<$YSVYJVE\)88M\9>+?^]"G)P#S^E)XBGDL;UHO[.6RCB 4 R[F*
M'G(.!NSP?855A:WN9T$ N+@,&^T%%Y'';I[]:VIU8M;E6.^UKXC6?C319[,$
M0RW,R(L9'+)G.=WX#CWKD=>T!+AI'BWE7;Y?D[= /T%6&TY;.S\RW:W\R$[W
MW3+EQU"[>N1ZCTJII_B^*.[_ 'NY6SEPSYW-ZCC]*ZEBW4>IGHC0E^%=S'':
MRRS6JP2M&K[1O^209XXY8 '.WE<BNHN_AX?#D%LSPI/I[J[LD4IVP9)56+$>
MRG'O5CX!:^=7/]C1SV@NOM,DT:3*@,Z,"<JS=QR.O.['.!7J6JZ%_:+[8[2S
MG\JWCADCN)GD\U=P\R5BO!<9&!C'Y5\KC\SJTZKIRT_R-HQ35SS;P3\6++X<
MZ+JGDS"ZN;A0;:39M^?)!5AVQP>^:YM?CYK]EJ\,LUP)X%;S'0A<S*>Q(Y[_
M %Z5E_&F.TM?%ATVSSLMXO+$8Q^[8G.&QQNQ@G\*9X/U+08E:'5M)75)+V80
M^;]H:![6)0%!4C(R6R?PKZ7+[U*49M[]S.6FQ[OX&\66/Q#T4:A8QM"ZR^7-
M [9=& 'Z=ZV&ARC'!9E!(P?;_P"L*^7-$\37_@UA<:?<26CLNTD-D.".I!Z]
MJ^A?B5J+6?PKM7L]3!O+[38;FYDB90D4SACY*GOA=I/0@M[5T;.Q!Y!\7O&-
MQXAUYH9[=K4VQ,8^8G=@_*3VZ9%<A<76P[LE8L<[N0 >O'^>M+=2R21(]PSR
M[U)1V8LQP3_4GK5>2-+M$60G]X 0&Z%1U)_*K4;#L9%OXUFT?Q"K>49K?S00
MK]2#P=K=O:O5M&U.+6[:*ZMF?&,?[2GT->9^(O#7]LI'L=8@@VYX.X&MSX0V
M!\,^,;=;BX:2Q>14NHRVT!20-PSSD>U:\RE&PK'JC^(]0U)7#RW#F<[Y&8EG
MD/N>Y^OK6AHOANZO<ED9..,_)]17#^*/BE+I%W<V^F>5##<AC$6X\I#VSUSP
M-I]S72>!?VBC>PQ1:M:1Q&.0*]Q"=JK&< $@^AZFN>-&$/@BEZ!YLZRZT"UT
MS1I9[HMY,0#2'& .0,_3FM3PYKNB:I$#9W5M,Q79C?\ O) N%X'4@8 !Z8Q7
MCOQ4^,S^.+>?2[&#RM.$P;S"2LD@4]QTP3BN)\/W\WA^\2XM,K.ORF3.WOD?
MATK3V>@['VI\+OC/KOP-UYM4\.36L%U+:_8G6ZM5N4\HL&VA3QU /\ZT/"'Q
MPF\)^&=8TV;P_P"&]8;6)6E:^O82;VVD9S)OB?.U<.=P&WMZ<5YC\/?%J>//
M#2:A% \*AO+P[ [F'!8=P,],UL20C [AB<5-W8GDC>YW=S\0/"O_  SYHOA:
MU\*^5XFL+[S[S79!"SW,9E9V56QY@.W:H!)& U>;:[X4TW5;RZNSI\"WUU<"
M5Y\L'7!Z\'!.WV["KH@ &"VWGCZ^]/C+ ;MI&WJ/2IW*A[GPD?QHD3Q-XPU6
MYAN42UN]1EEBD#8WPJ,)MST^49&?I7&Z1I"22)++93[MI*RM&%6)6_OYXP1M
M)Y)JQ\3OB=8>$X_*FD\V\?I$!DH,C)8]ACOWJMH_Q0TOQ'"WGE_-://E(H="
MW0D<C'7J:^:S;"XGVG/2CS)VV.BG*-M2W\/+7'C[3K(1R""_U.WME7: 6#3(
M#ST)YX]B*[CQAI[ZMXMO@OWM3U*0(-Q/^MG./?N/>N*LV^VZK!+ T]ND$F^W
MV/AT*[2&!ZAL@?E[5O2>()K'4+9(2XN4*RQNO6-E(*G\",CZ5ZV!I3C02J[F
M$M]#Z#_9_P# OPI\7?#3]HO4OB+Y,OBWS[H^$X6TV6XDN9%MYU40E(V5,3>6
M"21C&3TS7B7Q;$L?Q&UV.ZCE$]E*MLR2-O9?*B2+!/?[GY4_3OB'X@\/Z#>:
M98^(-?L;'479[VW@U"6*&Z=_OF1%8!L]\CFLOQ?J<GBW6-2OKTJMQJDCRRF$
M;%!;^Z!T [5TNZW)MU+/C:$6FK:? J%5L]'TZ$*5Z?Z,KD<^[FJ_Q5MX5\':
M5:R6ZO"_AJ&1OGQN+SW$@)/9N0?;%3:MJS:[J4U],JB2:*&'RT)VKY4*1+R>
M>5C'XU%XMNK;Q(;=3'Y<%MI]O9 $[\F- I;MU.3CMFIJ*2IOEWM^):>I@>!M
M&M6T:&6SDN+>SA C\R-P95=F!S(N?ER20" ,JN#R":Z:Q^'LFM6DB76C?VEI
M]G&9=]GE/NC._;T*\CECUIOP[;RC]C\BUBB<.)YHH \\P.1L!/4<@]NG%=2V
MJQ>'KR62_P!5A@LDEC2\N6432019P 44[V7H0!DYXZ5^,X[&XMXR5*-^=NR_
M+[SKC&+C<\[7XE76EWK^&;"2-((XC(;AE_U7SX0*", D'/MQBNB^$NFW<GQ?
M\.11LK"2^5;AG<XGB*L)V?\ V/+,F?;-4/BUIWA'X@>/DU+PCXIT#3[([H9X
MM1::UW^5Q%,N8R6W1[01UWH>N:WM2UBP\*6\PTJ\GU76-1L4L;K4VMQ####Y
M2HZ6Z?>+.%PTK;25) 49)K[[!9-.DX\R][2[\_\ ARO:4U&Z9R\(#6Z-G<C<
M@\].Q_&G*#(PVKA<=.I J2-=D8'IZ?RK;^&,YM_%D"@#;.CQ$#GDKG],5]3K
MN<#, R_NF!QC!4>A]C5[3/!,GB[3K6[CB3[/HJQV>R'Y6@A=V9..P$KN 0<E
MI ".<U7DB4RR#"\,P /L:L:!J\OAZ_F>-/-M[J%[6[MV9D2[@<8="PY!Z,K#
ME656'(K@S/!O%4/9)V?0J#LSUKX,_P#!/V^_:K\%ZG+'J=OH-O:((+=Y8@([
MB8-EEDR1MB3EG]6(' !KY4U?X1IXD\0>(K9I$O(+'4IK. V,B/%(5<HLD)!
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MA3YA7:N 3M'/!SFHH?B=9P_!J\\,R:'#)J-W>M=IJ;R+F/<R-@+LW'&T@?,
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M*XF\TL6E=MY+#EL]Z\^LOVC-'EE"3Z=?0Q,P02B13A>FYAV%>@.GG[?).]6
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M%/0@\\=<TR'3Q=&9QJAWF,,JJ2(B<\9![FO6^SS"3)+*;3K*3RK>8W$ETQ=
MZ;>^0K'/!Y[+WK421;J(JV=L;?/%C&22.O'RL?UK#NM(L@+N"WNY4FN),M,M
MNVY0!PA[!1W(Y.:Z+PGI,=OX<CLM1N?+:,O)]H9#)(X)^6-0.<\Y.2 HSSQ6
M-2ZZW;&R"PC"D2J298U63Y(D$SJ?O1\\8&1[GVK%U^\DU">07 ^>92[?*<3L
M3C!&<JP Z'BNX\/_  GU74[-P9G26YMOMEA-- 1'JJ;!\L;9P3N#+U.".:\_
MM]9BU%I+DR-:M;=3( O'09QR.IZYYJ:4_:2<8ZN(:IZFI!>M:1C[2([.)4X"
M-NYQ@.^.,@?S]:6SU.&5M^(Q\N%609S[\\\C/'_ZJK:=K4$K&5'#1Q*1C&64
M \<<9!YP?\:LZIK,'AJQ,DD(N;NZ20(&&T-UVMM7L,\\]!70U[ZBMQO1V9DS
MI+?7I\V2#8$)A9%5)(EZ8Y^[VP.!@5#INC#1")K!KA[J4'S$8;CDD?-S^/'(
M.:EL[XA4V0@7<Z;Y2JAE7:-N0._.?\:TO!_@K5O&LY^Q_8X^/,EDE0EG4?P!
M0"0V,G'Z\5HZSI1][0EHR+BW?5M1N+ZT%M;:E81&;[1=1;8BJ@@*!C:W/ XZ
MGK7$>*$N[[3CJ%O)->WUR!+<>8%58V/'&.N>W3Z5] ZAX"2R\,"#3+NXOKFY
M,DSVEP0L8RGREB2H;RU&5'5F;[O&#Y3::*^G7>PA+FV93YHE',A!ZA.I8#-&
M"QBF[TV9RBK:GE,6L>(?#5_]ID3Y(BH4' ;=C<-C#IZ\>E=AX)_:-UJ+1KO2
M6U[4=(@G!+6\;%3<$G)#/@MCOC.*W-4\!O;VIPL.[^ 2MND')V?)S@XZ9Z9K
MB==^$-W<^.3 MU#<1.5E?KN9&]/IST].E>IST:DN6:3,US+8U[>5H]0%PS&1
MF)?S#_$YZ$U?M8XX8XY&N-ZYVM'Y6W<3V!J7PO\ #MU@D:XO(E"N<P;\E1G
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M4G*Z]R7]?(U1\#_&W1M5N]6T_P#T.1].V$FX@&_SY,G 8_PX!.!WSWJL@62
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M]*\ZE^U6]U*+] S[V\PP$9<[LEL_WB1]*4QB)+BWD6>>3Y7BMUA^60*/X>I
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M6"\DC8-YN(O,;.<@],8Z]LC-=$)<LN52(E&ZO8XRUUF>ROHX96)7^ 8SCG
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M'<_N-MK:J0S-P0 ?NXZYSU;(K&^*OCV"PLI+"R6V+OS-)#,S;1MP%Y&!SN)
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M1_&%8YX4=<\\L<\'%<Y\?O'^AZ5X:TS3-#UFS:Y\Z-BUG*93 @);<)",E02
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M/>N:694V_=O<B2DSR_3_  ]XETN-@+-9(]1VVDEJ)U+/&<.!M!..,?2M_4?
M%[K6E6GD6EW.TC".S@M[?S(8(^ V]L99B?[O'O7H?A_P[;^"=/D76I(42Y=I
M+>.5?+N(6(*[E;A3@<'!P?PJ'P'\4=,\">&=1=;G4+S4+.\6+3K(+)%;36;(
MV;DRYR'4X7RRHSG.<<5,Z\YZTUJ"BGN8/PT\/V>A:I=/XGMX8);$&.SM([;R
M^0V"6<?>(&._2NN^(7A"\U*SM6L?LL]LB#:L,2PK:KUQ],GWZU=\WP.(+'4K
M?5IKZ\,$VH3VLEIA+1L\9.X[RQ/W?X!BJ$M_>:O<K<21K+%/B1TAD*&(E>%
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M\T34Y+&\C(=,,8IE;MR,'_/6N>*1W,F%WH[<'M@4R/3[B'>RDM'#\TDB_P
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M\#I37\+VEQ9P2:I=[-D/F!;24!YV+\;1UR!CCK[5U7C^>.W\-VL*A;1_-\H
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M(-PR4+X[UZ%/%4:BNF<LJ$XLLW)EO;EI95BD,F-SQ1JJYQUV  #/L*&LX+A
MJ97M@G.#]*T=.T./5F;^S+R&Z**&**Q$B C(S&<.,@]Q4%Q8RPY6:VZ$\J.
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MVQ>"X^',.BRE54S:/J<L+DC^(*Q*^O\ #4C>'M"NY4\F\N8'WD*3&3_*I/\
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M[P4]JWC0J]2741\B?#WX>7.NVDD]W.U@ FQ/(4!WZ;B0?NYZ9Q^-=EI>D?\
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>:B%:2]2%F+#:(RS*1^0_6O0AA::5YZ^IFY-['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833843936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jul. 24, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 29,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">exel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,035,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834526176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 248,407<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">251,516<span></span>
</td>
<td class="nump">204,607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Short-term restricted cash and investments</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">167,161<span></span>
</td>
<td class="nump">81,192<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,327<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">686,286<span></span>
</td>
<td class="nump">484,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">94,396<span></span>
</td>
<td class="nump">64,255<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">64,744<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">12,092<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">911,158<span></span>
</td>
<td class="nump">655,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">9,575<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">21,538<span></span>
</td>
<td class="nump">21,073<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">16,801<span></span>
</td>
<td class="nump">19,849<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">11,143<span></span>
</td>
<td class="nump">7,565<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">7,713<span></span>
</td>
<td class="nump">8,974<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">5,939<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">23,787<span></span>
</td>
<td class="nump">16,150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">99,944<span></span>
</td>
<td class="nump">115,170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">11,970<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Financing obligation for build-to-suit lease</a></td>
<td class="nump">20,646<span></span>
</td>
<td class="nump">14,530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">136,190<span></span>
</td>
<td class="nump">370,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 295,700,576 and 289,923,798 at September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,142,717<span></span>
</td>
<td class="nump">2,114,184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(731)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,367,316)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">774,968<span></span>
</td>
<td class="nump">284,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 911,158<span></span>
</td>
<td class="nump">$ 655,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833882448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td colspan="2" class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td colspan="2" class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td colspan="2" class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td colspan="2" class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">297,892,180<span></span>
</td>
<td colspan="2" class="nump">296,209,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">297,892,180<span></span>
</td>
<td colspan="2" class="nump">296,209,426<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834498160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">$ 145,836<span></span>
</td>
<td class="nump">$ 88,004<span></span>
</td>
<td class="nump">$ 280,108<span></span>
</td>
<td class="nump">$ 156,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">40,272<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">119,719<span></span>
</td>
<td class="nump">23,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">186,108<span></span>
</td>
<td class="nump">99,008<span></span>
</td>
<td class="nump">399,827<span></span>
</td>
<td class="nump">179,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
<td class="nump">11,636<span></span>
</td>
<td class="nump">6,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">42,488<span></span>
</td>
<td class="nump">28,214<span></span>
</td>
<td class="nump">80,245<span></span>
</td>
<td class="nump">51,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">51,853<span></span>
</td>
<td class="nump">40,667<span></span>
</td>
<td class="nump">105,869<span></span>
</td>
<td class="nump">74,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">100,338<span></span>
</td>
<td class="nump">71,895<span></span>
</td>
<td class="nump">197,750<span></span>
</td>
<td class="nump">132,596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">85,770<span></span>
</td>
<td class="nump">27,113<span></span>
</td>
<td class="nump">202,077<span></span>
</td>
<td class="nump">47,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">2,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,259)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(5,868)<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="num">(5,913)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">2,625<span></span>
</td>
<td class="num">(8,876)<span></span>
</td>
<td class="nump">4,689<span></span>
</td>
<td class="num">(12,228)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">88,395<span></span>
</td>
<td class="nump">18,237<span></span>
</td>
<td class="nump">206,766<span></span>
</td>
<td class="nump">35,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income per share, basic (in shares)</a></td>
<td class="nump">297,336<span></span>
</td>
<td class="nump">293,188<span></span>
</td>
<td class="nump">296,874<span></span>
</td>
<td class="nump">292,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income per share, diluted (in shares)</a></td>
<td class="nump">312,241<span></span>
</td>
<td class="nump">311,219<span></span>
</td>
<td class="nump">313,024<span></span>
</td>
<td class="nump">310,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821727920">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">156<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="num">(384)<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,650<span></span>
</td>
<td class="nump">$ 17,863<span></span>
</td>
<td class="nump">$ 202,967<span></span>
</td>
<td class="nump">$ 34,653<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities were nominal and there was no income tax expense related to other comprehensive income during those periods.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821262640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustments to net income resulting from realized gains or losses on sale of securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Income tax expense related to other comprehensive income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833967728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 203,351<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">18,588<span></span>
</td>
<td class="nump">9,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash', window );">401(k) matching contributions made in common stock</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other equity investments</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(490)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="num">(85,969)<span></span>
</td>
<td class="num">(2,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(1,714)<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,577)<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,535)<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">465<span></span>
</td>
<td class="num">(4,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseAccruedClinicalLiabilities', window );">Accrued clinical trial liabilities</a></td>
<td class="num">(3,048)<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseinAccruedCollaborationLiability', window );">Accrued collaboration liabilities</a></td>
<td class="num">(1,261)<span></span>
</td>
<td class="nump">5,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">5,910<span></span>
</td>
<td class="nump">28,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="nump">10,164<span></span>
</td>
<td class="nump">7,457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">146,577<span></span>
</td>
<td class="nump">74,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,182)<span></span>
</td>
<td class="num">(2,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(227,012)<span></span>
</td>
<td class="num">(154,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">139,948<span></span>
</td>
<td class="nump">200,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sale of investments</a></td>
<td class="nump">10,237<span></span>
</td>
<td class="nump">37,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from other equity investments</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(91,800)<span></span>
</td>
<td class="nump">81,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of convertible notes and term loan payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(185,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">6,550<span></span>
</td>
<td class="nump">12,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(2,976)<span></span>
</td>
<td class="num">(2,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on financing lease obligation</a></td>
<td class="num">(304)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">6,920<span></span>
</td>
<td class="num">(172,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">61,697<span></span>
</td>
<td class="num">(15,974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">188,314<span></span>
</td>
<td class="nump">155,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">250,011<span></span>
</td>
<td class="nump">139,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure - non-cash investing and financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Property and equipment deemed to have been acquired under build-to-suit lease</a></td>
<td class="nump">6,864<span></span>
</td>
<td class="nump">14,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred to acquire Property and equipment</a></td>
<td class="nump">$ 13,972<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseAccruedClinicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) accrued clinical liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseAccruedClinicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseinAccruedCollaborationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseinAccruedCollaborationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825053120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors, and RET: CABOMETYX&#174;&#160;(cabozantinib) tablets approved for advanced renal cell carcinoma (&#8220;RCC&#8221;); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&#174; (cobimetinib) tablets, is an inhibitor of MEK, marketed under a collaboration agreement with Genentech, Inc. (a member of the Roche Group) (&#8220;Genentech&#8221;), and is approved as part of a combination regimen to treat advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2018 will end on December 28, 2018 and fiscal year 2017 ended on December 29, 2017. For convenience, references in this report as of and for the fiscal periods ended June 29, 2018, March 30, 2018 and June 30, 2017, and as of and for the fiscal years ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2018, March 31, 2018 and June 30, 2017, and the years ended December&#160;31, 2018 and December&#160;31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended December 28, 2018 and the first day of the fiscal quarter ended June 29, 2018 are indicated as being as of January 1, 2018 and April 1, 2018, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts on the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to current period presentation. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, as a result of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">new information received during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the six months ended June 30, 2018, as described further in &#8220;Note 3. Collaboration Revenues - Genentech Collaboration&#8221;, we have reclassified the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in profit on the U.S. commercialization of COTELLIC for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenue in preparing our Condensed Consolidated Statements of Operations for the six months ended June 30, 2018. As a result of this reclassification, for the three months ended March 31, 2018, Collaboration revenues increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$78.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$79.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net revenues increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$212.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$213.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Selling, general and administrative expenses increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$52.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$54.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Operating expenses increased from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$96.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$97.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There was no impact on Net income or Net income per share as a result of this reclassification.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-18&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">etrospective transition method in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Condensed Consolidated Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-18, we no longer include purchases </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of restricted cash and proceeds from maturities of restricted cash </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our cash flows from investing activities. Accordingly, the adoption of ASU 2016-18 resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in Net cash provided by investing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 4. Cash and Investments - Cash, Cash Equivalents and Restricted Cash&#8221; for a reconciliation of cash and cash equivalents presented in our previously published Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Cash, cash equivalents and restricted cash reported in the accompanying Condensed Consolidated Statement of Cash Flows for the same period.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2018, we adopted ASU </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">No. 2014-09, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(&#8220;Topic 606&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605: Revenue Recognition (&#8220;Topic 605&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a net reduction of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$258.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to opening accumulated deficit as of January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> due to the cumulative impact of adopting Topic 606, with the impact primarily relating to a change in the recognition of upfront and non-substantive milestone payments received related to our collaboration arrangements with Ipsen Pharma SAS (&#8220;Ipsen&#8221;) and Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> The adoption of Topic 606 did not have an impact on our recognition of revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Balance Sheet </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of January 1, 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone from Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">European Medicines Agency (&#8220;EMA&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for cabozantinib, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced hepatocellular carcinoma (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC&#8221;),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> that was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">deemed probable under Topic 606 prior to January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eferred revenue as of January 1, 2018 is related to the up-front, nonrefundable, fees and milestones achieved </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that were allocated to our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development services performance obligation that had not been satisfied as of that date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Contract assets and liabilities are netted by collaboration agreement in our Condensed Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Statements of Operations as of and for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Balances Without the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Effect of Adoption</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Higher / (Lower)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">240,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">142,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,906</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,005</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Balances Without the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Effect of Adoption</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Higher / (Lower)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">142,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">422,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,750</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">229,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">225,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> recognized in accordance with Topic 606 included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenue, respectively, for a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC. We recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenue for this milestone in the first quarter of 2018 when we deemed achievement of the milestone was probable in accordance with Topic 606. If we had not adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606, we would have recognized the e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ntire </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone as revenue in the second quarter of 2018 upon achievement of the milestone. If we had not adopted </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606, we would also have recognized a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone in the first quarter of 2018 upon the validation of Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC that was recognized under Topic 606 as part of our adoption transition adjustment on January 1, 2018. The adoption of Topic 606 also resulted in a reduction of previously deferred revenue that was recorded as part of our adoption transition adjustment as of January 1, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to patients, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for product supply; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply, each of these payment types are within the scope of Topic 606. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accounting Standards Codification Topic 808, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;Topic 808&#8221;). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We expect to recognize an annual profit under the agreement for the year ended December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues on the accompanying Condensed Consolidated Statements of Operations. Historically, we had not recognized a profit for any annual period from the commercialization of cobimetinib in the U.S. and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses on the accompanying Condensed Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No.&#160;2016-02,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Leases (Topic 842),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-02&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require a right-of-use asset to be recognized on the balance sheet for both types of leases. ASU 2016-02 also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU No. 2018-11&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In issuing ASU No. 2018-11, the FASB is permitting another transition method for ASU 2016-02, which allows the transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are currently considering the potential of an early adoption of this standard in the second half of 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the transition method permitted by ASU 2018-11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Based on our initial evaluation of the impact of ASU 2016-02 on our build-to-suit lease of office and research facilities located in Alameda, California, we expect that the amount we have capitalized as Property and equipment related to the building shells and related financing liabilities, will be derecognized upon the adoption of ASU 2016-02. Upon adoption of ASU 2016-02 we will also be required to recognize a right-of-use asset and lease liability related to this lease. The adoption of ASU 2016-02 could also change the nature of future expenses related to the build-to-suit lease, reducing future depreciation and interest expense, which would be offset by an increase in lease expense. We are continuing to assess the impact of ASU No. 2016-02 on our consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819490512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">REVENUES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">172,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">332,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">178,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(26,810</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(12,254</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(51,974</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(21,336</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included revenues related to the portion of three milestones that were allocated to the transfer of intellectual property licenses and were recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> also included a milestone payment from Bristol-Myers Squibb Company (&#8220;BMS&#8221;). Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and License revenues no longer includes revenues related to the amortization of deferred revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development services performance obligation which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included net product supply revenues from Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Losses on the U.S. commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and therefore Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only net product supply revenues.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Duri</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ng the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net product revenues and License revenues related to goods transferred at a point in time and Research and development services revenues related to services performed over time.  License revenues and Research and development services revenues were recorded in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included the p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net product supply revenues, were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 for all periods presented</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">141,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,599</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52,809</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">44,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">137,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,985</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">150,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">287,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">163,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to regions based on the ship-to location. Collaboration revenues are attributed to regions based on the location of our collaboration partners&#8217; headquarters.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and Discounts for Prompt Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other Customer Credits/Fees and Co-pay Assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(30,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(47,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Topic 606</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">471</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(17,306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$32.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$103.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo Company, Limited (&#8220;Daiichi Sankyo&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819491376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">From time to time, we enter into collaborative arrangements for the development, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for non-refundable up-front license fees, development and commercial performance milestone payments, payments for product supply, development cost reimbursements, royalty payments and/or profit sharing. See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we had achieved various milestones totaling </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$125.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we achieved an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone upon the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">approval of cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">first-line treatment of advanced RCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone upon Ipsen&#8217;s filing with the EMA for cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced HCC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> commercial milestone upon </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ipsen&#8217;s achievement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales cumulatively over four consecutive quarters</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The timing and amount of revenue recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for those milestones is described below.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$199.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$40.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone upon the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">approval of cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC, and additional milestone payments for other future indications and/or jurisdictions. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">T</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">he collaboration agreement also provides that we will be eligible to receive contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$519.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with sales volume milestones. We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, which was reached in the second quarter of 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of annual net sales, with separate tiers for Canada and the remainder of Ipsen&#8217;s sales territory. These tiers will reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with BMS; CheckMate 040, the phase 1/2 study evaluating the combination of cabozantinib with nivolumab in patients with both previously treated and previously untreated advanced HCC being conducted in collaboration with BMS (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with the Roche Group. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product will be supplied</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">at our cost, as defined in the agreement, which excludes the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GSK on Ipsen&#8217;s net sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">U.S. Food and Drug Administration </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified the following performance obligations under the collaboration agreement with Ipsen: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib, as described above; and (2) r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development services, which includes certain committed studies for the development of cabozantinib, p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">harmacovigilance services and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">participation on the joint steering and development committees (as defined in the collaboration agreement).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We evaluated the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration agreement with Ipsen</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> under Topic 606 as of January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on the evaluation as of that date, the up-front, nonrefundable fees, the milestones earned and royalties earned as of December 31, 2017, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we expected to achieve in the first quarter of 2018 upon Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EMA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC, and the estimated reimbursements for our research and development services performance obligation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. The transaction price was allocated to the performance obligations identified based on our best estimate of the relative standalone selling price: for our license, the estimate was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate and for r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> services the estimate was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. Other than the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> HCC filing milestone discussed above, variable consideration related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate to the license transferred to Ipsen and therefore is recognized at the later of when the performance obligation is satisfied or the related sales occur. We re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Revenues related to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time, upon execution of the collaboration agreement in February 2016. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">research and development services performance obligation are being recognized using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union, which is early 2030. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$51.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenue for a commercial milestone from Ipsen that we earned in the second quarter of 2018 upon Ipsen&#8217;s achievement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in net sales cumulatively over four consecutive quarters. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that sales-based milestones relate entirely to the previously satisfied performance obligations for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the transfer of an</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> intellectual property license and therefore recognized the entire milestone in the quarter the milestone was achieved.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$46.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenue of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone from Ipsen for the approval of cabozantinib for the first-line treatment of advanced RCC by the European Commission (&#8220;EC&#8221;), of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was recognized in the first quarter of 2018. We determined recognition of the milestone during the first quarter of 2018 was appropriate following the Committee for Medicinal Products for Human Use&#8217;s (&#8220;CHMP&#8221;) positive opinion of cabozantinib for the first-line treatment of advanced RCC. The positive CHMP opinion was reviewed by the EC as part of their approval process. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our determination that we expected to achieve the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone resulted in a change in the overall </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">transaction price of the collaboration agreement, as it was probable that a significant reversal of cumulative revenue would not occur. We recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in revenue in the first quarter of 2018 which represents </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the portion of the milestone that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license and research and development services. The remainder </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the milestone </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was allocated to research and development services to be recognized in future periods as those services are delivered through early 2030, which included an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> recognized in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the second quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was included in Current portion of deferred revenue and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was included in Long-term deferred revenue on the accompanying Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upfront nonrefundable payment from Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018, we amended the collaboration agreement to modify the milestones we are eligible to receive under the agreement. As of June 30, 2018, we were eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to second-line RCC, first-line RCC and second-line HCC, as well as additional development,  regulatory and first-sale milestone payments for potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with sales volume milestones. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and after the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales. These tiers will reset each calendar year. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In accordance with the collaboration agreement, Takeda has opted into and is co-funding</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with BMS. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda, as well as a quality agreement setting forth, in detail, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">respective responsibilities pertaining to the quality requirements of the aforementioned supply to Takeda. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> years of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We identified the following performance obligations under the collaboration agreement with Takeda: (1) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the transfer of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an exclusive license for the commercialization and further development of cabozantinib, as described above; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">harmacovigilance services and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">participation on the joint executive and development committees (as defined in the collaboration agreement).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We evaluated the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration agreement with Takeda</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> under Topic 606 as of January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on the evaluation as of that date, the up-front, nonrefundable fee </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and the estimated reimbursements for our research and development services performance obligation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">constituted the amount of the consideration to be included in the transaction price as of December 31, 2017. The transaction price was allocated to the performance obligations identified based on our best estimate of the relative standalone selling price: for our license, the estimate was determined using a discounted cash flow valuation utilizing forecasted revenues and costs, and a discount rate and for r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">services the estimate was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. Variable consideration related to regulatory and development milestones not previously recognized was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones and royalties will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license transferred to Takeda and therefore is recognized at the later of when the performance obligation is satisfied or the related sales occur. We re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues related to our license performance obligation are recorded immediately as our license represents functional intellectual property that was transferred at a point in time, upon execution of the collaboration agreement in January 2017. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">research and development services performance obligation are being recognized using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in Japan, which is early 2030. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$28.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Takeda was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was included in Long-term deferred revenue on the accompanying Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty revenues on ex-U.S. sales and our share of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the profits and losses recognized in connection with COTELLIC&#8217;s commercialization in the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The royalty revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on ex-U.S. sales were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">included in Collaboration revenues. Prior to the adoption of topic 606, royalty revenues from the collaboration agreement with Genentech were based on amounts reported to us by our collaboration partner and were recorded when such information becomes available to us; beginning in the first quarter of 2017 such information became available in the current quarter and for 2016 such information was not available until the following quarter, meaning that through December 31, 2016 we recorded royalty revenues on a one quarter lag. As a result of this change, royalty revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in royalty revenues for sales in the fourth quarter of 2016 in addition to the royalty revenues for sales in the first half of 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Losses on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations; Selling, general and administrative expenses also included the profit for the first quarter of 2018 in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 2, 2018 as we were not expecting an overall profit for the year ended December 31, 2018. During the second quarter of 2018, we determined that we now expect an overall profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization of COTELLIC for the year ended December 31, 2018 and therefore we have included the profit for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in Collaboration revenues for those periods; accordingly, we have also reclassified the profit for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">first quarter of 2018 from Selling, general and administrative expenses to Collaboration revenue for that period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GSK Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,628</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">StemSynergy Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy Therapeutics, Inc. (&#8220;StemSynergy&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (&#8220;CK1&#945;&#8221;) a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. We paid</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> StemSynergy an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for initial research and development funding and StemSynergy is eligible to receive up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such funding. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> payment we made during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is included in Research and development expenses in the accompanying Condensed Consolidated Statements of Operations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">StemSynergy will also be eligible for up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Invenra Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we entered into a collaboration and license agreement with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra, Inc. (&#8220;Invenra&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on developing next-generation biologics, to discover and develop multispecific antibodies for the treatment of cancer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Invenra is responsible for antibody lead discovery and generation while we will lead Investigational New Drug enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement also provides that we will receive an exclusive, worldwide license to one preclinical asset </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(the &#8220;lead preclinical asset&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and that we and Invenra intend to pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, we paid Invenra an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and second project initiation fee of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of total payments we made during the six months ended June&#160;30, 2018 are included in Research and development expenses in the accompanying Condensed Consolidated Statements of Operations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Invenra is eligible to receive payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$131.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> based on the achievement of specific development and regulatory milestones for a product containing the lead preclinical asset in the first indication. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$325.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product. We also have the right to initiate five additional discovery projects for development subject to an upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for each project as well as additional global milestone payments and royalties for any products that arise from these discovery efforts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the later of (i) ten years after the first commercial sale of such product in such country or (ii) expiration of patent claims covering the product in such country. We may terminate the collaboration agreement in its entirety or on a project-by-project basis at any time prior to commercialization, for any or no reason, upon thirty days&#8217; written notice to Invenra. The collaboration agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of our other existing collaboration agreements, see &#8220;Note 2. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that each of our other </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">existing collaboration agreements </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">have one performance obligation, the delivery of an intellectual property license to each collaboration partner, which was satisfied for all such agreements prior to the adoption of Topic 606. As a result, any consideration earned and received from these collaborations will be recognized immediately as the licenses we provided represent functional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">intellectual property </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that was transferred at a point in time prior to the adoption of Topic 606, when the agreements were executed. Potential v</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ariable consideration for these collaborations related to regulatory and development milestones was constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. Any variable consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the licenses transferred and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon Daiichi Sankyo&#8217;s submission of a regulatory application to the Japanese Pharmaceutical and Medical Devices Agency for esaxerenone as a treatment for patients with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">essential </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">hypertension, we earned a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone, which is included in Collaboration revenues during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819334944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsAndInvestmentsTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CASH AND INVESTMENTS </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">248,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investments Available-for-sale</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Investments by security type were as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were nominal during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">200,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross unrealized losses on commercial paper in an unrealized loss position 12 months or greater were less than $1 thousand.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">149</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">500,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsAndInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsAndInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819428016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">765</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for both the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory expected to be used in production or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Condensed Consolidated Balance Sheets. As of both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the non-current portion of inventory consisted of a portion of our finished goods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819492096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PROPERTY AND EQUIPMENT </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">78,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leased Premises Placed in Service</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with Ascentris 105, LLC (&#8220;Ascentris&#8221;) for office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the &#8220;Premises&#8221;). The Lease was amended in October 2017 and June 2018 to increase the space leased to an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134,765</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. For a description of the Lease, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">see &#8220;Note 12. Commitments&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In June 2018, we relocated our offices and research facilities to the Premises. Accordingly, we placed into service </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$59.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in related Leasehold improvements, Buildings, Furniture and fixtures and Computer equipment and software, portions of which were included in Construction in progress at prior period ends. We are continuing to review the allocation of these additions between Leasehold improvements and Furniture and fixtures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises, including the building shells, did not qualify as &#8220;normal tenant improvements&#8221; under Accounting Standards Codification Topic 840, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;Topic 840&#8221;). Accordingly, for accounting purposes, we were deemed to be the owner of such portions of the Premises during the construction period. As such, we capitalized the construction costs as a build-to-suit property within Property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. Accordingly, we capitalized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs related to the Lease in construction in progress as of May 2, 2017, with a corresponding build-to-suit financing obligation in Other long-term liabilities. In June 2018, upon placing of the assets in service and in accordance with Topic 840, due to our continuing involvement in the Premises the Lease did not qualify for sale-leaseback accounting. Accordingly, the assets placed into service include the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> estimated fair value of the building shells that we are deemed to own. We have also recorded a related financing obligation of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in Other current liabilities and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in Financing obligation for build-to-suit lease in the accompanying Condensed Consolidated Balance Sheets for the buildings and related landlord allowance earned in the second quarter of 2018. Buildings are depreciated over their estimated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year useful life.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819429840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and restricted stock units (&#8220;RSUs&#8221;) to employees, directors and consultants. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19,509,911</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value per share of our stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock option activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">818,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,141,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(102,177</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,783,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.8 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,249,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">271,709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$39.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to unvested stock options will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.3 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RSU activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">300,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(341,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(120,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,601,202</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$56.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to unvested RSUs will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2.8 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819492096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> primarily relates to state taxes for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset our federal taxable income.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law. The Tax Cuts and Jobs Act contained significant changes to corporate taxation, included among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. Further guidance may be forthcoming from the FASB and the&#160;SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts. The Provision for income taxes for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> did not reflect any adjustment to the impact of the Tax Cuts and Jobs Act enactment that we recorded during the year ended December 31, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824979840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NET INCOME PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for diluted net income per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296,874</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">313,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year warrants to purchase an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock issued in January 2014 (&#8220;2014 Warrants&#8221;) were participating securities. The warrant holders did not have a contractual obligation to share in our losses. The 2014 Warrants were fully exercised in September 2017. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the 2014 Warrants, see &#8220;Note 7. Common Stock and Warrants&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potentially dilutive shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825053120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">540,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and there were no transfers of financial assets or liabilities classified as Level 3 during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our remaining financial assets and liabilities include Cash, Trade and other receivables, Unbilled collaboration revenue, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers, and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834437472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2018 will end on December 28, 2018 and fiscal year 2017 ended on December 29, 2017. For convenience, references in this report as of and for the fiscal periods ended June 29, 2018, March 30, 2018 and June 30, 2017, and as of and for the fiscal years ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2018, March 31, 2018 and June 30, 2017, and the years ended December&#160;31, 2018 and December&#160;31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended December 28, 2018 and the first day of the fiscal quarter ended June 29, 2018 are indicated as being as of January 1, 2018 and April 1, 2018, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts on the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to current period presentation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-18&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was adopted using the r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">etrospective transition method in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Condensed Consolidated Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-18, we no longer include purchases </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of restricted cash and proceeds from maturities of restricted cash </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in our cash flows from investing activities.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 supersedes all previous revenue recognition requirements in accordance with generally accepted accounting principles. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2018, we adopted ASU </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">No. 2014-09, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(&#8220;Topic 606&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 605: Revenue Recognition (&#8220;Topic 605&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adjustments due to the adoption of Topic 606 primarily related to a reduction in deferred revenue driven by the allocation of the transaction price to our license performance obligations in the Ipsen and Takeda collaborations, which were determined to be functional intellectual property that was transferred at a point in time and as a result, revenue was recorded at a point in time. Previously under Topic 605, revenue related to the upfront payments and one non-substantive milestone payment earned in 2016 had been deferred over the estimated period of performance pursuant to the terms of the contract. Contract assets as of January 1, 2018 primarily related to estimated revenue for reimbursements for our continuing research and development services and the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone from Ipsen&#8217;s filing with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">European Medicines Agency (&#8220;EMA&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for cabozantinib, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced hepatocellular carcinoma (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC&#8221;),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> that was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">deemed probable under Topic 606 prior to January 1, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eferred revenue as of January 1, 2018 is related to the up-front, nonrefundable, fees and milestones achieved </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that were allocated to our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">esearch and development services performance obligation that had not been satisfied as of that date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Contract assets and liabilities are netted by collaboration agreement in our Condensed Consolidated Balance Sheets; however, for illustration purposes the above amounts are shown prior to netting.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSalesOfGoods', window );">Net Product Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionRevenueReductions', window );">Product Sales Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Customers in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect our Customers will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates participating manufacturers to fund 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to patients, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty distributor that administers the copay program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, these payments are classified in Selling, general and administrative expenses in our Condensed Consolidated Statements of Operations.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for product supply; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Except for profit sharing arrangements and payments for product supply, each of these payment types are within the scope of Topic 606. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect Collaboration revenues and earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our Ipsen and Takeda arrangements include promises of future clinical development and drug safety services, as well as participation on certain joint committees. We have determined that these services collectively are distinct from the licenses provided to Ipsen and Takeda and as such, these promises are accounted for as a separate performance obligation recorded over time. We record revenue for these services as the performance obligations are satisfied, which we estimate using internal development costs incurred and projections through the term of the arrangements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit Sharing Arrangements: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are also entitled to low double-digit royalties on ex-U.S. net sales. We account for such arrangements in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accounting Standards Codification Topic 808, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;Topic 808&#8221;). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. We expect to recognize an annual profit under the agreement for the year ended December 31, 2018 and accordingly, those profits are recognized as Collaboration revenues on the accompanying Condensed Consolidated Statements of Operations. Historically, we had not recognized a profit for any annual period from the commercialization of cobimetinib in the U.S. and accordingly, losses for periods prior to 2018 were recognized as Selling, general and administrative expenses on the accompanying Condensed Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Sales-based Milestone Payments and Royalties:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No.&#160;2016-02,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Leases (Topic 842),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-02&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require a right-of-use asset to be recognized on the balance sheet for both types of leases. ASU 2016-02 also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-11, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU No. 2018-11&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In issuing ASU No. 2018-11, the FASB is permitting another transition method for ASU 2016-02, which allows the transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are currently considering the potential of an early adoption of this standard in the second half of 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using the transition method permitted by ASU 2018-11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Based on our initial evaluation of the impact of ASU 2016-02 on our build-to-suit lease of office and research facilities located in Alameda, California, we expect that the amount we have capitalized as Property and equipment related to the building shells and related financing liabilities, will be derecognized upon the adoption of ASU 2016-02. Upon adoption of ASU 2016-02 we will also be required to recognize a right-of-use asset and lease liability related to this lease. The adoption of ASU 2016-02 could also change the nature of future expenses related to the build-to-suit lease, reducing future depreciation and interest expense, which would be offset by an increase in lease expense. We are continuing to assess the impact of ASU No. 2016-02 on our consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=d3e5291-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionRevenueReductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy of sales arrangements for goods or services that reduce the amount of revenue recognized for example sales returns, allowances, incentives, rebates, discounts and loyalty programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68073604&amp;loc=d3e63242-111658<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68073604&amp;loc=d3e63164-111658<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68073604&amp;loc=d3e63207-111658<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionRevenueReductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSalesOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197222<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076378&amp;loc=d3e47119-111625<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionSalesOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824965248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Adoption of Topic 606</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Balance Sheet </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as of January 1, 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Adjustments Due to the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract assets: unbilled collaboration revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract liabilities: deferred revenue, gross:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">258,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,570,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of the adoption of Topic 606 on the accompanying Condensed Consolidated Statements of Operations as of and for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Balances Without the Adoption of Topic 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Effect of Adoption</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Higher / (Lower)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">240,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">142,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,906</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,005</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6627958240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">172,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">332,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">178,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(26,810</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(12,254</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(51,974</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(21,336</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included revenues related to the portion of three milestones that were allocated to the transfer of intellectual property licenses and were recognized in the current period and royalty revenue from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the recognition of deferred revenues from upfront payments and a non-substantive milestone that were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech. License revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> also included a milestone payment from Bristol-Myers Squibb Company (&#8220;BMS&#8221;). Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners between licenses and research and development services as well as the timing of recognition has changed. Therefore, among other changes, as of January 1, 2018, the portion of proceeds allocated to intellectual property licenses for our Ipsen and Takeda collaboration agreements are recognized immediately and License revenues no longer includes revenues related to the amortization of deferred revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development services performance obligation which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606 and therefore Research and development services revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only development cost reimbursements earned on our collaboration agreements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues for </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included net product supply revenues from Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Losses on the U.S. commercialization of COTELLIC for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> were included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations and therefore Other collaboration revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> included only net product supply revenues.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Duri</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ng the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Net product revenues and License revenues related to goods transferred at a point in time and Research and development services revenues related to services performed over time.  License revenues and Research and development services revenues were recorded in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included the p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net product supply revenues, were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 for all periods presented</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">141,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">270,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,599</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52,809</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">44,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">137,892</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">47,985</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">150,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">287,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">163,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and Discounts for Prompt Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other Customer Credits/Fees and Co-pay Assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(737</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(30,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(47,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract Assets and Liabilities under Topic 606</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Topic 606</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(213,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">471</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(17,306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824926240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Collaboration Revenues and Contract Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,628</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty revenues on ex-U.S. sales and our share of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the profits and losses recognized in connection with COTELLIC&#8217;s commercialization in the U.S. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Profits and losses on U.S. commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659493264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">248,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">188,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">139,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">155,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Investments by Security Type</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Investments by security type were as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">200,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross unrealized losses on commercial paper in an unrealized loss position 12 months or greater were less than $1 thousand.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">500,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">94,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824904944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">765</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825028624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">78,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14,154</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827393584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value per share of our stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Used to Estimate Grant-Date Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock option activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">818,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,141,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(102,177</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,783,471</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.8 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,249,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">271,709</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">RSU Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RSU activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">300,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(341,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(120,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,601,202</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6626825360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771605808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for diluted net income per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">203,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296,874</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">313,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Shares of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potentially dilutive shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825051088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 29, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">280,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">540,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">594,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6837519760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">23 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">$ 51,853<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 40,667<span></span>
</td>
<td class="nump">$ 105,869<span></span>
</td>
<td class="nump">$ 74,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">40,272<span></span>
</td>
<td class="nump">79,400<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">119,719<span></span>
</td>
<td class="nump">23,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">186,108<span></span>
</td>
<td class="nump">213,700<span></span>
</td>
<td class="nump">99,008<span></span>
</td>
<td class="nump">399,827<span></span>
</td>
<td class="nump">179,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">100,338<span></span>
</td>
<td class="nump">97,400<span></span>
</td>
<td class="nump">71,895<span></span>
</td>
<td class="nump">197,750<span></span>
</td>
<td class="nump">132,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Increase in net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,800)<span></span>
</td>
<td class="nump">81,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Reduction to accumulated deficit</a></td>
<td class="num">(1,367,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,367,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,829,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,570,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue</a></td>
<td class="nump">31,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,156<span></span>
</td>
<td class="nump">$ 100,938<span></span>
</td>
<td class="nump">20,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Prompt payment discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Percent of total available discounts expected to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember', window );">Products Derived from Cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">34,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,494<span></span>
</td>
<td class="nump">$ 87,852<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | HCC Filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | EMA Approval - RCC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | EMA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member', window );">ASU 2016-18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Increase in net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="num">(54,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">$ (54,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Reduction to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 258,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835315840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on Contract Assets, Contract Liabilities and Accumulated Deficit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 30, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets: unbilled collaboration revenue, gross:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities: deferred revenue, gross:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">5,939<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
<td class="nump">$ 31,984<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Current portion</a></td>
<td class="nump">11,970<span></span>
</td>
<td class="nump">25,441<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (1,367,316)<span></span>
</td>
<td class="num">(1,570,667)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balances Without the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets: unbilled collaboration revenue, gross:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities: deferred revenue, gross:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,829,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets: unbilled collaboration revenue, gross:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities: deferred revenue, gross:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826749072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on the Consolidated Statement of Operations (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 40,272<span></span>
</td>
<td class="nump">$ 79,400<span></span>
</td>
<td class="nump">$ 11,004<span></span>
</td>
<td class="nump">$ 119,719<span></span>
</td>
<td class="nump">$ 23,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">186,108<span></span>
</td>
<td class="nump">$ 213,700<span></span>
</td>
<td class="nump">99,008<span></span>
</td>
<td class="nump">399,827<span></span>
</td>
<td class="nump">179,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">88,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,237<span></span>
</td>
<td class="nump">206,766<span></span>
</td>
<td class="nump">35,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balances Without the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 94,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">240,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">142,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 140,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments Due to the Adoption of Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="num">$ (54,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(54,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="num">(54,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (53,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822240096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProductRevenuesAbstract', window );"><strong>Product revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross product revenues</a></td>
<td class="nump">$ 172,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,258<span></span>
</td>
<td class="nump">$ 332,082<span></span>
</td>
<td class="nump">$ 178,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Discounts and allowances</a></td>
<td class="num">(26,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,254)<span></span>
</td>
<td class="num">(51,974)<span></span>
</td>
<td class="num">(21,336)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">145,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,004<span></span>
</td>
<td class="nump">280,108<span></span>
</td>
<td class="nump">156,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationRevenuesAbstract', window );"><strong>Collaboration revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenues</a></td>
<td class="nump">31,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,156<span></span>
</td>
<td class="nump">100,938<span></span>
</td>
<td class="nump">20,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchAndDevelopmentServiceRevenue', window );">Research and development services revenues</a></td>
<td class="nump">6,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">16,904<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other collaboration revenues</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
<td class="num">(663)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total collaboration revenues</a></td>
<td class="nump">40,272<span></span>
</td>
<td class="nump">$ 79,400<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">119,719<span></span>
</td>
<td class="nump">23,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,700<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
<td class="nump">$ 179,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProductRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProductRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchAndDevelopmentServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Service Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchAndDevelopmentServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68051624&amp;loc=d3e47468-111626<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834085376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net product revenues</a></td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,700<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
<td class="nump">$ 179,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net product revenues</a></td>
<td class="nump">145,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,004<span></span>
</td>
<td class="nump">280,108<span></span>
</td>
<td class="nump">156,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net product revenues</a></td>
<td class="nump">141,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,861<span></span>
</td>
<td class="nump">270,055<span></span>
</td>
<td class="nump">143,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net product revenues</a></td>
<td class="nump">$ 4,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,143<span></span>
</td>
<td class="nump">$ 10,053<span></span>
</td>
<td class="nump">$ 13,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835829872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,700<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
<td class="nump">$ 179,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 34,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,494<span></span>
</td>
<td class="nump">$ 87,852<span></span>
</td>
<td class="nump">$ 10,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 26,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,435<span></span>
</td>
<td class="nump">$ 52,809<span></span>
</td>
<td class="nump">$ 32,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C. | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 23,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,846<span></span>
</td>
<td class="nump">$ 44,652<span></span>
</td>
<td class="nump">$ 24,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 18,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,599<span></span>
</td>
<td class="nump">$ 38,622<span></span>
</td>
<td class="nump">$ 42,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 19,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,619<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 23,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 64,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,015<span></span>
</td>
<td class="nump">$ 137,892<span></span>
</td>
<td class="nump">$ 47,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826642352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 213,700<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
<td class="nump">$ 179,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">150,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,371<span></span>
</td>
<td class="nump">287,072<span></span>
</td>
<td class="nump">163,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">34,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
<td class="nump">87,852<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_OtherGeographicalAreasMember', window );">Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 24,903<span></span>
</td>
<td class="nump">$ 6,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_OtherGeographicalAreasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_OtherGeographicalAreasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826669824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 9,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">52,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(47,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">13,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">32,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(30,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">2,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">6,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(6,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">5,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">14,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(10,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 9,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834406320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward', window );"><strong>Contract Assets - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues', window );">Increases as a result of a change in transaction price and recognition of revenues as services are performed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Transfer to receivables from contract assets recognized at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetCurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward', window );"><strong>Contract Assets - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues', window );">Increases as a result of a change in transaction price and recognition of revenues as services are performed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward', window );"><strong>Contract Liabilities - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue', window );">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityCurrentDeductions', window );">Revenue recognized that was included in the contract liability balance at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,939<span></span>
</td>
<td class="nump">5,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward', window );"><strong>Contract Liabilities - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue', window );">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityNoncurrentDeductions', window );">Revenue recognized that was included in the contract liability balance at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,970<span></span>
</td>
<td class="nump">11,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 32,200<span></span>
</td>
<td class="nump">103,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balances Without the Adoption of Topic 606</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward', window );"><strong>Contract Assets - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward', window );"><strong>Contract Assets - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward', window );"><strong>Contract Liabilities - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward', window );"><strong>Contract Liabilities - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,520<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeInContractWithCustomerAssetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerAssetNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetCurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Current, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetCurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Noncurrent, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetNoncurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityCurrentDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Current, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityCurrentDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Current, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityCurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityNoncurrentDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Noncurrent, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityNoncurrentDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Noncurrent, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=SL51747714-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6836928832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Ipsen Collaboration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">23 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,156,000<span></span>
</td>
<td class="nump">$ 100,938,000<span></span>
</td>
<td class="nump">$ 20,370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,984,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8,393,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,520,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 25,441,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payment(s)</a></td>
<td class="nump">$ 210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">199,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Contingent cash receipts (up to)</a></td>
<td class="nump">519,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Initial and Second</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Initial and Second | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Initial and Second | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Second</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | EMA Approval - RCC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 45,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | HCC Filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | Net Sales Achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsMinimumNetSalesAchievementAmount', window );">Net sales achievement level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | HCC Acceptance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen | EMA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsMinimumNetSalesAchievementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Minimum Net Sales Achievement Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsMinimumNetSalesAchievementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=SL51747714-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_SecondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_SecondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_RevenueAchievementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_RevenueAchievementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAApprovalHCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAApprovalHCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_EMAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_EMAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819335760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 40,272<span></span>
</td>
<td class="nump">$ 79,400<span></span>
</td>
<td class="nump">$ 11,004<span></span>
</td>
<td class="nump">$ 119,719<span></span>
</td>
<td class="nump">$ 23,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 34,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,494<span></span>
</td>
<td class="nump">$ 87,852<span></span>
</td>
<td class="nump">$ 10,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823088496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda Collaboration (Details) - Collaborative Arrangement with Takeda - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payment(s)</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum pre-specified payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PeriodOfSpecificSalesVolumeThreshold', window );">Sales volume period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Global</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Cumulative net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Initial | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Initial | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Final | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Final | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodOfSpecificSalesVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Specific Sales Volume, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodOfSpecificSalesVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=SL51747714-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819470944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 40,272<span></span>
</td>
<td class="nump">$ 79,400<span></span>
</td>
<td class="nump">$ 11,004<span></span>
</td>
<td class="nump">$ 119,719<span></span>
</td>
<td class="nump">$ 23,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 4,903<span></span>
</td>
<td class="nump">$ 6,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821552448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - Collaborative Arrangement with Genentech - COTELLIC - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="nump">$ 1,367<span></span>
</td>
<td class="nump">$ 2,895<span></span>
</td>
<td class="nump">$ 3,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossfromAgreement', window );">Profits and losses on U.S. commercialization</a></td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="num">$ (781)<span></span>
</td>
<td class="nump">$ 4,069<span></span>
</td>
<td class="num">$ (1,407)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossfromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossfromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822797440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Genentech Collaboration (Details) - Collaborative Arrangement with Genentech - COTELLIC - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="nump">$ 1,367<span></span>
</td>
<td class="nump">$ 2,895<span></span>
</td>
<td class="nump">$ 3,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Q4 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodGeneratedAxis=exel_Q416Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodGeneratedAxis=exel_Q416Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771727696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GlaxoSmithKline (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties accruing to GSK</a></td>
<td class="nump">$ 5,628<span></span>
</td>
<td class="nump">$ 2,962<span></span>
</td>
<td class="nump">$ 10,753<span></span>
</td>
<td class="nump">$ 5,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793930304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - StemSynergy Collaboration (Details) - Collaborative Arrangement with StemSynergy<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront payments</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember', window );">First Products to Reach Market</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">$ 56.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822255136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Invenra Collaboration (Details) - Collaborative Arrangement with Invenra<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront payments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProjectInitiationFeePayment', window );">Project initiation fee</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPaymentsAndProjectInitiationFeesPayments', window );">Total upfront payments and project initiation fees</a></td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">131.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Product Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Additional milestone achievement</a></td>
<td class="nump">325.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Discovery Projects</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront payments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProjectInitiationFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project Initiation Fee Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProjectInitiationFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPaymentsAndProjectInitiationFeesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payments And Project Initiation Fees Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPaymentsAndProjectInitiationFeesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825027936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Other Collaborations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Collaborative arrangements with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835085248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 248,407<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 135,212<span></span>
</td>
<td class="nump">$ 151,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash included in short-term restricted cash and investments</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash included in long-term restricted cash and investments</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,650<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 250,011<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 139,862<span></span>
</td>
<td class="nump">$ 155,836<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835550208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 595,607<span></span>
</td>
<td class="nump">$ 440,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(785)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">594,876<span></span>
</td>
<td class="nump">440,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">54,546<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">54,546<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">21,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">280,654<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">280,654<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">218,780<span></span>
</td>
<td class="nump">179,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(730)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">218,104<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,532<span></span>
</td>
<td class="nump">16,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 20,477<span></span>
</td>
<td class="nump">$ 16,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822989792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">$ 195,947<span></span>
</td>
<td class="nump">$ 154,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">4,155<span></span>
</td>
<td class="nump">22,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">200,102<span></span>
</td>
<td class="nump">177,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(780)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(785)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">177,129<span></span>
</td>
<td class="nump">140,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">179,624<span></span>
</td>
<td class="nump">160,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(725)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(730)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="nump">18,818<span></span>
</td>
<td class="nump">13,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">1,660<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">20,478<span></span>
</td>
<td class="nump">16,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (55)<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819502032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gain (loss) on sales of investments available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairment charges on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Realized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822133968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 500,480<span></span>
</td>
<td class="nump">$ 377,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">94,396<span></span>
</td>
<td class="nump">63,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 594,876<span></span>
</td>
<td class="nump">$ 440,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823323856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">9,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on inventory</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823265008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 78,898<span></span>
</td>
<td class="nump">$ 48,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(14,154)<span></span>
</td>
<td class="num">(22,800)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">64,744<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">41,003<span></span>
</td>
<td class="nump">4,715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">15,507<span></span>
</td>
<td class="nump">14,146<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">5,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,839<span></span>
</td>
<td class="nump">$ 22,114<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823358576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fair value of buildings</a></td>
<td class="nump">$ 78,898<span></span>
</td>
<td class="nump">78,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Financing obligations included in other current liabilities</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Financing obligation for build-to-suit lease</a></td>
<td class="nump">20,646<span></span>
</td>
<td class="nump">20,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember', window );">Leasehold Improvements, Buildings, Furniture and Fixtures, Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PropertyPlantAndEquipmentAdditionsAndTransfers', window );">Construction in progress capitalized</a></td>
<td class="nump">59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fair value of buildings</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fair value of buildings</a></td>
<td class="nump">$ 14,530<span></span>
</td>
<td class="nump">$ 14,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember', window );">Operating Leases and Other Financing Leases | Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PropertyPlantAndEquipmentAdditionsAndTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Additions And Transfers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PropertyPlantAndEquipmentAdditionsAndTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LeaseholdImprovementsBuildingsFurnitureAndFixturesComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823867408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 5,027<span></span>
</td>
<td class="nump">$ 18,588<span></span>
</td>
<td class="nump">$ 9,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">5,933<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 6,383<span></span>
</td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="nump">$ 12,655<span></span>
</td>
<td class="nump">$ 6,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819551168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares) | shares</a></td>
<td class="nump">19,509,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 39.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average cost recognition period</a></td>
<td class="text">2 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 56.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average cost recognition period</a></td>
<td class="text">2 years 10 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663832176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.82<span></span>
</td>
<td class="nump">$ 10.07<span></span>
</td>
<td class="nump">$ 10.37<span></span>
</td>
<td class="nump">$ 10.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 4.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823741808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.66%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">4 years 4 months 9 days<span></span>
</td>
<td class="text">4 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.94%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823560480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">22,208,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">818,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(1,141,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(102,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">21,783,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">16,249,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">22.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">15.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">7.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at end of period</a></td>
<td class="text">3 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">3 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period | $</a></td>
<td class="nump">$ 312,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period | $</a></td>
<td class="nump">$ 271,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823961008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity (Details) - RSUs<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">3,762,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">300,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(341,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(120,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at end of period (in shares) | shares</a></td>
<td class="nump">3,601,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">23.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">7.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">19.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at end of period</a></td>
<td class="text">1 year 7 months 27 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue', window );">RSUs outstanding at end of period | $</a></td>
<td class="nump">$ 77,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822687264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 3,415<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6836957232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income allocable to common stock for basic net income per share</a></td>
<td class="nump">87,494<span></span>
</td>
<td class="nump">17,596<span></span>
</td>
<td class="nump">203,351<span></span>
</td>
<td class="nump">34,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Adjustment to net income allocated to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income allocable to common stock for diluted net income per share</a></td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
<td class="nump">$ 34,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)</a></td>
<td class="nump">297,336<span></span>
</td>
<td class="nump">293,188<span></span>
</td>
<td class="nump">296,874<span></span>
</td>
<td class="nump">292,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</a></td>
<td class="nump">14,905<span></span>
</td>
<td class="nump">18,031<span></span>
</td>
<td class="nump">16,150<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities (in shares)</a></td>
<td class="nump">312,241<span></span>
</td>
<td class="nump">311,219<span></span>
</td>
<td class="nump">313,024<span></span>
</td>
<td class="nump">310,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834555936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Narrative (Details) - 2014 Warrants - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ClassofWarrantorRightPeriod', window );">Term of warrants</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ClassofWarrantorRightPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ClassofWarrantorRightPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819335088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Potentially Dilutive Shares of Common Stock (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares (in shares)</a></td>
<td class="nump">5,163<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding stock options, unvested RSUs and ESPP contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares (in shares)</a></td>
<td class="nump">5,163<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823608976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">$ 594,876<span></span>
</td>
<td class="nump">$ 440,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">54,546<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">540,330<span></span>
</td>
<td class="nump">394,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">54,546<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">54,546<span></span>
</td>
<td class="nump">45,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">21,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">21,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">280,654<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">280,654<span></span>
</td>
<td class="nump">199,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">218,104<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">218,104<span></span>
</td>
<td class="nump">179,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">20,477<span></span>
</td>
<td class="nump">16,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets</a></td>
<td class="nump">$ 20,477<span></span>
</td>
<td class="nump">$ 16,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_RNPBX8N[?_V/@B*#OX]2_D%U!+ P04    " #T@0%-F5R<(Q &  "<)P
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M7RD56'H4/DE?:MFCIP7!5Z&FF9PSTZC,0M!^;,+!]$^@^@M02P,$%     @
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M+<.$CP&5I[ \8#HDE,)3QW &QB_7H(])YXS1 NMC."6U2R8$LA[Y")(*C+%
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M*<O&A^Z+^]#Q@\_VUYO<OS3MI0G757\ZV-\TY7DX^8RNQZ^K_P!02P,$%
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M5>=%I5*1UW8L:C/>.O]O-#\!=@3X60+J"*@GJ&3O$9*.D+P3DKN$M".DGXV
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M_IDK79[:' N>7[_7_O,4? KFKNECW6[_WCP,S]?+L%P\Q,?F93M\:=]^B7-
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M4_%HR47:4OJ0LX.!R "(+('(&G2E<\H1P&8"1V;[RAB'#+;U*FEFG7QRJ?T
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MSK]!=."E)'=^A3K_P!9'0N."^=;;9EJSR7'8SR^(+<^X_ U02P,$%     @
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M.%NTV,I22PV]DZ8G%IJ"WJ?'4Q;B8\ /"9/;G$FHY&+,4S ^UP5-@B!04/G
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M_H,MAH3&A>.]/YMIS";#83__(+9\X_(O4$L#!!0    ( /2! 4WC/3AYM0$
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MJ%TX[OW9C&,V&@Z[Z0>Q^1L7?P%02P,$%     @ ]($!35+I \%( @  / @
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M;%"1#4(0)A[#3"2>)G@')0A%F'H4-)%[.M&I%*$(LX^")M)/T7;=4890A 6
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M]0]L<234+IB/WC;3FDV.PWY^06QYQL5O4$L#!!0    ( /2! 4U4"A:'T $
M )P$   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;'54;6_;(!#^*X@?
M4&SB>%UD6VI:39NT25&G=9^)?7Y1P7A XN[?#[#C>1[]$KCS\W)'.+)1JE?=
M ACT)GBO<]P:,QP(T64+@ND[.4!OO]12"69LJ!JB!P6L\B3!"8VBE C6];C(
M?.ZDBDQ>#.]Z."FD+T(P]?L(7(XYCO$M\=PUK7$)4F0#:^ [F!_#2=F(+"I5
M)Z#7G>R1@CK'#_'AF#J\![QT,.K5'KE.SE*^NN!+E>/(%00<2N,4F%VN\ B<
M.R%;QJ]9$R^6CKC>W]0_^=YM+V>FX5'RGUUEVAS?8U1!S2[</,OQ,\S][#&:
MF_\*5^ 6[BJQ'J7DVO^B\J*-%+.*+46PMVGM>K^.L_Z-%B;0F4 W!#(9^<J?
MF&%%IN2(U'3V W-_<7R@]FQ*E_1'X;_9XK7-7@L:W6?DZH1FS''"T!4F7A#$
MJB\6-&1QI/_1:9B^"U:X\_3=VCU)PP))4"#Q LD_+7[<M!C Q%'89!\TV0<$
MXHU)"//.4:1!DS0@L-N8A##)QH2L;H< U?BYT*B4E][/Y"J[C-X#];?K+WR:
MVV],-5VOT5D:>T?]3:JE-&!+B>YLPZU]*I: 0VW<]H/=JVE@IL#(87X+R/(@
M%7\ 4$L#!!0    ( /2! 4W;I_M$LP$  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;'53VXZ;,!#]%<L?L X.NUM%@+39JFJE5HJV:OOLP'#1
MVAYJF[#]^]J&4)K2%SPSG'/FXG$VHGFU+8 C;TIJF]/6N?[ F"U;4,+>80_:
M_ZG1*.&\:QIF>P.BBB0E&=_M'I@2G:9%%F,G4V0X.-EI.!EB!Z6$^74$B6-.
M$WH-O'1-ZT* %5DO&O@*[EM_,MYCBTK5*="V0TT,U#E]2@['-. CX'L'HUW9
M)'1R1GP-SJ<JI[M0$$@H75 0_KC ,T@9A'P9/V=-NJ0,Q+5]5?\0>_>]G(6%
M9Y0_NLJU.7U'206U&*1[P?$CS/W<4S(W_QDN(#T\5.)SE"AM_))RL [5K.)+
M4>)M.CL=SW'6O]*V"7PF\!L"FQ+%RM\+)XK,X$C,-/M>A"M.#MS/I@S!.(KX
MSQ=O??12\.0^8Y<@-&..$X:O,,F"8%Y]2<&W4ASY/W2^3=]O5KB/]/TZ>_H?
M@713((T"Z5\M/MRTN(5YO$G"5C-58)JX39:4..BXR:OHLK!//-[)'_BT[5^$
M:3IMR1F=O]DX_QK1@2]E=^=7J/4/;'$DU"Z8C]XVTYI-CL-^?D%L><;%;U!+
M P04    " #T@0%--7PV^MT!   !!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6QU5&V/G" 0_BN$'W HKKO7C9K<7M.T29MLKFG[F=7Q)0=B@5VO
M_[Z KK66?A%F>.9Y9D:&;)3J5;< !KT)WNL<M\8,1T)TV8)@^D$.T-N36BK!
MC#550_2@@%4^2'!"HVA/!.MZ7&3>=U9%)J^&=SV<%=)7(9CZ=0(NQQS'^.YX
MZ9K6. <ILH$U\!7,M^&LK$46EJH3T.M.]DA!G>.G^'@Z.+P'?.]@U*L]<I5<
MI'QUQJ<JQY%+"#B4QC$PN]S@&3AW1#:-GS,G7B1=X'I_9__@:[>U7)B&9\E_
M=)5I<_R(404UNW+S(L>/,->38C07_QENP"W<96(U2LFU_Z+RJHT4,XM-1;"W
M:>UZOXXS_STL'$#G +H)().0S_P],ZS(E!R1FGH_,/>+XR.UO2F=T[?"G]GD
MM?7>"AH_9N3FB&;,:<+0%29>$,2R+Q(T)'&B_X33<'@2S##QX<E:/4W"!+L@
MP<X3[/XJ\=VFQ "&1F&1-"B2!@CBC4@(\Y]6[(,B^P!!LA$)879AD4-0Y! @
M2#<B(<Q^(T)65U" :OSP:53*:^\'?^5=YON)^BO\!SX]#E^8:KI>HXLT=A#\
M=:VE-&!3B1YL5UO['BT&A]JX[<'NU325DV'D,#\X9'GUBM]02P,$%     @
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M[']IC =,976%(U3C!YL,!:4/QQV>[3!F@^%-._X@-GWC[#]02P,$%     @
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MS!D_H,%H QR_ 2[: $>\F;MHCXU"AR3^&.6\B>*/40!*T;?*H;P#&G\,0ZU
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MH)E.\Y^:@%:-'N<8)-/HJ(5ZS*+#H!$FPY>01Q<"!T2D$ABR0+XL%LBAH\L
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M%!A!EC^@.3F>9X2MCVSK8W(H0]A@2 T7E[#!$'U>P#US5<!L"3<'F*)82X,
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M4A2U:>;N?VE\:6O2]?DD,R]U>Q@UQ^5I[_ET4A>'?E_=.V_N3_\'4$L#!!0
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MB D CFUC&*7 %5N/49C2#!''/D]JA&8T\3N0>!U(1@Y@3/T"J5<@O7T/B%>
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M8DY&T&122! GAC5&#!U/+"9F!.%U']G<@TR)H$W_2 "9G-C@ F]K0M_/986
M(%&3H5HRE*2):1)QC2"82&B1 BU2&B2&.+A,$$PG4C4.(A1!&IOJBRL%L9$*
MHFL%">/0$ @7"V*C%D07@S"E6N+OH*9T<-D@B&Y$IM6-"P=!E$-?FCI(7YJ(
MO- D! ,=P 4&=('1UR;H D,3:IA)P.4%$'G1%B=8:P?@V@%@L3!'T%0O8^H;
M/@" :PQ8:,P:=/T@)(U5S7P7-B6$RPP@,A,1E9"^&:$@CP,J(5V-B$\3W\0(
M%R30!0E2DPM<:2"RWZ$!KB%@H2$96&\H )<&^(\M!>#2 !;2D('>]@:B%.]X
MZMM_7BG>R]1BJY!1O9?O?#HIWL\4V0N8!)<:MO@6?9J-H-A23*G:@=.W>#=0
MI!L4I5TAF$BMF'=SAJM8L^_/QZVSX:=:=*6Z&;V>P5?0G0'5<1K,UC(5_8WD
M(=\,Y\9_(89#_]>\V1=UZSQS(4^?_1EQQ[E@DK[_(.D?6+Z]/I1L)[K;6-XW
MPV%[>!#\./Z1X%W_S5C^!5!+ P04    " #T@0%-6&"E10D%  !\&P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R56=F.XC@4_164#^C$6Q8$2%54
M4U":D4K=FIGG%)A%G1 F"47/WT\60Q'?>P.\ #'G;K;/N4XR.F7YKV*K=3GX
MG2;[8NQLR_(P=-UBN=5I7'S+#GI?_;/.\C0NJ\M\XQ:'7,>KQBA-7.YYOIO&
MN[TS&35C[_EDE!W+9+?7[_F@.*9IG/_WK)/L-':8<Q[XL=MLRWK G8P.\4;_
MU.5?A_>\NG(O7E:[5.^+7;8?Y'H]=I[8\$VIVJ!!_+W3I^+J]Z NY2/+?M47
MB]78\>J,=**79>TBKKX^]50G2>VIRN-?X]2YQ*P-KW^?O<^:XJMB/N)"3[/D
MG]VJW(Z=T!FL]#H^)N6/[#37IB#E#$SU?^A/G53P.I,JQC)+BN9SL#P6998:
M+U4J:?R[_=[MF^^3\7\VPPVX,>#W&@AC("X&3/4:2&,@OPQDKX$R!NI> ]\8
M^/>F%!B#X-X(H3$(OPS\7H/(&$07@_X S#LOG&?EY+8KWFRAE[B,)Z,\.PWR
ME@6'N"8;&[)ZER[KT693-G]6VZBH1C\GPN<C][/V9##/+89W,**+F4),8$%F
M$,*ZB#E$<"4O&+>JY%(.1\MYYDBJTDH58JR"7Q!$9&&^0TQ@!9K=#/1ZV\D<
M<:*ZD#<$$BI\V@2^"T3C072FC? @<0^R\2"O/7C6\DY;3-!@]BV&15[H>9XU
MMQ 8,>4#W SBF.=% GI\A4CNB<"[!G:J5'B5"E0I ZO(%J*N(JE(1##W.W%S
MA4U:* %P 7/CH;51H*]01(*<!!^?!!\$4E8N4Q\4QUC4G>YV%GRX@BAP#CUR
M$2H.D0N8'I@'&+72&<G(B0CPB0A@I("0JQ#W$-[/NPCW$$'>^;ZEWQ$LMZZ5
MWOUU5T&;A8=4K&P1]^":<M4;CNI-# EG%V= G;T61;WA\-[QQ#@REX$=CD/>
MGN,1X0C-90()9^W4&0J*B$"$-#-$FP.;B"B($8$(=610@D1@M;PI0X2/^1ZB
M#0S*%4!V\R($BT%)$/;I9,H0S6KU!>1U![*;%Z$?# H(:"<&T^T3:%:W@=VD
M"$EBX6UY-YCK6$T;@4F%L).+OJ0(E6.(S%%2RPGQXM[]8LL)1>)0D80M@#,4
MY!.!""WBB!8% >&#$!C^P*F.$]K!,5FP18HCYS#5VV XH2 <4Q!"[CC!=NX_
M4#;!3 Z9B:PS F+4&A%LXY!MU?&5\$&0@T?W%RP(<@C8V6'!&$@0!0N"00(A
M1TCT&4&00_ '"J;N>)#&"@N&(!X0JR,(!@F$02$G?!"T$.J!@@E:"*P)@H(1
M4"B(0 1W!'8L#@D?!"W$ P=C0=!"P)X!3H]3 ^IT35NYS-3 4W2_QDF":A)A
M$;Q5AH=H["SR@N"D"ONR(G@IL;,VP6U)\%(^P$M)\%)BE+.WJ0%U3F#]:T$]
MM<#(29PK)$%.^0 Y)4%.B=RTPJJ1>^#>^RI),%0BC2L$T>!Y\CS'5#B"S!+K
M<<1Y2!)DE@_T.$403V%WK_;MI$((U5NU(@BE,$(11QE%$$H]0"A%$$HAC<Z6
MFYD!=:KV>ZL&A.K^33T_N_V0ZAG!^#8EW:OGVZG.-\TKEF*PS([[LB[C:O3R
M&N>)U\_'K?$I&WYGR/B,#5^Q\3D;+M!Q/EQ@_I^4'+XIB?Q3U7E^L^1^E="^
ME_HSSC>[?3'XR,HR2YO'\^LL*W4U/=ZW:GJV.EY=+A*]+NN?0?4[;]\'M1=E
M=C#ONMS+"[?)_U!+ P04    " #T@0%-Z/M \%D"  !H!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6R-5>UNFS 4?17$ ]1@/IQ$!*E)&FW2)E6=
MNOUVB!-0 3/;"=W;SS8.)8:F^8/MRSGG?H%OTE+VQG-"A/->E35?NKD0S0(
MGN6DPOR!-J26;PZ455C((SL"WC""]YI4E0!Z7@PJ7-1NFFC;,TL3>A)E49-G
MYO!356'V;T5*VBY=W[T87HIC+I0!I$F#C^07$:_-,Y,GT*OLBXK4O*"UP\AA
MZ3[ZBRU2> WX79"6#_:.RF1'Z9LZ?-\O74\%1$J2":6 Y7(F:U*62DB&\==H
MNKU+11SN+^I;G;O,98<Y6=/R3[$7^=*=N<Z>'/"I%"^T_49,/I'KF.1_D#,I
M)5Q%(GUDM.3ZZ60G+FAE5&0H%7[OUJ+6:VOT+[1I C0$V!.D[UN$P!""#T)X
MDQ :0G@O(3*$Z-Z08D.(+0^@*Y:N_@8+G":,M@[KOI\&J\_47\2ROYDRZG;J
M=[(!7%K/:3!#"3@K(8-9=1@XP*#@&O(TAO@] L@ ^BC@5!0K.*+#:P?K"<3<
MPFS&&!1:<7[I:'M3Y"J58+*@@>8'PX+&T;1 ."D0:H%P&(#=D Z"-*36D-"#
MR"[9&(7FH>=911NC?-_S[+I-H>;(GUO%&\-@X/F?U"^:3#\:I0\_:T \*1#?
MWP T*8"^;@ :Y1F$7FC]%)LQ*@KG=F7'H!F:1?97.4;))D&[+F#PUU>$'?6=
MS9V,GFJA2C*P]F/A$:I;P[*O_,7&G[ _R3'2W?H?\MT,^HG9L:BYLZ-"WE7Z
M1CE0*H@,WGN0/<WEV.L/)3D(M45RS[K+OSL(VIBY!OKAFOX'4$L#!!0    (
M /2! 4T]<X),U@(  *X,   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;)57ZVZ;,!A]%<0##%^X5DFD-=.T29M4==KVVTV<!!4PLYVD>_O9AK(4?XZ:
M_ C8G.\<'\/!9G$6\ED=.-?12]MT:AD?M.[ODD1M#KQEZH/H>6>N[(1LF39-
MN4]4+SG;NJ*V20A">=*RNHM7"]?W(%<+<=1-W?$'&:ECVS+Y]YXWXKR,<?S:
M\5CO#]IV)*M%S_;\!]<_^P=I6LG$LJU;WJE:=)'DNV7\$=^M*;(%#O&KYF=U
M<1Y9*T]"/-O&U^TR1G9$O.$;;2F8.9SXFC>-93+C^#.2QI.F+;P\?V7_[,P;
M,T],\;5H?M=;?5C&91QM^8X=&_THSE_X:"B+H]']-W[BC8';D1B-C6B4^X\V
M1Z5%.[*8H;3L93C6G3N>1_[7,KB C 5D*L#IU0(Z%M#_!;DS/XS,6?W$-%LM
MI#A'<KA;/;,/!;ZC9C(WMM/-G;MFW"K3>UK1LEPD)TLT8NX'#'F#J=YBUCZ&
M3(C$C& :!@&'05PYO93(,YB @@34$:1O"/*9CP%3.$SG,!D:?K!2"BJEOE*%
M9K.1>DH8797*0*D,D,(SJ<R3*NDUI1Q4R@$E,E.",!06*4"1PB<HYB*%9X>4
MU14[):A4 DITIE3Z2L45H0H4JH Y26$"C.  HO<_^CB080P\_.4\H "H"NG
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M<0):P-1VPO;O:QN')<;-Y@7LX9SCN>"9M"/TC148<^>]KAJV= O.VX7GL;S
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M:OWEP 4C2A_%$<E& -E;$J,HG,T2Q$A5^WEJ8UN1I_RD:%7#5GCRQ!@1?Y=
M>9OY@7\)/%?'4ID RM.&'.$'J)_-5N@3ZE7V%8-:5KSV!!PR_RE8;+#!6\"O
M"EHYV'NFDAWG+^;P=9_Y,V,(*!3**!"]G&$%E!HA;>./T_3[E(8XW%_4/]O:
M=2T[(F'%Z>]JK\K,?_2]/1S(B:IGWGX!5P_V/5?\-S@#U7#C1.<H.)7VURM.
M4G'F5+051EZ[M:KMVCK]"VV:$#I"V!,"?)<0.4+T1HCO$F)'B#^: 3L"'F5
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ML9: PEF9;:[WPKU;%R@^S",)+7.Q^@M02P,$%     @ ]($!39>V\5\_ @
M7P<  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULE57;CILP$/T5Q >L
ML;DE$4%*MJI:J96BK=H^.V02T!I,;2=L_[ZV(90FIDU?X@MGSCEC9\99Q\6K
M+ &4]U:S1J[]4JEVA9 L2JBI?.(M-/K+D8N:*KT4)R1; ?1@@VJ&2! DJ*95
MX^>9W=N)/.-GQ:H&=L*3Y[JFXN<6&._6/O:O&R_5J51F ^592T_P!=37=B?T
M"HTLAZJ&1E:\\00<U_X&K[8X-@$6\:V"3D[FGDEES_FK67P\K/W . (&A3(4
M5 \7> ;&#)/V\6,@]4=-$SB=7]G?V^1U,GLJX9FS[]5!E6M_X7L'.-(S4R^\
M^P!#0K'O#=E_@@LP#3=.M$;!F;2_7G&6BM<#B[92T[=^K!H[=@/_-<P=0(8
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MW;A@<%1FFNJYZ%M^OU"\'9XS-+ZI^2]02P,$%     @ ]($!38;B [K' 0
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M=SO"&=9*67!.HBMGI76/= DXU-9/;]Q<3U=U"JSJYU=(EK^"X@]02P,$%
M  @ ]($!39CA>(Z5 @  SP@  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&ULC9;1;ML@%(9?Q?(#U,8&[$5)I,9IM$F;5'7:=DT3DEBUC0<DZ=Y^@(GG
M .UZ8\/Q=_[##P@\OS#^(HZ4RNBU;3JQB(]2]K,D$=LC;8FX8SWMU)<]XRV1
MJLL/B>@Y)3N3U#9)EJ8X:4G=Q<NYB3WRY9R=9%-W])%'XM2VA/]9T89=%C&(
MKX&G^G"4.I LYSTYT.]4_N@?N>HEH\JN;FDG:M9%G.X7\3V8;4K-&^!G32]B
MTHZTDV?&7G3GRVX1IWI M*%;J16(>IUI19M&"ZEA_+::\5A2)T[;5_6-\:Z\
M/!-!*];\JG?RN(C+.-K1/3DU\HE=/E/K!\61-?^5GFFC<#T256/+&F&>T?8D
M)&NMBAI*2UZ'=]V9]\7J7]/""9E-R#Z:D-N$?$P \-T$:!/@F/ ^CRR//EH
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M279*=5(G#.]U60=]3;T,2KGK^E>AWYOQKC8..G6<[J'!Y3*\^@=02P,$%
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M80("$A!+0&X(')&K'I-;3-N+1-B-Q >1LH"5I*"2%%"2.DIZ3#IQ@G.<.TH
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M.C*QC/F:#(-MV##<J:'MC/\<LG]02P,$%     @ ]($!3=:Q#8LF @  ?@8
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MSN3(V*L^?#EE_DP'! 0*J16P6FZP!4*TD KCM]/T.Y>:V-^_JW\RN:M<CEC
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M;O F$M/'5N5U^^MLS[561>_%A%*D+]TS*]OGI??_:H8;L-Z #09=<B8->&_
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M=[)C[%UOONV7_DP7! 1*J16PNIUA#81H(57&'ZOI#RDU\7I]4?]B>E>][+"
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MJ!N,65W.5\ FD!@,,]5;&I,^-$/BF0VH5&O\\^ES"[ED(LZ;[%$S #UZ<KO
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MN[-M;4'G_/KZ<9)'_6@^Q^,0N6UK DK+.75*9VVE2:KIP*'48_"XRO_J<6^
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MIYB"@)Y:*EN*"2\X$TTPUWR^=?)K03V2L3H<U7AP^K$)OE) E0Z<YKOC*QM
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MF+6%=/$ 9?FTHQJLK7T$B'Q^OQ\Z],DD=ZLYLND-Y+Y/P!:4,.BN>N[4S3T
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M-,YM[BG$30AA"_$Q8W$M[/H6V[/6G>3 *G@/\ K2?HLPT@KCUK/P&ZMJH95
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M",1?BO(S&VF$AXL&\60P@?_.9A.,,%!_14%\ L'&(\PI 65;R3:#1R'1)O$
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M;0\/\XL5*QZ/DG5GG[_9E52CSM:?7J*$516. $L/.0>_&4_60I8CJT"*%3Z
MK<=DDVW%5FS<8.I?)DS;\VUQ7NVRK<6)2'CJP,E77R1;A<*W*0,+&+GEHRTQ
M@ H&#4#"%EZ0LJSD*E/A(D94"NZ<86&(O4RR*EDUQ89+D">]H9_:P@1Q[ LC
MF26MKF4+TQK9U$X\5U%"8H)"R?!]FK9/Y!N6U_"]"VO(&YJVEK'(I/2[(U7)
M0X."D)XBN%-6S#%H*E*1K?=&L6"'LP4C(RV:5.*X.U]BE(8'+6'JFU#SH\]I
M\>;)XK.S"VKKX8PW),XU6(>7^6OU7;C,PM@T[9-3VA/# <$E0DAMUZD/8I9,
M[1)GP5B_Z[L*'ES^,O18,@X]!E'N_TH+RY:.-LHX'[8\-[ATN2+W(1H,=-\I
MC<$ZCF[/%!4U%X^+>P;*9J6S0,,N:Q1@HR+4&W@D;=A=U]MB\?F<W7=XV,+<
MB"CUZQR?"V69VBM!H^%I77(ILFNL"R(0J?>*76XWS:X_OKO\P_E/%]=7+S!!
M]OW5V^N+CZ_>O3WU.FT5Q/R3+YTB..EZLRKV*19MPTGRD!;NT-4XT.I#*4-B
M4.SEA#?#BN764=GO@C5RI4\ETF%)ZP75Z$:+U+;7NGYONTS]-LFP;7D1E /;
M[5*YDC']"[;<8$#E2KJ3Z4F)T^-X,!W ]<,^V)D8%1BA1VFL+J-6^J(OJ3_E
MM-MNGV$H\6@ZI1\FP)\J!JJ4,M_;%H!5!M7O^!:MX$DOCQ@?:91:15KPCUCL
MW&H/'ZX_6;N(L@1Y04FMP?2=HM3:>CDB2Q-J/'"Q;90]ZLW \)[%LUZ/B^%H
M[K.I^'%# :J$L(C4LJF5Q4@@[L2\^0D$\N?SZP6HC_#,-W#\H^S;F$)/5/.Z
M6*8K'+T(8"S(TR $<J&B0#29ZR'%U ?<*TCQ6Z'C.3FA'(F.<3A3X>>4I]=0
M3M^3M:^]5P/K=*:<TMUA9%.W,Y!_NST>U9-HW)FB1V#4&6/H:=+IX17#SKA'
M1 C/&6;JBPPE.EW>.FDK<&VY,>L+@D-VM^:A_\UH\BSZD%6?SV_PX5YD)NIW
MQN/HAZC7F?3A'_BK2W^-I_#/BPS!RS"G?9:"G:)^HA^.?/I3@5A<*NXU&L+?
M]$C^U(/_7*E_%(^;"#4'#@<,.P/S:6@^]>43DK5]%KW.%%_2[<R&//P!_369
M?)]9],TLZ-.P,8NQ^H,.?' ZHZCYMF97]KU]E1XD=R!:BY(PJLZOF9?Q2L+"
ME)U#WM0QV5MX2SLLYF02NA- P\;;1'YY)F<XZ1<,Q6.UC@1Q9K+5P7S:GE,&
M*_*W6ZLY!5D,)G0HEH5REC:(EPN'6H2IFJJ*(XG'U9Z3%=9K3%'CX>;60TX8
MDP3KAKN\K\FJ^U/==W4PYA*#"J5D#<K!#+(=PQN;K2,&!>(&9_8UR_I?5)!>
MB""]4M*]IZF]AUOITN:5'ZB)GZB3)I;W$4V."^/'>H4./&"HA2 #WLG2%;LM
M%:$EX;(-.(KZ_;C?G<9#0@N '!Q$/\M1.44$R+!/87K<1#KB)=8:ZPU!/Q@R
MS&/4F0S1/W639EOZM=N/>Y,)!_1'G7ZW;30UF=6+)U/0&B@$->D,A]&@,Y4=
M#^I'CQ43&06=F(U'(.Y@"&<LB?$ARH&!$1HPC0F\H3MKJYHXF#G5J3!3,W=@
M[T%%T#% =Q1U;2@8 5 _9YZ;D_5<3U8;?NX;X=?!;?$/Q+3$&M$+9#@'A?*]
M>9=$P5'&'<23,;#$C'3526<RCBX>$M+K!]UN/)[@]_U!9S"*_L0K(T85^X'/
M!L# HTF?F!3N'GD,W._&TZG 9$!_Z 6'Y!-] .IR#[92G^\!+0^.4<-ZDTF,
M<=VV1MACIV'I5W,>2]"O8SC=9PV+[U5.I>H_)E_20** _G9JD!UK&D4?+_Y\
MU4@'<']#-Q:G^TGM%'K-%H=P#!W__52F V, G;*+,FHT[9%=-.R1UM@;';KI
MT46R3.3(0FQXU<GGCAV5W$<;:V=)V9-L]&# 2[K; ,L2+&J1E.4>P40/Y$(5
MAU("!_^:>-]>SL?\GGL*.V>^(%EPNSL0&7C(S6Y%S8EN,*6<@KCIDLPT&*54
M1D1ZP -SNYW[QA.'Q$%6NMR)\OSOQ;R*+A9;4WN1,@&SVUS=3ZOD@36)\&VV
MXH&;*J:P)(+**VX.1^A6>4DIRHAJ%3F,@#)KPLA[Q;/83>L\@M5/BM1C@X@-
M I%O"3];BDHRX-9P272S2K;FVW[OAP[Z^>E=M[N,?7^25$NMFA:(P[VU(("7
M%]<_:9H6QG:\HC&2"87G3\RJ\:9,MXEC\>Y6Y!:BQ^DB$4<J4T58*&21V5X,
M"\J@D[J0F5=V"*%FBZW8B]]S ZC#LDQO5ESQ;B]5Y=>I;0K&K]?U"'-"FL,E
M?)/X&(T/R/'1'XJG->3B6^!QD7]GB.U\:D_!^J5729D3O>TYV2XCWUY]C$06
MOK_Z$%W__N+#U2G72)(VQK^,]Q.Q:0OV\&0K@O'E5.R!1FV/_4,B]:"6\/V$
M[=O=.B4HP;/HK1TB]>WE!KX@(,8$=N]W!_%@U.,FOP/XRKG>*VCM=/5 %[-%
MV1E4_1BU5_-7KX<*:^-I4L'"LS/( TRT#=)3!@U#'LW&9L PW/X =$^/@?.O
M';Q-_YB</N:#7% C-KG^/&+WAYBZP1D!M%*_U!4*<6M);RMKECEJDP*@F%,I
MUM).R/YL0CD5_=D@[DV!56;C> JF1G_6C[O]&2@=*V[.8@GT#$XK^S9/%X]K
MFI+QSQ!"$G&N)"![6/EZA)['[J"'!@5FC6$*S:#[53,VV\\?:( 2!Y<'S9_^
M$-BH!TIF;P;_#JB3]8!*%<Y<)C WQ4+<)U&W0RD#W4YW3/^,I_1/K]]RGPZ%
M[IQZ=X[X3O:,89.Z<Y*;H$ZPVXO+)[&3NX&TB+N@FJ-;W!*.8UD.\;*JVC%I
MG,J*0^./I3]^D;=9B MAD5MVC;@R^1[" &-*G!XO'%CR<+).M =5K3NN*L3M
M$8K*.$>]H? 06 =*C:5,<)[-5G0=*CG<BBSQ'M=$F$P88 +7LT<#&:M&A_\,
M<!-38@#H9/=%>!_A\M3;_M3.N(.;!FMS[[C.!*C%52&% .8IU68[-Z__[8J0
M?JMT&L6]\0#VT60XP7P+V)2]>#S0K+#- =JVW%G7+=QD.LH$28,YXLYEUO0[
M%+A[>?'J0_2GB]>?KJ(W5Q?7GSY<!;/"6RYC[<9#+CM(46%O"5 [F;J.A_$N
M XD-8DE+:N"*KWF"IN2'1 6WGF<R9^3_KBSUM*H;H7_'I-;7Z ".>O*O!MA.
MS5 ]DI=:2T1MRT>MYY^VY:':QW'VZ3=DH7IY:!,__[3!#\[41\,N*!3=@[FH
MCR!I(+&T+9VTGC[:ED9JKI/DT6]((C6/XKQ1+WTT0"0SF0&09C;H.ZFDOZ2U
MPQ(,,?L$%T7QU3M*.]1AY>\E)PD=?JO"VDOO_?YFXB4<1(>D02@[#![:Y M3
M%$73=$S)%'K"UXWL]$H>1:G)!;]@P143-2:L%$_*2_S1(,I?=@5U&BH)Q&G+
MJ]OQ9@26$IRE*4.2F(U O9#8"U0:;ZZ7F%7*"&Q(TR*\- )=@:QV>COBJ0S6
M>5K>D[4B&XM'&=?RQ8CT'*\#IKE'(67O3+:B,L"1)W.EN^\QJ88@3MD:*%7J
MLB3>W=+GB6JY\$ #).B'2=!8<2YK:Y=<I3V7G/A88B5+IRPGE9C"4<"$/^5P
MUXJ<O8&DE5CACQ66]^-5O\ :YG7O,#Y=^L]7SB5:[)&[P3M#=!_COM>[Y$,Z
M-ZMPDZ;&9[@ .Q;4K5**9Q0>M(KSSH/(N(\U_FNA'J%J0;W-6(!0R@\O#15L
M_&(:;"&*R6[M9J[(N_(VR=T.IM>[]5HZT%X[CD$'8OH>E&?T?D5G^NEI_:D_
MD=@B<)/JV@$<5/@J#L.>@!,[I+H;L-E.BHQ<?4E7V9>L$DF%1!85Z0%,GM7^
M'%&KV(M]7F7++"G5,*HHLX"(KK4 G;)DO*#<U1C?2 <1!Y0ZT<6*ZY:5,A40
M.RON44=CL!W'W.)4*;J:J4I@8ZD,N=ZS$G68INY%39+N\F2WS!AI=CIQ[3!!
MCP,)E@81F2Y:& 0XF)P(O1%$%*;"+M!G9FT6(AH[1#'?;^U)7]L$B&+G6'HX
M8>^0;62"OUR@<0LR"PYD#)<;)V]T??YG-2&=ZDQD0'QA;S=G)G"Q+-,[X.JR
M!0\-#]IK&$&9#4ONR3OJ([XIBBU<2CV\0'&55MXTY0!%PJ2CENZP=JMTZXJ&
MRBP, 6HI'6$#P@P=]=15V3C38*M*AA6!(7(*1$2"+K?*AG/#4Q> D:>8GHA"
M@5-]29YL7/XJM+,K>L#9<6&[TIAR2C=D/JK%K/E\UB2P[*5F;6,/O 1S"L;\
MGNZM_VAPL%CACQ"PH_XYZ@:CP?E#FGX&VM'=9*MO4':)O6-7 M,6%"GQLH2]
ML">0!9ZVP'*.W@/4!VWCI?- #BYC@!$1-(4;Q9DZ0:L;_Y:)Z#/>];/8\8;
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M7_7UZ40OHOK&#J]DUBB?M-N<$[O&R)Z@E\%+&6I"H ]<"L?19EIOVF/!2V#
MI4:WTI$%;ND910]%GD?!3GQO6T@I4BS9<J)W@'4#2)(<^Z LN1YR:QO&DUL
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MV<*2]N69RWH9,$7*8$\).9M=0GM#3N8CFBM;G%)2G&0$<3QZNTQ/<B[D;SP
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MA:J@8,@CD3KU[NPOODHMBB9).!-EJ!.-E9F_Z/CVJ-P1+F?_$P&-H>ZBD5&
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MWM>(/NC80"8UJ(%;](5@1+RCYG-;L5H&\9GPPU]T^0N]W'6<4O[S09WQCLK
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M6S_JA3E3]#EB^I ^V7>K)I6?M%AX[&9F6F*OEXX7R\O% _<^NMI@OT:%&H8
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M!D54N?\=/OY!X?\800+>)4\(%8#-M+SS*D,]@C> /:7A=P+WFH_?1QT*3D@
M[(2/@@&*B/N#1\:?%[?S*$G]CG/!C1()90F"9851*\I;,V4MJ5D_HT\5?91:
M<0@-"$?C3,M#&4YR0HG$$Z)=M_]@K_R2\=UZ<^'N@\QKL_]Y<;=P1&7F'S>T
MP;0_66%9!6X-BXW4>ZH8M_E% Z;Q](RJ?O;?G7M)\M4VB.#&)^V0,)=/> UY
M)$Q] =5<8<H>U#?--)K\: _I$$24QQ(>C0@U@6+Z)?:61<])A^[/?RV&U-IG
M8P%;\7D^<>\=WD\&#[3<A#<_ ]W\[/%VN?WY<?_%- >AU_VX6J_1 /">,")E
M*Y3/T[$+G#'>KK8[%7(A@*Y3PG/^2&DL4PPK+#C?/N$\E0/TOO+'Q>/0&\.[
M_ \&'KDS,\WB>NG6#Y!_U-NE[,X[@"<P;A_3I_J85OD<@4"2D1D7$!?DPOJR
MW%*L"V<S1;,1/BWS L>C&"(PF[)-+X7MA5R8%BVMY)O%:@7J)NBGM[\^;IPE
M5(DK6\=AX09M/!AYL^A):'A/S(%P!:&<HX/C\;?#BQV9A(ZU_CPX<%-&'0W_
MYGN]?R+JVTB.Z -YVV/!]7"]3A<;Z\M1E;W07X-7,7J5LR^#Y=-N4JY#,W]J
ML[NM[71=]W<K2]<79IF6G#MR;;\1W-=>;#(54FGB"#Z$)>])-I*4GK1C1ZGP
M)/=J\>"5C#*Q-WP9<GYTL*8"0:QMD?#(_2AICC=#9<V:]PT@9_T1A:=%!^4,
M5PA$XPTR-W N=OM>;1F@A@)+I.5[,-QT==-T1GX"[-,>?-H'S!2\=A"3R2<T
M!=;27@*7[^V3MQ:V4O?'#KB2QUPW\)6<FX&RR]G5YK=;A=Y'T_$H<%[@HWUR
MQVB@F !F[COC#20C>9%\*+FQ>_%$Z"#W=A_ DN?@Z(-7ZEZN\)6<)?+B*SES
M\D L>6(=7I2ED<NY3WV&63C17-__Z[^D=?-OKK@TB!_(U7]KX9]<!(G%Q2L8
MGS/"9*;*)[KPBICE.@SFKU?YO;'*L0;"BCO05V_%TL0:6>O86OJSP-('T:\N
M%W>K>Y;?0_><!-;RV$!]65X_K DII'M1$0CXZ *)#R*""V_!=I0FM/CIC^AP
MO;A97BW0X("';( TCH?L$(XC7#_",-"-B[&0;??W!XR*@TUY_Q(&"_%*$#!K
M%NT!K[6'B-)C<S"?RUL%'I3YC%A.2*54JI"N3 NF\%^?5#L+8$U-H$IPSP;]
M)[XZ)DJ8=IX:>'/+BX%VAW&=[#A%4!<CBXQ$NK:N8KDFN$\\((ASZ&=DFL T
M3?0L1S^_-4+M/K@TYTSLEG^+%L ZZ<,?.9 @*KD$/LG2Z&KQZ)JK9Y_<*C=Q
M;YIH/!_?O3UL\'Q@8]:>T=GT?JIO_%3_/ XX#%=78K^HZFU'-\?I3:#$4T"Z
MP@9" !/*6<EY5;D9L?,Z<],#YY4G=W9>-9[$5!-:JONK-^"B<*.^*'RI[B6E
M-Y6Q\@Y7>1-F+7 JY\@1+%VJ[9![6;IPMDW9>UTAKVM[+U/ P8WW,D3R<MX'
M<;U\*Y)[KJQKY\O2&]BN_&3N@^ORL[47R<N2^9/K7GPG@1ZFYTSP*!)>]"HK
MFTHV#ALAT26^UIAK#<RM$5<;&$HCK@Z\%N[%:2_4@>2:/L!H<+0GKHPKC6%*
MX4/ 7*B)M]KK-O%F>QDGWCQZ5?=[H_ B3QQO E;9/J_8O4?B(K92=/H%=M];
MAH8<D,9!H+6]5@Y(.FEE/-?WB&$3"L_2E B]90\A[ -NVU=N2GRY,==Z,>=&
MW.>;[S/(LP'@OJ=0;>*V,XDX\=8032<.,X[$SSVHH_FP![16BED=M&<F;T@;
M5W"RC=Z'OS>+]D+:&U]+K+\XUP!Z _-5R'>^-YF"#3=X_W0H.X?_GP1>M_<$
M^P"]7(>B1J@;M-^?&[#.$&^NI>9BU3EGV!.1P'H>_YS(=3V/Z=]]/G_4C& J
MHL^4-$%!(;^,XHR#-)!Q@&!9^"YB& SEG.(+]WJ9",D5;OI-/-NAF1S,H,G>
M[SX!'L^BCE@GCV1Q-B<,KY;K3"_7\>_" \Y(+;8$/%YL;ZFS@YYK;ZBE!TVN
MAS1/9&QO0, '2#?YM- CQ:$*- 551SFH$O!-%*IL;7BZ7MJ][8!K=7_W8(G]
M(6'')ER;.9LC@.,6''SH!O<)75BS\-"A*SUCV@AH/4/Z+W1&W ,K+?C0)XQE
MS.O[W>[^W_\74$L#!!0    ( /2! 4W"SDUI<@(   $.   -    >&PO<W1Y
M;&5S+GAM;-67;6O;,!#'OXI0QFAAU';2N.MJ![9"8="-0O-B[XH2GV.!'CQ9
MSI)^^DF6'Q)O:==L'<F;2+K3_>\GZQS.4:'7#.XS (U6G(DBQIG6^0?/*^89
M<%*<R1R$\:12<:+-4BV\(E= DL(&<>8-?3_T.*$"3R)1\ANN"S27I= Q#EL3
M<O'7,H$8/YR\_5Y*??4&N7'P;C#P'TZO^O:3RG&*D=/XG,0X",^Q]^>B9[Z_
M6]@Z>^+C%XH_I=V3#G=(U]N-4A/9"[QX&=,32#WA]\\(W\(2V(XKVO3]]IHN
MK;A7U\,D2J7HRF*$G<%D)QS0DK 87Q-&9XK:J)1PRM;./+2&N612(6WJT= %
MUE(\.G?@5K94:QU.A515;I?!_<[J[3U'L[* E+$6<(B=81+E1&M0XL8LJLV5
M\1<7JN?3=6X(%XJL@^$8=P'58)+,I$I M6D"W)@F$8/4XBBZR.RH9>Y9I]:2
MFTE"R4(*4C$T$?7$R,Z!L7O['G]+M[17*7)[[)7X&%F*9FI.74^[6_,KY$TU
MI[TI>[Z7+LKI4NI/I3F.J-:V<.!.04I7U7J5M@!&G>0Y6W]D="$XN,,\FS#8
M,^$D(DT>E$E%'XV>+96Y,8#": E*T_FFY8<B^116NBFG5;HO\_ (F?_U<UZ
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M"Q>VEZ(N9Y;%G^.',3R/K>OEMJ[OP[8G_<V(N/UPC?8[UMM_ %!+ P04
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M<R\N<F5L<U!+ 0(4 Q0    ( /2! 4UF\PM@@@   +$    0
M  "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ]($!3;G%+>+N
M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ ]($!39E<G",0!@  G"<  !,              ( !M@(  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #T@0%-M+R+O&,"   5"
M&               @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ ]($!3:]N>F-)!0  SQL  !@              ( !D L  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /2! 4U_SV\]I@(
M 'T)   8              "  0\1  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " #T@0%-E9JA+Z$$  "*%0  &               @ 'K
M$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ]($!3>\O
M-1*- @  0P@  !@              ( !PA@  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( /2! 4U:7Y_Z%@(  $P&   8
M  "  84;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #T
M@0%-?[7?,B@%  #5&0  &               @ '1'0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ ]($!393ZTCVQ 0  T@,  !@
M         ( !+R,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( /2! 4VH!-_VM@$  -(#   8              "  18E  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #T@0%-]@V*'+(!  #2 P
M&0              @ $")P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( /2! 4V9<\#IM@$  -(#   9              "  >LH  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ]($!32EO*TBV
M 0  T@,  !D              ( !V"H  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " #T@0%-"FVO.;4!  #2 P  &0
M@ '%+   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /2!
M 4V4 $-AM@$  -(#   9              "  ;$N  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ ]($!30SW&)NV 0  T@,  !D
M         ( !GC   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " #T@0%-XSTX>;4!  #2 P  &0              @ &+,@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /2! 4W6UJ?HMP$  -(#
M   9              "  7<T  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ ]($!35+I \%( @  / @  !D              ( !938
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #T@0%-/:.2
M4+,!  #2 P  &0              @ 'D.   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( /2! 4U4"A:'T $  )P$   9
M  "  <XZ  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M]($!3=NG^T2S 0  T@,  !D              ( !U3P  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " #T@0%--7PV^MT!   !!0  &0
M            @ &_/@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( /2! 4T?"YKEN $  -(#   9              "  =-   !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ]($!323+O;FY 0
MT@,  !D              ( !PD(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " #T@0%-GT,?+>X!  !F!0  &0              @ &R
M1   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /2! 4T(
M\V3BMP$  -(#   9              "  ==&  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ ]($!3?DMTC;& 0  -P0  !D
M     ( !Q4@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /2! 4TJ.R!.2P,  ($,   9              "
M 8Y:  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ]($!
M3<"^7?#. @  -0H  !D              ( !$%X  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " #T@0%-'B]+O'4$  #H%P  &0
M        @ $580  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( /2! 4W_YX#\S@(  # *   9              "  <%E  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ]($!3;^O374] P  . X
M !D              ( !QF@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " #T@0%-K:N&JY@#  #9$   &0              @ $Z;
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( /2! 4U88*5%
M"04  'P;   9              "  0EP  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ ]($!3>C[0/!9 @  : <  !D
M ( !274  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #T
M@0%-/7."3-8"  "N#   &0              @ '9=P  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /2! 4W%98T=5P(  &4'   9
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M970T-2YX;6Q02P$"% ,4    " #T@0%-E[;Q7S\"  !?!P  &0
M    @ &]A@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M /2! 4V&X@.ZQP$  !8$   9              "  3.)  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ ]($!39CA>(Z5 @  SP@  !D
M             ( !,8L  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " #T@0%-.LRC)*X#  "2$@  &0              @ ']C0  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( /2! 4TEL;G*2@,
M !@/   9              "  >*1  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ ]($!3:-%(V-# @  50<  !D              ( !
M8Y4  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #T@0%-
M"Z8' NL!  #R!   &0              @ '=EP  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( /2! 4V(W#I?G (   <)   9
M      "  ?^9  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ ]($!37SUV<\6 P  K P  !D              ( !TIP  'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #T@0%-8('@=/X"   S#
M&0              @ $?H   >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( /2! 4WK7DW3>0(  $4(   9              "  52C  !X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ]($!3=:Q#8LF
M @  ?@8  !D              ( !!*8  'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " #T@0%-U=+#X4@"   K!P  &0
M@ %AJ   >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( /2!
M 4UZ^+KHRP(  "$,   9              "  >"J  !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ ]($!36L/<][A @  T@H  !D
M         ( !XJT  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " #T@0%->J,\2Z$"   I"0  &0              @ 'ZL   >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( /2! 4W7-H^Y#P(  (T%
M   9              "  =*S  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ ]($!32PQI6!4 P  O0T  !D              ( !&+8
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #T@0%-.\!=
M0]\!  "0!   &0              @ &CN0  >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( /2! 4WNI7KX,P(  .<&   9
M  "  ;F[  !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M]($!37\F7?'5 P  O14  !D              ( !([X  'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " #T@0%-<)"].;>6  !0:P( %
M            @ $OP@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4
M" #T@0%-PLY-:7("   !#@  #0              @ $860$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( /2! 4WHICI]AP0  #8K   /              "
M ;5; 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #T@0%-;.FO/C,"  #+
M)P  &@              @ %I8 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #T@0%-@:;^./D!   8)P  $P              @ '4
L8@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2P!+ '\4  #^9 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>234</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on Contract Assets, Contract Liabilities and Accumulated Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnContractAssetsContractLiabilitiesAndAccumulatedDeficitDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on Contract Assets, Contract Liabilities and Accumulated Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on the Consolidated Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfTopic606OnConsolidatedStatementOfOperationsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Impact of Adoption of Topic 606 on the Consolidated Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details</Role>
      <ShortName>Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Ipsen Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Takeda Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements - Genentech Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Genentech Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GlaxoSmithKline (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGlaxosmithklineDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GlaxoSmithKline (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403409 - Disclosure - Collaboration Agreements - StemSynergy Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsStemsynergyCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - StemSynergy Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403410 - Disclosure - Collaboration Agreements - Invenra Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Invenra Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2403411 - Disclosure - Collaboration Agreements - Other Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements - Other Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Net Income (Loss) Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareNarrativeDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Net Income (Loss) Per Share - Potentially Dilutive Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Potentially Dilutive Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20180629.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>exel-20180629.xml</File>
    <File>exel-20180629.xsd</File>
    <File>exel-20180629_cal.xml</File>
    <File>exel-20180629_def.xml</File>
    <File>exel-20180629_lab.xml</File>
    <File>exel-20180629_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0000939767-18-000136-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-18-000136-xbrl.zip
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M(\ I0K53T:X+0EWGH_^GD*NO#MC-9IZU>G_+&IW![=MN<QS%3NTL^049T$X
MS'*I7P:NW2B#<8T\2\KT[H=W/[@?3LLX%JI!%5$7+/M3\]TGF%77?KJN-9R]
M7=;[EY=HJ\>Q?WF$M<)3,]]3AGJUS9X* #["XMT9X<PC0E1UE:K>4:]=\BGL
MIQQC[G/F.4:-IG>F$6=2R:]KUN>>7YU5CT@=W>O.F4,X]W.RF9/0CB-T].=8
ML*I+,\\2?0WZ+D A-HH4IUPJJ8L"Z\G^U!#_*0>H&N"?2M@^0L1V:H9Z)G"B
MMMD:9%VB^9[@1FUMJO7V]=GCW[.JWM466]<T]U_8JO>W+\>Y5\T_K,M;A]*
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MH2>D3DM<Z!SS+L.)7AP0?=8!YK]_N"2XL4&K\]\_U&#@5,' *:KD<:O)WN$
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M=*#E/7\I,=D9ACQZIFYGO$Q%Y7V4X.D$]RP:&16/Q"KKC9?EK4"L%-Y9!?A
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MF *V]8/DAY?>VIQ\%//O]S=YKZAOE/HK*KB=3A$A_.; 9XDXYC2"!(*SF'/
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MZO*\BQX3D3"FX9Y%+64Z &DY ]CA;'F\KZ)X[MC"@4A9;A]@VBQ&H0+FE,=
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ME*SJQI?@P8+ <,<-EY%EJX4&OX;GS+DQBVWA>-X$!.P>= _DH1X#:T5?$@Y
MU3D9"5XKA/DV2A<U7NTFEE4JEUQSU:9OUX+)G<][-$_&IT?-9#HOE%N??@Z"
M!:JR,HQ!P,"S4T2!NRN-L1#-+FGHDI(MS/==!=16"*P8YLES("!#1H-.-R!
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M=0V,9)XRN <.O%MF=9:41^:D7AS@W4JAV!3+)6.RM\>SJR0*S[+!_1U:2T'
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M198D7GKA.E(%5I1''!Y1,. [OK"S8K])L,I^J*QDX HO_;2GCFFPRMYP,,[
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M4K"5<R>D#5DY)@*$.9I0C_DJ]""8!JDH]W$9RW6/S+,+UPZBM:!P806XIXX
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M9%+1D4P=1!G&J4"X6+:1D1K"Z9/@^^'XH8=L*L810DE-E&<X>L\3ZT5D3I"
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MN]WVNYNKB_A3Y]V;%CL7$X5YV2L-'[@"F&>.&\ P#3LT@<2V';UK?>1WKAO
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M25T%<N59Z!I%&8KR<4+78?7Q0![&-[#6H*E[XHS&*?N>2\]:Z!X\1>1-8"8
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M1<7[42/TDFW%C5#'4RT9@'74KD=Q.QYQ&\:#U X\)*Z5^_B4\GTTPT-JBU3
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MOYJJGF"-8*U(JO6U#K5W(U@C6"-8:Q:L3=H$:P1K!&L$:PV"M:$V[@X(UHJ
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M4.LDM_A]E;HLUP=W)D-Q7#%VIJE##G7(V>B0,SANJY!Z-SJAR=/D:S!Y:M=
M'4>>:8$47,0YLBB9,"/]M^R; U:*+6SV=)CB6H8IGK%&Q,/$PP?FX=\3$_LM
MN^1JB^"9K%L33*[5"I5;N+\, 6EXHY0+$?P(V%?7>S)<1;!.7%L-KOW=Q>EC
M-G#M^;96="=!J-B"$'P3?->/:U\,W]0]:*>BJ^_E'A6F/46IUVQKQG452C=7
MD(:5J,Y<Q0+,\2YJ]SEP^C(2-:72<CTAZ@!L5-EB\H1(A$C'Y@M"I$.*5\4!
MJ3(=">J$5K7K;@%6^F3<+YUTE6$F@KAJ1C\(UPC7BJ1:MS?6!MTV 5L1P%;
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M-3YN&JL2Y!*KUH15=T;5YQG+"^ >FU<I8>9 N1Q?/=<,C2#NM?MX_/^EK'Y
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M'8V@QTH:"> DT*R5R>/P %U6,S3@X>%R:6^/$RFO5:E5O.O."I@*#7QKW;2
M+<!3]0P+1I1XF!=?;J]^__WCA7Q<.MCD^N@>/^,!I)=KI)=%L#+F,\MA-Z#\
M )DU-@,>\'1;QCS-A>58?H!0 M8Q_[&401,55M<-0T:HT+:]<''OU(>GP5]B
MTUJ8T#<!_*,,R3OV!0QEP3K^F@'X)'(1:]6%M;(FWR,0MK\=MT=20*?[5%9
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M#+3^I+"Z6"0<)!Q-$@YP2L<#JJ=(TD'2D>?:M+5V<8V6FB(=E#'P,FZZYGZ
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MHU2]UF'/TS2.^C003?Y8)G\D!54K9X^GPVU2XM^S$O_P=$GFE']CP\'WXRX
M7%U^?:HU'+%KGET_BGOAL,+*+Q$K$BONQ(J9FB'$D\23A^9)N5U?JO*N4(;2
MGE(@/@%U%PR\Y1\B9!.8>&$Y#R^* U<^.V?O929W:%%R=%'U;L?H=B@9DY(Q
MJ[P!1KA&N/;<TJVZ@F*S5;[X5H:C"-Q.'=P(O[9PRBH"47LRO>H"0$<2&MZ3
M5(UPNG+?7M4YM<3<"^SP)3&1ITH;O(2&SPB"')L94!=YJI[H5$YOGX2(M)I&
M8UA8]QN2#I(.DHZZ2P=%^K<STKS9#'M3X(E'/A=^&<)5*%6K(G7[C-[412:/
M2/R.5Y754MI:@X;1ZW9(TDC22-)(TBHD:13SRYN3_AQ3= 0;>\_+&CD)5XUB
M?13-H&C&$]&,@=%L%*9_2#Q(/$@\:B\>%.W;BGN^G]^<LUM?'H!>R///=RC&
M+IY)9L$<^[?BP6B9\SWW[>!9M<X**T1?2[^JC'CA2^E8%ZD_(@$_7FUYDM+:
M:AB=?DG%STA025!)4$E0JRBH5 HX]PA5"GBYUE YW%90T;0*4K&X].IM"7;:
M:=9/4:DN8$4Q,<(?PI]"\*=AM-L- B "( (@ J # -"P8PSZ9 &57ATW,R^J
M%9H;.=4*/9J*D16[G29/M4(K;H51K5#YF!=4%WLO3#$;"S]3+[0IZX66VSJ<
M>)8*XKV49:E>*+%BE5B1ZH423U:()ZE>:/'QFR.I%UI!RE'IJ0V$Z72-3G_K
MHOPG?PSMB#"I<JJ4 (@ :#\)VU7@"T(A0B%"H6-!(3*#Z#3^BYEG'\6=CCEY
MG([C4P2N@ A<G46D.1P:O4YA!RQ(/$@\2#QJ+QX4-J]*M:1:'OJCT R%9BJI
MRFHI;<W^T&BT"MN[)TDC22-)(TFC:-])%G<Z9OD\0 VGNHAJ]:3RB'5?C46L
MV3-:O39)%TD721=)5S6DJ\QH)E5+>AFW%50LH!(N4N6J"% 233GDJPL@4H2K
MI#0_PKC#"^F18EQ[V#&&[>)BAP1R!'($<@1RE0*Y3J=A=)K[*U17":ZJ5 &I
M^.^__AH%9W><S]]><]O_%W<B<2'=O4]R_T%87]QOPHQ\'[CJD@=V< M4N'0\
M\\??_O,__KIR[WL[,!T/;TPO!+*Z2+MO8O+;J_>M1G/PS];[JU&[<?;[]\^M
MX2MF6[^]NN9F>-9N]KJ]T?"RV>Z,NIVKUD6_T6IUWU\/+MH7_>:P^>IO2TN2
M)>\3=:'6K>C&TEFR7!4*S_*:YR!M70VLX@6FP"/3UQ<?OK%_77S\?L4^75W<
M?/]V]>GJ\^W-HTRV0Z6QYU.P,]@#"56,8RI VG@0V!/ $Z03\R;,B_R5N =[
ML,.I[;(0[I@ G[-[9'0VM87/?7.Z@!]XR!Z$+]A,RXS<M/-Q!2S\$&;O@Q=Q
M_$V)%!NC3+$''L#;V,1S0/L'[^2[^ SP"EX_!UG"O3Z+B9^F$UDP;AY,#3:.
M0F:[ZAO;O1=!B!N$03(K?',@KV7BS\B&M\N?7\NI>!%0RPK>O"UK[:G*'%69
MVW0[%5H[VM$?U>2/)*VD<EX?59E[J8'U>^2*3(6YAJPPMW7 FOB52BA1A3EB
MQ9-E1:HP1SQ9(9ZD"G,G6V%.BX(,*!PT'^J8ZJZ40;1CZM=5>6:B;=9J:FC"
M-<*UJI]OJ3Q'$;B=.K@1?AU/!LB>3*^Z -"1A(;W56\%IROW[46 V_:6F'N!
M';XD)E+GHD94%H_"A@6$#>LL(JVFT1AV23I(.D@Z2#HHTE]H4;SRBQ;7LGH0
M5<6C $TE55DMI:TU:!B];H<DC22-)(TDK4*21C&_O#E9>HWE8Q8NBO51-(.B
M&4]$,P9&LU&8_B'Q(/$@\:B]>%"TKT9%BVOI5QV@FG'M?:\C$O#CU98G*:VM
MAM'I%]9HB@25!)4$E02U^H):0#23:BR_C-L**LU702KNKP(?I5EO0Z6Z@!7%
MQ A_"'\*P9^&T6[OK] G 1 !$ $0 5 *0,..,>B3!51Z0>',O*A6:&[D5"OT
M:"I&5NQVFCS5"JVX%4:U0N5C7E!=[+TPQ6PL_$R]T*:L%[IUS)EXE@KB4;U0
M8L63946J%TH\62&>I'JAQ<=OCJ1>: 4I1Z6G]M-%M@HL01E6U52E!$ $0/M)
MV*X"7Q *$0H1"AT+"I$91*?Q7\P\^RCN=,S)XW0<GR)P!43@ZBPBS>'0Z'4*
M.V!!XD'B0>)1>_&@L'E5JB75\M ?A68H-%-)559+:6OVAT:C5=C>/4D:21I)
M&DD:1?M.LKC3,<OG 6HXU454JR>51ZS[:BQBS9[1ZK5)NDBZ2+I(NJHA765&
M,ZE:TLNXK:!B 95PD2I718"2:,HA7UT D2)<):7Y$<8=7DB/%./:PXXQ;!<7
M.R20(Y CD".0JQ3(=3H-H]/<7Z&Z2G#5P0M([1HU?\D8=RA4U43N729Z#E.6
MBU!U!O!%\2R;/[0L'_B'8)9M,=<+V93?"\;=1<9A=FP^MAT[M$7 9G(?1UAR
M(\?'@\P6?@C9A-L^N^=.))CG,HZ_1;X/<V-C'M@!>-W,F[!PZ@7P+AZ*X)P]
M_E;EIC//S[W?=.![>V+C2P.F:DJTF>W"DT5V#%-;^-PWIPO]XI55+8I^FT]T
M_QZY(E.?I2'KLZRZ>X4N))+K %-]1CF:8J>+7 @K[POV@/]S/1;Z\(")\.6J
MOXR;K$CR+7)4N<,/[)]L!E=- R9 Y*V2B57NXT^(W<MG[/.3U$)3 9KCGML.
MJGP#1%J#N>W>BR#$A($ M0E(*ZB8/R,OA+_FOFV")$^ $Y1R267>=H/0C^1M
M\+"I;4X9*B(MYTWX?1Z%Y^Q+Y(.VFG';1:G/OHO[>@06BP(%";9OG<VY'R[D
MB_&[P(M\&$'\A@B&X(UARO>R(J0N/J%&:<#30\"I(&287AM(^%K8PK$8*$MX
M;_9.T*FF-P-X<!;Q7.7=," UW< &4G,_AC:>NUO.35VG![J&!"U-@E-DMORJ
MKR@*7)FLIK!=TXDLP48\F!KLUN>6D-=XJ'W0V!&V)#RL\7<7[G*$W-L#3M;P
M =?<"S<"MKXP33#=X1USOE",#M_XD;QA-A=NH*['IX^%*R8VLF]R":P!>@R@
MYY9,L^QCLN_-7?)-C!/&FPCXPP+Q"CU@OP 6$+2FD9D5&G"8I"-IX>&:"G^6
M?=XYNUT2N0W40T$R.9B#RE8T/9  Q8U\/O>]G_9,C@K>"@9<:L4%CW-F_/=?
M?XV"LSO.YV^OX=9_X9WO[<!T/+14@UM@KTO',W_\[3__XZ_)A? [=[X"KWA(
M+Q=Y\)N8_/;J/2JM?[;>7XW:C;/?OW]N#5\QV_KMU34WP[/>5?.Z<]6X[E_T
MF]UFZ_+BJM'N#X>=B\%P>''=ZKWZVY+ 9+GTB4*OZURT.LD;&/O*R+>\.6(9
M9]W6&>KO;OOL08@?P$2X)&P![AB;>XYM+H ?@%GN0 9\[@ *@HT4(/*C87;M
MVQ9?,%QDA%-@X=@&9>W5&G.%S@0?&$3S#3X\K,.[E75+'SH/E>47RC'"8]:Z
MG,7:$NPZ0UKD;_8  (7D1&HF=&L-E,FFP"%_2U\9J/GKA\K$A^?#,H(0 ;[9
MPC4!T'P!%CC^&2C7#'2.+^:>'VIO3+Y!:FP1OVDN95$;P@R-R?@%,*Q/Z,JQ
MV*:4M\LK]#=]A5H;GXVSB)^\?KHKDS(D9H&4P-*&RCT8"]04JR]9,_)XI,G(
MFX^/'!^S;I K_E1^M*ON%I(^F LSM$&_+\[9C;(1G,5C:P+"HXCE@R2A5$E'
M/4>]1XGWV,U_1F L"7_=LCY.X=^Y"[<N6';>%V#*./$W2U-]KJ;(*("L8OC@
M@A(6M_QGJD$2!;*]HAA>#T:=_JC?[71&W=;EU:#;N+YJMUM-N/[ZHC/8FZ)X
MF59H[$$IJ!_Q.2\HEO?A\^C+IRMV>_'?5S>G:+Q^];U[.T#K#D'(ECS+0OX3
M^.:!2U=@ C:@]Q"PUU+6O0@>;P5OWI9%+*K"7T85_EXA5?@[PU.JQ5ZQVVGR
M1SOZHYK\D9PYJEQ*0#+<?K7SKX^@@/'4%X)]4ML95SE?J*B-<>)7XM?"^/7&
M_KD;MQ+D5J1$?(&T/':F7KOE2FA+K%I)5BVL0!6Q:M585;]%AF@>/X%7 SZN
M&.1N3WMB<F+RPL&:JNQME7^\.89_2#39N Z%@<K1G6;8X;!"&40K]23#L%%8
M@[[J<Q(=TZJFEB=0(U KDFK= 8$:@1J!&H%:C4"M;72:78(U@C6"-8*U^L!:
MGT"-CM#7+"4W/BBP0I9"!Q#*_!M,DZ_+L>**':U'TAY@KGLX13_W[1GWX7[F
M"T>=Q//@Z=@!)N5@=5[O03#+2TLVN")DWES@H-T[YGA!(,_Y+<[@C@?N6\D!
M0\X<>V;C.8_T\JD=A)Z_4"=PU0=YM!$?HP\-!M%D8ILVGD*$ATPB/ ;F328!
MOA9NF@@+SX;A*/6I5Q2[TSS/FCV9U8I/ R'LW/*?;!3I4YF_>^. 79@A'K&1
MY[KPO$  DU''BSWF\ <\UKGI-CP"PVV\&F^R87$X3,*<<O=.L8V9- _"14%>
M-N+#LQ;C $MW^G0I,,,,CYL"SUF1*8^JZJ-#N4?(D])LXGLSN!06@:G4>UAT
M^0/<TN[^HCAL KR;?-MJ_G+.KB-?ONLNLBWNFG@<>\'& ODYG *KR*._^&AY
MI/#BYC(^SY2"R\W5R, #%0_"P>.M,-J[R)'SBH]SSWT1JB]4490(V.HN4,^-
M&53"<BQ0C-\)U[33,^.F%SE8326(G! /9R%'X0/Q#/MLSLTP4$M".J;N.B:N
MA^.+B2/,4);$X=:_(U61(#ZIIY@B%I?U@BI<N$3=A*=H ;>3:CV9^B;KSO;%
M9PF?>Z3NL:-S^2-V]S L /Z=CMAUVL/K5GMX<=6^ZG>OFJ/+T>6PT[NZ['<Z
M[R]ZUW3$;N<C=O^Z^GS[Y=O_G*(R35@4^3$ RP3M%GVN51ZL0_FAHW7'>[1N
M4,C)NG[WE(X85>QV.E_UK(A4,2EEM4G=JU5VWJJINBDR5[UDU:/>_2"F+H^I
MGU%3DA)1=XGB?^,/#.MO84$QRCVEK;]#;?VUC&:[0YM_16S^'1'(54ZG$ZP1
MK!7:'&!87(NGRG-2Y?K=U=9J^\/S?^!>T=SW3!&4TC.YY!(1):=']MN%'2^N
MBP153U@JI_U/1#B&0Q(.BA:\A'>N;=<.IL)B=YYGE:)V"J5I=42NU2L_L[4N
MLGA$8G>\&JR6<M8R!MWR@TAUD;/=7:IVKT:Z378*+XQY2NDG615'?^\AHVVI
M6:?0T=!HMGM[HV!E>(M<X.H&P G5"-5VI%[?:'>&A&H'M^,J[$3II-362[*D
M#YCDLT>"'AL1*T,XXL13YD3:0]2/4!]E:IX-3J]MJH=><D>>D[N9"A$F[9%-
ME9M7!J<>AB$/+LD5X[?*T8?XYT#6WO+IHR.%-_F(Y!37(06S$C'D8TKPJJ++
M.C#:_?)K"-;%&SUB<__@BH_PA_!G]1$]H]<M+&&G$AQ1N6A8?<V@+[($BN/A
M5(0_8^#3B9 21I>CTL6EY]1%CLA/)=&0VF?8(M'8FPM.&37[W7NN_)F:RFU*
MG]3QK3WGX%2>&REP4$U+A)"3D+-:R+GG/)_*<R-5^ZY/@< _8"'%F>4]N(&N
MF6QA<4[Q$\_BRD*<XN?<EF4V[:26(!8T-J?<O],7VS(P,_("6<I3GJ="]K28
MKN5JZE^":#YW;+AI[GM8*C>MIVN[<+OC\+$NGP-C@9=%(CAG-Q%6:\X,\T'X
M99>'_4OCO,O@=@>&4NZ;9+U;X)OI'HK>UJ74K7Q\_2JG;YY6R6733[+,>%H9
M%0!.F!KWQH)%@<(CC5&RG+>OX R_A<<CO,T\ *%PREW6;,5"E13@MK ^]MP7
M =8F@]N") $)2X<';'T@FWFNO)N;IC<#[;U T!UY2!@<$OPE5;Z$Z%QZ$X#D
M18#X*G&D-%ZI6(7I\F7Q&87;"GVOJG8/Y#TS(]_'RM=SSX_KRMOK*_KR[#6R
MHT#N>//S2V!O+FV]7 );E?0.1@F+7RZ 5T.?FV'$G4\\C$!Y+]X#W]ZB0?>"
M$MFC8;\Y[%U> N9TNY>CB\'%Q57K>MCN#MJM[OOVQ=Y*9!\ASF&Y_0FW?7;/
MG4@V%#!Y,&7BS\B&;W#AI"39Z4*RL>2M> &QI)Y<065X\4!7C@Z>K!M=Z#RV
MC"7LL(I4G[JZ]:G;ARW1?-P%IH]J\D>?V$[UJ9^5D7Q4I7RI/O6ATQ.(J?=4
MG_H1QJ:ZU<7N+R@72498&=!9]3+R?.8\KQSB_C)N*[,3<4SIN$>W[=5M-(S.
MH%$Z[2K#39014$WE3\!&P%9H"<-^WVAVJ3UW5<XHU-&4XQ.P^E-K+IP"@]Q-
MV<2^5]^44W"T!.>G*KG;PX[1'I:4OUA?Z:R>(%;.NB#I@D?TVD:K0(UX(M)%
MAR?H\$3%2$TIP.7$0L#\&/3I^$0UK!8*EA!V$G8>"W9V.@VCTRPNCDS8N:5-
MNOD Q=/)?R]-ZLLF!WX6#Q>F"0L1 @M_]3T7_C2%?.Y7H+VY4/]_04)@KW]]
M<=EK7_5Z_<MN\ZIY>=VYOKAJO!]VKAN-X75C;PF!+\O^>TGYR.<FS>VT)?Q-
MX+8U2U>/Y9=O-?'V)#+&V;48^Q'W%Y@$W%-INM>VRUW3YDZ66C<A=RWN6P&[
M]. ?]EJI\D&KU7AW?7%SF7QLOGO#[""(A,4N;KZSS]YYJO3Q'6>-EK%"ZQ)8
M)%LZDWT4/  )>7WKS6V3#3JM-^6-0;TQ2Q^D@YYZEDS[IL)YR<GEWX%]?9:9
MK,&XW/$7@CW8CH-'$7S,TO75R00?Y/3.A2?&IP4P:]>Q^=AV[- 6@3Q(Y*B5
M>[##J?J;X?D">39@S8&%<_9-/12EWV SN"'RI8 ;\NGZ! ./T\KQH(2+S\<?
M91;Q1.8!<]\.D.OE^0>N7SQ>I/.9^_8,+G(6:F:6@.=8>-S!#H.EVJR87\PQ
M>5T>;X I>7.!\ 2/E\\]SY),/4Y3"6Z39LR9-SF+ DTF?:8C(9X5'[(8ZP,4
M@:P/FQ["6LR%))>B9/YMW F\_"NM)#L^P#=-A3/7F=2>K\CDR:,>DP0D B"G
M)#&>,X%KQB+$C8((N2% U%!'0&:()  P]@QFKE8#P=</N>V&BR2+>PW]XX'?
M3F'Q<@/4A^W8GZ# ;5S5>R$?#)\!M?07>F82Y0T\ W-O6W(_ R 8UP>F8+L3
M5"AJM<9>%&:&'$A2^_I('WZ_9NI+9)U%08B+Q"UOCJ<9(CD9#DQJJ1,SO@A]
M+\!#.CA"L$'<0+.LXE(<HQ8 32+X$LP$M!TETUJV>NMM<NL2Y^"Q1#/A<WGZ
M LR#N\BV))-P-<6QN+-=%P>G+P(3S0'1"YD\L.,K"JH30NGQG_QD[8"!*:JG
M@B/F#E(4F];/Y'2XZV+2O2_D>0YX5WSB*'V[VEN*T[98LZO.VQA*[G%0"T5,
MG _</K-#.0Y08+]'SD)?+)47Z*(E_2-_/6OJ#+!](NZJVGG+;O&0*3+%AQFN
MLV*?/2NC#%$.JI!*GC9P!W(",M@**V1X)68HR8BN@K=4)$&)A%/@?N3LG&Y[
MF-KF%)D= 0L?E[D'D#,6.:4[ FT^H1*)H5MA@AG-(D?*V9D2(V#T?T?*68F?
M QI#BDD,\2"L@"" "L!&(!SX6Q"CDQ96/$"E!6:-WC\!V_8/H0YUJ_-FCCY<
M!CH)"2D)Y87P \(XTLI=1AD)B, <R<II^@:P>@!J4^Y,\!IDJ)+M*J4]ECA,
M<V6"A<A8FCVE6)<ZHG-VR0-E>>#!/!OM+51,>" KIW-L4"*F/"B?U1CZMG%D
M.Q;PT1F(:*CE!(_Z3<!R4GH<%0[W0<HFW(R-0G"KY7E16(X+A\^$Q0V&DP#Y
M=&WX^T'HXZ]H&F85.?XRY:"C3#Z7*/2_ZN@J^(% 13!!9&D 4)]S*7J9T@%2
M4^)@<1W O'*<0 ]/7:(- C3H4NO52&Q>X+G46(OF\9G8#*-EB'/.ON,5&W[%
M.<C'2L-MLSV]SFZ4UK4D<CS*17Z2P.S:(+W=/#X0H\BQU/M-L+WOA$(Z#)_(
MY9M$\J_$LEY'Q_RB&W"-%4GZZ9O!G(;)V-H@DV?YP#Y LT0_-D;?!SF8,;YX
M@G-$$]U%L]"7$P4>43/6MYVS&!4\]&JE9H!Q(7V"8 W#:HV195HS>V9YK27X
M>%AK)33UW)!2-ASUQ;_CL."23NEA:OAPX5I?,Z[.ETGBT]\D TW/P<+5-P#?
MTF-QP\QH\,W RB\(9UV_;UXU1]W+7J/7[@[ZH\'%5;O=&C6[HTZW]_[J/86S
M=@MG??GV]XO/'_[OQ>V'+Y_9Q>?W[.;[IT\7W_Z'?;EF-Q_^_OG#]8?1Q>=;
M=C$:??G^^?;#Y[^SKU\^?AA]N+K9V1BH*TDSPG2*!M/53^'8/VU07!]<\SSG
M,R0_9;P%EOG]06SZ!2 S^PO8T)D?HV I:@B*:VR#669.71C?W8+ILA'XKS9S
MM!K!* !N5"X,4!;WPO&4TI9A'+A6^(AU>C$1S=$2!UL!X,Q5@0U;>5]@#/C*
MU@"O'^[43O=<>'-'*._31)/;/V<WMC2]L1 ![L3HTRW-X;!3HF,I5R:<^D*4
M["OIVB!!0EDTCL(T=!NS0/J-M*7@MCL?0V)6DA!J@E#(.$5F85#%FP)\'#2:
M[M#?D467YK@&W%%1#WFJ3*AHT8S[/T0X=[@IRHY:WCYX)9.62XO&E[.7 2V3
MC[W_Q0B5:X\-9;!,[;$=8FQPPL =#&WDOG#A>V#Z"_8#E'>0A+N0\3Y=W1KL
MXK\_&NQ?5W^_EL2=8X!.4?+;U>U;-KJX_ *7_<]_ZQ7K=S*[[Z^S0WC#Y*X:
M!F#E@@CE['+K'CD?5PQC9'A<'Z4%) B4<@X>OHU&64%6A4Q&^/9O'_ZYQ>O!
M( \B1RR]/V8MH!M&<D..-I9MHAA'CH-;%N$4*&1;B82BV0IFK)]4XP+/X,OM
MU4?0>^DHV&O3&X.!D9^Z(=%G:24^7?V7H5D1+7<9WN;,S%7UXC!&%?V48/%W
MX2(?F],813F,5\:TM$?TS3/A_W\'49F_R1$QN3-+2K6>=H8RX+#,N1^J BD
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MER'\6/<HNA:;"KC6P[8JD<-QW#Y0T9OQ'/W*'?\_1J/LZI3=\2O!\7+?8PF
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M!Y:F#1A^I^"D?(OSZM-%R?1!.,XIK'+?!S+$,PH0WSX':L/?@:+I'$3,]J+
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MVC2,1G&-ENHB'90Q\#)N^B:"$&L?AU/!'CS?>4YQXZW%K;P*YH>40V,X*#_
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M221W%,E.W^@W"W,V221W\D+W+X[[KPCS>^0*!MX25H/97R.>EU"V,H>HJ-7
M'I"P9?0:Q9DFU&B@DG!7.>N#4(U0K=SB,*U!DU"-4(U0C5"M-J@V- :]XK)$
M"=4(U0C5"-4.C6K-MM'O4 _/LC+DJ===T5QKKK;[6FZ$8>4:8<Q5(XRYRCR1
M/>M\;*=F"0N;<G'XA&W4='^ZT,>R-7"!L.]QZ=03L8N=+V;<=NUU3<3PF:;#
M@\">V.JIJON!J8]R.S8?VXYJ1F:KGGC<-&%8W%W@ T<>D@P[YL%?4B9D*9TX
M@'DS%2(,SMG.:UO31GA -%@V,\1F$D+G%GW,D/P49>*/F(E%S/D@#2 )L@&C
M8YO(;B+3IQ&(Y2 K!N84Q 'Y7@2(778 GY%I99,\4U/ZG%W,=%.\97$RM>BE
M(L0>IL*5[Y6:#"M$Y1KD,3M@D0M?639^Y,XY^SZ'L:*PPDH"#6 HL-CI1&9\
M <__,[+AY=;_;^]+GQO'D3T_S_P5B-HW$=41M(OW47U$4->\[IWNJBF[7N]^
MVJ IR.(416IXV.7YZS<!DKHL6Y)%2B"5[^BR) ($$ID_Y(4$G= D\4(FO.7%
ME'Q ]Q'OC;W-(Y,\R^'9XI0.O"P+0O+(/P-"%#2)8:[W?#QL-# V)J8I""IT
M'MW39=;:YHR+ <#?U=OS.2^'!=,'V $ XM,?Y_2:P**PH7MA&E=C_ ]=M ,B
M>^,'+O$,B*9T0>X<IK>Y0'PL:0Z+XKVP%'G$VM#QQGV;U>OXL!:C&%\3@%&8
M*$>HXI;.4JJ\I52M EE!I-MX'OC$E$V\Y1!O.<1;#@5JWN[1X^3;,OF6)!T(
MY]E9#-<ZPUU)Y[\9J3G]_R/Y6FD^_37-YTNA^:!W$GE87!Y>,5P_DD%E6QS(
MNBW!Y%:M$%Z()]B"5(42/\<)^P5AO7Y81ZZMG6O_$;/ITV36?KYM%=U1$ 1;
M$(1OA._V<>V;X1NO\>WF-;X"TE"(2Y)$3'9IH)*6$'R!=57/P$;GOCM#",Y#
M1$)$0D0ZMW@)#DC")'VV":U:ETD,6KIC-U]G0QAF0H@3T_N!N(:X5NL9?<V6
M#!5O!:_[: 1>GYO]Z([C>77R8)%)^Q9/[\XZ0N?-OVCX8*91X\5O.PC5%4'$
M, H*UU[G U5);>I\($H72M=E2]=[59,,IZ%:*2^3ZF(*XJ$<HASN)X>*)LE6
M?24I41!KL/L$\G*=H62E%^5>\D24@XM67G9QV7JM08RE"2."+=XYNRAG-1N&
M*&@H:"AHV[JP)<W14,Y0SE#.FHWS&9*NU^>*Z;J@821OK8M?(S^A7LJ*@14U
MQ=(\S%A8SR,^KZO#"W\ET(E7U!J;)X%?%/%9K5:T+&+$.V)UQH*JPEA9K:B9
M"_+:++FZ59O8=D4ZT?&)HL$W-<G0:LO)0^% X>B2<#20?(\B@B*"(G(1(H)7
M?N_'0K?,Z)FP>JKQ6EUE7HUVL\CHLAXIBX&Q&JAW]#Z(>-GELBAJ4<05W1K[
MAK8=29'QKD6\_K2-6V<G)1+/?*);'Z4-I0VE#:4-I0VE#2-I^T72F/&W>MO'
MXF(0=NO(-* /Q44EA7TH$?K=#W,VW<4%&:O&95K%V=#C@QX?=(JB4Q1%!$4$
M1:2V+'R]MAQ\% T4C2Z)AB;9FH'"48,-=('!M"_K-QPR4R:;>AEY]-B]?<S@
M*8R@U=L#%[?V/54WEF)L35A%L//>CA;Y%H6N)XN2AY)W"9(G7-W4RQ:\][KD
M6,T?^\1T$G&%L[UF8R<E$K="#+D=R4*?P/9+B#?^5YYFQ47WSPAY+)-"%VD^
M?X' 0+\?G]W[ONQFGA5;CU*@*?1SH-IS$7ZE]XY16Y%:W'[1.7N90J3HDF77
M=IP4Y0CEZ"+E2)$,"X,<*!PH'%LW&4O2#JKSCIL,%I,\F)ZKQ23SB!)-/KB4
MY.L472MRJLV_DW&<WX7TJ(JPXE^/L2?UZ[ML91>9+^HVEB:\76\FL# \B6$C
M\0.VB*6(I2*R,6(I8NGY1!NA%*&T U!J2([6T.T1"*+M!5'A_&N(G(B<8B&G
MHDB.5=_MJ@B=>WI./V2L#-?6YU?^7IG7LP2-#>[;3(AAGS=IL08@NET]$40
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M:+4^MT@4.:?!)R!A+KUTJ&U)NJ/7182NY.BAMP/! <'A1\623 ,O-4%P0'!
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MJU#*7J;SI:)M5TXSH3 6TX;#DF):I7+VKY86QDF/Z*6Y+M(@1F\U>%?BK:+
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M<=7=S;H#$<@>B1\ -9\Y"^8?>W!_.OE ?.SU+'\!-Z-31FG@?7"8APB]DB^
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MR:NC^7'Y;'@)F+!G<G+^[:?_!U!+ P04    " #T@0%->.RXEK @  "Q60$
M%0   &5X96PM,C Q.# V,CE?8V%L+GAM;.U]6W,;.9+N^_X*G]YGC'&_3$S/
MABYVAV.[6P[;L[WGJ0)7J4Y3I*9(VM;^^I,H4K(N%%E258&T=Z([9(K")?-#
M ID)(!-_^X^OEY-7GV,SKV?3GW\B?\$_O8I3/POU]/SGG_[Q$1U]/'GW[J?_
M^/N__>W_(/3?QQ]^?74Z\\O+.%V\.FFB7<3PZDN]N'CU1XCS/U^E9G;YZH]9
M\V?]V2*TJO2J_3"IIW_^-?]P=AY??9W7?YW[BWAI?YUYNVC[OE@LKO[Z^O67
M+U_^\M4UD[_,FO/7%&/V^K;6DR7R;^BF&,I?(4(1(W_Y.@\_O0(.I_.V[PZ=
MW!3_^JC\%]:6)L:8U^U?;XO.ZTT%H5GR^K]_^_5CRR>JI_.%G?KXT]__[=6K
M%1S-;!(_Q/0J__N/#^_N-1*_QDG]M9[_Q<\N7^<"KT_L_.)H&MY-/\?Y(@_
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M>HOMN:MJ180)WF&,'%$1$14<4MAHY"*'/RECN##[VSVX0WXW)JN@G=,4'(=
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M5U?OEV!C0%,=MOG6"B/_<%#C[__V_P%02P,$%     @ ]($!3;CZ/1-76
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M9!I#I8&@2&)ORQ>05P_3#O 6511^ML"@/W[^,\O-[6*97:?YXH""];QQ0BW
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MC2"@3EN@7/72A SKM->G^OJK\EM;G+JO\GL<_J/77^67:B E!BY8,DA)H[P
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M0TTP*YVD#"''@P7(N*_H%'"(&;SQ6/=4A8P&TVFWFMHK:_T(8W=*W'K\Q"K
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M2XL(+FL9!ZHQ]\W-]R%?8VF>7Q49SV%F@T9XQG;'<UDUIE--XMV>/,S&8R6
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ME"?,F]OII+"'WL[7Q.CT(LO3RHHX?/^]\:")$U Y)BFA2@-A'8"Z.J,,L'9
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M\W%^R.9?PQI.UYO#XG.V',T>_GOAY_R0+?__='GO 6V;6=7DFPG16ABJ 96
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MP$-;<<.1%I6LA^RD;VS[#)DWKVBEK&,:IUTDZSDD1<UC:9$ SBGA"5*45#R
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MV.[6,0:JCH)1I31P9)WEA+(T2S,F%5Z%3Q,";HE*\_J\_\:<Q'?_)VUMU8C
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M;A0.58=T>U#_3R]C:+NMBINGK1AT.]O2N<PJ,>B;;GBGH6<&V)Z'@IEPY-4
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MV-[S'ODY+QYNGGC/%']]*V;1];;^N%D^556^ZD9J"PA3G^'(IQ$(W"!-(@!
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M3D)"FQ6ZY4KW IH'"?$0C"@+8QKY"4E<W$-S$R3U7OVH@"P+.UK]QU.];6]
M)5Q MJ4I:1\G7'(B/[M(J<G]'CY7\P:_A.!GFY63"3<FEWX3[)]( J,&=Q[I
M8%R77]V3/CK?TG?6[M6,E=6G_"M:+LNGS58\0%R5&_[ELKT%K5DQ8C#@:2G%
MQ(.!#T@2A@'M,<0L5!K:F[4\HNCS&#D<KK/'ZSP'K'<MKME R*G\=#%0DW.C
M]-NY>5>%R1/2;"<B\]!@2[Z]O-G7(H.RJBINA;RX[8>$G8#'#$<N3C&($*
MNI&7] LU!+N>TH7@6@8L:V1SZS4?_>Y&PGJ+TGK<R>F===K49$V=,2O:]18K
M)R1J$(GS4*)A+I0&&Y7B:&TG95=;/EO)JE7]Z^,JV^8\LA D_060E,8  2]A
M(>!_ 5R:L-XV'SFJO3Q@Q*+MT=G5KX[ \P$DBH,N,WQ*#K9&IU)QD+4?4.T
M.BW"GMV)IL-2S)T:5!EE?AX29MBGEX,H"XQ9+_P]W]U+A@A@F##/#4(&,28H
M\J*=^OI1,DKQKSR<V1< G^O>%SE&+.74=V9A5)/F<2(XKY+@<XGK(D<,ZCQ4
M?TR'394'ZW+]7K[(O_%NC^_%$;./FS</J-1UOL7M@_2?R_6:E94X<[8(6(AB
MZ@> I!%TTS D<=#!H-!-I-YUM&;<<B[8'>UJ\-7.!Z?#Z%R6E8B6G+[;X_ZT
MFL^"=L7*@P8M5^[]L;J_'1ZK.VM#<;8+Q&\"M],!E\RW]N*Q*I=/8KFLZ>KS
MCLLSJ)/'YT4V%0R)'!F#T$N:#*G+V1OYT#K]TV8_^^Z5(S5CQ2*\8P@^[4 L
M8$A=R*B/?89!R+"?)GU.I8D?PL5CDY[Y-*[:RDUX3%A5Z;8O :J6V"G6SYG@
M5&[*,3:1BGGIS4/>.[7[="!Y(]>]O4_;J0(W@Z3/8\QOU*.7)6O&V9(;M;\C
MK1\WRRK/ZKQNSIYW>MS,*/@OB2E'52Q%G<3G?%G>;9I9QL5M-T&I%Q@G"66>
MGU#?#7 0XR@)>\!A$DL=_9X!3,LS@1UX)^/_<_A//JVW8C<J<Y;MD*C8.-N]
M,\ZC\*8IDJKV_HA?J#J/Q ?5>?6E$&7/694[7-EOR^HAE[P5=P:<2TT_?IA6
MH9D03@Y_Q1I4WW!8<UG(;OQ\X*/3..D@<>/M06.YN.W+\"0?[YL!X4HSH!^F
M:6C.E>;11"2G5C:#<702-HL6,(?IVCR(*&?7.PU- 3F(=5;7Q6V1KZY+_J>\
M^-+>P^ E 8U=%V(2I3Y$"8[ZHP04$$87F_Q.G%$8.!G4MB^E4DFK4H=0Y:MJ
M1,1N\TI4YE<[7'5[M=6R5["L7?_LAC+_E:^<K#VC=9/?%9N-V 7G0QOQC79^
M:FB6J1^V@7-.N_&R,0,]1"QBN<<\D_GH,4IU9J>#PS/SN>IP_V1GKH:8-#*/
MO>#Z41T4I"Y@%*#8P\ -&8O#"'B@NP0_Q@Q@3^HPE1W+EF>;#1Z#8WYU9@W,
M[*R2:F>RUD!V#C!/&@.#4RFKL; [.Y*/B9F)SDNJ=.<NVI3_ -,1?=]49A@#
M&32Y;^2G"0E<G[K$2WWL ]?U^^D*"_P =?M&=#-THJ!@4WW7J(=G;,_H!]W1
MD&5VYJ-$'8\T=C34V%*H0RIVF\9?7YGGU+S>-XY0Y-$DCB,O3)D;^P2Y<8_$
M\[#4G5<V[8]>C71>;NX^\$]ZT*Y',A\#Z9*D2>G7JDHJ-D<N^][O ^^ #RU,
M,A\8Y=JD20,TJ#S)1J!4*I14F3M=I&0M#G,8:5KV\'6IDF4V38PZ]S@6J8M#
MXH6>2T#@HRCV/9KVQL,DB,P6+"D8_C%KEE28'5ZV9(E.\Y5+>Z#S&>KO,6F.
M]C78G_^ 7\<IA3&_-F?#%H#W9H?M*L*40W.]U.5:[0<II+[7'[%C*8VBX0O&
M8R']GW*F:1K(D'7O.;8-H^OD>P?G5-<T6MLPL1X_QS9B9?U^Q+8R<-W?4$B4
M]PG&;@ISF.W-A@NI?8AI(F1J*/5J^X0 R&B40.@#C[J)3PCK%G() #B5NH_.
MFO$?94=]"+]F!A=6J;4V7K"RM3XD&&:SN=6@6$_0H^VQ'R=L0/K4YO['R(CZ
M[BDFN8$\&E[Y9*$;)C#V"7"#((@08A[LC7O83TUNN2N8_7O<=3>Y%"?+[P^U
M%"?ME-Y2G!IG@W?@SXOLIE@7V^]O'-U.O(A%01+[ 8@3FKJI"_!.$A@RLP4_
M!,!8>_ ]QB(W<2V(A4 ,W(<?*P:F-^)WN(U=$6(A-H:VXL>*D:V]>/U8#=^,
M/\&=SFZ\B5#,83AJVT79_7AS? X9EKY$L4AY&_,(!3!!7@*3"*+ ZTU'.$[-
M;,<KFYW%9OQHP]*7]"@.2K79G>^05-\EB0'I0+Z4EC-/20#);_.JRM87M[\4
MZYS_S":O:59M\A7]MEP_K8K-W>?=^<1N[74!0N(""A,O#'P_\=S8];L;ZTG@
M L]37O,<'>%4.\'B,.>J<TC\^6'GDI,M[PN.?B5R>RLG9T[>>^AD#^(RW.>'
M1>M^GUACU6_\-J&P3COKYF"F4.CU*.W,Z5T3^W-[YYS6NS-GYY^S=[#?Q_LA
M6H#&XO"L6\+ %>2)6H3:8K/I +RW(CU9P.<P3YB<@[?6MB>.B/;&[6NLJZ=F
M6[E>B%H[#&/J^F$:1L2E*.BVCDGHLS3I[Z>X'K!U.\"\E 8]OY[B6OM*]L,1
MQ?8^X[+$QQ7%1D2O'8N((<ONRHIU[Y5STTY<C%Q9826&FOO"MN-F=$OX[9S1
M YZ0_('[P",%P>P6L&8P]#=_C[.DLN]K@.L9Y4[3GKVWVVN,/6-Y[M6&<Q(2
MX$&>6M. ^$'H,C_L-[I"#X)A]=N#K?\ )4K#&3:4BZR2:R\CF:Y2&AX/P^G)
M:ESL)ZDQ"I7>HVQ(QM*F_P?)6_K^J6:O@4P:W16B.$H03$A$*00Q!AX*_=XT
M0WYBHE1)V>C?4Z&2Z1TA66Y_H!TA:9=T=H34^#)7H/3V@6W?PZE'0. 2RACQ
M$@*3W6B6!C0U6Z.DAV&:,B5;]X4,#8BI6B7[L;!8KF3[[I"A03)=M&0_6"/4
M+4UQC\AI!@=5+PV+R1P&J2-XJ5S#9()5(P/6@YIBUX=I' (0L\2CD"$O#+I;
M34B4!H@8KF12L/QW6LRD760_A.,?8 "KXY7*&%:;M>&%37O36KN3D+I>PN>[
M'"BFJ9?Z:93V<($;JE^// 7(_REOFJ)E#*UPFE&C,%[D='@P<@9U3K:;@JE2
MIQDU"6O53K:;AH&"IV%AT*IY&BGR<YA=S($&Z<JG4>,R?%/X$.YN9QJ  (0Q
M3GT(L.]2/C"+20\"AJ[9^B<M!/]3 F4HDD-WGNU%S]:V\_-T8KH62B\*IO:;
MK4?#VF:S8E0,;#2_Q976+O,@TF>47RTX)[V_;(!#D[GPU3YW$"<HAA1SJVF"
M(Q3Z;+=(05@Z[+U>$P!^I#*I(3R;RU=6*;::M:S52PT)C/D49C5 HR2R40NG
MS-SR9#(./TYNTW=1(\,-Y-/TGA0 49I&ON\#%R$00(;<_KZIB&(<&ZVC4K#[
M=UE*970_2I;A'VL_2MHKS?TH-=:&],;+]K)NT00O;M;%79.+KO@_:_$PZ,?-
M995_*<JG^K)IW0L0HY#Z >:#X=!'S -L+Q-</V*9,>B(<"R/2/M[7@\79SC\
M_@;T9N&EW+E1.W7O2+/!U+G2+<%(#J#&C.7I<>Y,PVAF5^C  6?O@7-U&,#>
M">?R]!K:: JNQKJBN%L*Z7QUWY;#$BG!*M>RV8(4=79W5^6M]=VEUM?BD>CK
M_-LVY03^OF!^1&D:N$'@0N+2*(80-;:3  (*L$I",&/1LN8_!RF6T96V?0VS
M*R?1XQ.KIL)'.75^:S Z J33H)0NKS0CLU+,G5!2L\S/0RP-^U3:;*L*R[)B
M'W2SY"/QSO!5MLYKCF8IJG[09H76Z_*KD.3Z<R[>N\F[F5O] IK')]'0C0$D
M.&8 N2S>0W,ADE+$40%9%DRTW!9?VG,(XA4A/D%N:R,:R$Z/N1DW7Q5\$'U;
M++/-UL'9-K\K*_%K7 ]ZM]O/V'NNL.HX6GPEEH?G&%HUR7[N@2B%:7S8!:IY
MSV7OQNMX*RC[A+%46%&>8TSU5IC'C*W<HK,A;H\M0H\=NADL2H_N<CEA5S'T
M3 %'MENL>X$DH1Y 4> GD>^&- IA&/D]$@@"J;U9F_8MY_C=,DKW0+E(TH<'
M$)\VO"T[U^5CL71"$!IZUG5(//37ML8,A9G%K ;QLYA\GWQBI<&LXH*5J3C-
M8])EU4/9QRF,L2E9)[/F7Y<53Q)?<E15XKQ=LUDIFO=?UMFW\NJ!?_4O_/?S
M7_*'F[Q:>!Y,O2BD*46IR M^W%6N1@3&R/,52F2,V[8NP3O$?,R&^ RZ =QJ
MP0O$2K4:YH,@53\S*?^JNGL UCE$>\"^TP!V&L3.;RUFI0/>%@*A5"\S:4!T
M2V44 S.X-D:5I.-E,=;HGL'DPZ9WY3B-5FU*\;G\GJVWW^FWQWQ3YPN 8!3'
ML1=[/O!(0G (4&<D2%(&5&8+BA]M>T>\0=.L]2V7U9-8Z=N6SE^N_D5MR*_*
ME]QHWB)5BHMG+1"G0S+NR/LY"R<&U9ITS6.\K N^--)DU-3A:GF?KY[6^<7M
M4<'B(V]1'G3DKZ_W[Q&_7"+Q<9B&*?&3T$U A F$L=ON#2<,!HG4T[]SP#GJ
MZ'E7UR/FS.^L;:@)VZ2AEE/)'R7*:I+;>R4VDTX,"T5PN6L?EL=^Y/#E^B$+
MW6:TW&*L3B2&.;20>62963!1SJ__ZN:_CQLNO#R@_?V"+\R[29*(EZ80 !!2
M$J<0MHM,D0=23)3&S<:,6LY,.W2ZB68HIZI98T0Z]5/ #N3! Y2ST?+3#$H)
MLZ$@S$UE3;EU5#*-\B:K?Q^Y%#_DU]DWL06Z+NNG*D<W=3/H7#!$01JE/DYC
M+TV(FT2XM1ABA +PWN%Y$R;L]<@6E<-A.7M<SF\]LI$[X F.3O0Y$\S.HYL9
M\:0TW^X&=Z:#LD%,7 H)32"E" 0N@%'2FXP@4ZI6'F3(]J#A$[[XA3K7Z-_H
ME=JX81A]VF)DASDC:C39@. 436J"I,[N;!5)PY7W)4F7'_F*HK=G6F\A0'X"
M@\!''@*$I@"X7M(=_4-1" *IEW!LV+6] '=Q?H[2B\_H^N/%)P?]Y3.EO]!/
MUXKJ991H.3&;BF,U;3NZY#4/J5,@\605D/E0S$,(K7CVJNK'%GOR0[<W)E^+
M& >,,11 !@&,4<R'B]V<RT743ZC:F$W'PE@K/"_7(B3+0P;2)SMFL\V<ZF!-
MF31+@[0W>#DY.AO"XSS4:* /K\9CPQF159BNCOSJ/L^WYX+%HMR@;T6]B&$,
M<4HABV$2   12Y+.7 K]6&EBJ&W$LLYTN)P&F-,C<WX3V!2E1I]'.;49A4(U
MP=%CSXKF'&/GA.P,)G0>RC/<C=)P0QNN/Z1\R(K-(L%A@CR&Q#L$/@GX0(KN
M# 88*\W[!IB92(-:= 942)9-?1VR0*09)7J/P]&TJ 6BJ$:*M,Y7CU0=D5 D
M+6Y49UU%7G<UL-Q&"H+03R'"8H<?>#CM[1"6(IT9E_RGSW,_78,EM8F5'8+T
M)E6B?O?=(PI6IU,[-B2F4NK,S4,\!N _,H7294+J.%9S9:1X1U(\(]G60G;&
M8!AYL1^[/G%]%U#BPS3LC''%DIL\#31A633:2U37NT<TLP:;PNF= >2=EI$1
M>5/3DI:R_;NC7?6LQLFG =PI'' :AT.]<TRZ7,J=6CKJ^1O::XBJ&9Q!,N!$
M:;3Y:*Z5GQ>;_.,V?Z@7*  ^<M,H"9#OQ;'KN13TAFBHN5 N__%CC=N<WP0F
MIP&ENT*N0)KB\K@=OC37QN6HLKLNOB-$9E%<G;UY#>5T'#BV'*[+A;*"?,Z^
M_I+Q'EEDZWH18Q("ER4L#KTPX&8#/LOLU<IG>B*B9,&RCG LSD,/1E,^U!A3
M5!!K9&EOL G*=I#.G+]492W]BH!A-3DD1T90M,B<F:;H^7!,5@8PHJPL?RNK
MW\5MM>4RK^N%&[$ ()#@@(6(1K&7,-(;2SVU%6Y-$Y:U18!IK_9NX&BJBR)K
MBO)BCS!M?>EIZT!-JS#/^)&1&#U"9Z8QFDX<$YDAG"BK#"LV17V?K_Y2EJMZ
M$460T(B")/59P-(0(!QTQDA B=)-;)HF+*M,#\:Y*Y6?#= E35%D[/&E+3([
MUAI,TVK,,WID-$:/SYEIC*83QS1F""?*&M.TE@6*?3_&G 2""(K2 "0QZHW
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MDQW?7SF^W8G*,Z>!>.9PD).]QBO#W E!-$K\//30K$NEQ89J3@V[)=9%%*<
M\'^X*,6$#WU2FI+>,F0I-2>&LA;M:V&_^U=60O/FT_LZ8)J=3Y7?^?<]98\4
MNIX>6R9ZWB=.3&?<3?P (]>#T \BUPT9HUYOW(T#I0=$#)FTO&UP7F[N/O#?
M>YA?[]N3I-D!-5B>?Q_4<4JA&VIS-J0GGA<9'_P6V^^[_ L"''LX8-B/ NSY
MS U!U-EFA*3A\"RH;G.\.<&ZPU;D?&*PRF]S'I"5^:F !NWZ<P&[?)N9#.PP
MSFHN\(HY13G49WZ^:CC )PDQ',J8$2WL!T2,QBZ J8LC&OI!DB (@]XT8WYL
M4 IE3?[]S0A>4J3;!549_@%ZH+)+*AU0CR\C_>]@)!3&P"5)"#S& N)S@WQD
MU%L/O-@WV 45K/X=]T+MJ<$0GG^ OJCCE4IWU&9-_F+@;59L\E7_V@]:+I\>
MGIIC5"2_+9;%=H%0$H?$18F+ C\A'O2[)^&Y83]B4K>)&31G>7Y^@$C,! 0D
MU;N AS,J-^H?F4RU(7\/;O^@V4^'U'8 CS]/9^ERX/<8.R%O!NF>A[*9=.C5
M=<&&N9)^EWUYGZ^>UOG%[:?\:W>/# =P694;_N6RN=A [,;B>]Y81>78X<\4
MFV7QN,[KZ_S;-N5,_;Y +$(H@&D*,$2>'X:(M+5D"0%)$B=*3[F/"\VR3GY\
M>!03^O+60:OVW7?Q]77Y6"R=$(2*K[N/'#4Y?9UQP-2TN'=$1(B[XNQQ.L^=
M:6^X;=T1E\@\^\'>H^YE,T=XYC2NC?T(O=&XG%#\B1K /++#5,Z7L^B$:EF'
M%'5V=U>)BME"O)WYN5TY;M]V@R!D""0@Q EE(:,P])/6I.^F_+\J.620(<L9
MX3DVH34=.KV7*(=Q*J?PH]&IIM?Z3%K1VU,LG5!/(^3.0PO-N%)::'QJ.M7=
M:'M17>75EV+9OK4&&(U2<3 _=2$,D4OB?B#N>RA!2@^>:1FPK$L=IG9PT^&J
MM=YVU*-/3HJL,Z<F05JD65&?MX@YH3J#>)R'V@QSH338KK3418S&^A;3/6H&
M_#"*(C_Q/$AQ@K'K^7YOC[IRMU0-MS*-SF@]GCB 2B6YL<RB$<V9Y&G$H_R\
M+ST#.)V5_@SQXVT1&LR,HA)U5_9'#$0QXTP RD7/IV'BT\Z&CQ1?=%7[Y'$4
M1TM:9+E1DA,+M&A)R$1O#SYCX7VA4&1K5N*@BOUM0=!B0.I^$YS=E _Y]ONW
MSD2<)BPFH0N0&X=1#"& :6_"!:G40K[6!UN6 (S2BU_H];__F\+%%LK<G-8
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MQ"2%L=<KYO608::*00V9O-;9%V@1?3\3)_N&RJ,2H;IR:)Q$D_)W &YJK3N
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M(R\@=G"T%@U5R9ZKH&G[([TXJ,>4OHC1A\=U^3W//^?K9NBSWV==D#CB.DI
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M!2X=CWGT9!N.:6]Y*W(WL _OWI9\8\\]8K$K7ABGS(^9QP(_B?JGE A*_<A
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MW6WDZ!#69PGO!$;PE\6J_>-?%(M>HS6M9!GL/;2J8F%,(/KP70 &ATZ! Z_
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M(.UV"S&/Q%+O%IBS9GF2VUQD_:,&U;YZI3"7,<.GQ$1T<"K5II8-/'!U"SJ
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M(3BEB2==/>MORK*F[0#]JT(EQ@"!$I6O8;E3TZ\.F[A:KCDX=0%V^/3>%C%
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M"#.RWG>%8A9"T>-)PG=Y?LW5?#Z:7:_Z_OV(MLZ:<T0KF0HK,:58(06LTP!
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MCT4U,FN2GH0:((M:DWL=/TT3 CB96IM+EA=?_IF/5SW;OB?N*9U)XR12PA,
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MY>N_WN8I%YA([WW,16T4\<16*'@(SRPO:[/$./5ZVW&8OU:OMV! 0QXL7Q8
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M@^!.+3Z?+**N2+E2"B-:^6RQ@NO#=+3;$U>C5M"7!;/22<I0O*A-)>.^&J>
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M\RN)!="<:H X5-XR"KGPV-N*"U8+&N- NB0-Z714M(T%.(WA2:_.'F4:- @
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MYO/BK\WSYTX,3+BG: (UE,!AY1P'AC.^K2(EG%3*GW%/^>=D?E=7P_]_=V5
MY'T0;%6$?O6H O613,&3WI,Q B$B,FBMSE#FRK!-6O%#0<)&=D_4.4J*=+Q/
M9:L^T+#;'@(UU0:S:A#GVNP%F6:0.LX$9Q3JP(*PW<*:>N]L3(S- )'7$S+V
MXJ]#U@\#>$=C7IL,S\))[@S8I  [R:36DJ**<F^!'YDRU34<3D);*XZGPEHU
MR: GE3UZ:Z7H:+S7H6&9T\1)(<M;7 :UE<JIK<8H/"#6CBSSOEOA/]/2.^-S
M1'I015<YBTI!,('_L_7*Y_EJLK@RQ:?)O5JM9JMU^=RQ]*%6K\NT\QY33:'@
M'FB +."DIM9:&+-C#3 @HQ=4)>1_)VC[M"S*1J6?\V_!<-L?R=QH7 8=0:6Q
M3"&1CCL!&=O-/RBX,173!AB2D08_'3 ZO5)U6.]\WR!D]>1W90  ZJ6BE%GC
MB6'6"U[Q!!H8=20.>O-*H^/W(X54R/R]2DMYMSB\:#\7\WE8<W]-EE<'L-GB
M;9E#"CA+&?4( 4TLX4S5?,$4C.PBI4?<%*EE,0R3M/*VMK9)J_&9E51"+J@S
MVF LL LLKVD7MIE/LBL<WN;+67'U93U9KGM%8Z\8.<E.;2>%UHK>X<GL(CR_
M%D')^#E;E0_N]WY'OC$3@5Z)&6/:>D,L9T[M.$J &%FT=PK,I95(WR@L[Y$F
M\[(9;A6^]VFS/40B<<];RPH2'#CJ.#(26NEY6) 5[64RX$@RTI,AI 4BNY%,
M.E1^"K-;=HS)1^_,D*&6$FX\-U0(;[D2N*9;.S02^^4R$-E>+L/0%FU^M4V"
M;G]W]O"*3)+P?TY3+J'!!(F@O*C=BD0\QBW8W*WS:WGQKZ,XP'N6Q#"PV)7E
M0ESIZ_)E0K;$ D&*@:AIEX0E3<;96BYNT6^9^^% L)T,D@8JF>]E(<M2FZB"
M+=1JE6]"C][/)M]F\TT,TQ^+(.^OQ>ULR@![/8%(7#F E# &<"TT)$+:;7\@
M891DLM$&WBL/WBV">"9S=7L[GTVWC14V*\QL>S',?N;N^CJ?KC>)B)O#^EAD
M4MR+,TJ4">H$E9)!55;,Y8;4',,6CZP,=><X>CD0,HTP4IUZIU-S)):IW0LS
M:S>9(  ZRPDGUDE>W3"9LI+A.*/J>H=2<0;9#!>Y1P.BVKXR,QXS"QDAFCFJ
MG ;$[3C$*!]99%[?,(I&;2NII$N<G4^WK9DV>ERU%?QV-[LJE=-WBRTQ.K\N
MEGFMY!VOS=;ZI9D34#DF*:%* V$=@+K>3 RP=B0^Q'1@>I: FT@RR6HKS<*,
M ZNGN<[7?^7YXB!)9=+$]?K!7#F*Y"Y>GZ$RJDT1[CP3CF-I)30UYZ!4(RM;
MGQS39Y!1LLI05_\=[(5-\4]?+#_D?U77_;/%S:=EL0@_3K>E08^HP2>])_.$
MAI6MC46$8F E8]35O!">Q>S! \3KF;3?/D62"IYE!/K':W55W);\.+J9OO1X
M)KSAT.A@_BK@ ($<R7K56P-13,W- 1[X/4F]Z)S1R7:X'?U?UI/%U61YM?KC
M]BHH*.%Y N113#4:GUGG!%  2<] ^(>@]$M?TQYV^Y&!+$[\SYNW=L[@=%DB
M+;?V]PVB:>-?GBD+O+$>0<H\,<8JCOA.)IC+<<5VG^F@32ZGUN$3V^N6A]N6
M7_S%Y<U+%=1Q.**V[:LRZID2#E-@-2=0,V9%%4!G'(%R9*7[4\*B2"J99*ZC
M?11\V!%QR$=T?'1&F(/$.VRP-X!Y@[6L&>PDCC)$!A=8VS\XGM?U[U@ [3>^
M(^2^6TR79<FXU>8VK>+19D5.-D$<GY:S:;ZY6I\6-XO-*BU+]_Y::.?9%MGG
M1S-CI'0>8>DPI(:*LOI0S3DF1<QEYX!LZ&2@'9S$SK[)!B+FD]5J=CW+K[X6
MX6_Y[.>1^_N3WY51)*D3$!)CN<9$25,G3QH'XC(;VD:I73:.4XFBMZUXTX#V
MD1>C[>[Z]#T9X50)9 !DW@O&@Q5I946?!P;%.,D'U"QC6!MFI!#.O@=VIF@&
MO<92B!VT2 =E!T"(Z[W?4QS5+^KDXM']QD$.9Z=KS?Y(^WJV(_NO9U/:U2%N
M;&*?^K:,!RO122$X8MI#@:V"HJ85(9.T-=G8K>R>A3.$_:]9A?-&+\ATV8<>
M,00MH%AQ@9'3-?5,TI@:U$,VM_M#R0E;86LQ=*_I/4PEK=W=T7<SH@.;(-(P
MR ?3LD\!JN\BO'8\!L8#VF%3 GB(<NL3]]%&SOY79180[[@D! /DH,36^DK7
ML0 8'>/3'-"=SQ#1&2F*L9WVGD$F26 O@)12KI1'I*8>&:S'D_LUX+/^-"'T
M8OG4J5SWI]XNGORZ3")>IIZ+8$4*Z334$)C=@O,JQO89T-XW9-NG.^F<<SM\
M2L6)F^'3X9D."P99!XA42!+)B:H+REG C8C9"B_/\.D$(@UVPT@I1.M_AVBV
M&XE-YA^O?Y_-\_#,(E^YR7*17[F_I_.[;<7^C0[[G_RJ6N?'E,2NOY<!9B%P
M1")&,98("HBKZ$!+(1A5<8M4>!V2P#HU<)[/_T QBQ9OR4K7A"'"0<PTXQ8Z
M12OCS3+L=9I0ME3U+,Z'R5ZDT2O28FSI8^_*) MJ,@F+1U.+*8,>US5;+4,$
MQ+AZAGEI.""X10IC3/JC,UPJ4K8Q<@0( Y!BN*;<*QRS^0WW^G!@VN-I,NC7
MDN[L'O'P&S.,C$864&B=]Q9)2^1NFW?4)77AO')[N@L!#6)+;.UB?.$-&<1$
M"P: \!(YXE70?"OOF>6:JICZI!=L6$=BY93=L;4L^C&O'Z:3S,*.^V1&'$0R
MJ#2!7\9II+'FNN8:@&PDN=NIL3LPL?5C #TF(<K:?NE%&0 4,&$T)L!@Z,*B
M%K:FD##X6@WN'O#9ETSZ1ETGEO>!ZU,JI!+$F4"8EH8'?=OO#A3K==+BD2/=
M&OL5R?CT30"XUAQC#*!2@ 8M!]8W^MP9$U-5]V(-\?-HFZ=)XIQ(#-;C=;'\
M45:*^?AM/KO9"/Y+^'-5YF"4=:OSG[/B;K6W3'EW+\^ 4,QA:L+QP;#R"/B'
M]1L6]LB:Q?5=(C.Y0!Y@G* X[X=\O>MCMOV-G:TF-S?+K3*F[ZM_?3TE>8,1
M"S%6 'O/(0@2@G3K@);(4$$;J<3]\."19!['/!XKN'MH6$8 \PI(P(QTGGE'
M&-[FZD@,2]]J2M_*</:*QAAX5D2L,U:G.LRJ]?UQ^25?_BP#:P_7 'OI\0QX
M%PQCI5S85@E3T J@*LJ0"KKDN$#4C9"+SOF:&#%E ?=JLL?;<N\=DP',..=8
M(A0L#FD,1!C7-#H8U7QJ@-B)$_/+F(EF:F+@'*W&]<MS&?> BZ S > "D[!C
MLHIWD>4./;9F[1W(]&64M.)F>^?2Y%LX4-?W?Q_N6_SDL4QHZ8/I"(&"@G%!
M"""ZGAT$4?$_PY7UJ9(I.F-@A.\P?'0Y^_<1Z?[R5,84=X  9Q72Q$A9^@WJ
MN=E [+C,TBZ$&\._5)OZ'FWH?8/:=\>&9L8*I CD!C)8IG03C>J#,>QY466\
M!XB87O3*CGF<N.9B@\J)JPQ;8K&V E)/ #0>DQUK2&21I),/C9_Y\EMQ'IRT
M$.G+-0Y/Y6A2?U7]7WW_BY_*A#]NBN7]ZW%3.8FTL$([CH#P6$NC*W608&V:
M.6X:GO9/'(3'.A'O>3S#V&LB&";>0LP1\]SQ:L:$*Y^T,,!P7$V-Y5ATSN)4
MF_FF=6==3K\HKE:_+8O5H:W]Y0$9DF%/$](##Y"@4C&I=4T=XU&YI@,"4#<"
M+GK@:%*\A.U]4S(ZS'I]MUR4!O%# \0-"<< =/P-&0>&4*:$\=9["K U1M3T
M Q$5^=]<P4P:_M(+L#KG]-EVI@_YH;/YI<<S+IW14FE-O-<PF&BT:@$E"=50
MQE2%/ST=N5A/YA<&GCA^1K@PYD'"Q7+#\Z:JS<%!F?=&,DJTT)R%G=0JC>O=
ME'H<U;E^@.9JKPI.EXQ.M9F\GTWSQ6H'Z /[R),G,^LL(\QJ1S#'E%+DM*WI
MX53%Y. .3;'I2+!%EPQMO8>439C#X._AO+/AR_/BM@R@J_SV1\+-FXS-$"%!
M/0.:>>$0)40#LJ,#8#"J^L^= J,O%J?:2S8QF8^/Q\.*R4N/9T9II2"7Q@.+
M)93"&EA31J",">T84)V4'G>5#KB:.B2QP>'S]-%,B#)V$\F@DBM$@B(GE*\H
M8AZBM/E__2JP_> DDJ-#]*FCTO7+B/*2<\\Y8!C7&CT+VV),Z^H!&35]J[*1
M;#V+8_U)^.=O>7&SG-Q^GTT_YS=EE\U7XV!G&!$K!4-.,2[+?"]17=D"Z 3&
MXXH#18P(IZCP1.*P@*A@@-?4!J#3<9@@O6'@E#C0TUB=S!46Y+9I&OFPXB?S
M(\&@>\=D$#%. &+8(P.1]( J5M&(C(RJ93% .'4C[J?.L8Z8FPQ ^<W3V1X-
M"]T[)D-.$ 9TL-^%E50&G4S+FD;(HIH:#A! '<CZ*7HZXNQIZ%GETW_<%#__
M]^8V8'F_!4_UEZ>XJ7Z=_?'E!8 \_&/&.10:4!.LKJ!48XA$;7 !%-3SI.$=
M"9 0+[<BDH6I-@QWMRQN\Z/1P(\?RSS0P($R%] Z9X$0A((=)0"/++6M.S!T
MP,S67M*-&^67C:TL[WXX=/30F,Q *HC'@##%A#&0&5W%-X7C%?&8E($!.;:Z
M!T'7G!U#B"DM]?B@DBEJ//,&>JA)37'8)4=V9]>+HMHQCX?H#I,>4ZZE<H8J
MK1!U7/B: @W2MI ]&TI:"'2?'^PT?@[!#_9E=K.878?]<K&NO02OQQ5FI$)8
M.X,%Y-881 6H[LB@X%PWTKIZY4'+;O#'6=.VS3S6L.P)(DU9*TT!9;FL/,50
M&F=&MF%TCJ.7]XTTPDAU_OP^^>]B6;-H=<33]OSA#  )O$("EFT/E=#.<EY3
M!0T>6>)L*@@4'?,]%9H^3'[D'Z]_F>Y1[]O>,1G#844*":2F3 !"&=8[=B%K
M1E85(D;(13\L;6ULO[L-3#]L6S]Z)$,(:80\8<X&BY]I[CC8K0LK1G9.=2"=
MHA-&1N15+_,?D^6?[__Q_A_F'\>2JY\_FPD"B)#*(@T]!80#9DTU3R6D'%D2
M;L<"[X"CK26OKJ]G\UDP1E;%]>_3_YNO5L7"%,O;*ICE,!0:#0Z'),8T3!H8
M8JDPCAE3JV=*21D3ACI OUK'V.B#Q:W!8F>W\T#+^LMM/@WJTOK^T_?)\L=D
M>G\8)D>&96&'"RJ\  !**0T5.FQL]>PUBNHZ.:!:G3T!I%OFMM]'IM/ XN*_
M\C"%[^\6TPJB^=61'>3PL$P+90#FG$O@C O*4[#NZME[IY(VK[@X:'3+W+B+
MFIT>W.""YLFSF4+, 6F9(4)+[2@J6Z-6\V0,QB@7;/0@Z("C":.-IWGIY]F$
MT<Y6?^I[G2^FWTO=Z(@CX]C0#$,--.#&(2ZUX=P27:M36@D4X]88H()Z)K=&
MQU(X'^[J21_U=1P;FC&$C2_CM1U6D#$B,8$UQ8ZQF*ZR [2$NP/ 461%\?F<
MB<!'(U/V#\J<0<"$_S%AE ^D<FEW5&KF8Y*"+P)-;87>($&X%8?/>#)^#1,X
M_5"L1V4*"H6)M,@+!X+1B$6]$!$$7,7H5 ,TRH=S'K84P-F 5L[W]%/P853&
M#;.& NJY+9<HP<J#FDY/U<C*\W0B\6,H:LW=9"BJS(UG,S]Z]AT9F2%II<1*
M(B88A8@2#W5-KW0T)H'L$M#41O)/T=0IAQ-'546T5^PC*./]0^A265.D#)9D
M%E#I@;9U1@]"5D>9EP-T89[I.$TNIR'&##K/E0&R+,6+#>/(>"MK"I!CX\RH
M2R+R?5&%IW'\;)I:X$CYB\E-#D]1U1X-RZ1!3BOBE9>2(5762*KW?L20&-DM
M[AFQU:$4DD:Q;O;OUQ":Z@01E',+(#"8,(^YJ]9\4(@T:%4&M?\L[:]!%CI\
M]L_34Q=^'9^5!#M-(:60V'!:"T)433]P8&1Z=N>H."%ONRW/(ZI+3</NLPDJ
MV$SFEU*+OY18+ L=+7_F>C+?_/4HQ+I\?8:<823,G5@C?#AZO7C@!B0J!H'#
M/8LZ1^ 919*Z1M$O_%JM\I*R7?/'QMMCB[=ETB&@.,628\@<9V6-VYHO)%CH
MH_2E]K99]B^!)"K3EW68F)ZL\BM3_+C-%ZO-.\ZF.I7+?5ZL[I;YQ^O'$_J<
MSS>%[HO5>O7E>P# MW+*GR;WFYZ]#32JN!=G6"-N&3.60Q)V%8G+Y,!2<LR[
M4GIG5;2:$:8?$]90!8MY<Z81Q1:K,L6>88:0@MK7/!,8CJ1@>6J /=?9$@KI
MC%M2>?I/2Y+<C]MY<9_G+S_F_BY_S,^=G3C8?<Q!9K!!@!N(I0<2&5")F_IP
M(IUO'_LR_9Y?W<T#63L!;TN5/J#W!3A4=LJTN%G,_A/HW;I$2B8<2W'LY7N9
M5HPJ*XTN'<:, "NPW?%7^Y&Y/5.!\6E<Q !$E\IL*.-A?^2["DGO*TJ.A%0<
M&)59$8X9K EE)*B] A'"ZQV? 4!'=BR?&2M%7W(Y,_Z.QEH<')=!X(#0P1S7
MEC#C _,8KFF%C(TLVJ(3J3=#4BO^IKL_?*DB>:6Q'8VY:# Z\YI"1K5#V')F
M1%B+CM9T,VM'%L;:$0:>72AVS>=D8:SY/+SSYK=\D2\G\])C>/5CMIBM-A=8
M/_.*A/VI':W>DV$5K#4M,+!>(LV%5;#68C@E.@9S)WN 4S1@[ =U??(\%?ZZ
MT3#>-P@%ZOA+83U+ 83@,G#3(8DAUFS'3QO597R MQC#T@G/*\M4:V/GOGF9
MOFI]'X!\LQ=DP8+$1FG)@/$>&T,UKD\FSAE/>B.<8C<^&WJ*!.(YH[OQPV2Y
M/7G>/(E[G#>88P08%\! YP7496KF5I* (]BH7$+?GL0]JR%(=G&S45Y6^OZ9
M<US]-5E>-?<>1GXC0XHX;)E'#'I/F QG2+W@@-&N4:.%RS%94H%NK\<PK;B2
MG:Z;"1Y/M?KEN<PK[BBCT&G& (&N)&U'B\<C*W]T!@P\/2,CN)_,AF[-FP?J
M%E>?YI-%62#@> N$'CZ7,<,MX5@"K@! C&$A=,59J!P?F7>Q):J>[I#G%T1R
M,[U4_#[>EG0>+\._;TSFJ -*,.ZM!"XHL58Y4M-(-!G;)GI6F.RSG".%DM#_
MO5[.IJ615,[XC\5LO?K\Y8\FGN_]XS+-J= *$ *<]8H0Q0FJ:=48Q]0M&Z+O
M9D@ [%(P@SG@]_&OB5\R_N69@T))6"KS E* ("BK259<"\I_S.$]1#B?72E-
M+K+! _W#7;E\*XFLU,_);%YRV!?+W\+80RZ5OCZ9(6V 5-(+!KDB@B.VBPZ$
M#HB1W6NFA&17JZ%;"0[JQNI#L?@9#KI\>X*NOI8-:1__>^FT^5"L_W^^?O M
MQ]Y=M?EF1K06AFI )6 $*X(TJP]<A)$<V]%QOE4R%!%>_#+97L&$3:+Z5?G<
MH;3HM!/)@A(AL#>:.DZ1H4R&O]728( UBA:^G(RA,2ZH+N1ZQENXSZL[-5W/
M?L[6]V_W<"]?B6B*B6#42,21EUA812O;U7AF6*,+[[=[N#RS#FOO%%<2:&H0
M<Q+N^%@&M8U+Q4X%NM[NX4X3U[#OX03#UEJ#@#1$>8"9]'Y'"P)CL^[28^#@
M/=QIW!^,]^(2[N&PY$1:!8EFW!.G5<U96Q8OC?%,#Q#7+5&5Y![N)$%<]G4(
MU8QZ*CR6TEGH.<:U+]\"B-3;?5R'<#GI.N0TP0QFGSWS=0BRR'E@J 7.!PY"
MP"VNN>8)C@D/&Z)/Z^RZ07*1#1[H[M]WP?Q^MPAK^V[#^$VKCJ_?)XOME?MJ
MYY?X7,SGOEB6@_I8%*TFDG$6=A>LE*70.BX%\-#6TG DJN7;)9X''<*WJY63
M0JXC6F7;FZ;S+K#M'+*R29>T2 #GE/ $*4IJ&4"J14Q%J9/7UNW&T_EE/5FN
MA[G">H9Y^M78"@27OQ W][FK=U7YU;.LPU^GD%$BO;( 2$H<\U0!B40M 0)L
MTJ91*7*>7OT2C))_ZXJ<_='SSPW/)XNKS_D\+T>_L*I23R%C!ELON6:"0VJM
M<ACNN"I<5$YL\\M/N5U5B[(F:_7L*UU5 Y?_Y9]K03#7^2PPX:Q'V[-99)P@
M(1QT7'NKRU*9VM5^(XA]5&_5YCTKWM9ANM,M%@*7OQ2':.N5!6LY0, 9!;1Q
MC(0?:QEPRF-Z^IW<XGAKZ[G%VT(<, 1&M S_E<]NOI>!5\&ZF=SD&_7;AH/
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H;"TR,#$X,#8R.5]P<F4N>&UL4$L%!@     &  8 B@$  $>T P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
